Form 10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-16-541409.txt : 20160414 0001193125-16-541409.hdr.sgml : 20160414 20160414160915 ACCESSION NUMBER: 0001193125-16-541409 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 68 CONFORMED PERIOD OF REPORT: 20160229 FILED AS OF DATE: 20160414 DATE AS OF CHANGE: 20160414 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CRYO CELL INTERNATIONAL INC CENTRAL INDEX KEY: 0000862692 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 223023093 STATE OF INCORPORATION: DE FISCAL YEAR END: 1130 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-23386 FILM NUMBER: 161571830 BUSINESS ADDRESS: STREET 1: 700 BROOKER CREEK BLVD STREET 2: SUITE 1800 CITY: OLDSMAR STATE: FL ZIP: 34677 BUSINESS PHONE: 813-749-2104 MAIL ADDRESS: STREET 1: 700 BROOKER CREEK BLVD STREET 2: SUITE 1800 CITY: OLDSMAR STATE: FL ZIP: 34677 10-Q 1 d161362d10q.htm FORM 10-Q Form 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

FORM 10-Q

(Mark One)

x	Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

For the quarterly period ended February 29, 2016

¨	Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

For the transition period from to

Commission File Number 0-23386

CRYO-CELL INTERNATIONAL, INC.

(Exact name of Registrant as Specified in its Charter)

DELAWARE

22-3023093

(State or other Jurisdiction of

Incorporation or Organization)

(I.R.S. Employer

Identification No.)

700 Brooker Creek Blvd. Oldsmar, FL 34677

(Address of Principal Executive Offices) (Zip Code)

Issuer’s phone number, including area code: (813) 749-2100

(Former name, former address and former fiscal year, if changed since last report).

Check whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files. Yes x No ¨ Not Applicable ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “small reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

State the number of shares outstanding of each of the Registrant’s classes of common stock, as of the latest practicable date.

As of April 8, 2016, 12,481,065 shares of $0.01 par value common stock were issued and 9,087,254 were outstanding.

CRYO-CELL INTERNATIONAL, INC. AND SUBSIDIARIES

TABLE OF CONTENTS


	PAGE
PART I - FINANCIAL INFORMATION (UNAUDITED)

Item 1. Financial Statements

Consolidated Balance Sheets		3

Consolidated Statements of Comprehensive (Loss) Income		4

Consolidated Statements of Cash Flows		5

Notes to Consolidated Financial Statements		6

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		27

Item 3. Quantitative and Qualitative Disclosures about Market Risk		33

Item 4. Controls and Procedures		34

PART II - OTHER INFORMATION		35

Item 1. Legal Proceedings		35

Item 1A. Risk Factors		36

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		36

Item 3. Defaults Upon Senior Securities		36

Item 4. Mine Safety Disclosures		36

Item 5. Other Information		36

Item 6. Exhibits		37

SIGNATURES		38

CRYO-CELL INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS


	February 29, 2016 (Unaudited)			November 30, 2015
ASSETS

Current Assets
Cash and cash equivalents	$	3,581,736		$	4,152,162
Restricted cash		204,400			204,344
Marketable securities		617,108			610,424
Accounts receivable (net of allowance for doubtful accounts of $2,156,577 and $2,067,130, respectively)		3,216,990			3,058,379
Deferred tax assets, current portion		1,336,000			1,336,000
Prepaid expenses		429,309			427,819
Inventory, net		498,524			475,608
Other current assets		58,341			88,392

Total current assets		9,942,408			10,353,128

Property and Equipment-net		847,626			879,070

Other Assets
Intangible assets, net		503,877			516,328
Goodwill		1,777,822			1,777,822
Deferred tax assets, net of current portion		5,987,814			5,930,987
Deposits and other assets, net		40,611			40,611

Total other assets		8,310,124			8,265,748

Total assets	$	19,100,158		$	19,497,946

LIABILITIES AND STOCKHOLDERS’ DEFICIT

Current Liabilities
Accounts payable	$	1,685,775		$	1,328,619
Accrued expenses		1,566,676			2,005,351
Current portion of note payable		309,987			307,420
Deferred revenue		6,614,192			6,782,562

Total current liabilities		10,176,630			10,423,952

Other Liabilities
Deferred revenue, net of current portion		11,169,495			10,869,218
Note payable, net of current portion		790,957			868,947
Long-term liability - revenue sharing agreements		2,300,000			2,300,000

Total other liabilities		14,260,452			14,038,165

Total liabilities		24,437,082			24,462,117

Commitments and contingencies (Note 12)
Stockholders’ Deficit
Preferred stock ($.01 par value, 500,000 authorized and none issued and outstanding)		—			—
Series A Junior participating preferred stock ($.01 par value, 20,000 authorized and none issued and outstanding)		—			—
Common stock ($.01 par value, 20,000,000 authorized; 12,481,065 issued and 9,097,472 outstanding as of February 29, 2016 and 12,260,340 issued and 9,010,322 outstanding as of November 30, 2015)		124,810			122,603
Additional paid-in capital		28,780,474			28,530,368
Treasury stock, at cost		(8,726,486	)		(8,318,083	)
Accumulated other comprehensive income		76,205			169,932
Accumulated deficit		(25,591,927	)		(25,468,991	)

Total stockholders’ deficit		(5,336,924	)		(4,964,171	)

Total liabilities and stockholders’ deficit	$	19,100,158		$	19,497,946

The accompanying notes are an integral part of these consolidated financial statements.

CRYO-CELL INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

(Unaudited)


	For the Three Months Ended
	February 29, 2016			February 28, 2015
Revenue:
Processing and storage fees	$	5,020,459		$	4,673,969
Licensee and royalty income		—			169,412
Product revenue		131,739			—

Total revenue		5,152,198			4,843,381

Costs and Expenses:
Cost of sales		1,348,291			1,273,987
Selling, general and administrative expenses		3,597,253			2,913,973
Research, development and related engineering		8,684			11,988
Depreciation and amortization		41,548			18,242

Total costs and expenses		4,995,776			4,218,190

Operating Income		156,422			625,191

Other Income (Expense):
Other expense		(18,024	)		(4,075	)
Interest expense		(261,334	)		(301,286	)

Total other expense		(279,358	)		(305,361	)

Income before equity in losses of affiliate and income tax expense		(122,936	)		319,830

Equity in losses of affiliate		—			(8,248	)

Income before income tax expense		(122,936	)		311,582
Income tax expense		—			(25,412	)

Net (Loss) Income	$	(122,936	)	$	286,170

Net (loss) income per common share - basic	$	(0.01	)	$	0.03

Weighted average common shares outstanding - basic		8,971,373			9,824,566

Net (loss) income per common share - diluted	$	(0.01	)	$	0.03

Weighted average common shares outstanding - diluted		8,971,373			10,058,649

Other Comprehensive (Loss) Income
Unrealized loss on marketable securities (net of tax)	$	(93,727	)	$	—

Comprehensive (Loss) Income	$	(216,663	)	$	286,170

The accompanying notes are an integral part of these consolidated financial statements.

CRYO-CELL INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


	For the Three Months Ended
	February 29, 2016			February 28, 2015
Net (loss) income	$	(122,936	)	$	286,170
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization expense		74,618			58,994
Compensatory element of stock options		252,313			190,513
Provision for doubtful accounts		192,045			140,505
Equity in losses of affiliate		—			8,248
Changes in assets and liabilities:
Accounts receivable		(350,656	)		(268,511	)
Prepaid expenses		(1,490	)		46,080
Inventory		(22,916	)		—
Other current assets		30,051			(6,500	)
Deposits and other assets, net		—			9,575
Accounts payable		357,156			342,799
Accrued expenses		(438,675	)		(564,624	)
Deferred revenue		131,907			85,715

Net cash provided by operating activities		101,417			328,964

Cash flows from investing activities:
Release of restricted cash held in escrow		(56	)		(56	)
Purchases of property and equipment		(30,723	)		(23,303	)
Purchases of marketable securities and other investments, net		(157,238	)		4,413

Net cash used in investing activities		(188,017	)		(18,946	)

Cash flows from financing activities:
Treasury stock purchases		(408,403	)		(39,042	)
Repayments of note payable		(75,423	)		—

Net cash used in financing activities		(483,826	)		(39,042	)

Increase (decrease) in cash and cash equivalents		(570,426	)		270,976

Cash and cash equivalents - beginning of period		4,152,162			3,279,267

Cash and cash equivalents - end of period	$	3,581,736		$	3,550,243

Supplemental non-cash investing activities:
Unrealized loss on marketable securities	$	(93,727	)	$	—

The accompanying notes are an integral part of these consolidated financial statements.

CRYO-CELL INTERNATIONAL, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

February 29, 2016

(Unaudited)

Note 1 - Basis of Presentation and Significant Accounting Policies

The unaudited consolidated financial statements including the Consolidated Balance Sheets as of February 29, 2016 and November 30, 2015, the related Consolidated Statements of Comprehensive (Loss) Income and Cash Flows for the three months ended February 29, 2016 and February 28, 2015 have been prepared by Cryo-Cell International, Inc. and its subsidiaries (“the Company” or “Cryo-Cell”) pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial reporting. Certain financial information and note disclosures, which are normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America, have been condensed or omitted pursuant to those rules and regulations. It is suggested that these consolidated financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s November 30, 2015 Annual Report on Form 10-K. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and changes in cash flows for all periods presented have been made. The results of operations for the three months ended February 29, 2016 are not necessarily indicative of the results expected for any interim period in the future or the entire year ending November 30, 2016.

Revenue Recognition

Revenue Recognition for Arrangements with Multiple Deliverables

For multi-element arrangements, the Company allocates revenue to all deliverables based on their relative selling prices. In such circumstances, accounting principles establish a hierarchy to determine the selling price to be used for allocating revenue to deliverables as follows: (i) vendor-specific objective evidence of fair value (“VSOE”), (ii) third-party evidence of selling price (“TPE”), and (iii) best estimate of the selling price (“ESP”). VSOE generally exists only when the Company sells the deliverable separately and it is the price actually charged by the Company for that deliverable.

The Company has identified two deliverables generally contained in the arrangements involving the sale of its umbilical cord blood product. The first deliverable is the processing of a specimen. The second deliverable is either the annual storage of a specimen, the 21-year storage fee charged for a specimen or the life-time storage fee charged for a specimen. The Company has allocated revenue between these deliverables using the relative selling price method. The Company has VSOE for its annual storage fees as the Company renews storage fees annually with its customers on a stand-alone basis. Because the Company has neither VSOE nor TPE for the processing, 21-year storage and life-time storage deliverables, the allocation of revenue has been based on the Company’s ESPs. Amounts allocated to processing a specimen are recognized at the time the processing of the specimen is complete. Amounts allocated to the storage of a specimen are recognized ratably over the contractual storage period. Any discounts given to the customer are recognized by applying the relative selling price method whereby after the Company determines the selling price to be allocated to each deliverable (processing and storage), the sum of the prices of the deliverables is then compared to the arrangement consideration, and any difference is applied to the separate deliverables ratably.

The Company’s process for determining its ESP for deliverables without VSOE or TPE considers multiple factors that may vary depending upon the unique facts and circumstances related to each deliverable. Key factors considered by the Company in developing the ESPs for its processing, 21 year storage and life-time storage fee include the Company’s historical pricing practices, as well as expected profit margins.

The Company records revenue from processing and storage of specimens and pursuant to agreements with licensees. The Company recognizes revenue from processing fees upon completion of processing and recognizes storage fees ratably over the contractual storage period as well as other income from royalties paid by licensees related to long-term storage contracts which the Company has under license agreements. Contracted storage periods are annual, twenty-one years and lifetime. Deferred revenue on the accompanying consolidated balance sheets includes the portion of the annual storage fee, the twenty-one year storage fee and the life-time storage fee that is being recognized over the contractual storage period as well as royalties received from foreign licensees related to long-term storage contracts in which the Company has future obligations under the license agreement. The Company classifies deferred revenue as current if the Company expects to recognize the related revenue over the next 12 months. The Company also records revenue within processing and storage fees from shipping and handling billed to customers when earned. Shipping and handling costs that the Company incurs are expensed and included in cost of sales.

The Company records revenue from the sale of the Prepacyte^®-CB product line upon shipment of the product to the Company’s customers.

Income Taxes

Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to be recovered or settled. The Company has recorded a valuation allowance of $2,630,000 and $2,630,000 as of February 29, 2016 and November 30, 2015, respectively, as the Company does not believe it is “more likely than not” that all future income tax benefits will be realized. When the Company changes its determination as to the amount of deferred income tax assets that can be realized, the valuation allowance is adjusted with a corresponding impact to income tax expense in the period in which such determination is made. The ultimate realization of the Company’s deferred income tax assets depends upon generating sufficient taxable income prior to the expiration of the tax attributes. In assessing the need for a valuation allowance, the Company projects future levels of taxable income. This assessment requires significant judgment. The Company examines the evidence related to the recent history of losses, the economic conditions in which the Company operates and forecasts and projections to make that determination.

There was no U.S. income tax expense for the three months ended February 29, 2016 and February 28, 2015 due to the utilization of net operating losses and foreign tax credit carryforwards, which were not previously benefited in the Company’s financial statements.

The Company records foreign income taxes withheld from installment payments of non-refundable up-front license fees and royalty income earned on the processing and storage of cord blood stem cell specimens in geographic areas where the Company has license agreements. The Company recognized approximately $0 and $25,000 for the three months ended February 29, 2016 and February 28, 2015, respectively, of foreign income tax expense. Foreign income tax expense is included in income tax expense in the accompanying consolidated statements of comprehensive (loss) income.

The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For

tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Increases or decreases to the unrecognized tax benefits could result from management’s belief that a position can or cannot be sustained upon examination based on subsequent information or potential lapse of the applicable statute of limitation for certain tax positions.

The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. For the three months ended February 29, 2016 and February 28, 2015, the Company had no provisions for interest or penalties related to uncertain tax positions.

Long-Lived Assets

The Company evaluates the realizability of its long-lived assets, which requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment, such as reductions in demand or when significant economic slowdowns are present. Reviews are performed to determine whether the carrying value of an asset is impaired, based on comparisons to undiscounted expected future cash flows. If this comparison indicates that there is impairment and carrying value is in excess of fair value, the impaired asset is written down to fair value, which is typically calculated using: (i) quoted market prices or (ii) discounted expected future cash flows utilizing a discount rate. The Company did not note any impairment for the three months ended February 29, 2016 and February 28, 2015.

Stock Compensation

As of February 29, 2016, the Company has three stock-based compensation plans, which are described in Note 10 to the consolidated financial statements. The Company’s third stock-based employee compensation plan became effective December 1, 2011 as approved by the Board of Directors and approved by the stockholders at the 2012 Annual Meeting. The Company recognized approximately $252,000 and $191,000 for the three months ended February 29, 2016 and February 28, 2015, respectively, of stock-based compensation expense.

The Company recognizes stock-based compensation based on the fair value of the related awards. Under the fair value recognition guidance of stock-based compensation accounting rules, stock-based compensation expense is estimated at the grant date based on the fair value of the award and is recognized as expense over the requisite service period of the award. The fair value of service-based vesting condition and performance-based vesting condition stock option awards is determined using the Black-Scholes valuation model. For stock option awards with only service-based vesting conditions and graded vesting features, the Company recognizes stock compensation expense based on the graded-vesting method. To value awards with market-based vesting conditions the Company uses a binomial valuation model. The Company recognizes compensation cost for awards with market-based vesting conditions on a graded-vesting basis over the derived service period calculated by the binomial valuation model. The use of these valuation models involve assumptions that are judgmental and highly sensitive in the determination of compensation expense and include the expected life of the option, stock price volatility, risk-free interest rate, dividend yield, exercise price, and forfeiture rate. Forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period.

The estimation of stock awards that will ultimately vest requires judgment and to the extent that actual results or updated estimates differ from current estimates, such amounts will be recorded as a cumulative adjustment in the period they become known. The Company considered many factors when estimating forfeitures, including the recipient groups and historical experience. Actual results and future changes in estimates may differ substantially from current estimates.

The Company issues performance-based equity awards which vest upon the achievement of certain financial performance goals, including revenue and income targets. Determining the appropriate amount to expense based on the anticipated achievement of the stated goals requires judgment, including forecasting future financial results. The estimate of the timing of the expense recognition is revised periodically based on the probability of achieving the required performance targets and adjustments are made as appropriate. The cumulative impact of any revision is reflected in the period of the change. If the financial performance goals are not met, the award does not vest, so no compensation cost is recognized and any previously stock-recognized stock-based compensation expense is reversed.

The Company issues equity awards with market-based vesting conditions which vest upon the achievement of certain stock price targets. If the awards are forfeited prior to the completion of the derived service period, any recognized compensation is reversed. If the awards are forfeited after the completion of the derived service period, the compensation cost is not reversed, even if the awards never vest.

Fair Value of Financial Instruments

Management uses a fair value hierarchy, which gives the highest priority to quoted prices in active markets. The fair value of financial instruments is estimated based on market trading information, where available. Absent published market values for an instrument or other assets, management uses observable market data to arrive at its estimates of fair value. Management believes that the carrying amount of cash and cash equivalents, accounts receivable, notes receivable, accounts payable and accrued expenses approximate fair value due to the short-term nature of these instruments. The Company believes that the fair value of its Revenue Sharing Agreements (“RSA”) liability recorded on the balance sheet is between the recorded book value and up to the Company’s previous settlement experience, due to the various terms and conditions associated with each RSA.

The Company uses an accounting standard that defines fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the standard establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. The three levels of inputs used to measure fair value are as follows:


Level 1		Quoted prices in active markets for identical assets or liabilities.

Level 2		Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

Level 3		Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

The following table summarizes the financial assets and liabilities measured at fair value on a recurring basis as of February 29, 2016 and November 30, 2015, respectively, segregated among the appropriate levels within the fair value hierarchy:


			Fair Value Measurements
	Fair Value at		at February 29, 2016 Using
Description	February 29, 2016		Level 1		Level 2		Level 3
Assets:
Trading Securities	$	261,167	$	261,167		—		—
Available-for-sale		355,941		355,941		—		—

	$	617,108	$	617,108		—		—


			Fair Value Measurements
	Fair Value at		at November 30, 2015 Using
Description	November 30, 2015		Level 1		Level 2		Level 3
Assets:
Trading Securities	$	136,798	$	136,798		—		—
Available-for-sale		473,626		473,626		—		—

	$	610,424	$	610,424		—		—

The following is a description of the valuation techniques used for these items, as well as the general classification of such items pursuant to the fair value hierarchy:

Trading securities – Fair values for these investments are based on quoted prices in active markets and are therefore classified within Level 1 of the fair value hierarchy. For trading securities, there was ($19,800) and ($4,400) in unrealized holding losses, respectively, recorded in other income and expense on the accompanying consolidated statements of comprehensive loss for the three months ended February 29, 2016 and February 28, 2015, respectively.

Available-for-sale securities – During the second quarter of fiscal 2015, management reevaluated its marketable securities and determined that there was a change in certain securities from trading to available-for-sale classification. These investments are classified as available for sale and consist of marketable equity securities that we intend to hold for an indefinite period of time. Investments are stated at fair value and unrealized holding gains and losses are reported as a component of accumulated other comprehensive income until realized. Realized gains or losses on disposition of investments are computed using the first in, first out (FIFO) method and reported as income or loss in the period of disposition in the accompanying consolidated statements of comprehensive income. For available-for-sale securities, there was approximately ($94,000) and $0 in unrealized holding losses, net of tax, respectively, reported as comprehensive loss on the accompanying statements of comprehensive (loss) income for the three months ended February 29, 2016 and February 28, 2015, respectively.

Product Warranty and Cryo-Cell Cares^TM Program

increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients. Additionally, under the Cryo-Cell Cares^TM program, the Company was paying $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloblative transplant procedure. Effective October 13, 2014, the Company no longer offers the Cryo-Cell Cares^TMprogram to new clients. The product warranty is available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties. The Company does not maintain insurance for this warranty program and therefore maintains reserves to cover any estimated potential liabilities. The Company’s reserve balance is based on the $75,000 or $50,000 (as applicable) maximum payment and the $10,000 maximum expense reimbursement multiplied by formulas to determine the projected number of units requiring a payout. The Company determined the estimated expected usage and engraftment failure rates based on an analysis of the historical usage and failure rates and the historical usage and failure rates in other private and public cord blood banks based on published data. The Company’s estimates of expected usage and engraftment failure could change as a result of changes in actual usage rates or failure rates and such changes would require an adjustment to the established reserves. The historical usage and failure rates have been very low and a small increase in the number of transplants or engraftment failures could cause a significant increase in the estimated rates used in determining the Company’s reserve. In addition, the reserve will increase as additional umbilical cord blood specimens are stored which are subject to the warranty. As of February 29, 2016 and November 30, 2015 the Company recorded reserves under these programs in the amounts of approximately $17,000 and $17,000, respectively, which are included in accrued expenses in the accompanying consolidated balance sheets.

Recently Issued Accounting Pronouncements

In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. This update simplifies several aspects of the accounting for employee share-based payment transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. The Company is currently evaluating the effect that the updated standard will have on our financial statements.

In March 2016, the FASB issued Accounting Standards Update No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net). This update amends the principal-versus-agent implementation guidance and illustrations in the Board’s new revenue standard (ASC 606). The FASB issued the ASU in response to concerns identified by stakeholders, including those related to (1) determining the appropriate unit of account under the revenue standard’s principal-versus-agent guidance and (2) applying the indicators of whether an entity is a principal or an agent in accordance with the revenue standard’s control principle. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the effect that the updated standard will have on our financial statements.

In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases (Topic 842). This update requires organizations that lease assets with lease terms of more than 12 months to recognize assets and liabilities for the rights and obligations created by those leases on their balance sheets. It also requires new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the effect that the updated standard will have on its consolidated balance sheets and related disclosures.

In January 2016, the FASB issued Accounting Standards Update No. 2016-01, Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This update requires all equity investments to be measured at fair value with changes in fair value recognized in net income, requires an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments, and eliminates the requirement for public entities to disclose the methods and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet. The new standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted for the accounting guidance on financial liabilities under the fair value option. The Company is currently evaluating the impact of the new standard on our financial statements.

In November 2015, the FASB issued Accounting Standards Update No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes, which requires that deferred tax assets and liabilities be classified as non-current in a classified balance sheet. This update is effective for fiscal years, and interim reporting periods within those years, beginning after December 15, 2016. The standard permits the use of either the retrospective or prospective transition method. The adoption of this standard is expected to result in a reclassification between current and non-current deferred tax assets within the Company’s consolidated balance sheets and related disclosures.

In July 2015, the FASB issued Accounting Standards Update No 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. This update simplifies the subsequent measurement of inventory. It replaces the current lower of cost or market test with the lower of cost or net realizable value test. Net realizable value is defined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The new standard should be applied prospectively and is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those annual periods, with early adoption permitted. The Company does not expect the adoption of this standard to have a material impact on the Company’s financial statements.

In June 2014, the FASB issued Accounting Standards Update No. 2014-12, Compensation – Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could be Achieved after the Requisite Service Period (“ASU 2014-12”). This update requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition in determining expense recognition for the award. As a result, this type of performance condition may delay expense recognition until achievement of the performance target is probable. ASU 2014-12 is effective for reporting periods beginning after December 15, 2015, and early adoption is permitted. We will adopt ASU 2014-12 effective December 1, 2016 and it is not anticipated to have a material impact on our financial statements.

Date, which defers the effective date of the guidance in Accounting Standards Update No. 2014-09 by one year. This update is now effective for annual and interim periods beginning after December 15, 2017, which will require us to adopt these provisions in the first quarter of fiscal 2019. Early application is permitted for annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. This update permits the use of either the retrospective or cumulative effect transition method. The Company has not yet selected a transition method nor has it determined the effect of the standard its consolidated financial statements and related disclosures.

Note 2 – Acquisition

On June 11, 2015, the Company entered into an Asset Purchase Agreement (the “APA”) with CytoMedical Design Group LLC (“CytoMedical”), for the purchase of certain assets and assumption of certain liabilities and contracts that CytoMedical used in the operation of its cord blood business, including the Prepacyte-CB Processing System which is used in cell processing laboratories to process and store stem cells from umbilical cord blood (the “Acquisition”). This transaction has been accounted for as a business combination. The purchase price was $2,400,000, plus the value of inventory, comprised of $1,553,272 in cash and assumed liabilities of the seller less any prepayment made by the Company to CytoMedical ($966,597 at closing and $586,675 on or before September 30, 2015) and a note payable to the seller in the amount of $1,300,000. The closing was effective on June 30, 2015. As part of the closing, Cryo-Cell paid $861,783 as required per the Disbursement of Funds Schedule in the Amendment No. 1 to Asset Purchase Agreement (‘Amended APA’) dated June 30, 2015 with CytoMedical, dated June 30, 2015 and a prepayment for inventory of $104,000 paid by the Company to CytoMedical during the second quarter of fiscal 2015 was applied to the purchase. On September 30, 2015, $662,500 was due to be paid to CytoMedical. A portion of the amount due on September 30, 2015 ($225,000) was contingent on the number of the Company’s new clients choosing to have their umbilical cord blood processed using the Prepacyte-CB product during the months of July, August and September, 2015. This amount was reduced to $149,175. On September 30, 2015, the Company paid $586,675 in accordance with the APA. In connection with the Acquisition, the Company incurred approximately $22,000 in transaction costs, which have been included in selling, general and administrative expenses.

The following summarizes the fair value of the consideration for the Acquisition:


Consideration
Cash	$	375,374
Assumed liabilities of seller		1,073,898
Note payable to seller		1,300,000
Prepaid expense paid to seller by purchaser		104,000

Consideration	$	2,853,272

The following summarizes the allocation of the total purchase price for the Acquisition:


Inventory	$	529,097
Tooling molds		35,353
License agreement		470,000
Customer relationships		41,000

Total identifiable net assets acquired		1,075,450

Goodwill	$	1,777,822

In connection with the APA, the Company assumed an exclusive perpetual license agreement which enables the Company to use licensed technology in its umbilical cord blood processing and storage product for cord blood banking. Under the terms of the APA, the Company will pay a royalty of $5 per bag set unit sold, subject to minimum annual royalties totaling $35,000.

The goodwill is attributable to the manufacturing process used in the operation of the cord blood business. The goodwill recognized will be deductible for income tax purposes.

The fair value of inventory and tooling molds were estimated by applying a comparable cost/market approach, representing Level 2 measurements. The fair value of the license agreement and customer relationships were estimated by applying an income approach, representing Level 3 measurements. The fair value estimates are based on (1) an assumed discount rate of 16%, (2) long-term sustainable growth rate of 3%, and (3) a ten and fifteen year lives for the license agreement and customer relationships, respectively.

The fair values of the license agreement and customer relationships reflect the anticipated cash flows over their expected lives.

The operating results of Prepacyte CB have been included in the consolidated statements of comprehensive income since the date of acquisition.

Note 3 – Inventory

Inventory has been pledged as collateral on the note payable incurred in connection with the APA (Note 2). The components of inventory at February 29, 2016 and November 30, 2015 are as follows:


	February 29, 2016			November 30, 2015
Raw materials	$	14,228		$	9,041
Work-in-process		144,013			134,727
Finished goods		280,345			282,152
Collection kits		67,656			57,406
Inventory reserve		(7,718	)		(7,718	)

Total inventory	$	498,524		$	475,608

Note 4– Goodwill

Goodwill represents the excess of the purchase price of the assets acquired from CytoMedical (Note 2) over the estimated fair value of the net tangible and identifiable intangible assets acquired. The annual impairment assessment is performed as of September 1, 2015, and an assessment is performed at other times if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below its carrying value. Step one of the impairment assessment compares the fair value of the reporting unit to its carrying value and if the fair value exceeds its carrying value, goodwill is not impaired. If the carrying value exceeds the fair value, the implied fair value of goodwill is compared to the carrying value of goodwill. If the implied fair value exceeds the carrying value then goodwill is not impaired; otherwise, an impairment loss would be recorded by the amount the carrying value exceeds the implied fair value. As of February 29, 2016 and November 30, 2015, goodwill is reflected on the consolidated balance sheets at $1,777,822.

As of February 29, 2016, there were no indications of impairment and no impairment loss was recorded for goodwill.

Note 5– Intangible Assets

The Company incurs certain legal and related costs in connection with patent and trademark applications. If a future economic benefit is anticipated from the resulting patent or trademark or an alternate future use is available to the Company, such costs are capitalized and amortized over the expected life of the patent or trademark. The Company’s assessment of future economic benefit involves considerable management judgment. A different conclusion could result in the reduction of the carrying value of these assets.

Intangible assets were as follows as of February 29, 2016 and November 30, 2015:


	Useful lives	February 29, 2016			November 30, 2015
Patents	10-20 years	$	34,570		$	34,570
Less: Accumulated amortization			(8,541	)		(8,075	)
License agreement	10 years		470,000			470,000
Less: Accumulated amortization			(31,333	)		(17,917	)
Customer relationships	15 years		41,000			41,000
Less: Accumulated amortization			(1,819	)		(3,250	)

Net Intangible Assets		$	503,877		$	516,328

Amortization expense of intangibles was approximately $12,000 and $500 for the three months ended February 29, 2016 and February 28, 2015, respectively.

Note 6– Note Payable

On June 30, 2015, the Company entered into a note payable in the amount of $1,300,000 in connection with the APA (Note 2). The note is payable in 48 monthly installments of $29,938 including principal and interest at the rate of 5% per annum, commencing on July 31, 2015, and ending on June 30, 2019. Pursuant to the APA, the note is secured by all assets, inventory, molds and tools sold and transferred to the Company, tangible personal property held for sale or lease, accounts, contract rights, and other rights to payment and general intangibles.

In the event the Company sells less than 8,000 Prepacyte CB Processing System Units (“Units”) to outside customers during each of the twelve month periods during the note term beginning each July 1 and ending June 30, the note will be reduced by the lesser of $100,000 plus interest at the rate of 5% per annum or $25 times the difference between 8,000 and the actual number of Units sold plus interest at the rate of 5% per annum. Any annual note reduction shall serve to lower the remaining monthly note payments.

In addition, in the event that during the period from July 1, 2018 to June 30, 2019, the Company shall sell 4,000 Units, it will receive an additional $120,000 note reduction. However, if the Company sells more than 4,000 Units, it will owe additional principal in the amount of $25 times the difference between 8,000 and the actual number of Units sold plus interest at the rate of 5% per annum, which is payable on June 30, 2019. The Company expects that it will sell more than 4,000 Units for the periods noted and does not expect a note reduction.

As of the three months ended February 29, 2016, the Company made three installments of $29,938 and recognized $14,391 of interest expense related to the note payable. The remaining principal balance of the note payable is $1,100,944 and $1,176,367 and is reflected on the accompanying balance sheets as of February 29, 2016 and November 30, 2015, respectively.

Note 7– Segment Reporting

During the third quarter of fiscal 2015, the Company purchased certain assets and assumed certain liabilities and contracts that CytoMedical used in the operation of its cord blood business (See Note 2). The Company evaluated and determined that this acquisition qualifies as a separate segment.

The Company is organized in two reportable segments:

The cellular processing and cryogenic storage of umbilical cord blood and cord tissue stem cells for family use. Revenue is generated from the initial processing and testing fees and the annual storage fees charged each year for storage (the “Umbilical cord blood and cord tissue stem cell service”).

The manufacture of Prepacyte^® CB units, the processing technology used to process umbilical cord blood stem cells. Revenue is generated from the sales of the Prepacyte^® CB units (the “Prepacyte^®-CB”).

The following table shows, by segment: net revenue, cost of sales, operating profit, depreciation and amortization, interest expense, income tax benefit (expense) and other comprehensive income for the three months ended February 29, 2016:


Net revenue:
Umbilical cord blood and cord tissue stem cell service	$	5,020,459
Prepacyte^®-CB		131,739

Total net revenue	$	5,152,198

Cost of sales:
Umbilical cord blood and cord tissue stem cell service	$	1,245,023
Prepacyte^®-CB		103,268

Total cost of sales	$	1,348,291

Depreciation and amortization:
Umbilical cord blood and cord tissue stem cell service	$	28,678
Prepacyte^®-CB		12,870

Total depreciation and amortization	$	41,548

Operating income:
Umbilical cord blood and cord tissue stem cell service	$	127,951
Prepacyte^®-CB		28,471

Total operating income	$	156,422

Interest expense:
Umbilical cord blood and cord tissue stem cell service	$	246,943
Prepacyte^®-CB		14,391

Total interest expense	$	261,334

The following table shows the assets by segment as of February 29, 2016 and November 30, 2015:


Assets:
Umbilical cord blood and cord tissue stem cell service	$	16,349,269	$	16,697,621

Prepacyte^®-CB		2,750,889		2,800,325

Total assets	$	19,100,158	$	19,497,946

Note 8 – (Loss) Income per Common Share

Net (loss) income per common share data are based on net income. The following table sets forth the calculation of basic and diluted (loss) earnings per share:


	For the three months ended February 29, 2016			For the three months ended February 28, 2015
Numerator:
Net (Loss) Income	($	122,936	)	$	286,170
Denominator:
Weighted-average shares outstanding-basic		8,971,373			9,824,566
Dilutive common shares issuable upon exercise of stock options		—			234,083
Weighted-average shares-diluted		8,971,373			10,058,649

(Loss) Earnings per share:
Basic	($	0.01	)	$	0.03

Diluted	($	0.01	)	$	0.03

For the three months ended February 29, 2016, the Company excluded the effect all outstanding stock options from the computation of diluted earnings per share, as the effect of potentially dilutive shares from the outstanding stock options would be anti-dilutive. For the three months ended February 28, 2015, the Company excluded the effect of 271,000 outstanding stock options from the computation of diluted earnings per share, as the effect of potentially dilutive shares from the outstanding stock options would be anti-dilutive.

Note 9 - Investment in Saneron CCEL Therapeutics, Inc. (“Saneron”)

As of February 29, 2016 and November 30, 2015, the Company had an ownership interest of approximately 33% in Saneron, which is accounted for under the equity method of accounting. As of February 29, 2016 and November 30, 2015, the net Saneron investment reflected on the consolidated balance sheets is $0. During 2015 management reviewed the Saneron investment to determine if there were any indicators that would imply that the investment was impaired. Based on management’s

review, there was evidence of a loss in value in the fourth quarter of 2015 and the Company impaired the net Saneron investment, resulting in a charge of approximately $684,000. The main factors that led to this decision included a decline in grant funding, reduction in employees, and the inability to sustain research activities due to lack of funding. Without the ability to perform current and future research activities, management believes the carrying amount of the investment is impaired and not recoverable.

In October 2013, the Company entered into a Convertible Promissory Note Purchase Agreement with Saneron. Cryo-Cell will loan Saneron in quarterly payments an aggregate amount up to $300,000, subject to certain conditions. The initial loan amount was $150,000 to be paid in four quarterly installments of $37,500 per quarter. If after the initial loan amount, Saneron has made best efforts, satisfactory to Cryo-Cell in its sole discretion, to have started independently or via serving as a sponsor of a clinical trial related to its U-CORD-CELL™ program, then Cryo-Cell will agree to lend Saneron an additional $150,000 through a series of four additional quarterly payments of $37,500. Upon receipt of each quarterly payment, Saneron will deliver a convertible promissory note (“Note”) that matures five years from the date of the Note. Upon maturity of any Note, Saneron will have the option to repay all or a portion of the loan in cash or convert the outstanding principal and accrued interest under the applicable Note(s) into shares of Saneron common stock. The Company made five payments of $37,500 through November 30, 2014. The Company made no additional payments through February 29, 2016.

For the three months ended February 29, 2016 and February 28, 2015, the Company recorded equity in losses of Saneron operations of approximately $0 and $8,000, respectively, which related to certain stock awards that were granted by Saneron at below fair market value to certain employees, consultants and members of Saneron management who represent owners of Saneron and serve on its board of directors.

Note 10 – Stockholder’s Equity

The Company maintains the 2006 Stock Incentive Plan (the “2006 Plan”) under which it has reserved 1,000,000 shares of the Company’s common stock for issuance pursuant to stock options, restricted stock, stock-appreciation rights (commonly referred to as “SARs”) and stock awards (i.e. performance options to purchase shares and performance units). As of February 29, 2016 and November 30, 2015, there were 568,930 options issued, but not yet exercised, under the 2006 Plan, respectively. As of February 29, 2016, there were 253,679 shares available for future issuance under the 2006 Plan.

The Company also maintains the 2012 Equity Incentive Plan (the “2012 Plan”) which became effective December 1, 2011 as approved by the Board of Directors and approved by the stockholders at the 2012 Annual Meeting on July 10, 2012. The 2012 Plan originally reserved 1,500,000 shares of the Company’s common stock for issuance pursuant to stock options, restricted stock, SARs, and other stock awards (i.e. performance shares and performance units). In May 2012, the Board of Directors approved an amendment to the 2012 Plan to increase the number of shares of the Company’s common stock reserved for issuance to 2,500,000 shares. As of February 29, 2016, there were 400,000 service-based options issued, 129,729 service-based restricted common shares granted, 278,948 performance-based and 116,240 market-based restricted common shares granted under the 2012 plan. As of November 30, 2015, there were 400,000 service-based options issued, 129,729 service-based restricted common shares granted, 203,403 performance-based and 116,240 market-based restricted common shares granted under the 2012 plan.

Service-based vesting condition options

expected life of the Company’s stock options. The Company uses historical data to estimate option exercise and employee termination within the valuation model. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The expected term of options granted to employees is calculated, in accordance with the “simplified method” for “plain vanilla” stock options allowed under GAAP. Expected dividends are based on the historical trend of the Company not issuing dividends.

There were no options granted during the three months ended February 29, 2016 and February 28, 2015, respectively.

Stock option activity for the three months ended February 29, 2016, was as follows:


	Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
Outstanding at November 30, 2015		968,930	$	2.17		5.01	$	1,095,525

Granted		—		—				—
Exercised		—		—				—
Expired/forfeited		—		—				—

Outstanding at February 29, 2016		968,930	$	2.17		4.76	$	1,531,543

Exercisable at February 29, 2016		959,552	$	2.16		4.75	$	1,525,260

The aggregate intrinsic value represents the total value of the difference between the Company’s closing stock price on the last trading day of the period and the exercise price of the options, multiplied by the number of in-the-money stock options that would have been received by the option holders had all option holders exercised their options on either February 29, 2016 or February 28, 2015, as applicable. The intrinsic value of the Company’s stock options changes based on the closing price of the Company’s stock.

There were no options exercised during the three months ended February 29, 2016 and February 28, 2015.

Significant option groups exercisable at February 29, 2016 and related price and contractual life information are as follows:


	Outstanding						Exercisable
Range of Exercise Prices	Outstanding		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price		Outstanding		Weighted Average Exercise Price
$1.01 to $2.00		465,930		5.23	$	1.72		465,930	$	1.72
$2.01 to $3.00		480,500		4.23	$	2.56		480,500	$	2.56
$3.01 to $4.00		22,500		6.36	$	3.08		13,122	$	3.08

		968,930		4.76	$	2.17		959,552	$	2.16

A summary of the status of the Company’s non-vested options as of February 29, 2016, and changes during the three months ended February 29, 2016, is presented below:


	Options			Weighted Average Grant-Date Fair Value
Non-vested at November 30, 2015		15,003		$	1.90

Granted		—			—
Vested		(5,625	)		1.90
Forfeited		—			—

Non-vested at February 29, 2016		9,378		$	1.90

As of February 29, 2016 there was approximately $15,000 of total unrecognized compensation cost related to non-vested service related share-based compensation arrangements granted under the 2000 Plan, 2006 Plan and the 2012 Plan. The cost is expected to be recognized over a weighted-average period of .36 years as of February 29, 2016. The total fair value of shares vested during the three months ended February 29, 2016 was approximately $11,000.

Performance and market-based vesting condition options

There were no performance-based or market-based vesting condition options granted during the three months ended February 29, 2016 and February 28, 2015. As of February 29, 2016 and February 28, 2015, there were no performance or market-based vesting condition options outstanding.

Restricted common shares

During the first quarter 2014, the Company entered into Amended and Restated Employment Agreements (“Employment Agreements”) with each of the Company’s Co-CEOs. Per the Employment Agreements, each of the Co-CEOs is to receive base grant equity awards in the form of restricted shares of the Company’s common stock. As of December 1, 2013, David Portnoy and Mark Portnoy were granted 70,270 and 59,459 shares of the Company’s common stock, respectively. The shares shall be issued under the Company’s 2012 Stock Plan and will vest 1/3 upon grant, 1/3 on December 1, 2014 and the remaining 1/3 on December 1, 2015. The fair value of the shares vested as of February 28, 2015 was $160,000 and is reflected as selling, general and administration expenses in the accompanying consolidated statements of comprehensive (loss) income. As of February 29, 2016, there was approximately $0 of total unrecognized compensation cost related to the non-vested shares of restricted common stock.

and Mark Portnoy 31,087 and 27,033 shares of restricted common shares, respectively. The fair value of these shares as of February 28, 2015 was $134,000 and is reflected as selling, general and administrative expense in the accompanying consolidated statements of comprehensive (loss) income. As of February 29, 2016, certain market and performance thresholds were met during fiscal year 2015 and the Board agreed to grant David Portnoy and Mark Portnoy 118,062 and 102,663 shares of restricted common shares, respectively. The fair value of the shares with a grant date during the 2015 fiscal year was approximately $336,000 and is reflected as selling, general and administrative expense in the accompanying consolidated statements of comprehensive (loss) income for the year ended November 30, 2015. There was approximately $242,000 of total unrecognized compensation cost as of November 30, 2015 which was recognized during the first quarter of fiscal year 2016 and is reflected as selling, general and administrative expense in the accompanying consolidated statements of comprehensive (loss) income as the Board granted certain subjective performance shares with a grant date during the 2016 fiscal year.

Preferred Stock Rights Plan

On November 26, 2014, the Board of Directors of the Company declared a dividend payable December 5, 2014 of one preferred share purchase right (a “Right”) for each share of common stock, par value $0.01 per share, of the Company (a “Common Share”) outstanding as of the close of business on December 5, 2014 (the “Record Date”) and authorized the issuance of one Right for each additional Common Share that becomes outstanding between the Record Date and the earliest of the close of business on the Distribution Date (hereinafter defined), the Redemption Date (hereinafter defined), and the close of business on the Final Expiration Date (hereinafter defined), and for certain additional Common Shares that become outstanding after the Distribution Date, such as upon the exercise of stock options or conversion or exchange of securities or notes.

The Rights will be issued pursuant to a Rights Agreement dated as of December 5, 2014 (the “Rights Agreement”), between the Company and Continental Stock and Transfer Trust, as Rights Agent (the “Rights Agent”). The Rights will not and are not intended to prevent an acquisition of the Company that the Board of Directors of the Company considers favorable to and in the best interests of all shareholders of the Company. Rather, because the exercise of the Rights may cause substantial dilution to an Acquiring Person (hereinafter defined) unless the Rights are redeemed by the Board of Directors before an acquisition transaction, the Rights Agreement ensures that the Board of Directors has the ability to negotiate with an Acquiring Person on behalf of unaffiliated shareholders. A description of the material terms and general effect of the Rights Agreement is set forth below.

Each Right represents the right to purchase from the Company one one-thousandth (1/1,000) of a share of Series A Junior Participating Preferred Stock (the “Preferred Shares”), subject to adjustment as provided in the Rights Agreement. This fraction of a Preferred Share is substantially similar to a Common Share, in that the Rights Agreement provides for each Preferred Share to have the voting, liquidation and dividend rights that are equivalent to 1,000 times the rights of a Common Share.

Initially, the Rights are not exercisable, are transferable only in connection with the transfer of Common Shares, and, generally, are evidenced only by the certificates for Common Shares. The holders of Rights will, solely by reason of their ownership of Rights, have no rights as shareholders of the Company, including, without limitation, the right to vote or to receive dividends. The Rights will become exercisable and trade separately from the Common Shares upon the Distribution Date (the “Distribution Date”), which takes place upon the earlier of:

(i)

The tenth day after the earlier of either the public announcement or public disclosure of facts indicating that a person has become an Acquiring Person; or

(ii)

The tenth business day (or such later date as may be determined by the Board of Directors of the Company prior to any person becoming an Acquiring Person) after the date of the commencement or announcement of the intention to commence a tender or exchange offer, the consummation of which would result in any person becoming an Acquiring Person.

For the purposes of the Rights Agreement, an Acquiring Person is any person who, together with all affiliates and associates, becomes the Beneficial Owner (as defined in the Rights Agreement) of 20% or more of the outstanding Common Shares, other than: the Company; any subsidiary of the Company; any employee benefit plan of the Company or of any subsidiary of the Company, or any entity holding Common Shares pursuant to any such plan; any person who becomes the Beneficial Owner of 20% or more of outstanding Common Shares solely as a result of an acquisition of Common Shares by the Company, until such person thereafter becomes the Beneficial Owner (other than through a dividend or stock split) of an additional 0.25% or more of the outstanding Common Shares; any person who, the Board determines in good faith, inadvertently crossed the ownership threshold and then promptly sells down below the threshold (unless such divestiture requirement is waived by the Board); any person, along with its affiliates and associates, that, as of the time of the adoption of the Rights Agreement, is the Beneficial Owner of 20% or more of the Common Shares, until such person increases their ownership to 22.5% or above; and any person who or which is the Beneficial Owner of the common shares of an existing shareholder who is the Beneficial Owner of 20% or more of the Common Shares, until such person increases their percentage ownership by 0.25% or more.

In the event that a person becomes an Acquiring Person, the Board of Directors of the Company may elect to exchange any then-unexercised Rights (other than those of an Acquiring Person, which Rights become void), in whole or in part, for Common Shares at an exchange ratio of one Common Share per Right (subject to adjustment as provided in the Rights Agreement). In lieu of fractional Common Shares, the Company will pay to the Rights holders an amount of cash equal to the same fraction of the current per share market value of a whole Common Share, based upon the closing market price of the last trading day prior to exchange. If the Board of Directors determines, before the Distribution Date, to effect an exchange, the Board may delay the occurrence of the Distribution Date, provided that the Distribution Date must occur no later than 20 days after the earlier of the public announcement or public disclosure of facts indicating that an Acquiring Person has become such. However, notwithstanding the foregoing, the Board of Directors may not effect such an exchange at any time after an Acquiring Person, together with all affiliates and associates, becomes the Beneficial Owner of a majority of the outstanding Common Shares.

The Board of Directors may, at its option, at any time prior to a person becoming an Acquiring Person, redeem the Rights in whole, but not in part, at a price of $0.01 per Right (the “Redemption Price”) (the date of such action by the Board of Directors being the “Redemption Date”). Immediately upon the action of the Board of Directors electing to redeem the Rights, without any further action and without any notice, the right to exercise the Rights will terminate and each Right will thereafter represent only the right to receive the Redemption Price.

Assuming that the Board of Directors has not elected to exchange or redeem the Rights, in the event that, after any person becomes an Acquiring Person, (i) the Company merges into another entity, (ii) another entity merges into the Company and all of the outstanding Common Shares do not remain outstanding after such merger, or (iii) the Company sells 50% or more of its assets, each holder of a Right will, upon exercise, become entitled to receive the number of common shares of the acquiring entity having a value equal to (x) multiplying the Purchase Price of a Right by the number of Rights exercisable by the holder, and dividing that product by (y) 50% of the current per share market price of the common shares of the acquiring entity. The acquiring entity is required to assume the obligations of the Company under the Rights Agreement and to reserve sufficient shares of its common stock to satisfy its obligations

under the Rights Agreement. Pursuant to the Rights Agreement, the Company will not enter into any consolidation, merger or sale, unless it enters into a supplemental agreement with the acquiring entity for the benefit of the Rights holders.

Any of the terms of the Rights may be amended or terminated by the Board of Directors at any time, without the consent of the holders of the Rights, except that after such time as any person becomes an Acquiring Person, no such amendment may adversely affect the interests of the holders of the Rights (other than the Acquiring Person).

The Rights will expire on December 5, 2017, unless earlier redeemed, exchanged, terminated, or unless the expiration date is extended.

Note 11 – License Agreements

The Company enters into two types of licensing agreements and in both types, the Company earns revenue on the initial license fees. Under the technology agreements, the Company earns processing and storage royalties from the affiliates that process in their own facility. Under the marketing agreements, the Company earns processing and storage revenues from affiliates that store specimens in the Company’s facility in Oldsmar, Florida.

Technology Agreements

The Company has entered into a definitive License and Royalty Agreement with LifeCell International Private Limited, formerly Asia Cryo-Cell Private Limited, (“LifeCell”) to establish and market its umbilical cord blood and menstrual stem cell programs in India.

The Company changed the methodology used to record the processing and storage royalty income during fiscal year 2015 from recognizing royalty income based on historical estimates of specimens processed and stored to utilizing actual specimens processed and stored. The Company accounted for this change as a change in accounting estimate.

Per the License and Royalty Agreement with Lifecell, there is a $1 Million cap on the amount of royalties due to the Company per year and a $10 Million cap on the amount of royalties due to the Company for the term of the License and Royalty Agreement. The cap(s) are calculated based on Lifecell’s fiscal year end, March 31^st. As of the end of the Company’s fiscal year ended November 30, 2015, Lifecell had reached the $1 Million cap and paid the Company in full for Lifecell’s fiscal year ended March 31, 2016. The Company expects to begin to record licensee income during the second quarter of fiscal 2016. As of February 29, 2016, Lifecell has paid the Company $4.1 Million for royalties due under the terms of the License and Royalty Agreement.

Marketing Agreements

termination, payment was received for outstanding processing and storage fees due from Ecuador. In August 2013, the Company was notified that its affiliate in Ecuador was closed by the National Institute of Organic Donation (INDOT). As a result, the Company recorded an allowance for uncollectible receivables for the $150,000 processing and storage fee receivable due from Ecuador in the third quarter of fiscal 2013. During the fourth quarter of fiscal 2013, the Company began to bill the Ecuadorian clients directly for cord blood specimens that are stored at the Company’s facility in Oldsmar, Florida.

The following table details the initial license fees for the technology and marketing agreements and processing and storage royalties earned for the technology agreements for the three months ended February 29, 2016 and February 28, 2015. The initial license fees and processing and storage royalties are reflected in licensee income in the accompanying consolidated statements of comprehensive loss.


	For the three months ended
	February 29, 2016						February 28, 2015
	License Fee		Process and Storage Royalties		Total		License Fee		Process and Storage Royalties		Total
India	$	—	$	—	$	—	$	—	$	169,412	$	169,412

Total	$	—	$	—	$	—	$	—	$	169,412	$	169,412

Note 12– Legal Proceedings

On December 3, 2015, a complaint styled Gary T. Brotherson, M.D., et al. v. Cryo-Cell International, Inc., Case No. 15-007461-CI, Circuit Court, Sixth Judicial Circuit, Pinellas County, Florida, was served on the Company, naming it as defendant and alleging, among other things, that the Company breached certain agreements with plaintiffs and seeking damages in excess of $15,000, the jurisdictional amount of the court in which the action is pending. On January 12, 2016, the Company served its answer, affirmative defenses, and counterclaim against the plaintiffs. The Company believes the plaintiffs’ claims are without merit and it intends to contest the action vigorously. At this time, it is not possible for the Company to estimate the loss or the range of possible loss in the event of an unfavorable outcome, as the ultimate resolution of the complaint is uncertain at this time. No amounts have been accrued as of February 29, 2016.

On January 20, 2016, a class action complaint was filed in the Court of the Chancery of the State of Delaware against the Company and certain current officers and directors of the Company (Case No. 11915-VCG). The complaint alleges breaches of fiduciary duties and is seeking appropriate injunctive relief and a declaratory judgment against defendants that a certain provision of the Company’s Amended and Restated Bylaws, as amended through September 22, 2014 is in violation of Section 141(k) of the Delaware General Corporation Law. The Company believes the litigation is without merit and intends to defend the litigation vigorously. The Company’s maximum deductible under its Directors and Officers insurance policy for this claim is $500,000.

action is pending. The Company believes the plaintiffs’ claims are without merit and it intends to contest the action vigorously. At this time, it is not possible for the Company to estimate the loss or the range of possible loss in the event of an unfavorable outcome, as the ultimate resolution of the complaint is uncertain at this time. No amounts have been accrued as of February 29, 2016.

In addition, from time to time the Company is subject to proceedings, lawsuits, contract disputes and other claims in the normal course of its business. The Company believes that the ultimate resolution of current matters should not have a material adverse effect on the Company’s business, consolidated financial position or results of operations. It is possible, however, that there could be an unfavorable ultimate outcome for or resolution which could be material to the Company’s results of operations for a particular quarterly reporting period. Litigation is inherently uncertain and there can be no assurance that the Company will prevail. The Company does not include an estimate of legal fees and other related defense costs in its estimate of loss contingencies.

Note 13– Share Repurchase Plan

In December 2011, the Company’s Board of Directors authorized management at its discretion to repurchase up to one million (1,000,000) shares of the Company’s outstanding common stock. On June 6, 2012, the Board of Directors of the Company increased the number of shares of the Company’s outstanding common stock that management is authorized to repurchase to up to three million (3,000,000) shares. On April 8, 2015, the Board of Directors of the Company increased the number of shares of the Company’s outstanding common stock that management is authorized to repurchase to up to six million (6,000,000) shares. The repurchases must be effectuated through open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission or in such other manner as will comply with the provisions of the Securities Exchange Act of 1934.

On June 30, 2015, the Company commenced a partial tender offer to purchase up to 750,000 shares of its common stock, at a price of $3.25 per share. The maximum number of shares proposed to be purchased in the tender offer represented 7.76% of Cryo-Cell’s outstanding common shares (including shares of unvested restricted stock) as of June 30, 2015. On June 29, 2015, the last trading day prior to the commencement of the tender offer, the last sale price of Cryo-Cell’s shares reported on the OTCBB was $2.29 per share. The tender offer expired on July 28, 2015. Cryo-Cell accepted for purchase 557,805 shares of its common stock, including all “odd lots” properly tendered, at a purchase price of $3.25 per share, for an aggregate cost of $1,812,866 excluding fees and expenses relating to the tender offer.

As of February 29, 2016, the Company had repurchased an aggregate of 3,383,365 shares of the Company’s common stock at an average price of $2.58 per share through open market and privately negotiated transactions. The Company purchased 133,575 and 16,421 shares of the Company’s common stock during the first quarters of fiscal 2016 and 2015, respectively, at an average price of $3.06 per share and $2.38 per share, respectively.

The repurchased shares will be held as treasury stock at cost and have been removed from common shares outstanding as of February 29, 2016 and November 30, 2015. As of February 29, 2016 and November 30, 2015, 3,383,365 and 2,231,532 shares, respectively, were held as treasury stock.

Subsequent to the balance sheet date, the Company repurchased an additional 10,218 shares of the Company’s common stock at an average price of $3.41 per share through open market and privately negotiated transactions.

Note 14– Subsequent Event

On March 22, 2016, subsequent to the balance sheet date, the Company received a Commitment Letter from a Lender for a term loan of up to $8,000,000 in senior credit facilities. The Commitment Letter is subject to execution and delivery to the Lender of financing documents required by the Lender. If the loan has not been fully executed and closed by May 30, 2016, the commitment will expire and there will be no obligation for the Lender to fund the loan.

On April 4, 2016, subsequent to the balance sheet date, the Company received a Commitment Letter from an additional lender for a subordinated loan of up to $1,000,000. The funding of the loan will be subject to certain terms and conditions outlined in the term sheet. The Commitment Letter for the subordinated loan expires on April 30, 2016.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward Looking Statements

This Form 10-Q, press releases and certain information provided periodically in writing or orally by the Company’s officers or its agents may contain statements which constitute “forward-looking statements”. The terms “Cryo-Cell International, Inc.,” “Cryo-Cell,” “Company,” “we,” “our” and “us” refer to Cryo-Cell International, Inc. The words “expect,” “anticipate,” “believe,” “goal,” “strategy,” “plan,” “intend,” “estimate” and similar expressions and variations thereof, if used, are intended to specifically identify forward-looking statements. Those statements appear in a number of places in this Form 10-Q and in other places, and include statements regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things:

(i)

our future performance and operating results;

(ii)

our future operating plans;

(iii)

our liquidity and capital resources; and

(iv)

our financial condition, accounting policies and management judgments.

Investors and prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. The factors that might cause such differences include:

(i)

any adverse effect or limitations caused by recent increases in government regulation of stem cell storage facilities;

(ii)

any increased competition in our business including increasing competition from public cord blood banks particularly in overseas markets but also in the U.S.;

(iii)

any decrease or slowdown in the number of people seeking to store umbilical cord blood stem cells or decrease in the number of people paying annual storage fees;

(iv)

any new services relating to other types of stem cells that have not yet been offered commercially, and there is no assurance that other stem cell services will be launched or will gain market acceptance;

(v)

any adverse impacts on revenue or operating margins due to the costs associated with increased growth in our business, including the possibility of unanticipated costs relating to the operation of our facility and costs relating to the commercial launch of new types of stem cells;

(vi)

any unique risks posed by our international activities, including but not limited to local business laws or practices that diminish our affiliates’ ability to effectively compete in their local markets;

(vii)

any technological or medical breakthroughs that would render our business of stem cell preservation obsolete;

(viii)

any material failure or malfunction in our storage facilities; or any natural disaster or act of terrorism that adversely affects stored specimens;

(ix)

any adverse results to our prospects, financial condition or reputation arising from any material failure or compromise of our information systems;

(x)

the costs associated with defending or prosecuting litigation matters, particularly including litigation related to intellectual property, and any material adverse result from such matters;

(xi)

the success of our licensing agreements and their ability to provide us with royalty fees;

(xii)

any difficulties and increased expense in enforcing our international licensing agreements;

(xiii)

any adverse performance by or relations with any of our licensees;

(xiv)

any inability to enter into new licensing arrangements including arrangements with non-refundable upfront fees;

(xv)

any inability to realize cost savings as a result of recent acquisitions;

(xvi)

any inability to realize a return on an investment;

(xvii)

any increased U.S. income tax expense as a result of inability to utilize or exhaustion of net operating losses;

(xviii)

any adverse impact on our revenues and operating margins as a result of discounting of our services in order to generate new business in tough economic times where consumers are selective with discretionary spending;

(xix)

the success of our global expansion initiatives;

(xx)

our actual future ownership stake in future therapies emerging from our collaborative research partnerships;

(xxi)

our ability to minimize our future costs related to R&D initiatives and collaborations and the success of such initiatives and collaborations;

(xxii)

any inability to successfully identify and consummate strategic acquisitions;

(xxiii)

any inability to realize benefits from any strategic acquisitions;

(xxiv)

the Company’s ability to realize a profit on the acquisition of Prepacyte-CB;

(xxv)

the costs associated with proxy contests and its impact on our business and

(xxvi)

other factors many of which are beyond our control.

We undertake no obligation to publicly update or revise the forward-looking statements made in this Form 10-Q to reflect events or circumstances after the date of this Form 10-Q or to reflect the occurrence of unanticipated events.

Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date hereof. Cryo-Cell International, Inc. undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof. Readers should carefully review the risk factors described in other documents the Company files from time to time with the Securities and Exchange Commission, including the Annual Report on Form 10-K filed by the Company and any Current Reports on Form 8-K filed by the Company.

Overview

The Company’s principal sources of revenues are service fees for cord blood processing and preservation for new customers and recurring annual storage fees. Effective July 2015, the Company offers two pricing models, a standard plan and premium plan. The Company charges fees of $1,400 for the standard plan and $1,950 for the premium plan to new clients for the collection kit, processing, testing and return medical courier service, with discounts in the case of multiple children from the same family and in other circumstances. The Company charges an annual storage fee of $150 for new clients that enroll in the standard and premium plans; storage fees for existing customers depend on the contracts with such customers. The Company continues to offer a one-time payment plan for 21 years of storage and a life-time payment plan, pursuant to which the client is charged $3,799 for the standard plan and $4,249 for the premium plan and $6,000 for the standard plan and $7,000 for the premium plan, respectively, less discounts in the case of multiple children from the same family and in other circumstances. The one-time plan includes the collection kit, processing and testing, return medical courier service and 21 years of pre-paid storage fees. The life-time plan includes the collection kit, processing and testing, return medical courier service and pre-paid storage fees for the life of the client. The Company also receives other income from licensing fees and royalties from global affiliates.

On June 11, 2015, the Company entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with CytoMedical Design Group LLC (“CytoMedical”), for the purchase of certain assets and assumption of certain liabilities and contracts that CytoMedical used in the operation of its cord blood business. The Prepacyte-CB Processing System is used in cell processing laboratories to process and store stem cells from umbilical cord blood. The purchase price was $2,400,000, plus the value of inventory, comprised of $1,553,272 in cash and assumed liabilities less any prepayment made by the Company to CytoMedical ($966,597 at closing and $586,675 on or before September 30, 2015) and a note payable to the seller in the amount of $1,300,000. The closing was effective on June 30, 2015.

During the three months ended February 29, 2016, the Company’s revenues increased 6% as compared to the same period in 2015. The Company reported a net loss of approximately $123,00, or ($0.01) per basic common share for the three months ended February 29, 2016 compared to net income of approximately $286,000 or $0.03 per basic common share for the same period in 2015. The net loss for the three months ended February 29, 2016 principally resulted from a 23% increase in selling, general and administrative expenses and a 6% increase in cost of sales. This was partially offset by a 6% increase in revenues.

At February 29, 2016, the Company had cash and cash equivalents of $3,581,736. The Company’s cash decreased by approximately $570,000 during the first three months of fiscal 2016, primarily as a result of approximately $188,000 of cash used to purchase property and equipment and marketable securities and approximately $408,000 used for stock repurchase offset by approximately $101,000 of cash provided by operations.

Consistent with its fiduciary duties, the board of directors and management has reviewed and will continue to review strategic options and opportunities for the Company, in order to maximize shareholder value. These options may include, but are not limited to, strategic mergers or acquisitions, investments in other public and/or private companies, repurchases of RSA interests, a deregistration of the Company’s common stock under the Securities Exchange Act of 1934 or a going-private transaction. In order to undertake any of the aforementioned activities, the Company may take on substantial debt or equity capital which could increase the risk of investment in the Company.

Results of Operations

Revenues. Revenues for the three months ended February 29, 2016 were $5,152,198 as compared to $4,843,381 for the same period in 2015, a 6% increase. The increase in revenue was primarily attributable to a 7% increase in processing and storage fees.

Processing and Storage Fees. The increase in processing and storage fee revenue is attributable to a 3% increase in domestic recurring annual storage fee revenue and an 8% increase in the number of new cord blood specimens processed in the first quarter of fiscal 2016 versus the same period in 2015.

Product Revenue. On June 11, 2015, the Company entered into an Asset Purchase Agreement as described in Note 2 of the Company’s financial statements. For the three months ended February 29, 2016, revenue from the product sales was $131,739 compared to $0 for the three months ended February 28, 2015.

Licensee Income. Licensee income for the three months ended February 29, 2016, was $0 as compared to $169,412 for the 2015 period. Licensee income for the three months ended February 28, 2015 consists of royalty income earned on the processing and storage of specimens in India where the Company has a definitive License and Royalty Agreement.

The Company changed the methodology used to record the processing and storage royalty income during the fourth quarter of fiscal year 2015 from recognizing royalty income based on historical estimates of specimens processed and stored to utilizing actual specimens processed and stored. The Company accounted for this change as a change in accounting estimate.

Per the License and Royalty Agreement with Lifecell, there is a $1,000,000 cap on the amount of royalties due to the Company per year and a $10,000,000 cap on the amount of royalties due to the Company for the term of the License and Royalty Agreement. The cap(s) are calculated based on Lifecell’s fiscal year end, March 31^st. As of the end of the Company’s fiscal year ended November 30,

2015, Lifecell had reached the $1 Million cap and paid the Company in full for Lifecell’s fiscal year ended March 31, 2016. The Company expects to begin to record licensee income during the second quarter of fiscal 2016. As of February 29, 2016, Lifecell has paid the Company $4,100,000 for royalties due under the terms of the License and Royalty Agreement.

Cost of Sales. Cost of sales for the three months ended February 29, 2016 was $1,348,291 as compared to $1,273,987 for the same period in 2015, representing a 6% increase. Cost of sales includes wages and supplies associated with process enhancements to the existing production procedures and quality systems in the processing of cord blood specimens at the Company’s facility in Oldsmar, Florida and depreciation expense of approximately $33,000 and $41,000 for the three months ended February 29, 2016 and February 28, 2015, respectively. Also, included in Cost of Sales is $103,268 and $0 related to the costs associated with production of the Prepacyte^®-CB processing and storage system for the three months ended February 29, 2016 and February 28, 2015, respectively.

Selling, General and Administrative Expenses. Selling, general and administrative expenses for the three months ended February 29, 2016 were $3,597,253 as compared to $2,913,973 for the 2015 period representing a 23% increase. These expenses are primarily comprised of expenses for consumer advertising, salaries and wages for personnel and professional fees. The increase in selling, general and administrative expenses is primarily due to approximately $385,000 or 34% increase in selling and marketing expenses of which $250,000 is related to the implementation of a new consumer marketing campaign and an increase of approximately $235,000 in professional fees.

Research, Development and Related Engineering Expenses. Research, development and related engineering expenses for the three months ended February 29, 2016 were $8,684 as compared to $11,988 for the three months ended February 28, 2015. The expenses for each period primarily relate to the Company’s cord tissue service.

Depreciation and Amortization. Depreciation and Amortization (not included in Cost of Sales) for the three months ended February 29, 2016 was $41,548 compared to $18,242 for the 2015 period.

Interest Expense. Interest expense for the three months ended February 29, 2016 were $261,334 compared to $301,286 for the three months ended February 28, 2015. Interest expense for the three months ended February 29, 2016 consists of $14,391 related to the repayment of the note payable as a result of the Asset Purchase Agreement (Note 2 and Note 6). The remaining interest expense is mainly comprised of amounts due to the parties to the Company’s revenue sharing agreements (“RSAs”) based on the Company’s storage revenue collected. Interest expense for the three months ended February 28, 2015 is mainly comprised of amounts due to the parties to the Company’s RSAs based on the Company’s storage revenue. The Company changed the methodology used to calculate the RSA payments owed to the RSA holders during the fourth quarter of fiscal year 2015 from calculating on the amount billed to customers to the amount collected from customers as noted per the RSA contracts. The Company accounted for this change as a change in accounting estimate.

Equity in Losses of Affiliate. Equity in losses of affiliate was $0 for the three months ended February 29, 2016, compared to $8,248 for the 2015 period. Equity in losses of affiliate for the three months ended February 29, 2016 and February 28, 2015 is related to compensation expense for stock option awards that were granted by Saneron to certain consultants and employees.

Income Taxes. Deferred tax assets and liabilities are measured using enacted tax rates expected to be recovered or settled. The ultimate realization of our deferred tax assets depends upon generating sufficient future taxable income prior to the expiration of the tax attributes. In assessing the need for a valuation allowance, we must project future levels of taxable income. This assessment requires significant judgment. We examine the evidence related to the recent history of tax losses, the economic conditions in which we operate and our forecasts and projections to make that determination.

The Company records foreign income taxes withheld from installment payments of non-refundable up-front license fees and royalty income earned on the processing and storage of cord blood stem cell specimens in geographic areas where the Company has license agreements. The Company recorded approximately $0 and $25,000 for the three months ended February 29, 2016 and February 28, 2015, respectively, of foreign income tax expense, which is included in income tax expense in the accompanying consolidated statements of comprehensive loss.

Liquidity and Capital Resources

Through February 29, 2016, the Company’s principal source of cash has been from sales of its umbilical cord blood program to customers and royalties from licensees. The Company does not expect a change in its principal source of cash flow.

At February 29, 2016, the Company had cash and cash equivalents of $3,581,736 as compared to $4,152,162 at November 30, 2015. The decrease in cash and cash equivalents during the three months ended February 29, 2016 was primarily attributable to the following:

Net cash provided by operating activities for the three months ended February 29, 2016 was $101,417, which was primarily attributable to the Company’s operating results.

Net cash provided by operating activities for the three months ended February 28, 2015 was $328,964, which was primarily attributable to the Company’s operating results.

Net cash used in investing activities for the three months ended February 29, 2016 was $188,017, which was primarily attributable to the purchases of property and equipment in the amount of $30,723 and sales and purchases of marketable securities and other investments in the amount of $157,238.

Net cash used in investing activities for the three months ended February 28, 2015 was $18,946, which was primarily attributable to the purchases of property and equipment.

Net cash used by financing activities for the three months ended February 29, 2016 was $483,826 which was primarily attributable to the stock repurchase plan pursuant to which the Company has repurchased 133,575 shares of the Company’s common stock for approximately $408,000.

Net cash used by financing activities for the three months ended February 28, 2015 was $39,042 which was attributable to the stock repurchase plan pursuant to which the Company has repurchased 16,421 shares of the Company’s common stock.

The Company does not have a line of credit.

The Company anticipates making discretionary capital expenditures of approximately $500,000 over the next twelve months for software enhancements and purchases of property and equipment. The Company anticipates funding future property and equipment purchases with cash-on-hand and cash flows from future operations.

The Company anticipates that its cash and cash equivalents, marketable securities and cash flows from future operations will be sufficient to fund its known cash needs for at least the next 12 months. Cash flows from operations will depend primarily upon increasing revenues from sales of its umbilical cord blood and cord tissue cellular storage services and managing discretionary expenses. If expected increases in revenues are not realized, or if expenses are higher than anticipated, the Company may be required to reduce or defer cash expenditures or otherwise manage its cash resources during the next 12 months so that they are sufficient to meet the Company’s cash needs for that period. In addition, the Company may consider seeking equity or debt financing if deemed appropriate for its plan of operations, and if such financing can be obtained on acceptable terms. There is no assurance that any reductions in expenditures, if necessary, will not have an adverse effect on the Company’s business operations, including sales activities and the development of new services and technology.

Critical Accounting Policies

This discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make judgments, estimates, and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and disclosures of contingent assets and liabilities. For a full discussion of our accounting policies please refer to Note 1 to the Consolidated Financial Statements included in our 2015 Annual Report on Form 10-K filed with the SEC. Our most critical accounting policies and estimates include: recognition of revenue and the related allowance for doubtful accounts, stock-based compensation, income taxes and license and revenue sharing agreements. We continually evaluate our judgments, estimates and assumptions. We base our estimates on the terms of underlying agreements, historical experience and other factors that we believe are reasonable based on the circumstances, the results of which form our management’s basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. There have been no material changes to our critical accounting policies and estimates from the information provided in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our 2015 Annual Report on Form 10-K.

Recently Issued Accounting Pronouncements

See Note 1 to the Consolidated Financial Statements.

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements that have or are reasonable likely to have a current or future effect on its financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Based on their most recent review, as of the end of the period covered by this report, the Company’s principal executive officer and principal financial officer have concluded that the Company’s disclosure controls and procedures were not effective, and that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure and are ineffective to ensure that such information is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

As previously disclosed in the Company’s 10-K filed February 29, 2016, the Company’s principal executive officers and principal financial officer concluded that the Company’s disclosure controls and procedures and internal controls over financial reporting were not effective, due to a material weakness surrounding the Company’s identification and application of the appropriate accounting treatment for non-routine transactions and related documentation thereof. The Company’s controls over non-routine transactions were not conducive to identify certain items with sufficient precision. Management has undertaken steps to design and implement more effective internal controls, including the implementation of a review process of non-routine transactions and has engaged qualified consultants to assist the Company with the application of the appropriate accounting treatment of non-routine transactions when necessary. During the quarter ended November 30, 2015, the Company’s principal executive officers and principal financial officer concluded that the Company’s disclosure controls and procedures and internal controls over financial reporting were not effective, due to a material weakness surrounding manual controls related to storage revenue for customers that are on a payment plan. The Company’s control over the manual process was not conducive to identify the timeliness of recording the revenue. Management has undertaken steps to design and implement more effective internal controls, including the implementation of a more comprehensive review process of manual invoicing procedures. Management will address in the Company’s second quarter Form 10-Q.

The Company has not made an amended 8-K filing with respect to the Current Reports on Form 8-K that was filed on July 16, 2015 to announce the acquisition of Prepacyte. Accordingly, the Company is not deemed a timely filer. Management intends to subsequently make this amended 8-K filing to include the required pre-acquisition financial statements of Prepacyte as well as the required pro forma financial information.

Changes in Internal Control Over Financial Reporting

The changes in the Company’s internal control over financial reporting described in the previous paragraph were implemented during the quarter ended November 30, 2015 and continued to be remediated during the quarter ended February 29, 2016.

There were no other changes in the Company’s internal controls over financial reporting during the three months ended February 29, 2016 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Limitations on the Effectiveness of Controls

Our management, including our co-CEOs and CFO, does not expect that our disclosure controls and internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations

include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management or board override of the control.

The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

CEO and CFO Certifications

Appearing as exhibits 31.1, 31.2 and 31.3 to this report there are Certifications of the Co-CEOs and the CFO. The Certifications are required in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (the Section 302 Certifications). This Item of this report is the information concerning the evaluation referred to in the Section 302 Certifications and this information should be read in conjunction with the Section 302 Certifications for a more complete understanding of the topics presented.

PART II - OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

On February24, 2016, a complaint styled Charles D. Nyberg and Mary J. Nyberg and as trustees of the CDMJNyberg Family Trust v. Cryo-Cell International, Inc., Case No. 8:16CV408t30, United States District Court, Middle District of Florida, Hillsborough County, Florida, was served on the Company, naming it as defendant and alleging, among other things, that the Company breached certain agreements with plaintiffs and seeking damages in excess of $75,000, the jurisdictional amount of the court in which the action is pending. The Company believes the plaintiffs’ claims are without merit and it intends to contest the action vigorously. At this time, it is not possible for the Company to estimate the loss or the range of possible loss in the event of an unfavorable outcome, as the ultimate resolution of the complaint is uncertain at this time. No amounts have been accrued as of February 29, 2016.

ITEM 1A.

RISK FACTORS

Not applicable.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

ISSUER PURCHASE OF EQUITY SECURITIES


Period	Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs
December 1 – 31, 2015	41,313	$	3.27	41,313	2,709,366
January 1 – 31, 2016	21,701	$	3.10	21,701	2,687,665
February 1 – 29, 2016	70,561	$	2.92	70,561	2,617,104

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.

MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5.

OTHER INFORMATION

None.

ITEM 6.

EXHIBITS

(a)

Exhibits



31.1		Certification of Co-CEO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

31.2		Certification of Co-CEO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

31.3		Certification of CFO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

32		Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Cryo-Cell International, Inc.

/s/ DAVID PORTNOY

David Portnoy

Co-Chief Executive Officer

Cryo-Cell International, Inc.

/s/ MARK PORTNOY

Mark Portnoy

Co-Chief Executive Officer

Cryo-Cell International, Inc.

/s/ JILL M. TAYMANS

Jill M. Taymans

Vice President, Finance, Chief Financial Officer

Date: April 14, 2016

EX-31.1 2 d161362dex311.htm CERTIFICATION OF CO-CEO Certification of Co-CEO

EXHIBIT 31.1

CERTIFICATION OF CO-CHIEF EXECUTIVE OFFICER

I, David Portnoy, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Cryo-Cell International, Inc. (the “Registrant”);

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The Registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) for the Registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)	Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)	disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting;

5.	The Registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.


Dated: April 14, 2016						/s/ David Portnoy
						David Portnoy

EX-31.2 3 d161362dex312.htm CERTIFICATION OF CO-CEO Certification of Co-CEO

EXHIBIT 31.2

CERTIFICATION OF CO-CHIEF EXECUTIVE OFFICER

I, Mark Portnoy, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Cryo-Cell International, Inc. (the “Registrant”);

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)	Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)	disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting;

5.	The Registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.


Dated: April 14, 2016						/s/ Mark Portnoy
						Mark Portnoy

EX-31.3 4 d161362dex313.htm CERTIFICATION OF CFO Certification of CFO

EXHIBIT 31.3

CERTIFICATION OF CHIEF FINANCIAL OFFICER

I, Jill M. Taymans, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Cryo-Cell International, Inc. (the “Registrant”);

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)	Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)	disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting;

5.	The Registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.


Dated: April 14, 2016						/s/ Jill M. Taymans
						Jill M. Taymans

EX-32 5 d161362dex32.htm CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 Certification Pursuant to 18 U.S.C. Section 1350

Exhibit 32

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Cryo-Cell International, Inc. (the “Company”) on Form 10-Q for the quarter ended February 29, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David Portnoy, Co-Chief Executive Officer of the Company, I, Mark Portnoy, Co-Chief Executive Officer of the Company and I, Jill M. Taymans, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ David Portnoy

David Portnoy

Co-Chief Executive Officer

April 14, 2016

/s/ Mark Portnoy

Mark Portnoy

Co-Chief Executive Officer

April 14, 2016

/s/ Jill M. Taymans

Jill M. Taymans

Vice President, Finance (Chief Financial Officer)

April 14, 2016

EX-101.INS 6 ccel-20160229.xml XBRL INSTANCE DOCUMENT

1000000

0.01

6000000

0.05

1300000

225000

662500 149175

1000000

9087254

8000000

3000000

3550243

104000

959552

968930

20000000

2.17

2.16

9378

1.90

9097472

2.17

968930

0.01

959552

500000

12481065

0.01

3383365

7718

28780474

790957

-5336924

2300000

14260452

6614192

1685775

2156577

1566676

-25591927

24437082

19100158

11169495

124810

1100944

10176630

2630000

76205

309987

14228

1525260

8310124

19100158

503877

498524

3216990

847626

8726486

9942408

58341

617108

280345

204400

503877

1777822

144013

429309

3581736

5987814

1531543

1336000

3 40611 17000 2.16 67656 3

31333

470000

8541

34570

1819

41000

37500 37500 150000

355941

617108

261167

186487

162163

16349269

2750889

0.33

150000 300000

1300000

1073898

35353

529097

470000

41000

22000

1075450

1777822

1553272 104000 1000000

480500

2.56

480500

465930

1.72

465930

13122

3.08

22500

0.20

1500000

242000

15000

1000000

253679

568930

15000

20000

0.01

355941

617108

261167

3279267

968930

20000000

2.17

15003

1.90

9010322

0.01

500000

12260340

0.01

2231532

7718

28530368

868947

-4964171

2300000

14038165

6782562

1328619

2067130

2005351

-25468991

24462117

19497946

10869218

122603

1176367

10423952

2630000

169932

307420

9041

8265748

19497946

516328

475608

3058379

879070

8318083

10353128

88392

610424

282152

204344

516328

1777822

134727

427819

4152162

5930987

1095525

1336000

40611 17000 57406

17917

470000

8075

34570

3250

41000

473626

610424

136798

16697621

2800325

0.33

1000000 568930

20000

0.01

473626

610424

136798

2019-06-30 2015-07-31

29938

586675

500000 75000

10218

3.41

134000

31087

27033

336000

118062

102663

70270

59459

15000 75000 10000 3.25 0.0776 2.29 861783 750000

557805

3.25

1812866

50000

2500000

150000

5 37500

P5Y4D

203403

400000

129729

116240

0.03

328964

10058649

234083

9824566

0.03

23303

286170

4843381

-4413

-4400

39042

4673969

625191

169412

-4075

-305361

268511

6500

-46080

286170

311582

-8248

319830

25412

190513

25000

85715

270976

301286

-18946

4218190

-39042

11988

1273987

-564624

191000

2913973

500

342799

58994

18242

140505

169412 -9575

160000

8000

271000

169412

16421

2.38

-0.01

101417

3383365

<div> The following summarizes the allocation of the total purchase price for the Acquisition:   <table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="85%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Inventory </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">529,097</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Tooling molds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">35,353</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> License agreement </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">470,000</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Customer relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">41,000</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total identifiable net assets acquired </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,075,450</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Goodwill </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,777,822</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

2.58

<div> Intangible assets were as follows as of February 29, 2016 and November 30, 2015:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="55%"></td> <td valign="bottom" width="7%"></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center">Useful lives</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">February 29, 2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">November 30, 2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Patents </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap" align="center"> 10-20 years</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">34,570</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">34,570</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Less: Accumulated amortization </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8,541</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8,075</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> License agreement </td> <td valign="bottom">  </td> <td valign="bottom" align="center">10 years</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">470,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">470,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Less: Accumulated amortization </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(31,333</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(17,917</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Customer relationships </td> <td valign="bottom">  </td> <td valign="bottom" align="center">15 years</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">41,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">41,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Less: Accumulated amortization </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,819</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,250</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top" colspan="3"> Net Intangible Assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">503,877</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">516,328</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   </div>

2016 false

P20D

10-Q 0000862692

P4Y9M4D

<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Note 10 – Stockholder’s Equity <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> The Company maintains the 2006 Stock Incentive Plan (the “2006 Plan”) under which it has reserved 1,000,000 shares of the Company’s common stock for issuance pursuant to stock options, restricted stock, stock-appreciation rights (commonly referred to as “SARs”) and stock awards (i.e. performance options to purchase shares and performance units). As of February 29, 2016 and November 30, 2015, there were 568,930 options issued, but not yet exercised, under the 2006 Plan, respectively. As of February 29, 2016, there were 253,679 shares available for future issuance under the 2006 Plan. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> The Company also maintains the 2012 Equity Incentive Plan (the “2012 Plan”) which became effective December 1, 2011 as approved by the Board of Directors and approved by the stockholders at the 2012 Annual Meeting on July 10, 2012. The 2012 Plan originally reserved 1,500,000 shares of the Company’s common stock for issuance pursuant to stock options, restricted stock, SARs, and other stock awards (i.e. performance shares and performance units). In May 2012, the Board of Directors approved an amendment to the 2012 Plan to increase the number of shares of the Company’s common stock reserved for issuance to 2,500,000 shares. As of February 29, 2016, there were 400,000 service-based options issued, 129,729 service-based restricted common shares granted, 278,948 performance-based and 116,240 market-based restricted common shares granted under the 2012 plan. As of November 30, 2015, there were 400,000 service-based options issued, 129,729 service-based restricted common shares granted, 203,403 performance-based and 116,240 market-based restricted common shares granted under the 2012 plan. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> Service-based vesting condition options <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> The fair value of each option award is estimated on the date of the grant using the Black-Scholes valuation model that uses the assumptions noted in the following table. Expected volatility is based on the historical volatility of the Company’s stock over the most recent period commensurate with the expected life of the Company’s stock options. The Company uses historical data to estimate option exercise and employee termination within the valuation model. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The expected term of options granted to employees is calculated, in accordance with the “simplified method” for “plain vanilla” stock options allowed under GAAP. Expected dividends are based on the historical trend of the Company not issuing dividends. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> There were no options granted during the three months ended February 29, 2016 and February 28, 2015, respectively. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> Stock option activity for the three months ended February 29, 2016, was as follows: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Options</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Weighted Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Weighted Average Remaining Contractual Life (Years)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at November 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">968,930</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.17</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.01</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,095,525</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Expired/forfeited </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at February 29, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">968,930</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.17</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.76</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,531,543</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Exercisable at February 29, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">959,552</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.16</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.75</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,525,260</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> The aggregate intrinsic value represents the total value of the difference between the Company’s closing stock price on the last trading day of the period and the exercise price of the options, multiplied by the number of in-the-money stock options that would have been received by the option holders had all option holders exercised their options on either February 29, 2016 or February 28, 2015, as applicable. The intrinsic value of the Company’s stock options changes based on the closing price of the Company’s stock. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> There were no options exercised during the three months ended February 29, 2016 and February 28, 2015. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> Significant option groups exercisable at February 29, 2016 and related price and contractual life information are as follows: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="59%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center">Outstanding</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Exercisable</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> Range of Exercise Prices </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Outstanding</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Weighted Average Remaining Contractual Life (Years)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Weighted Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Outstanding</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Weighted Average Exercise Price</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> $1.01 to $2.00 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">465,930</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.23</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.72</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">465,930</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.72</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> $2.01 to $3.00 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">480,500</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.23</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.56</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">480,500</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.56</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> $3.01 to $4.00 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,500</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.36</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.08</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,122</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.08</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">968,930</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.76</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.17</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">959,552</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.16</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> A summary of the status of the Company’s non-vested options as of February 29, 2016, and changes during the three months ended February 29, 2016, is presented below: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Options</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"> Weighted Average Grant-Date Fair Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Non-vested at November 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,003</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.90</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Vested </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5,625</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.90</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Forfeited </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Non-vested at February 29, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,378</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.90</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> As of February 29, 2016 there was approximately $15,000 of total unrecognized compensation cost related to non-vested service related share-based compensation arrangements granted under the 2000 Plan, 2006 Plan and the 2012 Plan. The cost is expected to be recognized over a weighted-average period of .36 years as of February 29, 2016. The total fair value of shares vested during the three months ended February 29, 2016 was approximately $11,000. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> Performance and market-based vesting condition options <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> There were no performance-based or market-based vesting condition options granted during the three months ended February 29, 2016 and February 28, 2015. As of February 29, 2016 and February 28, 2015, there were no performance or market-based vesting condition options outstanding. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> Restricted common shares <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> During the first quarter 2014, the Company entered into Amended and Restated Employment Agreements (“Employment Agreements”) with each of the Company’s Co-CEOs. Per the Employment Agreements, each of the Co-CEOs is to receive base grant equity awards in the form of restricted shares of the Company’s common stock. As of December 1, 2013, David Portnoy and Mark Portnoy were granted 70,270 and 59,459 shares of the Company’s common stock, respectively. The shares shall be issued under the Company’s 2012 Stock Plan and will vest 1/3 upon grant, 1/3 on December 1, 2014 and the remaining 1/3 on December 1, 2015. The fair value of the shares vested as of February 28, 2015 was $160,000 and is reflected as selling, general and administration expenses in the accompanying consolidated statements of comprehensive (loss) income. As of February 29, 2016, there was approximately $0 of total unrecognized compensation cost related to the non-vested shares of restricted common stock. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> The Employment Agreements also provide for the grant of restricted shares of the Company’s common stock based on certain performance measures being attained by each of the Company’s Co-CEOs. The Employment Agreements state if David Portnoy and Mark Portnoy are employed by the Company on November 30, 2014, then no later than February 15, 2015, the Company will grant up to 186,487 and 162,163 shares of restricted common shares, respectively, based on certain performance thresholds, as defined in the agreements. In addition, if David Portnoy and Mark Portnoy are employed by the Company on November 30, 2015, then no later than February 15, 2016, the Company will grant up to an additional 186,487 and 162,163 shares of restricted common shares, respectively, based on similar performance thresholds, as defined in the agreements. As of February 28, 2015, certain market and performance thresholds were met during fiscal year 2014 and the Board agreed to grant David Portnoy and Mark Portnoy 31,087 and 27,033 shares of restricted common shares, respectively. The fair value of these shares as of February 28, 2015 was $134,000 and is reflected as selling, general and administrative expense in the accompanying consolidated statements of comprehensive (loss) income. As of February 29, 2016, certain market and performance thresholds were met during fiscal year 2015 and the Board agreed to grant David Portnoy and Mark Portnoy 118,062 and 102,663 shares of restricted common shares, respectively. The fair value of the shares with a grant date during the 2015 fiscal year was approximately $336,000 and is reflected as selling, general and administrative expense in the accompanying consolidated statements of comprehensive (loss) income for the year ended November 30, 2015. There was approximately $242,000 of total unrecognized compensation cost as of November 30, 2015 which was recognized during the first quarter of fiscal year 2016 and is reflected as selling, general and administrative expense in the accompanying consolidated statements of comprehensive (loss) income as the Board granted certain subjective performance shares with a grant date during the 2016 fiscal year. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> Preferred Stock Rights Plan <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> On November 26, 2014, the Board of Directors of the Company declared a dividend payable December 5, 2014 of one preferred share purchase right (a “Right”) for each share of common stock, par value $0.01 per share, of the Company (a “Common Share”) outstanding as of the close of business on December 5, 2014 (the “Record Date”) and authorized the issuance of one Right for each additional Common Share that becomes outstanding between the Record Date and the earliest of the close of business on the Distribution Date (hereinafter defined), the Redemption Date (hereinafter defined), and the close of business on the Final Expiration Date (hereinafter defined), and for certain additional Common Shares that become outstanding after the Distribution Date, such as upon the exercise of stock options or conversion or exchange of securities or notes. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> The Rights will be issued pursuant to a Rights Agreement dated as of December 5, 2014 (the “Rights Agreement”), between the Company and Continental Stock and Transfer Trust, as Rights Agent (the “Rights Agent”). The Rights will not and are not intended to prevent an acquisition of the Company that the Board of Directors of the Company considers favorable to and in the best interests of all shareholders of the Company. Rather, because the exercise of the Rights may cause substantial dilution to an Acquiring Person (hereinafter defined) unless the Rights are redeemed by the Board of Directors before an acquisition transaction, the Rights Agreement ensures that the Board of Directors has the ability to negotiate with an Acquiring Person on behalf of unaffiliated shareholders. A description of the material terms and general effect of the Rights Agreement is set forth below. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> Each Right represents the right to purchase from the Company one one-thousandth (1/1,000) of a share of Series A Junior Participating Preferred Stock (the “Preferred Shares”), subject to adjustment as provided in the Rights Agreement. This fraction of a Preferred Share is substantially similar to a Common Share, in that the Rights Agreement provides for each Preferred Share to have the voting, liquidation and dividend rights that are equivalent to 1,000 times the rights of a Common Share. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> Initially, the Rights are not exercisable, are transferable only in connection with the transfer of Common Shares, and, generally, are evidenced only by the certificates for Common Shares. The holders of Rights will, solely by reason of their ownership of Rights, have no rights as shareholders of the Company, including, without limitation, the right to vote or to receive dividends. The Rights will become exercisable and trade separately from the Common Shares upon the Distribution Date (the “Distribution Date”), which takes place upon the earlier of: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%"> </td> <td valign="top" width="4%" align="left">(i)</td> <td valign="top" align="left">The tenth day after the earlier of either the public announcement or public disclosure of facts indicating that a person has become an Acquiring Person; or</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%"> </td> <td valign="top" width="4%" align="left">(ii)</td> <td valign="top" align="left">The tenth business day (or such later date as may be determined by the Board of Directors of the Company prior to any person becoming an Acquiring Person) after the date of the commencement or announcement of the intention to commence a tender or exchange offer, the consummation of which would result in any person becoming an Acquiring Person.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> For the purposes of the Rights Agreement, an Acquiring Person is any person who, together with all affiliates and associates, becomes the Beneficial Owner (as defined in the Rights Agreement) of 20% or more of the outstanding Common Shares, other than: the Company; any subsidiary of the Company; any employee benefit plan of the Company or of any subsidiary of the Company, or any entity holding Common Shares pursuant to any such plan; any person who becomes the Beneficial Owner of 20% or more of outstanding Common Shares solely as a result of an acquisition of Common Shares by the Company, until such person thereafter becomes the Beneficial Owner (other than through a dividend or stock split) of an additional 0.25% or more of the outstanding Common Shares; any person who, the Board determines in good faith, inadvertently crossed the ownership threshold and then promptly sells down below the threshold (unless such divestiture requirement is waived by the Board); any person, along with its affiliates and associates, that, as of the time of the adoption of the Rights Agreement, is the Beneficial Owner of 20% or more of the Common Shares, until such person increases their ownership to 22.5% or above; and any person who or which is the Beneficial Owner of the common shares of an existing shareholder who is the Beneficial Owner of 20% or more of the Common Shares, until such person increases their percentage ownership by 0.25% or more. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> In the event that a person becomes an Acquiring Person, the Board of Directors of the Company may elect to exchange any then-unexercised Rights (other than those of an Acquiring Person, which Rights become void), in whole or in part, for Common Shares at an exchange ratio of one Common Share per Right (subject to adjustment as provided in the Rights Agreement). In lieu of fractional Common Shares, the Company will pay to the Rights holders an amount of cash equal to the same fraction of the current per share market value of a whole Common Share, based upon the closing market price of the last trading day prior to exchange. If the Board of Directors determines, before the Distribution Date, to effect an exchange, the Board may delay the occurrence of the Distribution Date, provided that the Distribution Date must occur no later than 20 days after the earlier of the public announcement or public disclosure of facts indicating that an Acquiring Person has become such. However, notwithstanding the foregoing, the Board of Directors may not effect such an exchange at any time after an Acquiring Person, together with all affiliates and associates, becomes the Beneficial Owner of a majority of the outstanding Common Shares. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> The Board of Directors may, at its option, at any time prior to a person becoming an Acquiring Person, redeem the Rights in whole, but not in part, at a price of $0.01 per Right (the “Redemption Price”) (the date of such action by the Board of Directors being the “Redemption Date”). Immediately upon the action of the Board of Directors electing to redeem the Rights, without any further action and without any notice, the right to exercise the Rights will terminate and each Right will thereafter represent only the right to receive the Redemption Price. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> Assuming that the Board of Directors has not elected to exchange or redeem the Rights, in the event that, after any person becomes an Acquiring Person, (i) the Company merges into another entity, (ii) another entity merges into the Company and all of the outstanding Common Shares do not remain outstanding after such merger, or (iii) the Company sells 50% or more of its assets, each holder of a Right will, upon exercise, become entitled to receive the number of common shares of the acquiring entity having a value equal to (x) multiplying the Purchase Price of a Right by the number of Rights exercisable by the holder, and dividing that product by (y) 50% of the current per share market price of the common shares of the acquiring entity. The acquiring entity is required to assume the obligations of the Company under the Rights Agreement and to reserve sufficient shares of its common stock to satisfy its obligations under the Rights Agreement. Pursuant to the Rights Agreement, the Company will not enter into any consolidation, merger or sale, unless it enters into a supplemental agreement with the acquiring entity for the benefit of the Rights holders. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> Any of the terms of the Rights may be amended or terminated by the Board of Directors at any time, without the consent of the holders of the Rights, except that after such time as any person becomes an Acquiring Person, no such amendment may adversely affect the interests of the holders of the Rights (other than the Acquiring Person). <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> The Rights will expire on December 5, 2017, unless earlier redeemed, exchanged, terminated, or unless the expiration date is extended. </div>

<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Note 1 - Basis of Presentation and Significant Accounting Policies <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> The unaudited consolidated financial statements including the Consolidated Balance Sheets as of February 29, 2016 and November 30, 2015, the related Consolidated Statements of Comprehensive (Loss) Income and Cash Flows for the three months ended February 29, 2016 and February 28, 2015 have been prepared by Cryo-Cell International, Inc. and its subsidiaries (“the Company” or “Cryo-Cell”) pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial reporting. Certain financial information and note disclosures, which are normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America, have been condensed or omitted pursuant to those rules and regulations. It is suggested that these consolidated financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s November 30, 2015 Annual Report on Form 10-K. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and changes in cash flows for all periods presented have been made. The results of operations for the three months ended February 29, 2016 are not necessarily indicative of the results expected for any interim period in the future or the entire year ending November 30, 2016. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Revenue Recognition <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> Revenue Recognition for Arrangements with Multiple Deliverables <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> For multi-element arrangements, the Company allocates revenue to all deliverables based on their relative selling prices. In such circumstances, accounting principles establish a hierarchy to determine the selling price to be used for allocating revenue to deliverables as follows: (i) vendor-specific objective evidence of fair value (“VSOE”), (ii) third-party evidence of selling price (“TPE”), and (iii) best estimate of the selling price (“ESP”). VSOE generally exists only when the Company sells the deliverable separately and it is the price actually charged by the Company for that deliverable. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> The Company has identified two deliverables generally contained in the arrangements involving the sale of its umbilical cord blood product. The first deliverable is the processing of a specimen. The second deliverable is either the annual storage of a specimen, the 21-year storage fee charged for a specimen or the life-time storage fee charged for a specimen. The Company has allocated revenue between these deliverables using the relative selling price method. The Company has VSOE for its annual storage fees as the Company renews storage fees annually with its customers on a stand-alone basis. Because the Company has neither VSOE nor TPE for the processing, 21-year storage and life-time storage deliverables, the allocation of revenue has been based on the Company’s ESPs. Amounts allocated to processing a specimen are recognized at the time the processing of the specimen is complete. Amounts allocated to the storage of a specimen are recognized ratably over the contractual storage period. Any discounts given to the customer are recognized by applying the relative selling price method whereby after the Company determines the selling price to be allocated to each deliverable (processing and storage), the sum of the prices of the deliverables is then compared to the arrangement consideration, and any difference is applied to the separate deliverables ratably. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> The Company’s process for determining its ESP for deliverables without VSOE or TPE considers multiple factors that may vary depending upon the unique facts and circumstances related to each deliverable. Key factors considered by the Company in developing the ESPs for its processing, 21 year storage and life-time storage fee include the Company’s historical pricing practices, as well as expected profit margins. <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> The Company records revenue from processing and storage of specimens and pursuant to agreements with licensees. The Company recognizes revenue from processing fees upon completion of processing and recognizes storage fees ratably over the contractual storage period as well as other income from royalties paid by licensees related to long-term storage contracts which the Company has under license agreements. Contracted storage periods are annual, twenty-one years and lifetime. Deferred revenue on the accompanying consolidated balance sheets includes the portion of the annual storage fee, the twenty-one year storage fee and the life-time storage fee that is being recognized over the contractual storage period as well as royalties received from foreign licensees related to long-term storage contracts in which the Company has future obligations under the license agreement. The Company classifies deferred revenue as current if the Company expects to recognize the related revenue over the next 12 months. The Company also records revenue within processing and storage fees from shipping and handling billed to customers when earned. Shipping and handling costs that the Company incurs are expensed and included in cost of sales. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> The Company records revenue from the sale of the Prepacyte®-CB product line upon shipment of the product to the Company’s customers. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Income Taxes <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to be recovered or settled. The Company has recorded a valuation allowance of $2,630,000 and $2,630,000 as of February 29, 2016 and November 30, 2015, respectively, as the Company does not believe it is “more likely than not” that all future income tax benefits will be realized. When the Company changes its determination as to the amount of deferred income tax assets that can be realized, the valuation allowance is adjusted with a corresponding impact to income tax expense in the period in which such determination is made. The ultimate realization of the Company’s deferred income tax assets depends upon generating sufficient taxable income prior to the expiration of the tax attributes. In assessing the need for a valuation allowance, the Company projects future levels of taxable income. This assessment requires significant judgment. The Company examines the evidence related to the recent history of losses, the economic conditions in which the Company operates and forecasts and projections to make that determination. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> There was no U.S. income tax expense for the three months ended February 29, 2016 and February 28, 2015 due to the utilization of net operating losses and foreign tax credit carryforwards, which were not previously benefited in the Company’s financial statements. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> The Company records foreign income taxes withheld from installment payments of non-refundable up-front license fees and royalty income earned on the processing and storage of cord blood stem cell specimens in geographic areas where the Company has license agreements. The Company recognized approximately $0 and $25,000 for the three months ended February 29, 2016 and February 28, 2015, respectively, of foreign income tax expense. Foreign income tax expense is included in income tax expense in the accompanying consolidated statements of comprehensive (loss) income. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Increases or decreases to the unrecognized tax benefits could result from management’s belief that a position can or cannot be sustained upon examination based on subsequent information or potential lapse of the applicable statute of limitation for certain tax positions. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. For the three months ended February 29, 2016 and February 28, 2015, the Company had no provisions for interest or penalties related to uncertain tax positions. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Long-Lived Assets <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> The Company evaluates the realizability of its long-lived assets, which requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment, such as reductions in demand or when significant economic slowdowns are present. Reviews are performed to determine whether the carrying value of an asset is impaired, based on comparisons to undiscounted expected future cash flows. If this comparison indicates that there is impairment and carrying value is in excess of fair value, the impaired asset is written down to fair value, which is typically calculated using: (i) quoted market prices or (ii) discounted expected future cash flows utilizing a discount rate. The Company did not note any impairment for the three months ended February 29, 2016 and February 28, 2015. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Stock Compensation <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> As of February 29, 2016, the Company has three stock-based compensation plans, which are described in Note 10 to the consolidated financial statements. The Company’s third stock-based employee compensation plan became effective December 1, 2011 as approved by the Board of Directors and approved by the stockholders at the 2012 Annual Meeting. The Company recognized approximately $252,000 and $191,000 for the three months ended February 29, 2016 and February 28, 2015, respectively, of stock-based compensation expense. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> The Company recognizes stock-based compensation based on the fair value of the related awards. Under the fair value recognition guidance of stock-based compensation accounting rules, stock-based compensation expense is estimated at the grant date based on the fair value of the award and is recognized as expense over the requisite service period of the award. The fair value of service-based vesting condition and performance-based vesting condition stock option awards is determined using the Black-Scholes valuation model. For stock option awards with only service-based vesting conditions and graded vesting features, the Company recognizes stock compensation expense based on the graded-vesting method. To value awards with market-based vesting conditions the Company uses a binomial valuation model. The Company recognizes compensation cost for awards with market-based vesting conditions on a graded-vesting basis over the derived service period calculated by the binomial valuation model. The use of these valuation models involve assumptions that are judgmental and highly sensitive in the determination of compensation expense and include the expected life of the option, stock price volatility, risk-free interest rate, dividend yield, exercise price, and forfeiture rate. Forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> The estimation of stock awards that will ultimately vest requires judgment and to the extent that actual results or updated estimates differ from current estimates, such amounts will be recorded as a cumulative adjustment in the period they become known. The Company considered many factors when estimating forfeitures, including the recipient groups and historical experience. Actual results and future changes in estimates may differ substantially from current estimates. <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> The Company issues performance-based equity awards which vest upon the achievement of certain financial performance goals, including revenue and income targets. Determining the appropriate amount to expense based on the anticipated achievement of the stated goals requires judgment, including forecasting future financial results. The estimate of the timing of the expense recognition is revised periodically based on the probability of achieving the required performance targets and adjustments are made as appropriate. The cumulative impact of any revision is reflected in the period of the change. If the financial performance goals are not met, the award does not vest, so no compensation cost is recognized and any previously stock-recognized stock-based compensation expense is reversed. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> The Company issues equity awards with market-based vesting conditions which vest upon the achievement of certain stock price targets. If the awards are forfeited prior to the completion of the derived service period, any recognized compensation is reversed. If the awards are forfeited after the completion of the derived service period, the compensation cost is not reversed, even if the awards never vest. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Fair Value of Financial Instruments <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> Management uses a fair value hierarchy, which gives the highest priority to quoted prices in active markets. The fair value of financial instruments is estimated based on market trading information, where available. Absent published market values for an instrument or other assets, management uses observable market data to arrive at its estimates of fair value. Management believes that the carrying amount of cash and cash equivalents, accounts receivable, notes receivable, accounts payable and accrued expenses approximate fair value due to the short-term nature of these instruments. The Company believes that the fair value of its Revenue Sharing Agreements (“RSA”) liability recorded on the balance sheet is between the recorded book value and up to the Company’s previous settlement experience, due to the various terms and conditions associated with each RSA. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> The Company uses an accounting standard that defines fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the standard establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. The three levels of inputs used to measure fair value are as follows: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="8%"></td> <td valign="bottom" width="3%"></td> <td width="89%"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top">Level 1</td> <td valign="bottom">  </td> <td valign="bottom">Quoted prices in active markets for identical assets or liabilities.</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="2"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top">Level 2</td> <td valign="bottom">  </td> <td valign="bottom">Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="2"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top">Level 3</td> <td valign="bottom">  </td> <td valign="bottom">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> The following table summarizes the financial assets and liabilities measured at fair value on a recurring basis as of February 29, 2016 and November 30, 2015, respectively, segregated among the appropriate levels within the fair value hierarchy: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="10" align="center">Fair Value Measurements</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Fair Value at</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center">at February 29, 2016 Using</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> Description </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">February 29, 2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom" colspan="5"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Trading Securities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">261,167</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">261,167</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Available-for-sale </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">355,941</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">355,941</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">617,108</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">617,108</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="12"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="10" align="center">Fair Value Measurements</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Fair Value at</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center">at November 30, 2015 Using</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> Description </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">November 30, 2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Trading Securities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">136,798</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">136,798</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Available-for-sale </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">473,626</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">473,626</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">610,424</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">610,424</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> The following is a description of the valuation techniques used for these items, as well as the general classification of such items pursuant to the fair value hierarchy: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> Trading securities – Fair values for these investments are based on quoted prices in active markets and are therefore classified within Level 1 of the fair value hierarchy. For trading securities, there was ($19,800) and ($4,400) in unrealized holding losses, respectively, recorded in other income and expense on the accompanying consolidated statements of comprehensive loss for the three months ended February 29, 2016 and February 28, 2015, respectively. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> Available-for-sale securities – During the second quarter of fiscal 2015, management reevaluated its marketable securities and determined that there was a change in certain securities from trading to available-for-sale classification. These investments are classified as available for sale and consist of marketable equity securities that we intend to hold for an indefinite period of time. Investments are stated at fair value and unrealized holding gains and losses are reported as a component of accumulated other comprehensive income until realized. Realized gains or losses on disposition of investments are computed using the first in, first out (FIFO) method and reported as income or loss in the period of disposition in the accompanying consolidated statements of comprehensive income. For available-for-sale securities, there was approximately ($94,000) and $0 in unrealized holding losses, net of tax, respectively, reported as comprehensive loss on the accompanying statements of comprehensive (loss) income for the three months ended February 29, 2016 and February 28, 2015, respectively. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Product Warranty and Cryo-Cell CaresTM Program <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February 1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients. Additionally, under the Cryo-Cell CaresTM program, the Company was paying $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloblative transplant procedure. Effective October 13, 2014, the Company no longer offers the Cryo-Cell CaresTM program to new clients. The product warranty is available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties. The Company does not maintain insurance for this warranty program and therefore maintains reserves to cover any estimated potential liabilities. The Company’s reserve balance is based on the $75,000 or $50,000 (as applicable) maximum payment and the $10,000 maximum expense reimbursement multiplied by formulas to determine the projected number of units requiring a payout. The Company determined the estimated expected usage and engraftment failure rates based on an analysis of the historical usage and failure rates and the historical usage and failure rates in other private and public cord blood banks based on published data. The Company’s estimates of expected usage and engraftment failure could change as a result of changes in actual usage rates or failure rates and such changes would require an adjustment to the established reserves. The historical usage and failure rates have been very low and a small increase in the number of transplants or engraftment failures could cause a significant increase in the estimated rates used in determining the Company’s reserve. In addition, the reserve will increase as additional umbilical cord blood specimens are stored which are subject to the warranty. As of February 29, 2016 and November 30, 2015 the Company recorded reserves under these programs in the amounts of approximately $17,000 and $17,000, respectively, which are included in accrued expenses in the accompanying consolidated balance sheets. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Recently Issued Accounting Pronouncements <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. This update simplifies several aspects of the accounting for employee share-based payment transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. The Company is currently evaluating the effect that the updated standard will have on our financial statements. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> In March 2016, the FASB issued Accounting Standards Update No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net). This update amends the principal-versus-agent implementation guidance and illustrations in the Board’s new revenue standard (ASC 606). The FASB issued the ASU in response to concerns identified by stakeholders, including those related to (1) determining the appropriate unit of account under the revenue standard’s principal-versus-agent guidance and (2) applying the indicators of whether an entity is a principal or an agent in accordance with the revenue standard’s control principle. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the effect that the updated standard will have on our financial statements. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases (Topic 842). This update requires organizations that lease assets with lease terms of more than 12 months to recognize assets and liabilities for the rights and obligations created by those leases on their balance sheets. It also requires new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the effect that the updated standard will have on its consolidated balance sheets and related disclosures. <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> In January 2016, the FASB issued Accounting Standards Update No. 2016-01, Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This update requires all equity investments to be measured at fair value with changes in fair value recognized in net income, requires an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments, and eliminates the requirement for public entities to disclose the methods and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet. The new standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted for the accounting guidance on financial liabilities under the fair value option. The Company is currently evaluating the impact of the new standard on our financial statements. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> In November 2015, the FASB issued Accounting Standards Update No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes, which requires that deferred tax assets and liabilities be classified as non-current in a classified balance sheet. This update is effective for fiscal years, and interim reporting periods within those years, beginning after December 15, 2016. The standard permits the use of either the retrospective or prospective transition method. The adoption of this standard is expected to result in a reclassification between current and non-current deferred tax assets within the Company’s consolidated balance sheets and related disclosures. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> In July 2015, the FASB issued Accounting Standards Update No 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. This update simplifies the subsequent measurement of inventory. It replaces the current lower of cost or market test with the lower of cost or net realizable value test. Net realizable value is defined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The new standard should be applied prospectively and is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those annual periods, with early adoption permitted. The Company does not expect the adoption of this standard to have a material impact on the Company’s financial statements. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> In June 2014, the FASB issued Accounting Standards Update No. 2014-12, Compensation – Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could be Achieved after the Requisite Service Period (“ASU 2014-12”). This update requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition in determining expense recognition for the award. As a result, this type of performance condition may delay expense recognition until achievement of the performance target is probable. ASU 2014-12 is effective for reporting periods beginning after December 15, 2015, and early adoption is permitted. We will adopt ASU 2014-12 effective December 1, 2016 and it is not anticipated to have a material impact on our financial statements. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606). This update provides a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. In August 2015, the FASB issued Accounting Standards Update No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which defers the effective date of the guidance in Accounting Standards Update No. 2014-09 by one year. This update is now effective for annual and interim periods beginning after December 15, 2017, which will require us to adopt these provisions in the first quarter of fiscal 2019. Early application is permitted for annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. This update permits the use of either the retrospective or cumulative effect transition method. The Company has not yet selected a transition method nor has it determined the effect of the standard its consolidated financial statements and related disclosures. </div>

P4Y9M

Smaller Reporting Company

5625

One Common Share per Right

P4Y9M4D

2017-12-05

--11-30

CRYO CELL INTERNATIONAL INC

8971373

<div> The following summarizes the fair value of the consideration for the Acquisition:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="85%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Consideration </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Cash </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">375,374</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Assumed liabilities of seller </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,073,898</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Note payable to seller </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,300,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Prepaid expense paid to seller by purchaser </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">104,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Consideration </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,853,272</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

1.90

8971373

2016-02-29

CCEL

Open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission

-0.01

75423

30723

-122936

5152198

157238

-19800

408403

5020459

156422

22916

-18024

-279358

350656

-30051

1490

-216663

-93727

-122936

252313

131907

-570426

261334

-188017

4995776

-483826

8684

1348291

-438675

252000

3597253

12000

357156

74618

41548

192045

14391

29938

Monthly

The Commitment Letter is subject to execution and delivery to the Lender of financing documents required by the Lender. If the loan has not been fully executed and closed by May 30, 2016, the commitment will expire and there will be no obligation for the Lender to fund the loan.

P10Y

P20Y

P10Y

P15Y

4 4

966597

186487 162163 0.333 0.333

5020459

127951

246943

1245023

28678

131739

28471

14391

103268

12870

0 P5Y

0.16

0.03

2853272

375374

120000

5 2400000

100000

35000

4100000

10000000

3.00

2.01

P4Y2M23D

2.00

1.01

P5Y2M23D

4.00

3.01

P6Y4M10D

8000 4000 0.225 0.0025 0.333

278948

400000

129729

116240

Each Right represents the right to purchase from the Company one one-thousandth (1/1,000) of a share of Series A Junior Participating Preferred Stock (the "Preferred Shares"), subject to adjustment as provided in the Rights Agreement. This fraction of a Preferred Share is substantially similar to a Common Share, in that the Rights Agreement provides for each Preferred Share to have the voting, liquidation and dividend rights that are equivalent to 1,000 times the rights of a Common Share.

P4M10D

11000

In addition, if David Portnoy and Mark Portnoy are employed by the Company on November 30, 2015, then no later than February 15, 2016, the Company will grant up to an additional 186,487 and 162,163 shares of restricted common shares, respectively, based on similar performance thresholds, as defined in the agreements

133575

3.06

684000

0000862692 ccel:SaneronMember 2015-09-01 2015-11-30 0000862692 us-gaap:CommonStockMember 2015-12-01 2016-02-29 0000862692 ccel:MarketBasedVestingConditionOptionsMember 2015-12-01 2016-02-29 0000862692 us-gaap:RestrictedStockMember 2015-12-01 2016-02-29 0000862692 us-gaap:PerformanceSharesMember 2015-12-01 2016-02-29 0000862692 country:IN 2015-12-01 2016-02-29 0000862692 ccel:ServiceBasedVestingConditionOptionsMemberus-gaap:StockOptionMember 2015-12-01 2016-02-29 0000862692 ccel:PreferredStockRightsPlanMember 2015-12-01 2016-02-29 0000862692 ccel:MarketBasedStockOptionsMemberccel:TwoThousandTwelvePlanMember 2015-12-01 2016-02-29 0000862692 ccel:ServiceBasedRestrictedSharesMemberccel:TwoThousandTwelvePlanMember 2015-12-01 2016-02-29 0000862692 ccel:ServiceBasedStockOptionsMemberccel:TwoThousandTwelvePlanMember 2015-12-01 2016-02-29 0000862692 ccel:PerformanceBasedStockOptionsMemberccel:TwoThousandTwelvePlanMember 2015-12-01 2016-02-29 0000862692 us-gaap:RestrictedStockMemberccel:TwoThousandTwelvePlanMember 2015-12-01 2016-02-29 0000862692 ccel:StockholderRightsAgreementMemberus-gaap:MinimumMember 2015-12-01 2016-02-29 0000862692 us-gaap:MinimumMember 2015-12-01 2016-02-29 0000862692 us-gaap:MaximumMember 2015-12-01 2016-02-29 0000862692 ccel:RangeThreeMember 2015-12-01 2016-02-29 0000862692 ccel:RangeOneMember 2015-12-01 2016-02-29 0000862692 ccel:RangeTwoMember 2015-12-01 2016-02-29 0000862692 us-gaap:MaximumMemberccel:LifecellLicenseAndAgreementMember 2015-12-01 2016-02-29 0000862692 ccel:LifecellLicenseAndAgreementMember 2015-12-01 2016-02-29 0000862692 us-gaap:MinimumMemberccel:AssetPurchaseAgreementMember 2015-12-01 2016-02-29 0000862692 us-gaap:MaximumMemberccel:AssetPurchaseAgreementMember 2015-12-01 2016-02-29 0000862692 ccel:AssetPurchaseAgreementMember 2015-12-01 2016-02-29 0000862692 ccel:StockAwardsMemberccel:SaneronMember 2015-12-01 2016-02-29 0000862692 ccel:SaneronMember 2015-12-01 2016-02-29 0000862692 ccel:UmbilicalCordBloodAndCordTissueStemCellServiceAndPrepacytecbMember 2015-12-01 2016-02-29 0000862692 ccel:PrepacytecbMember 2015-12-01 2016-02-29 0000862692 ccel:UmbilicalCordBloodAndCordTissueStemCellServiceMember 2015-12-01 2016-02-29 0000862692 ccel:DecemberOneTwoThousandFifteenMemberus-gaap:RestrictedStockMemberccel:TwoThousandTwelvePlanMember 2015-12-01 2016-02-29 0000862692 ccel:DecemberOneTwoThousandFourteenMemberus-gaap:RestrictedStockMemberccel:TwoThousandTwelvePlanMember 2015-12-01 2016-02-29 0000862692 us-gaap:RestrictedStockMemberccel:CoCeoTwoMember 2015-12-01 2016-02-29 0000862692 us-gaap:RestrictedStockMemberccel:CoCeoOneMember 2015-12-01 2016-02-29 0000862692 ccel:CytoMedicalDesignGroupLlcMemberccel:AssetPurchaseAgreementMember 2015-12-01 2016-02-29 0000862692 ccel:AdditionalLoanMemberccel:SaneronMember 2015-12-01 2016-02-29 0000862692 ccel:InitialLoanMemberccel:SaneronMember 2015-12-01 2016-02-29 0000862692 us-gaap:CustomerRelationshipsMemberccel:AssetPurchaseAgreementMember 2015-12-01 2016-02-29 0000862692 us-gaap:CustomerRelationshipsMember 2015-12-01 2016-02-29 0000862692 us-gaap:PatentsMemberus-gaap:MinimumMember 2015-12-01 2016-02-29 0000862692 us-gaap:PatentsMemberus-gaap:MaximumMember 2015-12-01 2016-02-29 0000862692 us-gaap:LicensingAgreementsMemberccel:AssetPurchaseAgreementMember 2015-12-01 2016-02-29 0000862692 us-gaap:LicensingAgreementsMember 2015-12-01 2016-02-29 0000862692 us-gaap:LetterOfCreditMemberccel:SeniorCreditFacilityMember 2015-12-01 2016-02-29 0000862692 ccel:NotesPayableMemberccel:AssetPurchaseAgreementMember 2015-12-01 2016-02-29 0000862692 ccel:NotesPayableMember 2015-12-01 2016-02-29 0000862692 2015-12-01 2016-02-29 0000862692 us-gaap:CommonStockMember 2014-12-01 2015-02-28 0000862692 ccel:MarketBasedVestingConditionOptionsMember 2014-12-01 2015-02-28 0000862692 us-gaap:PerformanceSharesMember 2014-12-01 2015-02-28 0000862692 country:IN 2014-12-01 2015-02-28 0000862692 us-gaap:EmployeeStockOptionMember 2014-12-01 2015-02-28 0000862692 ccel:StockAwardsMemberccel:SaneronMember 2014-12-01 2015-02-28 0000862692 us-gaap:RestrictedStockMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberccel:TwoThousandTwelvePlanMember 2014-12-01 2015-02-28 0000862692 2014-12-01 2015-02-28 0000862692 ccel:MarketBasedStockOptionsMemberccel:TwoThousandTwelvePlanMember 2014-12-01 2015-11-30 0000862692 ccel:ServiceBasedRestrictedSharesMemberccel:TwoThousandTwelvePlanMember 2014-12-01 2015-11-30 0000862692 ccel:ServiceBasedStockOptionsMemberccel:TwoThousandTwelvePlanMember 2014-12-01 2015-11-30 0000862692 ccel:PerformanceBasedStockOptionsMemberccel:TwoThousandTwelvePlanMember 2014-12-01 2015-11-30 0000862692 2014-12-01 2015-11-30 0000862692 ccel:SaneronMember 2013-12-01 2014-11-30 0000862692 us-gaap:AffiliatedEntityMembercountry:EC 2013-08-01 2013-08-31 0000862692 us-gaap:EmployeeStockOptionMemberccel:TwoThousandTwelvePlanMember 2012-05-01 2012-05-31 0000862692 2005-12-01 2005-12-31 0000862692 us-gaap:CommonStockMember 2015-06-01 2015-06-30 0000862692 us-gaap:MaximumMember 2015-06-01 2015-06-30 0000862692 ccel:AssetPurchaseAgreementMember 2015-06-01 2015-06-30 0000862692 2015-06-01 2015-06-30 0000862692 2016-02-01 2016-02-02 0000862692 ccel:CaseOneMember 2015-12-03 2015-12-03 0000862692 us-gaap:RestrictedStockMemberccel:TwoThousandTwelvePlanMemberccel:CoCeoTwoMember 2013-11-30 2013-11-30 0000862692 us-gaap:RestrictedStockMemberccel:TwoThousandTwelvePlanMemberccel:CoCeoOneMember 2013-11-30 2013-11-30 0000862692 us-gaap:RestrictedStockMemberccel:TwoThousandTwelvePlanMemberccel:CoCeoTwoMember 2016-02-29 2016-02-29 0000862692 us-gaap:RestrictedStockMemberccel:TwoThousandTwelvePlanMemberccel:CoCeoOneMember 2016-02-29 2016-02-29 0000862692 us-gaap:RestrictedStockMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberccel:TwoThousandTwelvePlanMember 2016-02-29 2016-02-29 0000862692 us-gaap:RestrictedStockMemberccel:TwoThousandTwelvePlanMemberccel:CoCeoTwoMember 2015-02-28 2015-02-28 0000862692 us-gaap:RestrictedStockMemberccel:TwoThousandTwelvePlanMemberccel:CoCeoOneMember 2015-02-28 2015-02-28 0000862692 us-gaap:RestrictedStockMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberccel:TwoThousandTwelvePlanMember 2015-02-28 2015-02-28 0000862692 us-gaap:SubsequentEventMember 2016-03-01 2016-03-01 0000862692 ccel:CaseThreeMember 2016-02-24 2016-02-24 0000862692 ccel:CaseTwoMember 2016-01-20 2016-01-20 0000862692 ccel:CytoMedicalDesignGroupLlcMemberccel:AssetPurchaseAgreementMember 2015-09-30 2015-09-30 0000862692 ccel:NotesPayableMemberccel:AssetPurchaseAgreementMember 2015-06-30 2015-06-30 0000862692 ccel:NotesPayableMember 2015-06-30 2015-06-30 0000862692 us-gaap:FairValueMeasurementsRecurringMember 2015-11-30 0000862692 us-gaap:SeriesAPreferredStockMember 2015-11-30 0000862692 us-gaap:EmployeeStockOptionMemberccel:TwoThousandSixPlanMember 2015-11-30 0000862692 us-gaap:MaximumMemberccel:LifecellLicenseAndAgreementMember 2015-11-30 0000862692 ccel:SaneronMember 2015-11-30 0000862692 ccel:PrepacytecbMember 2015-11-30 0000862692 ccel:UmbilicalCordBloodAndCordTissueStemCellServiceMember 2015-11-30 0000862692 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2015-11-30 0000862692 us-gaap:CustomerRelationshipsMember 2015-11-30 0000862692 us-gaap:PatentsMember 2015-11-30 0000862692 us-gaap:LicensingAgreementsMember 2015-11-30 0000862692 2015-11-30 0000862692 2014-11-30 0000862692 us-gaap:FairValueMeasurementsRecurringMember 2016-02-29 0000862692 ccel:PerformanceAndMarketBasedVestingConditionOptionsMember 2016-02-29 0000862692 us-gaap:RestrictedStockMember 2016-02-29 0000862692 us-gaap:SeriesAPreferredStockMember 2016-02-29 0000862692 ccel:ServiceBasedVestingConditionOptionsMemberccel:TwoThousandPlanMember 2016-02-29 0000862692 us-gaap:EmployeeStockOptionMemberccel:TwoThousandSixPlanMember 2016-02-29 0000862692 ccel:ServiceBasedVestingConditionOptionsMemberccel:TwoThousandSixPlanMember 2016-02-29 0000862692 ccel:ServiceBasedVestingConditionOptionsMemberccel:TwoThousandTwelvePlanMember 2016-02-29 0000862692 ccel:TwoThousandTwelvePlanMember 2016-02-29 0000862692 ccel:StockholderRightsAgreementMemberus-gaap:MinimumMember 2016-02-29 0000862692 ccel:RangeThreeMember 2016-02-29 0000862692 ccel:RangeOneMember 2016-02-29 0000862692 ccel:RangeTwoMember 2016-02-29 0000862692 us-gaap:MaximumMemberccel:LifecellLicenseAndAgreementMember 2016-02-29 0000862692 ccel:AssetPurchaseAgreementMember 2016-02-29 0000862692 ccel:SaneronMember 2016-02-29 0000862692 ccel:PrepacytecbMember 2016-02-29 0000862692 ccel:UmbilicalCordBloodAndCordTissueStemCellServiceMember 2016-02-29 0000862692 us-gaap:RestrictedStockMemberccel:CoCeoTwoMember 2016-02-29 0000862692 us-gaap:RestrictedStockMemberccel:CoCeoOneMember 2016-02-29 0000862692 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2016-02-29 0000862692 ccel:AdditionalLoanMemberccel:SaneronMember 2016-02-29 0000862692 ccel:InitialLoanMemberccel:SaneronMember 2016-02-29 0000862692 us-gaap:CustomerRelationshipsMember 2016-02-29 0000862692 us-gaap:PatentsMember 2016-02-29 0000862692 us-gaap:LicensingAgreementsMember 2016-02-29 0000862692 ccel:NotesPayableMember 2016-02-29 0000862692 2016-02-29 0000862692 ccel:CytoMedicalDesignGroupLlcMemberccel:AssetPurchaseAgreementMember 2015-05-31 0000862692 ccel:PerformanceAndMarketBasedVestingConditionOptionsMember 2015-02-28 0000862692 2015-02-28 0000862692 2012-06-06 0000862692 us-gaap:LetterOfCreditMemberccel:SeniorCreditFacilityMemberus-gaap:SubsequentEventMember 2016-03-22 0000862692 2016-04-08 0000862692 us-gaap:LetterOfCreditMemberus-gaap:SubsequentEventMember 2016-04-04 0000862692 ccel:AssetPurchaseAgreementMember 2015-09-30 0000862692 ccel:CytoMedicalDesignGroupLlcMemberccel:AssetPurchaseAgreementMember 2015-09-30 0000862692 ccel:AssetPurchaseAgreementMember 2015-06-30 0000862692 ccel:NotesPayableMemberccel:AssetPurchaseAgreementMember 2015-06-30 0000862692 2015-04-08 0000862692 ccel:PreferredStockRightsPlanMember 2014-11-26 0000862692 2011-12-31 shares iso4217:USD shares pure iso4217:USD ccel:CompensationPlan ccel:Installments ccel:Installment ccel:Deliverables ccel:Agreement iso4217:USD ccel:System_Unit ccel:Segments iso4217:USD ccel:Unit

EX-101.SCH 7 ccel-20160229.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Consolidated Statements of Comprehensive (Loss) Income link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Basis of Presentation and Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Acquisition link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Inventory link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Goodwill link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Intangible Assets link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Note Payable link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Segment Reporting link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - (Loss) Income per Common Share link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Investment in Saneron CCEL Therapeutics, Inc. ("Saneron") link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Stockholder's Equity link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - License Agreements link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Legal Proceedings link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Share Repurchase Plan link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Subsequent Event link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Acquisition (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Inventory (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Intangible Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Segment Reporting (Tables) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - (Loss) Income per Common Share (Tables) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Stockholder's Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - License Agreements (Tables) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Basis of Presentation and Significant Accounting Policies - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Acquisition - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Acquisition - Summary of Fair Value of Consideration for the Acquisition (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Acquisition - Summary of Allocation of Total Purchase Price for the Acquisition (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Inventory - Components of Inventory (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Goodwill - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Intangible Assets - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Note Payable - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Segment Reporting - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Segment Reporting - Net Revenue and Operating Profit of Each Segment (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - (Loss) Income per Common Share - Calculation of Basic and Diluted Net (Loss) Income per Common Share (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - (Loss) Income per Common Share - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 144 - Disclosure - Investment in Saneron CCEL Therapeutics, Inc. ("Saneron") - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 145 - Disclosure - Stockholder's Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 146 - Disclosure - Stockholder's Equity - Stock Option Activity for Options (Detail) link:calculationLink link:presentationLink link:definitionLink 147 - Disclosure - Stockholder's Equity - Significant Option Groups Exercisable Option and its Price and Contractual Life (Detail) link:calculationLink link:presentationLink link:definitionLink 148 - Disclosure - Stockholder's Equity - Summary of Non-Vested Options (Detail) link:calculationLink link:presentationLink link:definitionLink 149 - Disclosure - License Agreements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 150 - Disclosure - License Agreements - Summary of License Fees Earned (Detail) link:calculationLink link:presentationLink link:definitionLink 151 - Disclosure - Legal Proceedings - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 152 - Disclosure - Share Repurchase Plan - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 153 - Disclosure - Subsequent Event - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 ccel-20160229_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 ccel-20160229_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 ccel-20160229_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable, Current Accounts payable Accounts Receivable, Net, Current Accounts receivable (net of allowance for doubtful accounts of $2,156,577 and $2,067,130, respectively) Accrued Liabilities, Current Accrued expenses Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Additional loan. Additional Loan [Member] Additional Loan [Member] Additional Paid in Capital, Common Stock Additional paid-in capital Additional payment warranty. Additional Payment Warranty Additional payment warranty Additional percentage of outstanding shares acquired. Additional Percentage Of Outstanding Shares Acquired Addition of common stock outstanding percentage Additional restricted stocks number of shares granted. Additional Restricted Stocks Number Of Shares Granted Additional restricted common shares to be granted Amortization Depreciation and amortization expense Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided by operating activities: Affiliated Entity [Member] Affiliated Entity [Member] Allocated Share-based Compensation Expense Stock option compensation expense Allowance for Doubtful Accounts Receivable, Current Accounts receivable, allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Period Increase (Decrease) Accounts receivable, additional allowance for doubtful accounts Amendment Flag Amendment Flag Amortization of Intangible Assets Amortization expense Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Number of outstanding stock options excluded from computation of diluted earnings per share Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Asset purchase agreement closing date. Asset Purchase Agreement Closing Date Asset purchase agreement closing date Asset purchase agreement commencement date. Asset Purchase Agreement Commencement Date Asset purchase agreement commencement date Asset Purchase Agreement [Member] Asset Purchase Agreement [Member] Asset Purchase Agreement [Member] Asset purchase agreement number of units to be sold. Asset Purchase Agreement Number Of Units To Be Sold Number of Prepacyte CB Processing System Units to be sold Asset purchase agreement per unit amount on completion of sales criteria. Asset Purchase Agreement Per Unit Amount On Completion Of Sales Criteria Per unit amount on completion of sales criteria Assets Total assets Total assets Assets [Abstract] ASSETS Assets, Current Total current assets Assets, Current [Abstract] Current Assets Associate stock purchase plan price percentage of common stock market price. Associate Stock Purchase Plan Price Percentage Of Common Stock Market Price Market price for common stock, percentage Available-for-sale Securities, Current Available-for-sale Award Date [Axis] Award Date [Axis] Award Date [Domain] Award Date [Domain] Award Type [Axis] Award Type [Axis] Basis of Presentation and Significant Accounting Policies [Text Block] Basis of Presentation and Significant Accounting Policies Business Acquisition, Contingent Consideration [Line Items] Business Acquisition, Contingent Consideration [Line Items] Business Acquisition, Transaction Costs Transaction costs Business Acquisition [Line Items] Business Acquisition [Line Items] Business Combination, Consideration Transferred Consideration Business Combination, Consideration Transferred [Abstract] Consideration Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer, less cash outflow and prepaid expense paid to seller by purchaser. Business Combination, Consideration Transferred Less Cash And Prepaid Expense Asset Purchase Agreement, purchase price less cash and prepaids Business Combination Disclosure [Text Block] Acquisition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Total identifiable net assets acquired Business combination recognized identifiable assets acquired and liabilities assumed cash and inventory. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash And Inventory Asset Purchase Agreement, cash and inventory paid Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability Portion of contingent liability Business combination recognized identifiable assets acquired and liabilities assumed contingent liability reduced amount. Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Contingent Liability Reduced Amount Contingent liability, reduced amount Business combination, recognized identifiable assets acquired and liabilities assumed, current assets, prepaid expenses paid Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expenses Paid Prepaid expense paid to seller by purchaser Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment Tooling molds Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets License agreement Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Customer relationships Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Assumed liabilities of seller Business Combinations [Abstract] Business Combinations [Abstract] Case One [Member] Case One [Member] Case No.15-007461-CI [Member] Case Three [Member] Case Three [Member] Case No. 8:16CV408t30 [Member] Case Two [Member] Case Two [Member] Case No.11915-VCG [Member] Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents - end of period Cash and cash equivalents - beginning of period Cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Increase (decrease) in cash and cash equivalents Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental non-cash investing activities: Cash paid for disbursement of funds. Cash Paid For Disbursement Of Funds Cash paid as disbursement of funds Class of Stock [Domain] Class of Stock [Domain] Class of Treasury Stock [Table] Class of Treasury Stock [Table] Co CEO One [Member] Co CEO One [Member] David Portnoy [Member] Co CEO Two [Member] Co CEO Two [Member] Mark Portnoy [Member] Commitments and Contingencies Commitments and contingencies (Note 12) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Common Stock [Member] Common Stock [Member] Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Value, Issued Common stock ($.01 par value, 20,000,000 authorized; 12,481,065 issued and 9,097,472 outstanding as of February 29, 2016 and 12,260,340 issued and 9,010,322 outstanding as of November 30, 2015) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive (Loss) Income Contracted storage period option one. Contracted Storage Period Option One Contracted storage periods option one Contracted storage period option three. Contracted Storage Period Option Three Contracted storage periods option three Contracted storage period option two. Contracted Storage Period Option Two Contracted storage periods option two Cost of Services Cost of sales Total cost of sales Costs and Expenses Total costs and expenses Costs and Expenses [Abstract] Costs and Expenses: Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Current Fiscal Year End Date Current Fiscal Year End Date Current Foreign Tax Expense (Benefit) Foreign income tax expense Customer Relationships [Member] Customer Relationships [Member] Cyto Medical Design Group Llc [Member] Cyto Medical Design Group Llc [Member] CytoMedical [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Disclosure [Text Block] Note Payable Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Frequency of Periodic Payment Repayment interval Debt Instrument, Interest Rate, Stated Percentage Annual interest rate Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Debt Instrument, Periodic Payment Monthly installment amount Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] December One Two Thousand Fifteen [Member] December One Two Thousand Fifteen [Member] December One Two Thousand Fifteen [Member] December One Two Thousand Fourteen [Member] December One Two Thousand Fourteen [Member] December One Two Thousand Fourteen [Member] Deferred Revenue, Current Deferred revenue Deferred Revenue Disclosure [Abstract] Deferred Revenue Disclosure [Abstract] Deferred Revenue, Noncurrent Deferred revenue, net of current portion Deferred revenue recognition period. Deferred Revenue Recognition Period Deferred revenue recognition period Deferred Tax Assets, Net of Valuation Allowance, Current Deferred tax assets, current portion Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Deferred tax assets, net of current portion Deferred Tax Assets, Valuation Allowance Valuation allowance Deposits and other assets. Deposits And Other Assets Deposits and other assets, net Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Total depreciation and amortization Description of minimum requirement to be satisfied by employee for additional restricted common share. Description Of Minimum Requirement To Be Satisfied By Employee For Additional Restricted Common Share Description of minimum requirement to be satisfied by employee for additional restricted common share Directors and officers insurance claims deductible. Directors And Officers Insurance Claims Deductible Directors and officers insurance policy claim deductible Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] Earnings Per Share [Abstract] Earnings Per Share, Basic Basic Net (loss) income per common share - basic Earnings Per Share, Basic and Diluted [Abstract] (Loss) Earnings per share: Earnings Per Share, Diluted Diluted Net (loss) income per common share - diluted Earnings Per Share [Text Block] (Loss) Income per Common Share ECUADOR Ecuador affiliate [Member] Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Weighted-average period Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Unrecognized compensation cost related to non-vested share-based compensation arrangements granted Employee Stock Option [Member] Employee Stock Incentive Plan [Member] Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Equity Component [Domain] Equity Component [Domain] Investment, Name [Domain] Investment, Name [Domain] Equity Method Investment, Other than Temporary Impairment Impairment of investment in Saneron Equity Method Investment, Ownership Percentage Ownership interest Equity Method Investments Equity method investment Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments and Joint Ventures Disclosure [Text Block] Investment in Saneron CCEL Therapeutics, Inc. ("Saneron") Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value Inputs, Discount Rate Fair value assumed discount rate Fair Value, Inputs, Level 1 [Member] Level 1 [Member] Fair Value Inputs, Long-term Revenue Growth Rate Fair value long-term sustainable growth rate Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value, Measurements, Recurring [Member] Fair Value, Measurements, Recurring [Member] Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Financial Instrument [Axis] Financial Instrument [Axis] Finite-Lived Intangible Assets, Accumulated Amortization Less: Accumulated amortization Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Gross Customer relationships Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Net Net Intangible Assets Finite-Lived Intangible Assets, Net [Abstract] Finite-Lived Intangible Assets, Net [Abstract] Finite-Lived Intangible Asset, Useful Life Useful lives Goodwill Goodwill Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill Disclosure [Text Block] Goodwill Goodwill, Impairment Loss Goodwill impairment loss Guarantees, Indemnifications and Warranties Policies [Policy Text Block] Product Warranty and Cryo-Cell CaresTM Program Impairment of Long-Lived Assets Held-for-use Impairment on long lived assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Long-Lived Assets INDIA India [Member] Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Income before income tax expense Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Income before equity in losses of affiliate and income tax expense Income (Loss) from Equity Method Investments Equity in losses Equity in losses of affiliate Equity in losses of affiliate Income Statement [Abstract] Income Statement [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Income Tax Expense (Benefit) Total income tax expense Income tax expense Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability U.S. Income tax expense Income Tax, Policy [Policy Text Block] Income Taxes Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Accrued Liabilities Accrued expenses Increase (Decrease) in Deferred Revenue Deferred revenue Increase (decrease) in deposits and other assets. Increase Decrease In Deposits And Other Assets Deposits and other assets, net Increase (Decrease) in Inventories Inventory Increase (Decrease) in Operating Capital [Abstract] Changes in assets and liabilities: Increase (Decrease) in Other Current Assets Other current assets Increase (Decrease) in Prepaid Expense Prepaid expenses Increase (Decrease) in Restricted Cash Release of restricted cash held in escrow Increased payment warranty. Increased Payment Warranty Increased payment warranty Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Dilutive common shares issuable upon exercise of stock options Initial Loan [Member] Initial Loan [Member] Initial Loan [Member] Intangible Assets Disclosure [Text Block] Intangible Assets Intangible Assets, Net (Excluding Goodwill) Intangible assets, net Intangible Assets, Net (Excluding Goodwill) [Abstract] Intangible Assets, Net (Excluding Goodwill) [Abstract] Interest Expense Total interest expense Interest expense Interest Expense, Debt Notes payable, interest expense Inventory, collection kits. Inventory Collection Kits Collection kits EX-101.PRE 11 ccel-20160229_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Feb. 29, 2016	Apr. 08, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Feb. 29, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q1
Trading Symbol	CCEL
Entity Registrant Name	CRYO CELL INTERNATIONAL INC
Entity Central Index Key	0000862692
Current Fiscal Year End Date	--11-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		9,087,254

XML 13 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($)	Feb. 29, 2016	Nov. 30, 2015
Current Assets
Cash and cash equivalents	$ 3,581,736	$ 4,152,162
Restricted cash	204,400	204,344
Marketable securities	617,108	610,424
Accounts receivable (net of allowance for doubtful accounts of $2,156,577 and $2,067,130, respectively)	3,216,990	3,058,379
Deferred tax assets, current portion	1,336,000	1,336,000
Prepaid expenses	429,309	427,819
Inventory, net	498,524	475,608
Other current assets	58,341	88,392
Total current assets	9,942,408	10,353,128
Property and Equipment-net	847,626	879,070
Other Assets
Intangible assets, net	503,877	516,328
Goodwill	1,777,822	1,777,822
Deferred tax assets, net of current portion	5,987,814	5,930,987
Deposits and other assets, net	40,611	40,611
Total other assets	8,310,124	8,265,748
Total assets	19,100,158	19,497,946
Current Liabilities
Accounts payable	1,685,775	1,328,619
Accrued expenses	1,566,676	2,005,351
Current portion of note payable	309,987	307,420
Deferred revenue	6,614,192	6,782,562
Total current liabilities	10,176,630	10,423,952
Other Liabilities
Deferred revenue, net of current portion	11,169,495	10,869,218
Note payable, net of current portion	790,957	868,947
Long-term liability - revenue sharing agreements	2,300,000	2,300,000
Total other liabilities	14,260,452	14,038,165
Total liabilities	$ 24,437,082	$ 24,462,117
Commitments and contingencies (Note 12)
Stockholders' Deficit
Preferred stock
Common stock ($.01 par value, 20,000,000 authorized; 12,481,065 issued and 9,097,472 outstanding as of February 29, 2016 and 12,260,340 issued and 9,010,322 outstanding as of November 30, 2015)	$ 124,810	$ 122,603
Additional paid-in capital	28,780,474	28,530,368
Treasury stock, at cost	(8,726,486)	(8,318,083)
Accumulated other comprehensive income	76,205	169,932
Accumulated deficit	(25,591,927)	(25,468,991)
Total stockholders' deficit	(5,336,924)	(4,964,171)
Total liabilities and stockholders' deficit	$ 19,100,158	$ 19,497,946
Series A Junior Participating Preferred Stock [Member]
Stockholders' Deficit
Preferred stock

XML 14 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - USD ($)	Feb. 29, 2016	Nov. 30, 2015
Accounts receivable, allowance for doubtful accounts	$ 2,156,577	$ 2,067,130
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	20,000,000	20,000,000
Common stock, shares issued	12,481,065	12,260,340
Common stock, shares outstanding	9,097,472	9,010,322
Series A Junior Participating Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	20,000	20,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

XML 15 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Comprehensive (Loss) Income - USD ($)	3 Months Ended
	Feb. 29, 2016	Feb. 28, 2015
Revenue:
Processing and storage fees	$ 5,020,459	$ 4,673,969
Licensee and royalty income		169,412
Product revenue	131,739
Total revenue	5,152,198	4,843,381
Costs and Expenses:
Cost of sales	1,348,291	1,273,987
Selling, general and administrative expenses	3,597,253	2,913,973
Research, development and related engineering	8,684	11,988
Depreciation and amortization	41,548	18,242
Total costs and expenses	4,995,776	4,218,190
Operating Income	156,422	625,191
Other Income (Expense):
Other expense	(18,024)	(4,075)
Interest expense	(261,334)	(301,286)
Total other expense	(279,358)	(305,361)
Income before equity in losses of affiliate and income tax expense	(122,936)	319,830
Equity in losses of affiliate		(8,248)
Income before income tax expense	(122,936)	311,582
Income tax expense	0	(25,412)
Net (Loss) Income	$ (122,936)	$ 286,170
Net (loss) income per common share - basic	$ (0.01)	$ 0.03
Weighted average common shares outstanding - basic	8,971,373	9,824,566
Net (loss) income per common share - diluted	$ (0.01)	$ 0.03
Weighted average common shares outstanding - diluted	8,971,373	10,058,649
Other Comprehensive (Loss) Income
Unrealized loss on marketable securities (net of tax)	$ (93,727)	$ 0
Comprehensive (Loss) Income	$ (216,663)	$ 286,170

XML 16 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Feb. 29, 2016	Feb. 28, 2015
Statement of Cash Flows [Abstract]
Net (loss) income	$ (122,936)	$ 286,170
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization expense	74,618	58,994
Compensatory element of stock options	252,313	190,513
Provision for doubtful accounts	192,045	140,505
Equity in losses of affiliate		8,248
Changes in assets and liabilities:
Accounts receivable	(350,656)	(268,511)
Prepaid expenses	(1,490)	46,080
Inventory	(22,916)
Other current assets	30,051	(6,500)
Deposits and other assets, net		9,575
Accounts payable	357,156	342,799
Accrued expenses	(438,675)	(564,624)
Deferred revenue	131,907	85,715
Net cash provided by operating activities	101,417	328,964
Cash flows from investing activities:
Release of restricted cash held in escrow	(56)	(56)
Purchases of property and equipment	(30,723)	(23,303)
Purchases of marketable securities and other investments, net	(157,238)	4,413
Net cash used in investing activities	(188,017)	(18,946)
Cash flows from financing activities:
Treasury stock purchases	(408,403)	(39,042)
Repayments of note payable	(75,423)
Net cash used in financing activities	(483,826)	(39,042)
Increase (decrease) in cash and cash equivalents	(570,426)	270,976
Cash and cash equivalents - beginning of period	4,152,162	3,279,267
Cash and cash equivalents - end of period	3,581,736	3,550,243
Supplemental non-cash investing activities:
Unrealized loss on marketable securities	$ (93,727)	$ 0

XML 17 R6.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Significant Accounting Policies

3 Months Ended

Feb. 29, 2016

Accounting Policies [Abstract]

Basis of Presentation and Significant Accounting Policies

Note 1 - Basis of Presentation and Significant Accounting Policies

Revenue Recognition

Revenue Recognition for Arrangements with Multiple Deliverables

The Company records revenue from the sale of the Prepacyte^®-CB product line upon shipment of the product to the Company’s customers.

Income Taxes

The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Increases or decreases to the unrecognized tax benefits could result from management’s belief that a position can or cannot be sustained upon examination based on subsequent information or potential lapse of the applicable statute of limitation for certain tax positions.

Long-Lived Assets

Stock Compensation

Fair Value of Financial Instruments


Level 1		Quoted prices in active markets for identical assets or liabilities.

Level 2		Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

Level 3		Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.


			Fair Value Measurements
	Fair Value at		at February 29, 2016 Using
Description	February 29, 2016		Level 1		Level 2		Level 3
Assets:
Trading Securities	$	261,167	$	261,167		—		—
Available-for-sale		355,941		355,941		—		—

	$	617,108	$	617,108		—		—


			Fair Value Measurements
	Fair Value at		at November 30, 2015 Using
Description	November 30, 2015		Level 1		Level 2		Level 3
Assets:
Trading Securities	$	136,798	$	136,798		—		—
Available-for-sale		473,626		473,626		—		—

	$	610,424	$	610,424		—		—

The following is a description of the valuation techniques used for these items, as well as the general classification of such items pursuant to the fair value hierarchy:

Product Warranty and Cryo-Cell Cares^TM Program

In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February 1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients. Additionally, under the Cryo-Cell Cares^TM program, the Company was paying $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloblative transplant procedure. Effective October 13, 2014, the Company no longer offers the Cryo-Cell Cares^TMprogram to new clients. The product warranty is available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties. The Company does not maintain insurance for this warranty program and therefore maintains reserves to cover any estimated potential liabilities. The Company’s reserve balance is based on the $75,000 or $50,000 (as applicable) maximum payment and the $10,000 maximum expense reimbursement multiplied by formulas to determine the projected number of units requiring a payout. The Company determined the estimated expected usage and engraftment failure rates based on an analysis of the historical usage and failure rates and the historical usage and failure rates in other private and public cord blood banks based on published data. The Company’s estimates of expected usage and engraftment failure could change as a result of changes in actual usage rates or failure rates and such changes would require an adjustment to the established reserves. The historical usage and failure rates have been very low and a small increase in the number of transplants or engraftment failures could cause a significant increase in the estimated rates used in determining the Company’s reserve. In addition, the reserve will increase as additional umbilical cord blood specimens are stored which are subject to the warranty. As of February 29, 2016 and November 30, 2015 the Company recorded reserves under these programs in the amounts of approximately $17,000 and $17,000, respectively, which are included in accrued expenses in the accompanying consolidated balance sheets.

Recently Issued Accounting Pronouncements

In June 2014, the FASB issued Accounting Standards Update No. 2014-12, Compensation – Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could be Achieved after the Requisite Service Period (“ASU 2014-12”). This update requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition in determining expense recognition for the award. As a result, this type of performance condition may delay expense recognition until achievement of the performance target is probable. ASU 2014-12 is effective for reporting periods beginning after December 15, 2015, and early adoption is permitted. We will adopt ASU 2014-12 effective December 1, 2016 and it is not anticipated to have a material impact on our financial statements.

In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606). This update provides a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. In August 2015, the FASB issued Accounting Standards Update No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which defers the effective date of the guidance in Accounting Standards Update No. 2014-09 by one year. This update is now effective for annual and interim periods beginning after December 15, 2017, which will require us to adopt these provisions in the first quarter of fiscal 2019. Early application is permitted for annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. This update permits the use of either the retrospective or cumulative effect transition method. The Company has not yet selected a transition method nor has it determined the effect of the standard its consolidated financial statements and related disclosures.

XML 18 R7.htm IDEA: XBRL DOCUMENT

Acquisition

3 Months Ended

Feb. 29, 2016

Business Combinations [Abstract]

Acquisition

Note 2 – Acquisition

The following summarizes the fair value of the consideration for the Acquisition:


Consideration
Cash	$	375,374
Assumed liabilities of seller		1,073,898
Note payable to seller		1,300,000
Prepaid expense paid to seller by purchaser		104,000

Consideration	$	2,853,272

The following summarizes the allocation of the total purchase price for the Acquisition:


Inventory	$	529,097
Tooling molds		35,353
License agreement		470,000
Customer relationships		41,000

Total identifiable net assets acquired		1,075,450

Goodwill	$	1,777,822

The goodwill is attributable to the manufacturing process used in the operation of the cord blood business. The goodwill recognized will be deductible for income tax purposes.

The fair values of the license agreement and customer relationships reflect the anticipated cash flows over their expected lives.

The operating results of Prepacyte CB have been included in the consolidated statements of comprehensive income since the date of acquisition.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

XML 19 R8.htm IDEA: XBRL DOCUMENT

Inventory

3 Months Ended

Feb. 29, 2016

Inventory Disclosure [Abstract]

Inventory

Note 3 – Inventory

Inventory has been pledged as collateral on the note payable incurred in connection with the APA (Note 2). The components of inventory at February 29, 2016 and November 30, 2015 are as follows:


	February 29, 2016			November 30, 2015
Raw materials	$	14,228		$	9,041
Work-in-process		144,013			134,727
Finished goods		280,345			282,152
Collection kits		67,656			57,406
Inventory reserve		(7,718	)		(7,718	)

Total inventory	$	498,524		$	475,608

XML 20 R9.htm IDEA: XBRL DOCUMENT

Goodwill	3 Months Ended
Goodwill	Feb. 29, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Note 4– Goodwill Goodwill represents the excess of the purchase price of the assets acquired from CytoMedical (Note 2) over the estimated fair value of the net tangible and identifiable intangible assets acquired. The annual impairment assessment is performed as of September 1, 2015, and an assessment is performed at other times if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below its carrying value. Step one of the impairment assessment compares the fair value of the reporting unit to its carrying value and if the fair value exceeds its carrying value, goodwill is not impaired. If the carrying value exceeds the fair value, the implied fair value of goodwill is compared to the carrying value of goodwill. If the implied fair value exceeds the carrying value then goodwill is not impaired; otherwise, an impairment loss would be recorded by the amount the carrying value exceeds the implied fair value. As of February 29, 2016 and November 30, 2015, goodwill is reflected on the consolidated balance sheets at $1,777,822. As of February 29, 2016, there were no indications of impairment and no impairment loss was recorded for goodwill.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Intangible Assets

3 Months Ended

Feb. 29, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Note 5– Intangible Assets

Intangible assets were as follows as of February 29, 2016 and November 30, 2015:


	Useful lives	February 29, 2016			November 30, 2015
Patents	10-20 years	$	34,570		$	34,570
Less: Accumulated amortization			(8,541	)		(8,075	)
License agreement	10 years		470,000			470,000
Less: Accumulated amortization			(31,333	)		(17,917	)
Customer relationships	15 years		41,000			41,000
Less: Accumulated amortization			(1,819	)		(3,250	)

Net Intangible Assets		$	503,877		$	516,328

Amortization expense of intangibles was approximately $12,000 and $500 for the three months ended February 29, 2016 and February 28, 2015, respectively.

XML 22 R11.htm IDEA: XBRL DOCUMENT

Note Payable	3 Months Ended
Note Payable	Feb. 29, 2016
Debt Disclosure [Abstract]
Note Payable	Note 6– Note Payable On June 30, 2015, the Company entered into a note payable in the amount of $1,300,000 in connection with the APA (Note 2). The note is payable in 48 monthly installments of $29,938 including principal and interest at the rate of 5% per annum, commencing on July 31, 2015, and ending on June 30, 2019. Pursuant to the APA, the note is secured by all assets, inventory, molds and tools sold and transferred to the Company, tangible personal property held for sale or lease, accounts, contract rights, and other rights to payment and general intangibles. In the event the Company sells less than 8,000 Prepacyte CB Processing System Units (“Units”) to outside customers during each of the twelve month periods during the note term beginning each July 1 and ending June 30, the note will be reduced by the lesser of $100,000 plus interest at the rate of 5% per annum or $25 times the difference between 8,000 and the actual number of Units sold plus interest at the rate of 5% per annum. Any annual note reduction shall serve to lower the remaining monthly note payments. In addition, in the event that during the period from July 1, 2018 to June 30, 2019, the Company shall sell 4,000 Units, it will receive an additional $120,000 note reduction. However, if the Company sells more than 4,000 Units, it will owe additional principal in the amount of $25 times the difference between 8,000 and the actual number of Units sold plus interest at the rate of 5% per annum, which is payable on June 30, 2019. The Company expects that it will sell more than 4,000 Units for the periods noted and does not expect a note reduction. As of the three months ended February 29, 2016, the Company made three installments of $29,938 and recognized $14,391 of interest expense related to the note payable. The remaining principal balance of the note payable is $1,100,944 and $1,176,367 and is reflected on the accompanying balance sheets as of February 29, 2016 and November 30, 2015, respectively.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Segment Reporting

3 Months Ended

Feb. 29, 2016

Segment Reporting [Abstract]

Segment Reporting

Note 7– Segment Reporting

The Company is organized in two reportable segments:


Net revenue:
Umbilical cord blood and cord tissue stem cell service	$	5,020,459
Prepacyte^®-CB		131,739

Total net revenue	$	5,152,198

Cost of sales:
Umbilical cord blood and cord tissue stem cell service	$	1,245,023
Prepacyte^®-CB		103,268

Total cost of sales	$	1,348,291

Depreciation and amortization:
Umbilical cord blood and cord tissue stem cell service	$	28,678
Prepacyte^®-CB		12,870

Total depreciation and amortization	$	41,548

Operating income:
Umbilical cord blood and cord tissue stem cell service	$	127,951
Prepacyte^®-CB		28,471

Total operating income	$	156,422

Interest expense:
Umbilical cord blood and cord tissue stem cell service	$	246,943
Prepacyte^®-CB		14,391

Total interest expense	$	261,334

The following table shows the assets by segment as of February 29, 2016 and November 30, 2015:


Assets:
Umbilical cord blood and cord tissue stem cell service	$	16,349,269	$	16,697,621

Prepacyte^®-CB		2,750,889		2,800,325

Total assets	$	19,100,158	$	19,497,946

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

(Loss) Income per Common Share

3 Months Ended

Feb. 29, 2016

Earnings Per Share [Abstract]

(Loss) Income per Common Share

Note 8 – (Loss) Income per Common Share

Net (loss) income per common share data are based on net income. The following table sets forth the calculation of basic and diluted (loss) earnings per share:


	For the three months ended February 29, 2016			For the three months ended February 28, 2015
Numerator:
Net (Loss) Income	($	122,936	)	$	286,170
Denominator:
Weighted-average shares outstanding-basic		8,971,373			9,824,566
Dilutive common shares issuable upon exercise of stock options		—			234,083
Weighted-average shares-diluted		8,971,373			10,058,649

(Loss) Earnings per share:
Basic	($	0.01	)	$	0.03

Diluted	($	0.01	)	$	0.03

XML 25 R14.htm IDEA: XBRL DOCUMENT

Investment in Saneron CCEL Therapeutics, Inc. ("Saneron")	3 Months Ended
	Feb. 29, 2016
Equity Method Investments and Joint Ventures [Abstract]
Investment in Saneron CCEL Therapeutics, Inc. ("Saneron")	Note 9 - Investment in Saneron CCEL Therapeutics, Inc. (“Saneron”) As of February 29, 2016 and November 30, 2015, the Company had an ownership interest of approximately 33% in Saneron, which is accounted for under the equity method of accounting. As of February 29, 2016 and November 30, 2015, the net Saneron investment reflected on the consolidated balance sheets is $0. During 2015 management reviewed the Saneron investment to determine if there were any indicators that would imply that the investment was impaired. Based on management’s review, there was evidence of a loss in value in the fourth quarter of 2015 and the Company impaired the net Saneron investment, resulting in a charge of approximately $684,000. The main factors that led to this decision included a decline in grant funding, reduction in employees, and the inability to sustain research activities due to lack of funding. Without the ability to perform current and future research activities, management believes the carrying amount of the investment is impaired and not recoverable. In October 2013, the Company entered into a Convertible Promissory Note Purchase Agreement with Saneron. Cryo-Cell will loan Saneron in quarterly payments an aggregate amount up to $300,000, subject to certain conditions. The initial loan amount was $150,000 to be paid in four quarterly installments of $37,500 per quarter. If after the initial loan amount, Saneron has made best efforts, satisfactory to Cryo-Cell in its sole discretion, to have started independently or via serving as a sponsor of a clinical trial related to its U-CORD-CELL™ program, then Cryo-Cell will agree to lend Saneron an additional $150,000 through a series of four additional quarterly payments of $37,500. Upon receipt of each quarterly payment, Saneron will deliver a convertible promissory note (“Note”) that matures five years from the date of the Note. Upon maturity of any Note, Saneron will have the option to repay all or a portion of the loan in cash or convert the outstanding principal and accrued interest under the applicable Note(s) into shares of Saneron common stock. The Company made five payments of $37,500 through November 30, 2014. The Company made no additional payments through February 29, 2016. For the three months ended February 29, 2016 and February 28, 2015, the Company recorded equity in losses of Saneron operations of approximately $0 and $8,000, respectively, which related to certain stock awards that were granted by Saneron at below fair market value to certain employees, consultants and members of Saneron management who represent owners of Saneron and serve on its board of directors.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Stockholder's Equity

3 Months Ended

Feb. 29, 2016

Equity [Abstract]

Stockholder's Equity

Note 10 – Stockholder’s Equity

Service-based vesting condition options

The fair value of each option award is estimated on the date of the grant using the Black-Scholes valuation model that uses the assumptions noted in the following table. Expected volatility is based on the historical volatility of the Company’s stock over the most recent period commensurate with the expected life of the Company’s stock options. The Company uses historical data to estimate option exercise and employee termination within the valuation model. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The expected term of options granted to employees is calculated, in accordance with the “simplified method” for “plain vanilla” stock options allowed under GAAP. Expected dividends are based on the historical trend of the Company not issuing dividends.

There were no options granted during the three months ended February 29, 2016 and February 28, 2015, respectively.

Stock option activity for the three months ended February 29, 2016, was as follows:


	Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
Outstanding at November 30, 2015		968,930	$	2.17		5.01	$	1,095,525

Granted		—		—				—
Exercised		—		—				—
Expired/forfeited		—		—				—

Outstanding at February 29, 2016		968,930	$	2.17		4.76	$	1,531,543

Exercisable at February 29, 2016		959,552	$	2.16		4.75	$	1,525,260

There were no options exercised during the three months ended February 29, 2016 and February 28, 2015.

Significant option groups exercisable at February 29, 2016 and related price and contractual life information are as follows:


	Outstanding						Exercisable
Range of Exercise Prices	Outstanding		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price		Outstanding		Weighted Average Exercise Price
$1.01 to $2.00		465,930		5.23	$	1.72		465,930	$	1.72
$2.01 to $3.00		480,500		4.23	$	2.56		480,500	$	2.56
$3.01 to $4.00		22,500		6.36	$	3.08		13,122	$	3.08

		968,930		4.76	$	2.17		959,552	$	2.16

A summary of the status of the Company’s non-vested options as of February 29, 2016, and changes during the three months ended February 29, 2016, is presented below:


	Options			Weighted Average Grant-Date Fair Value
Non-vested at November 30, 2015		15,003		$	1.90

Granted		—			—
Vested		(5,625	)		1.90
Forfeited		—			—

Non-vested at February 29, 2016		9,378		$	1.90

Performance and market-based vesting condition options

Restricted common shares

The Employment Agreements also provide for the grant of restricted shares of the Company’s common stock based on certain performance measures being attained by each of the Company’s Co-CEOs. The Employment Agreements state if David Portnoy and Mark Portnoy are employed by the Company on November 30, 2014, then no later than February 15, 2015, the Company will grant up to 186,487 and 162,163 shares of restricted common shares, respectively, based on certain performance thresholds, as defined in the agreements. In addition, if David Portnoy and Mark Portnoy are employed by the Company on November 30, 2015, then no later than February 15, 2016, the Company will grant up to an additional 186,487 and 162,163 shares of restricted common shares, respectively, based on similar performance thresholds, as defined in the agreements. As of February 28, 2015, certain market and performance thresholds were met during fiscal year 2014 and the Board agreed to grant David Portnoy and Mark Portnoy 31,087 and 27,033 shares of restricted common shares, respectively. The fair value of these shares as of February 28, 2015 was $134,000 and is reflected as selling, general and administrative expense in the accompanying consolidated statements of comprehensive (loss) income. As of February 29, 2016, certain market and performance thresholds were met during fiscal year 2015 and the Board agreed to grant David Portnoy and Mark Portnoy 118,062 and 102,663 shares of restricted common shares, respectively. The fair value of the shares with a grant date during the 2015 fiscal year was approximately $336,000 and is reflected as selling, general and administrative expense in the accompanying consolidated statements of comprehensive (loss) income for the year ended November 30, 2015. There was approximately $242,000 of total unrecognized compensation cost as of November 30, 2015 which was recognized during the first quarter of fiscal year 2016 and is reflected as selling, general and administrative expense in the accompanying consolidated statements of comprehensive (loss) income as the Board granted certain subjective performance shares with a grant date during the 2016 fiscal year.

Preferred Stock Rights Plan

(i)

The tenth day after the earlier of either the public announcement or public disclosure of facts indicating that a person has become an Acquiring Person; or

(ii)

The Rights will expire on December 5, 2017, unless earlier redeemed, exchanged, terminated, or unless the expiration date is extended.

XML 27 R16.htm IDEA: XBRL DOCUMENT

License Agreements

3 Months Ended

Feb. 29, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

License Agreements

Note 11 – License Agreements

Technology Agreements

Marketing Agreements

The Company has definitive license agreements to market the Company’s umbilical cord blood stem cell programs in Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama and Pakistan. In October 2012, the Company sent a notice of termination to the Company’s Venezuelan affiliate for failure to meet its payment obligation in accordance with the contract. Subsequent to the notice of termination, payment was received for outstanding processing and storage fees due from Venezuela. The Company is in the process of discussing a new agreement. The Company continues to accept umbilical cord blood stem cell specimens to be processed and stored during the negotiations. In December 2012, the Company sent a notice of termination to the Company’s affiliate in Ecuador for failure to meet its payment obligation in accordance with the contract. Subsequent to the notice of termination, payment was received for outstanding processing and storage fees due from Ecuador. In August 2013, the Company was notified that its affiliate in Ecuador was closed by the National Institute of Organic Donation (INDOT). As a result, the Company recorded an allowance for uncollectible receivables for the $150,000 processing and storage fee receivable due from Ecuador in the third quarter of fiscal 2013. During the fourth quarter of fiscal 2013, the Company began to bill the Ecuadorian clients directly for cord blood specimens that are stored at the Company’s facility in Oldsmar, Florida.


	For the three months ended
	February 29, 2016						February 28, 2015
	License Fee		Process and Storage Royalties		Total		License Fee		Process and Storage Royalties		Total
India	$	—	$	—	$	—	$	—	$	169,412	$	169,412

Total	$	—	$	—	$	—	$	—	$	169,412	$	169,412

XML 28 R17.htm IDEA: XBRL DOCUMENT

Legal Proceedings	3 Months Ended
Legal Proceedings	Feb. 29, 2016
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	Note 12– Legal Proceedings On December 3, 2015, a complaint styled Gary T. Brotherson, M.D., et al. v. Cryo-Cell International, Inc., Case No. 15-007461-CI, Circuit Court, Sixth Judicial Circuit, Pinellas County, Florida, was served on the Company, naming it as defendant and alleging, among other things, that the Company breached certain agreements with plaintiffs and seeking damages in excess of $15,000, the jurisdictional amount of the court in which the action is pending. On January 12, 2016, the Company served its answer, affirmative defenses, and counterclaim against the plaintiffs. The Company believes the plaintiffs’ claims are without merit and it intends to contest the action vigorously. At this time, it is not possible for the Company to estimate the loss or the range of possible loss in the event of an unfavorable outcome, as the ultimate resolution of the complaint is uncertain at this time. No amounts have been accrued as of February 29, 2016. On January 20, 2016, a class action complaint was filed in the Court of the Chancery of the State of Delaware against the Company and certain current officers and directors of the Company (Case No. 11915-VCG). The complaint alleges breaches of fiduciary duties and is seeking appropriate injunctive relief and a declaratory judgment against defendants that a certain provision of the Company’s Amended and Restated Bylaws, as amended through September 22, 2014 is in violation of Section 141(k) of the Delaware General Corporation Law. The Company believes the litigation is without merit and intends to defend the litigation vigorously. The Company’s maximum deductible under its Directors and Officers insurance policy for this claim is $500,000. On February 24, 2016, a complaint styled Charles D. Nyberg and Mary J. Nyberg and as trustees of the CDMJNyberg Family Trust v. Cryo-Cell International, Inc., Case No. 8:16CV408t30, United States District Court, Middle District of Florida, Hillsborough County, Florida, was served on the Company, naming it as defendant and alleging, among other things, that the Company breached certain agreements with plaintiffs and seeking damages in excess of $75,000, the jurisdictional amount of the court in which the action is pending. The Company believes the plaintiffs’ claims are without merit and it intends to contest the action vigorously. At this time, it is not possible for the Company to estimate the loss or the range of possible loss in the event of an unfavorable outcome, as the ultimate resolution of the complaint is uncertain at this time. No amounts have been accrued as of February 29, 2016. In addition, from time to time the Company is subject to proceedings, lawsuits, contract disputes and other claims in the normal course of its business. The Company believes that the ultimate resolution of current matters should not have a material adverse effect on the Company’s business, consolidated financial position or results of operations. It is possible, however, that there could be an unfavorable ultimate outcome for or resolution which could be material to the Company’s results of operations for a particular quarterly reporting period. Litigation is inherently uncertain and there can be no assurance that the Company will prevail. The Company does not include an estimate of legal fees and other related defense costs in its estimate of loss contingencies.

XML 29 R18.htm IDEA: XBRL DOCUMENT

Share Repurchase Plan	3 Months Ended
Share Repurchase Plan	Feb. 29, 2016
Equity [Abstract]
Share Repurchase Plan	Note 13– Share Repurchase Plan In December 2011, the Company’s Board of Directors authorized management at its discretion to repurchase up to one million (1,000,000) shares of the Company’s outstanding common stock. On June 6, 2012, the Board of Directors of the Company increased the number of shares of the Company’s outstanding common stock that management is authorized to repurchase to up to three million (3,000,000) shares. On April 8, 2015, the Board of Directors of the Company increased the number of shares of the Company’s outstanding common stock that management is authorized to repurchase to up to six million (6,000,000) shares. The repurchases must be effectuated through open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission or in such other manner as will comply with the provisions of the Securities Exchange Act of 1934. On June 30, 2015, the Company commenced a partial tender offer to purchase up to 750,000 shares of its common stock, at a price of $3.25 per share. The maximum number of shares proposed to be purchased in the tender offer represented 7.76% of Cryo-Cell’s outstanding common shares (including shares of unvested restricted stock) as of June 30, 2015. On June 29, 2015, the last trading day prior to the commencement of the tender offer, the last sale price of Cryo-Cell’s shares reported on the OTCBB was $2.29 per share. The tender offer expired on July 28, 2015. Cryo-Cell accepted for purchase 557,805 shares of its common stock, including all “odd lots” properly tendered, at a purchase price of $3.25 per share, for an aggregate cost of $1,812,866 excluding fees and expenses relating to the tender offer. As of February 29, 2016, the Company had repurchased an aggregate of 3,383,365 shares of the Company’s common stock at an average price of $2.58 per share through open market and privately negotiated transactions. The Company purchased 133,575 and 16,421 shares of the Company’s common stock during the first quarters of fiscal 2016 and 2015, respectively, at an average price of $3.06 per share and $2.38 per share, respectively. The repurchased shares will be held as treasury stock at cost and have been removed from common shares outstanding as of February 29, 2016 and November 30, 2015. As of February 29, 2016 and November 30, 2015, 3,383,365 and 2,231,532 shares, respectively, were held as treasury stock. Subsequent to the balance sheet date, the Company repurchased an additional 10,218 shares of the Company’s common stock at an average price of $3.41 per share through open market and privately negotiated transactions.

XML 30 R19.htm IDEA: XBRL DOCUMENT

Subsequent Event	3 Months Ended
Subsequent Event	Feb. 29, 2016
Subsequent Events [Abstract]
Subsequent Event	Note 14– Subsequent Event On March 22, 2016, subsequent to the balance sheet date, the Company received a Commitment Letter from a Lender for a term loan of up to $8,000,000 in senior credit facilities. The Commitment Letter is subject to execution and delivery to the Lender of financing documents required by the Lender. If the loan has not been fully executed and closed by May 30, 2016, the commitment will expire and there will be no obligation for the Lender to fund the loan. On April 4, 2016, subsequent to the balance sheet date, the Company received a Commitment Letter from an additional lender for a subordinated loan of up to $1,000,000. The funding of the loan will be subject to certain terms and conditions outlined in the term sheet. The Commitment Letter for the subordinated loan expires on April 30, 2016.

XML 31 R20.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Significant Accounting Policies (Policies)

3 Months Ended

Feb. 29, 2016

Accounting Policies [Abstract]

Revenue Recognition

Revenue Recognition

Revenue Recognition for Arrangements with Multiple Deliverables

The Company records revenue from the sale of the Prepacyte^®-CB product line upon shipment of the product to the Company’s customers.

Income Taxes

Income Taxes

Long-Lived Assets

Long-Lived Assets

Stock Compensation

Stock Compensation

Fair Value of Financial Instruments

Fair Value of Financial Instruments


Level 1		Quoted prices in active markets for identical assets or liabilities.

Level 2		Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

Level 3		Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.


			Fair Value Measurements
	Fair Value at		at February 29, 2016 Using
Description	February 29, 2016		Level 1		Level 2		Level 3
Assets:
Trading Securities	$	261,167	$	261,167		—		—
Available-for-sale		355,941		355,941		—		—

	$	617,108	$	617,108		—		—


			Fair Value Measurements
	Fair Value at		at November 30, 2015 Using
Description	November 30, 2015		Level 1		Level 2		Level 3
Assets:
Trading Securities	$	136,798	$	136,798		—		—
Available-for-sale		473,626		473,626		—		—

	$	610,424	$	610,424		—		—

The following is a description of the valuation techniques used for these items, as well as the general classification of such items pursuant to the fair value hierarchy:

Product Warranty and Cryo-Cell CaresTM Program

Product Warranty and Cryo-Cell Cares^TM Program

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References + Details

XML 32 R21.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Significant Accounting Policies (Tables)

3 Months Ended

Feb. 29, 2016

Accounting Policies [Abstract]

Financial Assets and Liabilities Measured at Fair Value on Recurring Basis


			Fair Value Measurements
	Fair Value at		at February 29, 2016 Using
Description	February 29, 2016		Level 1		Level 2		Level 3
Assets:
Trading Securities	$	261,167	$	261,167		—		—
Available-for-sale		355,941		355,941		—		—

	$	617,108	$	617,108		—		—


			Fair Value Measurements
	Fair Value at		at November 30, 2015 Using
Description	November 30, 2015		Level 1		Level 2		Level 3
Assets:
Trading Securities	$	136,798	$	136,798		—		—
Available-for-sale		473,626		473,626		—		—

	$	610,424	$	610,424		—		—

XML 33 R22.htm IDEA: XBRL DOCUMENT

Acquisition (Tables)

3 Months Ended

Feb. 29, 2016

Business Combinations [Abstract]

Summary of Fair Value of Consideration for the Acquisition

The following summarizes the fair value of the consideration for the Acquisition:


Consideration
Cash	$	375,374
Assumed liabilities of seller		1,073,898
Note payable to seller		1,300,000
Prepaid expense paid to seller by purchaser		104,000

Consideration	$	2,853,272

Summary of Allocation of Total Purchase Price for the Acquisition

The following summarizes the allocation of the total purchase price for the Acquisition:


Inventory	$	529,097
Tooling molds		35,353
License agreement		470,000
Customer relationships		41,000

Total identifiable net assets acquired		1,075,450

Goodwill	$	1,777,822

XML 34 R23.htm IDEA: XBRL DOCUMENT

Inventory (Tables)

3 Months Ended

Feb. 29, 2016

Inventory Disclosure [Abstract]

Components of Inventory

The components of inventory at February 29, 2016 and November 30, 2015 are as follows:


	February 29, 2016			November 30, 2015
Raw materials	$	14,228		$	9,041
Work-in-process		144,013			134,727
Finished goods		280,345			282,152
Collection kits		67,656			57,406
Inventory reserve		(7,718	)		(7,718	)

Total inventory	$	498,524		$	475,608

XML 35 R24.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

3 Months Ended

Feb. 29, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

Intangible assets were as follows as of February 29, 2016 and November 30, 2015:


	Useful lives	February 29, 2016			November 30, 2015
Patents	10-20 years	$	34,570		$	34,570
Less: Accumulated amortization			(8,541	)		(8,075	)
License agreement	10 years		470,000			470,000
Less: Accumulated amortization			(31,333	)		(17,917	)
Customer relationships	15 years		41,000			41,000
Less: Accumulated amortization			(1,819	)		(3,250	)

Net Intangible Assets		$	503,877		$	516,328

XML 36 R25.htm IDEA: XBRL DOCUMENT

Segment Reporting (Tables)

3 Months Ended

Feb. 29, 2016

Segment Reporting [Abstract]

Summary of Net Revenue Cost of Sales, Operating Profit, Depreciation and Amortization, Interest Expense, Income Tax Benefit (Expense), Other Comprehensive Income, and Assets by Segment


Net revenue:
Umbilical cord blood and cord tissue stem cell service	$	5,020,459
Prepacyte^®-CB		131,739

Total net revenue	$	5,152,198

Cost of sales:
Umbilical cord blood and cord tissue stem cell service	$	1,245,023
Prepacyte^®-CB		103,268

Total cost of sales	$	1,348,291

Depreciation and amortization:
Umbilical cord blood and cord tissue stem cell service	$	28,678
Prepacyte^®-CB		12,870

Total depreciation and amortization	$	41,548

Operating income:
Umbilical cord blood and cord tissue stem cell service	$	127,951
Prepacyte^®-CB		28,471

Total operating income	$	156,422

Interest expense:
Umbilical cord blood and cord tissue stem cell service	$	246,943
Prepacyte^®-CB		14,391

Total interest expense	$	261,334

The following table shows the assets by segment as of February 29, 2016 and November 30, 2015:


Assets:
Umbilical cord blood and cord tissue stem cell service	$	16,349,269	$	16,697,621

Prepacyte^®-CB		2,750,889		2,800,325

Total assets	$	19,100,158	$	19,497,946

XML 37 R26.htm IDEA: XBRL DOCUMENT

(Loss) Income per Common Share (Tables)

3 Months Ended

Feb. 29, 2016

Earnings Per Share [Abstract]

Calculation of Basic and Diluted Net (Loss) Income per Common Share

The following table sets forth the calculation of basic and diluted (loss) earnings per share:


	For the three months ended February 29, 2016			For the three months ended February 28, 2015
Numerator:
Net (Loss) Income	($	122,936	)	$	286,170
Denominator:
Weighted-average shares outstanding-basic		8,971,373			9,824,566
Dilutive common shares issuable upon exercise of stock options		—			234,083
Weighted-average shares-diluted		8,971,373			10,058,649

(Loss) Earnings per share:
Basic	($	0.01	)	$	0.03

Diluted	($	0.01	)	$	0.03

XML 38 R27.htm IDEA: XBRL DOCUMENT

Stockholder's Equity (Tables)

3 Months Ended

Feb. 29, 2016

Equity [Abstract]

Stock Option Activity for Options

Stock option activity for the three months ended February 29, 2016, was as follows:


	Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
Outstanding at November 30, 2015		968,930	$	2.17		5.01	$	1,095,525

Granted		—		—				—
Exercised		—		—				—
Expired/forfeited		—		—				—

Outstanding at February 29, 2016		968,930	$	2.17		4.76	$	1,531,543

Exercisable at February 29, 2016		959,552	$	2.16		4.75	$	1,525,260

Significant Option Groups Exercisable Option and its Price and Contractual Life

Significant option groups exercisable at February 29, 2016 and related price and contractual life information are as follows:


	Outstanding						Exercisable
Range of Exercise Prices	Outstanding		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price		Outstanding		Weighted Average Exercise Price
$1.01 to $2.00		465,930		5.23	$	1.72		465,930	$	1.72
$2.01 to $3.00		480,500		4.23	$	2.56		480,500	$	2.56
$3.01 to $4.00		22,500		6.36	$	3.08		13,122	$	3.08

		968,930		4.76	$	2.17		959,552	$	2.16

Summary of Non-Vested Options

A summary of the status of the Company’s non-vested options as of February 29, 2016, and changes during the three months ended February 29, 2016, is presented below:


	Options			Weighted Average Grant-Date Fair Value
Non-vested at November 30, 2015		15,003		$	1.90

Granted		—			—
Vested		(5,625	)		1.90
Forfeited		—			—

Non-vested at February 29, 2016		9,378		$	1.90

XML 39 R28.htm IDEA: XBRL DOCUMENT

License Agreements (Tables)

3 Months Ended

Feb. 29, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of License Fees Earned


	For the three months ended
	February 29, 2016						February 28, 2015
	License Fee		Process and Storage Royalties		Total		License Fee		Process and Storage Royalties		Total
India	$	—	$	—	$	—	$	—	$	169,412	$	169,412

Total	$	—	$	—	$	—	$	—	$	169,412	$	169,412

XML 40 R29.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)		1 Months Ended	3 Months Ended
	Feb. 02, 2016 USD ($)	Dec. 31, 2005 USD ($)	Feb. 29, 2016 USD ($) CompensationPlan Deliverables	Feb. 28, 2015 USD ($)	Nov. 30, 2015 USD ($)
Accounting Policies [Abstract]
Number of deliverables for revenue recognized \| Deliverables			2
Period of doubtful for accounts receivable due from client			21 years
Contracted storage periods option two			21 years
Contracted storage periods option one			1 year
Contracted storage periods option three			Lifetime
Deferred revenue recognition period			12 months
Valuation allowance			$ 2,630,000		$ 2,630,000
U.S. Income tax expense			0	$ 0
Foreign income tax expense			$ 0	25,000
Minimum percentage probability of realized tax benefit on settlement			50.00%
Provisions for interest or penalties related to uncertain tax positions			$ 0	0
Uncertain tax provisions			0	0
Impairment on long lived assets			$ 0	0
Number of employee stock based compensation plan \| CompensationPlan			3
Stock option compensation expense			$ 252,000	191,000
Unrealized holding gain (losses), trading securities			(19,800)	(4,400)
Unrealized gain (losses) on marketable securities, net of tax			(93,727)	$ 0
Payment warranty		$ 50,000
Increased payment warranty	$ 75,000
Additional payment warranty	$ 10,000
Reserves recorded under programs			$ 17,000		$ 17,000

XML 41 R30.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Significant Accounting Policies - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($)	Feb. 29, 2016	Nov. 30, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	$ 617,108	$ 610,424
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities	261,167	136,798
Available-for-sale	355,941	473,626
Total	617,108	610,424
Level 1 [Member] \| Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities	261,167	136,798
Available-for-sale	355,941	473,626
Total	$ 617,108	$ 610,424

XML 42 R31.htm IDEA: XBRL DOCUMENT

Acquisition - Additional Information (Detail)		1 Months Ended	3 Months Ended
Acquisition - Additional Information (Detail)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Feb. 29, 2016 USD ($) $ / Unit	Nov. 30, 2015 USD ($)	May. 31, 2015 USD ($)
Business Acquisition [Line Items]
Note payable to seller			$ 1,100,944	$ 1,176,367
License Agreement [Member]
Business Acquisition [Line Items]
Useful lives			10 years
Customer Relationships [Member]
Business Acquisition [Line Items]
Useful lives			15 years
Asset Purchase Agreement [Member]
Business Acquisition [Line Items]
Asset Purchase Agreement, purchase price less cash and prepaids			$ 2,400,000
Prepaid expense paid to seller by purchaser			104,000
Contingent liability, reduced amount	$ 149,175
Asset Purchase Agreement, cash and inventory paid			1,553,272
Asset Purchase Agreement, cash paid			375,374
Note payable to seller			1,300,000
Cash paid as disbursement of funds		$ 861,783
Transaction costs			$ 22,000
Royalty payment per bag set unit sold \| $ / Unit			5
Fair value assumed discount rate			16.00%
Fair value long-term sustainable growth rate			3.00%
Asset Purchase Agreement [Member] \| License Agreement [Member]
Business Acquisition [Line Items]
Useful lives			10 years
Asset Purchase Agreement [Member] \| Customer Relationships [Member]
Business Acquisition [Line Items]
Useful lives			15 years
Asset Purchase Agreement [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Minimum annual royalties			$ 35,000
Asset Purchase Agreement [Member] \| CytoMedical [Member]
Business Acquisition [Line Items]
Prepaid expense paid to seller by purchaser	662,500				$ 104,000
Portion of contingent liability	225,000
Asset Purchase Agreement, cash paid	$ 586,675		$ 966,597

XML 43 R32.htm IDEA: XBRL DOCUMENT

Acquisition - Summary of Fair Value of Consideration for the Acquisition (Detail) - USD ($)	3 Months Ended
	Feb. 29, 2016	Nov. 30, 2015
Consideration
Note payable to seller	$ 1,100,944	$ 1,176,367
Asset Purchase Agreement [Member]
Consideration
Cash	375,374
Assumed liabilities of seller	1,073,898
Note payable to seller	1,300,000
Prepaid expense paid to seller by purchaser	104,000
Consideration	$ 2,853,272

XML 44 R33.htm IDEA: XBRL DOCUMENT

Acquisition - Summary of Allocation of Total Purchase Price for the Acquisition (Detail) - USD ($)	Feb. 29, 2016	Nov. 30, 2015
Business Acquisition [Line Items]
Goodwill	$ 1,777,822	$ 1,777,822
Asset Purchase Agreement [Member]
Business Acquisition [Line Items]
Inventory	529,097
Tooling molds	35,353
License agreement	470,000
Customer relationships	41,000
Total identifiable net assets acquired	1,075,450
Goodwill	$ 1,777,822

XML 45 R34.htm IDEA: XBRL DOCUMENT

Inventory - Components of Inventory (Detail) - USD ($)	Feb. 29, 2016	Nov. 30, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 14,228	$ 9,041
Work-in-process	144,013	134,727
Finished goods	280,345	282,152
Collection kits	67,656	57,406
Inventory reserve	(7,718)	(7,718)
Total inventory	$ 498,524	$ 475,608

XML 46 R35.htm IDEA: XBRL DOCUMENT

Goodwill - Additional Information (Detail) - USD ($)	3 Months Ended
Goodwill - Additional Information (Detail) - USD ($)	Feb. 29, 2016	Nov. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$ 1,777,822	$ 1,777,822
Goodwill impairment loss	$ 0

XML 47 R36.htm IDEA: XBRL DOCUMENT

Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($)	3 Months Ended
	Feb. 29, 2016	Nov. 30, 2015
Finite-Lived Intangible Assets [Line Items]
Net Intangible Assets	$ 503,877	$ 516,328
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Customer relationships	34,570	34,570
Less: Accumulated amortization	$ (8,541)	(8,075)
Patents [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful lives	10 years
Patents [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful lives	20 years
License Agreement [Member]
Finite-Lived Intangible Assets [Line Items]
Useful lives	10 years
Customer relationships	$ 470,000	470,000
Less: Accumulated amortization	$ (31,333)	(17,917)
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Useful lives	15 years
Customer relationships	$ 41,000	41,000
Less: Accumulated amortization	$ (1,819)	$ (3,250)

XML 48 R37.htm IDEA: XBRL DOCUMENT

Intangible Assets - Additional Information (Detail) - USD ($)	3 Months Ended
	Feb. 29, 2016	Feb. 28, 2015
Finite-Lived Intangible Assets, Net [Abstract]
Amortization expense	$ 12,000	$ 500

XML 49 R38.htm IDEA: XBRL DOCUMENT

Note Payable - Additional Information (Detail)		3 Months Ended
Note Payable - Additional Information (Detail)	Jun. 30, 2015 USD ($) Installments	Feb. 29, 2016 USD ($) Installments $ / System_Unit shares	Nov. 30, 2015 USD ($)
Debt Instrument [Line Items]
Note payable		$ 790,957	$ 868,947
Number of Prepacyte CB Processing System Units to be sold \| shares		4,000
Per unit amount on completion of sales criteria \| $ / System_Unit		25
Notes payable, principal amount outstanding		$ 1,100,944	$ 1,176,367
Maximum [Member]
Debt Instrument [Line Items]
Number of Prepacyte CB Processing System Units to be sold \| shares		8,000
Minimum [Member]
Debt Instrument [Line Items]
Number of Prepacyte CB Processing System Units to be sold \| shares		4,000
Notes Payable [Member]
Debt Instrument [Line Items]
Monthly installment amount		$ 29,938
Asset purchase agreement commencement date	Jul. 31, 2015
Asset purchase agreement closing date	Jun. 30, 2019
Notes payable, number of installments paid \| Installments		3
Notes payable, interest expense		$ 14,391
Asset Purchase Agreement [Member]
Debt Instrument [Line Items]
Note payable	$ 1,300,000
Reduction in note payable		120,000
Notes payable, principal amount outstanding		1,300,000
Asset Purchase Agreement [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Reduction in note payable		$ 100,000
Asset Purchase Agreement [Member] \| Notes Payable [Member]
Debt Instrument [Line Items]
Number of monthly installments \| Installments	48
Repayment interval		Monthly
Monthly installment amount	$ 29,938
Annual interest rate	5.00%

XML 50 R39.htm IDEA: XBRL DOCUMENT

Segment Reporting - Additional Information (Detail)	3 Months Ended
Segment Reporting - Additional Information (Detail)	Feb. 29, 2016 Segments
Umbilical Cord Blood and Cord Tissue Stem Cell Service and Prepacyte-CB [Member]
Segment Reporting Information [Line Items]
Number of reportable segments	2

XML 51 R40.htm IDEA: XBRL DOCUMENT

Segment Reporting - Net Revenue and Operating Profit of Each Segment (Detail) - USD ($)	3 Months Ended
	Feb. 29, 2016	Feb. 28, 2015	Nov. 30, 2015
Segment Reporting Information [Line Items]
Total net revenue	$ 5,152,198	$ 4,843,381
Total cost of sales	1,348,291	1,273,987
Total depreciation and amortization	41,548	18,242
Total operating income	156,422	625,191
Total interest expense	261,334	301,286
Total income tax expense	0	$ 25,412
Total assets	19,100,158		$ 19,497,946
Umbilical Cord Blood and Cord Tissue Stem Cell Service [Member]
Segment Reporting Information [Line Items]
Total net revenue	5,020,459
Total cost of sales	1,245,023
Total depreciation and amortization	28,678
Total operating income	127,951
Total interest expense	246,943
Total income tax expense	0
Total assets	16,349,269		16,697,621
Prepacyte CB [Member]
Segment Reporting Information [Line Items]
Total net revenue	131,739
Total cost of sales	103,268
Total depreciation and amortization	12,870
Total operating income	28,471
Total interest expense	14,391
Total income tax expense	0
Total assets	$ 2,750,889		$ 2,800,325

XML 52 R41.htm IDEA: XBRL DOCUMENT

(Loss) Income per Common Share - Calculation of Basic and Diluted Net (Loss) Income per Common Share (Detail) - USD ($)	3 Months Ended
	Feb. 29, 2016	Feb. 28, 2015
Denominator:
Weighted-average shares outstanding-basic	8,971,373	9,824,566
Dilutive common shares issuable upon exercise of stock options		234,083
Weighted-average shares-diluted	8,971,373	10,058,649
(Loss) Earnings per share:
Basic	$ (0.01)	$ 0.03
Diluted	$ (0.01)	$ 0.03
Net (loss) income	$ (122,936)	$ 286,170

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 53 R42.htm IDEA: XBRL DOCUMENT

(Loss) Income per Common Share - Additional Information (Detail)	3 Months Ended
	Feb. 28, 2015 shares
Employee Stock Incentive Plan [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of outstanding stock options excluded from computation of diluted earnings per share	271,000

XML 54 R43.htm IDEA: XBRL DOCUMENT

Investment in Saneron CCEL Therapeutics, Inc. ("Saneron") - Additional Information (Detail)	3 Months Ended			12 Months Ended
	Feb. 29, 2016 USD ($) Installment	Nov. 30, 2015 USD ($)	Feb. 28, 2015 USD ($)	Nov. 30, 2014 USD ($) Installment
Schedule of Equity Method Investments [Line Items]
Equity in losses			$ (8,248)
Saneron [Member]
Schedule of Equity Method Investments [Line Items]
Ownership interest	33.00%	33.00%
Equity method investment	$ 0	$ 0
Impairment of investment in Saneron		$ 684,000
Loan Saneron in quarterly payments an aggregate amount	300,000
Initial loan amount	$ 150,000
Additional quarterly payments \| Installment	0			5
Date of maturity	5 years
First initial quarterly payment				$ 37,500
Saneron [Member] \| Stock Awards [Member]
Schedule of Equity Method Investments [Line Items]
Equity in losses	$ 0		$ 8,000
Saneron [Member] \| Initial Loan [Member]
Schedule of Equity Method Investments [Line Items]
Additional quarterly payments \| Installment	4
Quarterly installments per quarter	$ 37,500
Saneron [Member] \| Additional Loan [Member]
Schedule of Equity Method Investments [Line Items]
Initial loan amount	$ 150,000
Additional quarterly payments \| Installment	4
Quarterly installments per quarter	$ 37,500

XML 55 R44.htm IDEA: XBRL DOCUMENT

Stockholder's Equity - Additional Information (Detail) - USD ($)				1 Months Ended	3 Months Ended		12 Months Ended
	Feb. 29, 2016	Feb. 28, 2015	Nov. 30, 2013	May. 31, 2012	Feb. 29, 2016	Feb. 28, 2015	Nov. 30, 2015	Nov. 26, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, Shares					0	0
Options, exercised					0	0
Stock option activity for options	968,930				968,930		968,930
Shares granted during period					0
Common stock, par value	$ 0.01				$ 0.01		$ 0.01
Share distribution period					20 days
Common shares exchange ratio					One Common Share per Right
Preferred Stock, redemption price Per Share	$ 0.01				$ 0.01
Market price for common stock, percentage					50.00%
Assets sale percentage					50.00%
Rights expiration date					Dec. 05, 2017
2006 Plan [Member] \| Employee Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock for issuance pursuant to stock options or restricted stock	1,000,000				1,000,000
Option issued	568,930				568,930		568,930
Shares issued under stock incentive plan	253,679				253,679
2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock for issuance pursuant to stock options or restricted stock	1,500,000				1,500,000
Unrecognized compensation cost related to non-vested share-based compensation arrangements granted	$ 242,000				$ 242,000
2012 Plan [Member] \| Employee Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in common stock reserved for issuance				2,500,000
Preferred Stock Rights Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, par value								$ 0.01
Terms for right to purchasing preferred stock					Each Right represents the right to purchase from the Company one one-thousandth (1/1,000) of a share of Series A Junior Participating Preferred Stock (the "Preferred Shares"), subject to adjustment as provided in the Rights Agreement. This fraction of a Preferred Share is substantially similar to a Common Share, in that the Rights Agreement provides for each Preferred Share to have the voting, liquidation and dividend rights that are equivalent to 1,000 times the rights of a Common Share.
Service Based Stock Options [Member] \| 2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, Shares					400,000		400,000
Service Based Restricted Shares [Member] \| 2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, Shares					129,729		129,729
Performance Based Options [Member] \| 2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, Shares					278,948		203,403
Market Based Options [Member] \| 2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, Shares					116,240		116,240
Service-Based Vesting Condition Options [Member] \| 2000 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested share-based compensation arrangements granted	15,000				$ 15,000
Service-Based Vesting Condition Options [Member] \| 2006 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested share-based compensation arrangements granted	15,000				15,000
Service-Based Vesting Condition Options [Member] \| 2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested share-based compensation arrangements granted	15,000				15,000
Restricted Common Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested share-based compensation arrangements granted	$ 0				$ 0
Description of minimum requirement to be satisfied by employee for additional restricted common share					In addition, if David Portnoy and Mark Portnoy are employed by the Company on November 30, 2015, then no later than February 15, 2016, the Company will grant up to an additional 186,487 and 162,163 shares of restricted common shares, respectively, based on similar performance thresholds, as defined in the agreements
Restricted Common Shares [Member] \| David Portnoy [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock for issuance pursuant to stock options or restricted stock	186,487				186,487
Additional restricted common shares to be granted					186,487
Restricted Common Shares [Member] \| Mark Portnoy [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock for issuance pursuant to stock options or restricted stock	162,163				162,163
Additional restricted common shares to be granted					162,163
Restricted Common Shares [Member] \| 2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation, percentage of vesting upon grant					33.30%
Restricted Common Shares [Member] \| 2012 Plan [Member] \| December One Two Thousand Fourteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation, percentage of vesting upon grant					33.30%
Restricted Common Shares [Member] \| 2012 Plan [Member] \| December One Two Thousand Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation, percentage of vesting upon grant					33.30%
Restricted Common Shares [Member] \| 2012 Plan [Member] \| David Portnoy [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted during period	118,062	31,087	70,270
Restricted Common Shares [Member] \| 2012 Plan [Member] \| Mark Portnoy [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted during period	102,663	27,033	59,459
Restricted Common Shares [Member] \| Selling, General and Administrative Expenses [Member] \| 2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation vested period fair value	$ 336,000	$ 134,000				$ 160,000
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, Shares					0	0
Market-Based Vesting Condition Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, Shares					0	0
Performance and Market-Based Vesting Condition Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option activity for options	0	0			0	0
Stock Option [Member] \| Service-Based Vesting Condition Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average period					4 months 10 days
Total fair value of shares vested					$ 11,000
Stockholder Rights Agreement [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Acquisition of common stock outstanding percentage	20.00%				20.00%
Addition of common stock outstanding percentage					0.25%
Increase in common stock outstanding percentage					22.50%

XML 56 R45.htm IDEA: XBRL DOCUMENT

Stockholder's Equity - Stock Option Activity for Options (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Feb. 29, 2016	Feb. 28, 2015	Nov. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Outstanding at November 30, 2015	968,930
Granted	0	0
Exercised	0	0
Expired/forfeited	0
Outstanding at February 29, 2016	968,930		968,930
Exercisable at February 29, 2016	959,552
Outstanding at November 30, 2015, Weighted Average Exercise Price	$ 2.17
Granted, Weighted Average Exercise Price	0
Exercised, Weighted Average Exercise Price	0
Expired/forfeited, Weighted Average Exercise Price	0
Outstanding at February 29, 2016, Weighted Average Exercise Price	2.17		$ 2.17
Exercisable at February 29, 2016, Weighted Average Exercise Price	$ 2.16
Outstanding at February 29, 2016, Weighted Average Remaining Contractual Term (Years)	4 years 9 months 4 days		5 years 4 days
Exercisable at February 29, 2016, Weighted Average Remaining Contractual Term (Years)	4 years 9 months
Outstanding at November 30, 2015	$ 1,095,525
Granted	0
Exercised	0
Expired/forfeited	0
Outstanding at February 29, 2016	1,531,543		$ 1,095,525
Exercisable at February 29, 2016	$ 1,525,260

XML 57 R46.htm IDEA: XBRL DOCUMENT

Stockholder's Equity - Significant Option Groups Exercisable Option and its Price and Contractual Life (Detail)	3 Months Ended
	Feb. 29, 2016 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, Outstanding \| shares	968,930
Outstanding, Weighted Average Remaining Contractual Life (Years)	4 years 9 months 4 days
Outstanding, Weighted Average Exercise Price	$ 2.17
Exercisable, Outstanding \| shares	959,552
Exercisable, Weighted Average Exercise Price	$ 2.16
Range 1 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices Minimum	1.01
Range of Exercise Prices Maximum	$ 2.00
Outstanding, Outstanding \| shares	465,930
Outstanding, Weighted Average Remaining Contractual Life (Years)	5 years 2 months 23 days
Outstanding, Weighted Average Exercise Price	$ 1.72
Exercisable, Outstanding \| shares	465,930
Exercisable, Weighted Average Exercise Price	$ 1.72
Range 2 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices Minimum	2.01
Range of Exercise Prices Maximum	$ 3.00
Outstanding, Outstanding \| shares	480,500
Outstanding, Weighted Average Remaining Contractual Life (Years)	4 years 2 months 23 days
Outstanding, Weighted Average Exercise Price	$ 2.56
Exercisable, Outstanding \| shares	480,500
Exercisable, Weighted Average Exercise Price	$ 2.56
Range 3 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices Minimum	3.01
Range of Exercise Prices Maximum	$ 4.00
Outstanding, Outstanding \| shares	22,500
Outstanding, Weighted Average Remaining Contractual Life (Years)	6 years 4 months 10 days
Outstanding, Weighted Average Exercise Price	$ 3.08
Exercisable, Outstanding \| shares	13,122
Exercisable, Weighted Average Exercise Price	$ 3.08

XML 58 R47.htm IDEA: XBRL DOCUMENT

Stockholder's Equity - Summary of Non-Vested Options (Detail)	3 Months Ended
	Feb. 29, 2016 $ / shares shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Non-vested at November 30, 2015, Shares \| shares	15,003
Granted, Shares \| shares	0
Vested, Shares \| shares	(5,625)
Forfeited, Shares \| shares	0
Non-vested at February 29, 2016, Shares \| shares	9,378
Non-vested at November 30, 2015, Weighted Average Grant-Date Fair Value \| $ / shares	$ 1.90
Granted, Weighted Average Grant-Date Fair Value \| $ / shares	0
Vested, Weighted Average Grant-Date Fair Value \| $ / shares	1.90
Forfeited, Weighted Average Grant-Date Fair Value \| $ / shares	0
Non-vested at February 29, 2016, Weighted Average Grant-Date Fair Value \| $ / shares	$ 1.90

XML 59 R48.htm IDEA: XBRL DOCUMENT

License Agreements - Additional Information (Detail)	1 Months Ended	3 Months Ended
License Agreements - Additional Information (Detail)	Aug. 31, 2013 USD ($)	Feb. 29, 2016 USD ($) Agreement	Nov. 30, 2015 USD ($)
License Agreements [Line Items]
Types of agreements \| Agreement		2
Ecuador affiliate [Member] \| Affiliated Entity [Member]
License Agreements [Line Items]
Accounts receivable, additional allowance for doubtful accounts	$ 150,000
LifeCell License and Agreement [Member]
License Agreements [Line Items]
Royalty revenue		$ 4,100,000
LifeCell License and Agreement [Member] \| Maximum [Member]
License Agreements [Line Items]
Royalties receivable		1,000,000	$ 1,000,000
Royalty revenue		$ 10,000,000

XML 60 R49.htm IDEA: XBRL DOCUMENT

License Agreements - Summary of License Fees Earned (Detail) - USD ($)	3 Months Ended
	Feb. 29, 2016	Feb. 28, 2015
License Agreements [Line Items]
License Fee	$ 0	$ 0
Process and Storage Royalties		169,412
Total		169,412
India [Member]
License Agreements [Line Items]
License Fee	$ 0	0
Process and Storage Royalties		169,412
Total		$ 169,412

XML 61 R50.htm IDEA: XBRL DOCUMENT

Legal Proceedings - Additional Information (Detail) - USD ($)	Feb. 24, 2016	Jan. 20, 2016	Dec. 03, 2015
Case No.15-007461-CI [Member]
Loss Contingencies [Line Items]
Directors and officers insurance policy claim deductible			$ 15,000
Case No.11915-VCG [Member]
Loss Contingencies [Line Items]
Directors and officers insurance policy claim deductible		$ 500,000
Case No. 8:16CV408t30 [Member]
Loss Contingencies [Line Items]
Directors and officers insurance policy claim deductible	$ 75,000

XML 62 R51.htm IDEA: XBRL DOCUMENT

Share Repurchase Plan - Additional Information (Detail) - USD ($)		1 Months Ended	3 Months Ended
	Mar. 01, 2016	Jun. 30, 2015	Feb. 29, 2016	Feb. 28, 2015	Nov. 30, 2015	Apr. 08, 2015	Jun. 06, 2012	Dec. 31, 2011
Equity, Class of Treasury Stock [Line Items]
Number of shares authorized to repurchase						(6,000,000)	(3,000,000)	(1,000,000)
Share repurchase plan			Open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
Tender offer to purchase common stock price per share		$ 3.25
Percentage of outstanding common shares purchased under tender offer		7.76%
Tender offer sales price		$ 2.29
Number of shares repurchased			3,383,365
Average price per share (repurchased)			$ 2.58
Treasury stock, shares			3,383,365		2,231,532
Subsequent Event [Member]
Equity, Class of Treasury Stock [Line Items]
Number of shares repurchased	10,218
Average price per share (repurchased)	$ 3.41
Maximum [Member]
Equity, Class of Treasury Stock [Line Items]
Tender offer to purchase common stock shares		750,000
Common Stock [Member]
Equity, Class of Treasury Stock [Line Items]
Number of shares repurchased		557,805	133,575	16,421
Average price per share (repurchased)		$ 3.25	$ 3.06	$ 2.38
Share repurchase plan, shares repurchased value		$ 1,812,866

XML 63 R52.htm IDEA: XBRL DOCUMENT

Subsequent Event - Additional Information (Detail) - Commitment Letter [Member] - USD ($)	3 Months Ended
	Feb. 29, 2016	Apr. 04, 2016	Mar. 22, 2016
Subsequent Event [Member]
Subsequent Event [Line Items]
Subordinated loan amount		$ 1,000,000
Senior Credit Facilities [Member]
Subsequent Event [Line Items]
Term loan, description	The Commitment Letter is subject to execution and delivery to the Lender of financing documents required by the Lender. If the loan has not been fully executed and closed by May 30, 2016, the commitment will expire and there will be no obligation for the Lender to fund the loan.
Senior Credit Facilities [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Term loan, maximum borrowing capacity			$ 8,000,000

EXCEL 64 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
O[E\K;:;K+9 M]K]V?OGQ<9W7'P[ZI__46 >\/:/ MR]MR47]Z=?7J;?TW@?B'_+Y ,,/$/V7+QO:N/OSS^P2^?IN\^>GCJP\_77Y\ M\_ZG2_S75<> 5["'#:S_#6#+E^0?\\?&D+O-I@Z1+NB>G@X&IZ-^QU2OBT6^ M2:[@N_MRTYCG9IDM\/F'?%UNM@BS+6>_ILD-W87D M_6Y;;>'"P.>-?92KJEP4;?)T5\R3_ E2R:F[ES>H3? T(DB:P M@?K3]]L'P!&=(FN%_,=R"XBZ_YWK#1#I#: 145YM/.&=O/^,T*D.V^ M0&CK[EM&^+$LYY^+1>.:MT)/#NT $%_"):D*.#Q* MYF^+[+98[$>_=?:(N-?R?+/+N\_\*MXM F!5;O.NX3S@-CG@RJ[Q/$: 1?>Z M^6SW;*P^T['G\Y-9_;'?O"U7]Z?;?+/T*WX$PB03$[-'HIC=;_)\V49'["GO MV3._MN<%)*S%EJ9@^@7B!,R6&/*MVL*:*V5ZVA>.I&@"$^[9;[A;$ZA@A M9L!+-_D#W#Z@Y$FQ@G^WW5+_U;S]9!AYJN@0][YJ$P ==2G-R!+P?N7R1] M.@:>=9W!A9D5ZXS$@H =A$S)O[PC\#;$SGT,_P2&! 1_R&'<;/&\6P!H8:SI M(8YZ )W3@*T'WV01WR#RL5\P;A[[=KE/; J7;<_*X]<.+KOU]?8UM[ZZ=\'F MV&^V\!\F97 3KZ)+C& -88SMM%P ],G5^TB!>SO*J("##6 M;[)[0)>\26[?%C/DB3F]N"D?LP70_?8+"J/.=[/M?K;7\? *R 1?P5?"A!N+ MQE<03!7(J8UEWN2+!6PG38 1Y*@PX%#9?%FL2!]! ;&3O8.$"UK#["&%"P]R M9+GV>NTF9W*3@Q2URO--RWF"J -WKV EDR9=(O_\UZR-APKG]WOM6M%[$/Z8 MFKQIA30+!H(:)P*QYPV(\6LR28MPF .N;KN>6W[=.00MX#8'.I.3#D&XD2P MSN#L@KP)"VRVA#\F3'B*_VC;%_^L.#OSGXQD\@"47WKO6%!;T@\ZV9 M>Q$-P,L/-_4VJXI9_$\^T@K*KFO@2WN4:;] M%[4/NBU'C1-I2DY_VE4BJVY+9-(EB*FP>=RP(FQ)_R(U?+TI/Q5S6/WM8U)Z M&I"A?DN0:MSPO=2G"\L1I/![AEILDB_\GEEB+=?X;9M&^JFH<-2CA(JK!] \ MD6FN1&VCU1EQJ[&5%E&F4_=N.XBC -AJ!;FC8[[;E$M8[B<@B0> _@%@EE4Y M@FP3&T>2AWR!9"[)J]FF_-R X0ZX3"9D;6U5_%Q5_+V?M-^>H&/SZ@G=6A5M M#Z9=E=,RV[9["$1WQ0IDRP,@BA6!9*V[:((2M%!_2_)OZ*A. MYCG_A3>5QSG&]M5I)$,:G8-,L,+Y\3#)O/J4SW,\M:X/;W;K-=]+8,&K9D(PB<01"'%$7/(X 8+W;$_^ FN7VZ MV1[MVS5TZ12'\V)D-X-R^V1_W*_A1TA_<=3MPP;$\B5Y4UR.WI0.FT#X5=2$ MY '$ $#@?.76:.[<,,&\VCR6IU<@2"/!3A8;+6[K8IYD:$. M[$[^^I=_Q[6(+?RO?_E_$U@=_.C'@I^>X_VO=GA4V](10'8+(5R;_!Y5>N0X M) ' PYN8M+WZ,B->0A9UT,'@58<@*'"-Q=(W_O"H\>A!,+I>PSUF6 MFE,#?)XC9Y\CM,MEL<4O#)!AH++J ',O>0.R1^6JW3TP:/QP^Y!M<>HJ/^*B MW"(Z9[A:7,6?=JL9@92VBLMO_0B7@ "O\)5-#EA@(1LAT/^HFA:IY))@[]CW M@B3M-9Q0,NB?_B/LA@,-D\X8UD%=BMV">)E((P#4E MO)L%P6AF."N<(RZ5V0$A%,X#\/&'#MN:Y[T$")MK';Z5+B1-NN"8+A":;_WN M"L+V.> 9JKQ[BW6X+5RF1=<#Z"_C7(WKD)_#6O-RRW=( M ^!;^/@6-NY0DEFB84!0K?GEJYMK_+*7X-R))Y@N_U*@_82N[F?@F-%QXC!$ M9>SYP:^P5)AL0=*V*Y TDL\&P@F.Z+%<#DW]\P,[:!\L[*MA6N/1 Q] X3; M!*&P!8@B1?U4C7FA1$T6\_RPO2*&B! MS/C42!@-07?)#0>G=,N-'=&#DI#4OZ^T85' +E^X[J_X=U92.N=]7XO M=YMO/^>,"E4>@WY7*3C;;VVRS(%;SIOG26A'D@9QL @(:"G%BV6P!*CR*@=2 M'K]"GR&B(K7"@6; 64"HVY!DGB5D=CG-%N4*-H'2;B_Y(9]E<+\C#,3UK.1, M:%W LQ*X6DKT73AC(*RUXV#-NP;P"$A\C$I+F(LJ.<&IB?]8&ACQ:[BH5<]= M+EE]#X<#I,J@GD$"9#X;INVHI[#TX6AU37REBZ!? F:BJV@!!+*7-&9T)/GD M[:A:GQ7H >S],0&6Q"#$F[EA4N!'8/X&4\$9H+#($]X#X%:)3*8'BN,[,S[0 MD RTN,>CL \)V2:_?739W5:NG1Z]9P95)S>P('=Y!O*-OP(-)#%D=21-8K =G<'>T,& :,@2(KP MO1+F:#8G1Q-=2<(TV0F;H 0NN"V\6("%^'O,^_#:E;LMWQFY,KK.BF4$0"9@ M=C, 2L5$?ID] N/;(.37++,E/I&MH M\AK@"N*%4,3!Z^7I4'S/D_H]=\U[CH15Q=WZS7TH\"WD*@X/G_$*C0LLM0#\ M4!O,C (\]\!^UP"H2Y EXB()B+_9AX$*3(7M2,?(IE>3 :DU5Y"$ '3S87X MH*J(%83+UCTE$6$Z/2$;3-Q<;55FI(A\UVE$8FB$BVF$A99:XTA[IR6QXPQ5 M6@HN@HON]^2M [#QA8^QT,%UPDK44\MPD#+O0+[?*( ,X'IH;* O\WF-FE5$ MJ9@S 0WX#*\_G@+_(62J/+= ).HE]0@3H?\.)5I:!8(PTAIOQ5Q2L;E$4$\D M$1] XUHD"P YTZ3:FB)4QN7A MH1G539 AD62\2>&C_Q!,-YL34:A1(R?I:; MO+A?!8QT1YX>:$B- T36ZE1G D7@7A0Y/E,6DVKG&E^ V2(#'+[#9<[KYY15 M/J"GN(MFY;N,#HEP@R(SE3]JA=DJ_[)-!D/1*>,U9(NJ;-Q\O+6PXXZ[3U<+ MP>FJAV*]UL>@&,^)M8&@NV"(!F&)!'W !1"<>\F-^*TES5:QP";UP.G(BX3K;=;HK;'5MX 6J!XU9>,&XQRR0SX-YT?[.E M#[4DY8J#@W21KAXDHSJP1E[2BE ZK R]"/MU>_:[)#KYB@H4#HEA0 M.<]X6-)!^'PBM@G0@5&W"\2'NN3.9X;G[%"#%:.?CXKAB-+I2**P.*+4_Y,$ MH'9#:HMYU\:?(L=TD>A6PC;1RG(+E'\FI,1*5NA.1*- MIX2]:'V0LS98LQF.[/P]]\>Z%NR-3-O*RTD"AF;9RL['--H#U@7 HGQ'IC,8BVV?J*PBB$J6HPI8WHQ8O$$/N95J1 HF M)2:8:$^I;0+F"<8PE.'(D,#K\_I+7=9IV:5B)@MZ(BBPJDYWH-K=80 8WA5X MFU5C\;QO,/!+K-FP@6(3S4L0E%LI9B&T(Y;*8(7'B@,$.ML MSJMT"0$FH@J1>UHBB8 M8]:LUH%.H=\8K^#7?)G,0. RFD"!]Z^\WV1K@!%RB*QBU;AA#9$%.2ORUF&A M]H4UK.<+$0F \3,E^1.B]Z@R'F$U;T<2U\8$T'C:. !%RAZZ+LPS9Q&VJ*Q4 MTH;20B.M].TBZ;N*PE[BL-HH5*6).:( =3AQ%#?9J(+$4]T=;(EEPX55RKTD M!E0D_Y0Q$=6@R^VC^USN !OKG)"N1 4\)%-^H-.P$9MQ*B'/;H\L_3BJO@2, M ;0.I;(X]BF/?8ICG^+8>- 5AOB*T8O9H$$7=6:TNHD9/@NT4U9;IS"AK9)E M,@%TS-B$ ZN<])&=S3C,'Y91/"#B P1)/W'>4T^,QS,REFL(Z-ZMU@[#GM,( MARHADXC^0PCV;F7V%0D1,P2^.)*8(@2O&5$;$EGN1" )AX"R ,P$_P%8PO[U MJ'03S$>82GJ#(;J,25K=1FY8N'GK*#2&J,, @I9/\7:[,*"IM:0"/<5V2=B?N1S2/X0K\V"F+@!GJ MVNCMT$.9YTL*?=KPYU;&\:)(!11C7GY>LHY$&SA8T4$>PYPDAT.5XB<1+ 5;*61MX\IGJZYK"+SQN,(@"H M K1PS?8+\9G#$A[7:"Q.?(8!!DDW M#!(6LXC*._V"=,&8O<^+.?NO2XHM?K3P4,WYZUEZSW'NAH^41#WGLCWPIWZ+ M*Z$(%/EV2BCA9F:<9+W(5E&XR1RC!8M;OA4<^]17J?-@0$8$%J+ 0&[11>*^_9I-IQ,F#0PXEG"-YQZR:U;C#!3(E_%Y/I_##RG>'5"J3$6MXRTA!ZR<_> FC<\!L3(7&_*^9JR^B/RV;A610=9^0F\MXV8"# K%',]&.PO@<=F> \R-Y_B' M109PNYD!,N>5T=B7Y3Q?L"C0-AQ);R0=1XMVC46S2@6 GILMW8$@R9%IL9F5+"''K\*1ZSS>%N5,5,%F#1>(1)<8NRS?$BJU?_D[+Y2"KEE[0\,U*+MZ MMUPKA%!B!K*NAA9)1GHH[A^ <5:HC&TYRU$6:DU;HK0U#M18K-7FQ!P4_2!Z M9QC[4@VZ)@\Q+##;DEP'A*ZH?@5]/L^=%RN1LZ; 3BQP5H_P+:"U% M)2[A5.T:=WE![)K8,>I>\H-8U^N$@[PSL#1CX2)?&PAQN;?Z-5QL>I[B>B=2 M*T,+@'A[@B\$;C*)JOX$@WVBK8F8ZO0@V'C-FE'^94MF/3HL]OG[J+H-J#+, M<'5+E6.;.FM*ZE?Q3U5"%3-Z,-"J&1H Y"1Y%4\^Q!?6C)[P)QJ!2-GX=062 M6,W?$[S&2XI+$F\R.T<$1D@YPLFDMLEE#!=D\2JOA2!�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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.1.900 html 138 281 1 false 54 0 false 12 false false R1.htm 101 - Document - Document and Entity Information Sheet http://cryo-cell.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Consolidated Balance Sheets Sheet http://cryo-cell.com/taxonomy/role/StatementOfFinancialPositionClassified Consolidated Balance Sheets Statements 2 false false R3.htm 104 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://cryo-cell.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Consolidated Statements of Comprehensive (Loss) Income Sheet http://cryo-cell.com/taxonomy/role/StatementOfIncomeAlternative Consolidated Statements of Comprehensive (Loss) Income Statements 4 false false R5.htm 106 - Statement - Consolidated Statements of Cash Flows Sheet http://cryo-cell.com/taxonomy/role/StatementOfCashFlowsIndirect Consolidated Statements of Cash Flows Statements 5 false false R6.htm 107 - Disclosure - Basis of Presentation and Significant Accounting Policies Sheet http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock Basis of Presentation and Significant Accounting Policies Notes 6 false false R7.htm 108 - Disclosure - Acquisition Sheet http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock Acquisition Notes 7 false false R8.htm 109 - Disclosure - Inventory Sheet http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock Inventory Notes 8 false false R9.htm 110 - Disclosure - Goodwill Sheet http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsGoodwillDisclosureTextBlock Goodwill Notes 9 false false R10.htm 111 - Disclosure - Intangible Assets Sheet http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock Intangible Assets Notes 10 false false R11.htm 112 - Disclosure - Note Payable Sheet http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock Note Payable Notes 11 false false R12.htm 113 - Disclosure - Segment Reporting Sheet http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock Segment Reporting Notes 12 false false R13.htm 114 - Disclosure - (Loss) Income per Common Share Sheet http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock (Loss) Income per Common Share Notes 13 false false R14.htm 115 - Disclosure - Investment in Saneron CCEL Therapeutics, Inc. ("Saneron") Sheet http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsEquityMethodInvestmentsDisclosureTextBlock Investment in Saneron CCEL Therapeutics, Inc. ("Saneron") Notes 14 false false R15.htm 116 - Disclosure - Stockholder's Equity Sheet http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsShareholdersEquityAndShareBasedPaymentsTextBlock Stockholder's Equity Notes 15 false false R16.htm 117 - Disclosure - License Agreements Sheet http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsLicenseAgreementsTextBlock License Agreements Notes 16 false false R17.htm 118 - Disclosure - Legal Proceedings Sheet http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock Legal Proceedings Notes 17 false false R18.htm 119 - Disclosure - Share Repurchase Plan Sheet http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsTreasuryStockTextBlock Share Repurchase Plan Notes 18 false false R19.htm 120 - Disclosure - Subsequent Event Sheet http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock Subsequent Event Notes 19 false false R20.htm 121 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) Sheet http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlockPolicies Basis of Presentation and Significant Accounting Policies (Policies) Policies http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock 20 false false R21.htm 122 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables) Sheet http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlockTables Basis of Presentation and Significant Accounting Policies (Tables) Tables http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock 21 false false R22.htm 123 - Disclosure - Acquisition (Tables) Sheet http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables Acquisition (Tables) Tables http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock 22 false false R23.htm 124 - Disclosure - Inventory (Tables) Sheet http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables Inventory (Tables) Tables http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock 23 false false R24.htm 125 - Disclosure - Intangible Assets (Tables) Sheet http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables Intangible Assets (Tables) Tables http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock 24 false false R25.htm 126 - Disclosure - Segment Reporting (Tables) Sheet http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables Segment Reporting (Tables) Tables http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock 25 false false R26.htm 127 - Disclosure - (Loss) Income per Common Share (Tables) Sheet http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables (Loss) Income per Common Share (Tables) Tables http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock 26 false false R27.htm 128 - Disclosure - Stockholder's Equity (Tables) Sheet http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsShareholdersEquityAndShareBasedPaymentsTextBlockTables Stockholder's Equity (Tables) Tables http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsShareholdersEquityAndShareBasedPaymentsTextBlock 27 false false R28.htm 129 - Disclosure - License Agreements (Tables) Sheet http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsLicenseAgreementsTextBlockTables License Agreements (Tables) Tables http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsLicenseAgreementsTextBlock 28 false false R29.htm 130 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) Sheet http://cryo-cell.com/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformation Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) Details 29 false false R30.htm 131 - Disclosure - Basis of Presentation and Significant Accounting Policies - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) Sheet http://cryo-cell.com/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis Basis of Presentation and Significant Accounting Policies - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) Details 30 false false R31.htm 132 - Disclosure - Acquisition - Additional Information (Detail) Sheet http://cryo-cell.com/taxonomy/role/DisclosureAcquisitionAdditionalInformation Acquisition - Additional Information (Detail) Details 31 false false R32.htm 133 - Disclosure - Acquisition - Summary of Fair Value of Consideration for the Acquisition (Detail) Sheet http://cryo-cell.com/taxonomy/role/DisclosureAcquisitionSummaryOfFairValueOfConsiderationForTheAcquisition Acquisition - Summary of Fair Value of Consideration for the Acquisition (Detail) Details 32 false false R33.htm 134 - Disclosure - Acquisition - Summary of Allocation of Total Purchase Price for the Acquisition (Detail) Sheet http://cryo-cell.com/taxonomy/role/DisclosureAcquisitionSummaryOfAllocationOfTotalPurchasePriceForTheAcquisition Acquisition - Summary of Allocation of Total Purchase Price for the Acquisition (Detail) Details 33 false false R34.htm 135 - Disclosure - Inventory - Components of Inventory (Detail) Sheet http://cryo-cell.com/taxonomy/role/DisclosureInventoryComponentsOfInventory Inventory - Components of Inventory (Detail) Details 34 false false R35.htm 136 - Disclosure - Goodwill - Additional Information (Detail) Sheet http://cryo-cell.com/taxonomy/role/DisclosureGoodwillAdditionalInformation Goodwill - Additional Information (Detail) Details 35 false false R36.htm 137 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Detail) Sheet http://cryo-cell.com/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssets Intangible Assets - Schedule of Intangible Assets (Detail) Details 36 false false R37.htm 138 - Disclosure - Intangible Assets - Additional Information (Detail) Sheet http://cryo-cell.com/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation Intangible Assets - Additional Information (Detail) Details 37 false false R38.htm 139 - Disclosure - Note Payable - Additional Information (Detail) Sheet http://cryo-cell.com/taxonomy/role/DisclosureNotePayableAdditionalInformation Note Payable - Additional Information (Detail) Details 38 false false R39.htm 140 - Disclosure - Segment Reporting - Additional Information (Detail) Sheet http://cryo-cell.com/taxonomy/role/DisclosureSegmentReportingAdditionalInformation Segment Reporting - Additional Information (Detail) Details 39 false false R40.htm 141 - Disclosure - Segment Reporting - Net Revenue and Operating Profit of Each Segment (Detail) Sheet http://cryo-cell.com/taxonomy/role/DisclosureSegmentReportingNetRevenueAndOperatingProfitOfEachSegment Segment Reporting - Net Revenue and Operating Profit of Each Segment (Detail) Details 40 false false R41.htm 142 - Disclosure - (Loss) Income per Common Share - Calculation of Basic and Diluted Net (Loss) Income per Common Share (Detail) Sheet http://cryo-cell.com/taxonomy/role/DisclosureLossIncomePerCommonShareCalculationOfBasicAndDilutedNetLossIncomePerCommonShare (Loss) Income per Common Share - Calculation of Basic and Diluted Net (Loss) Income per Common Share (Detail) Details 41 false false R42.htm 143 - Disclosure - (Loss) Income per Common Share - Additional Information (Detail) Sheet http://cryo-cell.com/taxonomy/role/DisclosureLossIncomePerCommonShareAdditionalInformation (Loss) Income per Common Share - Additional Information (Detail) Details 42 false false R43.htm 144 - Disclosure - Investment in Saneron CCEL Therapeutics, Inc. ("Saneron") - Additional Information (Detail) Sheet http://cryo-cell.com/taxonomy/role/DisclosureInvestmentInSaneronCCELTherapeuticsIncSaneronAdditionalInformation Investment in Saneron CCEL Therapeutics, Inc. ("Saneron") - Additional Information (Detail) Details http://cryo-cell.com/taxonomy/role/NotesToFinancialStatementsEquityMethodInvestmentsDisclosureTextBlock 43 false false R44.htm 145 - Disclosure - Stockholder's Equity - Additional Information (Detail) Sheet http://cryo-cell.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation Stockholder's Equity - Additional Information (Detail) Details 44 false false R45.htm 146 - Disclosure - Stockholder's Equity - Stock Option Activity for Options (Detail) Sheet http://cryo-cell.com/taxonomy/role/DisclosureStockholdersEquityStockOptionActivityForOptions Stockholder's Equity - Stock Option Activity for Options (Detail) Details 45 false false R46.htm 147 - Disclosure - Stockholder's Equity - Significant Option Groups Exercisable Option and its Price and Contractual Life (Detail) Sheet http://cryo-cell.com/taxonomy/role/DisclosureStockholdersEquitySignificantOptionGroupsExercisableOptionAndItsPriceAndContractualLife Stockholder's Equity - Significant Option Groups Exercisable Option and its Price and Contractual Life (Detail) Details 46 false false R47.htm 148 - Disclosure - Stockholder's Equity - Summary of Non-Vested Options (Detail) Sheet http://cryo-cell.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfNonVestedOptions Stockholder's Equity - Summary of Non-Vested Options (Detail) Details 47 false false R48.htm 149 - Disclosure - License Agreements - Additional Information (Detail) Sheet http://cryo-cell.com/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformation License Agreements - Additional Information (Detail) Details 48 false false R49.htm 150 - Disclosure - License Agreements - Summary of License Fees Earned (Detail) Sheet http://cryo-cell.com/taxonomy/role/DisclosureLicenseAgreementsSummaryOfLicenseFeesEarned License Agreements - Summary of License Fees Earned (Detail) Details 49 false false R50.htm 151 - Disclosure - Legal Proceedings - Additional Information (Detail) Sheet http://cryo-cell.com/taxonomy/role/DisclosureLegalProceedingsAdditionalInformation Legal Proceedings - Additional Information (Detail) Details 50 false false R51.htm 152 - Disclosure - Share Repurchase Plan - Additional Information (Detail) Sheet http://cryo-cell.com/taxonomy/role/DisclosureShareRepurchasePlanAdditionalInformation Share Repurchase Plan - Additional Information (Detail) Details 51 false false R52.htm 153 - Disclosure - Subsequent Event - Additional Information (Detail) Sheet http://cryo-cell.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation Subsequent Event - Additional Information (Detail) Details 52 false false All Reports Book All Reports ccel-20160229.xml ccel-20160229.xsd ccel-20160229_cal.xml ccel-20160229_def.xml ccel-20160229_lab.xml ccel-20160229_pre.xml true true ZIP 70 0001193125-16-541409-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-16-541409-xbrl.zip M4$L#!!0 ( $Z!CDAYL[GO5 X! )M<"@ 1 8V-E;"TR,#$V,#(R.2YX M;6SLO>F2VTB2+OJ_S?0.N#K58RHS(@4$$%A44WT,:[5ZM(VDZIX^?V1($LQ$ M%TFP 5"IG*>_[A%8 B"X)LED2IREE"2QA'MX^!8>G__G__TVG4A?XRQ/TMFO MS]4KY;D4SX;I*)G=_/I\D1+-1-$EG\:_/[^/\^?_]R[,__>?_ M)\O2QX^2G\YF\602WTO_,XPG<185L?1ZAG<,8_AQN)C&LV(@74=Y/)+2F?0_ M[LFV*.:O7KZ\N[N[RK)1]9BK83I]*%D<%7"Z-8!RO)**HAJSHLJI_5LU7Q'BEJO]/O#J=WV?)S6TA MO1C^#!9Q]C4=7 MY4._76<3"7@ZRW]]+I"'7U^EV(7V,BFY\YQ?^0I_G:RY?I+,_D#VU=?C M%ZWK[S1VM6K;]DOV:W5IDJ1G*7 M I"4FRB:UW>.H_R:W5?^ />K5%9465.K6T9Q\R(VHCP>7MVD7U_"#WBYWKY\ M"+)57S_,[E,9OI@P6<$Y5@BQA<$4]_,X[QT-^Z5G.#B$4=$>44DX?6O/6R- MOPUO^V_"7WKX-(N28=Y_!_NIAZ9D]C7.B_Y[^&\]%.7)< 7CDF'/.V;Q#:SW MT4HYMU]FZ21^65Y6W[68]M\Q*K*7*"DOX8HX2X;U#: 2-M^3SN3.?8LB6S,T M^/4Y* ])8NIC\BIGB^QC/);86GZ%3_WU>9Y,YQ-<<>R[*!LB1=MI#7;';1:/ M?WV.ZTBN5LS5MWRTAU+97E^]Y&256N#5IR(=_O$QGB^RX2W\_B%+;[)H^FXQ MO8ZS]^-/MU$6Y\ZBN$VSY'_CT>?4C9N+1](PG17QM^(CDA&GDR\? E4Q34.6 M9=50%?F_%44A7SY]]K\H7U! 5**I7\">+68)OR=GSW\NC>)A,HTF(,6OWX7/ MI02D)AE]4175U(EA?E%]30M\UY=5RU%DW;8=V35-1;8,0LT W@2_?\$G_T55 MV/_\Y\N#T-=F%=B::3IC#_P09>^S3P4*[M^CR2+^$&?L43LR1 >.&/"G:FBV M0NN%LBNH<,"]2F\ MT7(,V]3A:H7Q3+E2U(9A6U#Y>!)$%5VQCB9!&G+#.*($^?%U@7Y8QARPUT Y MW%M\! 9S+@.#A_!#=+.K(%'%T!0N2*IN6M^ :ENA%GXV+:I_4RW%5FQ=X!N, M,-[,-?XVSZ+BWB_$-T'UU/'L",%<0+JTKD@;(G!_1R(:E:1W3ZB&F3ZR[R9!;G M.:RZZV3&W.2/\3"]F:$LO1X!AY)Q@K1X7N3/\]R+)XI$S&[V!KY-)4B0@ M?7D.7!YYP"4($N">ZK?[G3EG5YS3J&F#/C)U73$.PLF0FHH9AD1V-#L$3H:6 M;(6^)E/#55S%,D)J6RA+Y MY_A=":(N11V83GQ.TPX=]$W/R"G[EARR>1\DH M^#:/9SE*0[*[\CN'V5%!11HX/?_Y\N0,.]8\+4O$QWBT&,+E4_3O]Y^GT\R+ MCJ_70/_HMFK28\S+!@9U'(+%=9J-\)WQ",W CNPSP,;KI9@KMOH-_J5$8Y\- M\)CPLV8:QE[L5'P+_C2I3'S?E75+=67;\@.9A*I"335P5<$O6O8E.X1QLB$X M?A4 ?XI[P77B;L'[1<'2-,"[/9BPGZ-C.J'IF:[L.\26=<\''T0 ;I!U10UDFX)%\U1S=,XFK<^HU(%^C\"Y=$V+,;4&!>% M U.^X!$PB^9D601V"4,,][ZY!%QM_,JYB[+1^SECJZ#)N!#NQRW0.CHQ*84( MBRH6H;NOJ2"T;-,'$Z00#03'):9L.X8NNUJH>&#MO=!V.>N4EN FE MF#-Z5*=7QS6L@D5^1*=WO1AT]>GOLU&<,17,9__#))KEP3>(N1/4QWPCL%05M,X7 MW7K^%Z)TO9TUXS^:]/PCQOU.4"I?XRRZB5L2_6"F;=&> G!3QC&X+:,#)3N.K+/;GO2&P9]J'C&J*1Z[HA9\*\$\1]RR,\6=Q' Z)YNBL3 MQ_4@[@-OQ+6I)QL^M7R;DL#SG2;NVRH8.3@OCEW]L8^X/\@,F@^O]7B@FR[X M?><:_!K;YAD>0/5F9^ILXU\-XE_:B7[7$["9V-=YOC@_0NV-3B,?]P9'XRR) MTX$XE>B6JAATC9/11V";$1_C43SEZA4UZF-K0D=U?-T$LV(8Z+,Z1)%M#8+< MT'-U':R(K5G^EYZBMZV(6L>')VH2M"63L!U9;59\SN(H7V3W[);V%M]?X\G) M9#]0;2UPPU#V/#>4=>+9LF-HJAQ03?-#W7-IZ->;^YH&%D$4_@U$M"E^#5'( MK$BS>^1*F?YGIPX>[D#ML'UANW886H'LZHH*N9%\Z2()H*6."&QVP9/*KCTEFDIH 4: MBC=39?.AGM5!9QBWE!&5Y6*M@??)I E0X0-Q+,FDF ]&C$47?2D5U/0 M+93F1NAC#*IJ$>]7X'$"*HF!U9"JKMH"D?V#[^C6(3LY5"W1\R40RPH-BYJF M8"K[!]\A<#))[S"/$::9GRZNB_%B4MWW,1[&R=>SIAOFE:C4 +H%LG"O3*A%(;UK PV9M)Z2]22T[J FZKC#'1J>N:J5B"GA*&O)(69S9Z$@X# MK%?51M^>6KT$]M*QUN:@^\N'88\W:BR$[VY MB9[MG2.5B&Y-ZX-*1-7#E(@"@Y*";9IA:655L3\\N$+ZEB>O9LGDU^<%F(3] M59*^=!3UD:(M#QY+ P5S1C!,W3>(;"E$D2DU+#_T["# (EYVO@(FR]:%B&1U ME/4D++V)58VJ:1A:C_2MLO&5E@&!Y"6+=1:A]H]..GE.H%DNE0/'#&7=L4/9 M,BF5:4!]"I0Y)&P.=!!#:P==6]"R+NEW!/5YH,5E+"TNP7]A01CN9&3Q;3S+ MDZ_QZ]DPG<9OTCQ_%Q?OQ\".\Y-6"@O0-(C2CD-VH6FUMCG?)4KQ:(5M6V:_ MTNE=H75^[V-T]Q:8DR4PBO/+2RHL04#Z$I/BP+>I;EC>BKO>O!7W>E9D"8C* MD"WC@]8J;&"08^DNM35-MEW# K8$H+0"PY%MXCFJ;:A@<'SU$Z0ME^&B[Z[R *4_J4P:@ MYX)OP\D"2QA^2]/173*9G!]]*L4-9,T2,RO;4+)"Q\&EYTT)MOD:/5L)52&:MFV=Z,J2_NR5 M2<%6G"]-8!2HI>EJKXGK)>MME/T1%[@8/\5@ ,\[%-6?_\50356XQ":^C=G'H.3MH08IQC' (^1?(9#TSINAAW M[TA3FR'(JR)^ R'>J,=O.*D;;VC4(($<4L.3==VBLFW9F.0CFD4"TS-4PK>2 MNO[.>A+:Y)ZQ)X?1B6F:%A$V%3:X:_](LS]>S\"(#N/\#-_CF$452]S%<.K!5'9KL$@ODQ-7-P T"W?9I4S%:8C]L3Y# !3^>X^X=;LT)COOYS;.*-D(Q5+4D MMG_< F%5Z2C"7V2C\M1-B?9S-/IZ)Y.HMNZYIB,[CFFCB3?P+U7V'\ Q(YQ38@0["'/G$OE&=!S\)-P3&U_Z7ETXF\1!O M_Z_DI$MG2]\1!,LP#5JQ:,6X>S0C0^:?3-C6/=8GOY_MA9K'".PBP H$BZ_9 MN)BVVQ0O:Q>ZFK&?H*VC.&%;SYFF69'\+V\?L#=#B$8,A(F#KU9@*Q\DTBM/ M*VI@*+6M8KT5A&[-J-^R=-\@ZL1L 6=<-]M[[YOH.@-QL:S]4":WX@LI%X]% MQ:S>$Y"6XW,%G2U0LT])6'3%5.CQV%+'*I9J/R%A.057=% MZAZ:I3;2.2^: M>ST#']<9?<6BG_QSZHS'R20!_N7.S4W&>E1PK-OWX_]>1%D19Y-[P- M7SBRG6%^4RU3(:K.D.T4A<)GC$S-O=AG&L0R*'%EE80!."HZHL!:AAQ0/01W MQ:.4ZARV' V6V: Y'Y0AY\MH32$G9#0M'>BS9?1K(#R))D^6M^S(@J(\C+D" M$SK[G5^C9(*A2IAFGZ*#[:./6TAJ75*+5%YV,CH4?>87QDCI ';$)^SB+, M]S57/4D.L!I9535,L1B@0]B!LL6KD*#WYQO5L8..J2N4"C"]X(OHAA@&;WF8 MW%4,Q0[!XPALB()UWU-DFYB^3'V".T2V8JIA[:VJEJ%;AT S7,65,V>ZC:#Z M^NF8SB15-0B\Z&1,?TC&EF'5F1V1;\WR9 M*+JO$Z*&CNDTO0M C]C$L-=7$!Z0)NUX-%61,D'(;6L#2?QDU]L8)G'4N 'O M[V9QEM\F\[T[+ E4KW!LNAV5>M*MNN931W,,H,_59)T:FFRIJBT[NAJZ(<0V MKJ\);;G$--+6=&W#C@=,^8.]NNUYT#X5M8*2LW!]3^/J:B53CN#J[O\H?$;9 M\>)4_.L'E-N:@W6WBH=P4"#[T(?83MHWJ-S9[8!1G*9?V8./3!^$4YICN;Y* M--E6+$?655>7;=UT9"5T5</<#SPIT339!-/'8GBK;-GPDAN&:6N"HQ#.;[24*_WL/P^^:&K\X /XE9Z-DN.R&+CCDWU9N>QCQH2WL+1^)& M/\O9W?S,OY?FX'54CPM8M[;/$-GFT;#Z^3%9NKV[86-SSUZ6[DCM\:3T"2D* MG;DD5*='$M$^A?"P@O03,XAN+%$_?#\G7F1\#G9_^V7)=E"H1A!S_N@<>1J= MQQXGR- ?O=,8+XM,[Z,)WMJ4!O!*$0UPX5 M3Y/50/6Q0 UXZ\!8B!DZ)+1\QR)^'>^KBACP]]'VA)JL(0,MHMG?5-/6"%%W M3[-OU72MRKKJED*58X/O;]5T[4EU:EHS2\?KW%1GRJ_H^79N.I/V&N:8IJ[]$B M?BM[IE=;DII*SJ(G]E,U9]U).IXYJZ9,NU*Z+5POYNS0YNP@T[J5.3O!M/Z0 MYFQ?[;F-.:OFC)#'B\Y8,O+#(AO>P@O?C\5FC'4UW_N9<#(#LO;%3O7V!9Q]A7$N?]M=2]F]N#\<\I;:M6_XS;MN[3X9UPT.Q;- MD_A-W?[.!Y^-'6J1;=UP#9B!T+=]67>\4'8H->5 )[ZAA%1W-!O=8(WI#;V] MB?UH#/NNYJTY06!:)M&L/?>&L'* _.U0.#5=U=<-V#9.5 M&&OUTKI,Y*$FTE)4U31./)'D?"?R[.R5,$$VY;NP-MG#S3*('ZB:X#1;ML"QD$W=5)S0U"QPX[ZT=U^?V/$HX33D;W#O RIF'X'S[#@CH9IAVH=G M?)RHL:IH^NYK8#M(.5;41#?V4A?HV4S\ :SAZ6AG^,*+G-*#IP'FLPI*=X=/>88T/*ZJFK*OB#)OF,J MOA)@SE>%6 %".YOZ+L0*JJ4YN@>JN]S4T/ 4.3%M(E*[![S\8VM3NL2M+;4G MM2!R9F;?4A19#T-;MGW/ESVJ6GZ@.5H0Z+4JL,L8^$0J5-A9>F"\L#=[MO** MR!?=*H.#5GRP9OQ'DYYU^\D/9MKQL*G5NC1:/03^TFY\.=!D<&03A/3+%@R& MHNN U4[=B9>X[YDVU2W9#"T"#A(XJBY\)UN*[8>V"OI?"^L)P,S)(<"8=F7& M,3,E1U_]ROYID1,PN"/Z+-/K0W0:1DFVCV4^D%XP+4LS;<4&1:!3<$C @P=^ M4SE0P'1[G@/"JC9B>64?PNX><,W"SF5GD+H\.J'V7GG*)=D_2^)T($XEQ% T?9V+ M>;)$[*E7K;:T:O?)NK9ZHK8WX_X:3TXVYX%J:X$;AK+GN:&L$\^6'4-3Y8!J MFA_JGDM#OX%R)9I*-2)&XVN)6-&R#[E2GCOGK7(..>&':+U"\-"\::I]G>27 M!M])MHU&#' DFN#Y]]'4GH!73+)9AV;H0W/6-O.,;([FWZ6049SGWW,Z/,DJ?_T76;4-7 M34$U+8^\?]:PG\[>70A/,6\HHUU4P?[!]S1C%I KSII(/'VC*YJE&D)/W]44 M]+?_^QB#JEKLV33T!%02 _M:680:@B7I'WQ_7_MRB9XO@=@13B.6(;96Z1]\ MA\#))+W#\Q5AFOGIXKH8+R;5?0VTR-G2C1W=%,-4Q<3L3B0M37>V:(%8GBWE M1&=95ZI1M37C_>/OMN,NHF06CX(HPQ,V8J,=6!3),#E#>BG0*Q.J@R&U!8HW MD](Q/GOCM9Y"&6.9C:X;1!43P2LA545PI-GH23@,V&W;UFW3UHU> GOI6&MS MSMFX$@Q;%C7KR1@961^\$3E8 M [?4U;D.H6OGX*23YP2:Y5(Y<$R&]!C*EDFI3 /J4],P'!+J0N\:K1UQ;$'+ MH8OK3K.XC*7%)1AO%H'@!D<6W\:S//D:OYX-TVG\)LVQ1??[,;#C_*25X@(T M;%M,6.U(U&IU<[YKE&(W KAE!?I^[Q*MLUL?H[NWP)PL@5&<7U:.[1>)%6"] MX^Z)_\MN\F?LG:C@G5C$H*9N=2+_[M@/T'#G%&*H]#F7?>B_7;#P=WC\9#A9 MX(;?GLC IY@O6&84BW9;.>+-E*Q8=W#I^=%H(V@\-92^-#@,N#\YTP3U<,G9 M:DFF)"EN^R]G:/HHZ!KU=!YGQ3W"-!3@.]=-'\YR&E4"JL6T%;.U([F:@C7[ M5&<:^U"D4$.X*FW%WE1/^,/7Z-E*J(JU)HI&-554,:U!KS1TYTL4[KY8FDUZ M;=R1J[9/$81CB38$2/H>)=JU:L5NT_EM/$*3<89.&)X"MH@J1H#]0^^F.?,B M2X9%#=Y^T!KM4^0#,<6K:[HNYCMWHFGK7NFG-2-;=49GV?VNP[.>A(,T>3B% M4C(VMG18$O1_I-D?KV=@18?QSEWM3[!&T79HNDG,GC7:&OI2LD) \#];+6N! M7TI,2]Q=ZQWY\8^&G"*0PHY!E*CB9ND>VF8I<04+]*SC81/4C:TIMM@%>3T1 M1SO) +HM2V9Y,CRUB#B6[@(3--EV#0O6>!#*5F XLDT\1[4--0B4YL""JMB4 M$J%NX&@6^45G^RJFT'QEW?@[S6B9 ?32R21F;;_^*SGI#&YIO($^:L(4"MUD M>\:]M3,II+R=:9H5R?\R/; ?W0BI0C2"!T!A%1'[> XGVX)A4VV+^^^[$[HU MHW[+TGU]N1.SI:>;XR:ZSD!<+,LX8GR"KP^;-'P]9@")G0[KIR'L)R"*_I2@]+=A.708!,"%W338- R&N%@PP\& M(O!MQ2.*#@PQK5#6P\"7;?A1)J8)GHAB4,]7N,+%MCNF9A!Q*^NQP"?.@R/D M 9G.AX)1G <'<(,3P1 M<DH6PJ M=@ 4>D2V-<^7@6 ?4>U"QW0:X@S#-@VBKM^]/2!-VO%HJKP#8BF*)L;(?23Q M.L>W<7&;L@ZC.:N1>W\WB[/\-IDWT.+[4PW.&_VF6BK55',-3GK/665=\ZFC M.0;0YVH00Q@0!:JJ+3NZ&KHAZ'/7;P!LE2M-V!#;FJYMV/& *5]!_/93OCT/ MU#;>53\EAVU2*A+Z>$U*R2Y-2L\09E7@XB/ K&J/"[-Z%,R)T\$TDO-!YWP, MVL\$G?,Q2#\C=,[-Y!\9G9.<#3KG3JPX&#HGZ4/G/%YT>#K/7SW3:/"4'#B/ MZ.^4%&\?[3%_@<4556Q:0I9G@( 9 FZ6%$/RX-BY83A$[K0E>LV+(M9NS<=B;24RG M\,^0_7T>=%)&)Y454];4]71VQM[=Y[PN&KPF4-9).DJ&I:]W&#+KH '<75NQ M5ZKHM3*]%6:UOJFWJ MH(4.(A8A-14S#(GL:#:H.BVT9"OT-9D:KN(JEA%2V^)V&PN]+,,0]U$VT2GN MD\.OPR+-V(;S>)P,XRP'!BXR/!OE3:)DFOOQ:#$LDIT.[:D'5 W\ .C5OU4#*1WHE#@S-MD MEDP7T[^!M*-><[\X$07>2#J8'!VF(?J7>-N(%A!::BR+YK@4>' MS>/PJ3*EGJ.1P%&HJ]><,&G#B#4$K:DA+^,?+D<[1#4EY1J.@V4.55UE>0#3 M,':/:@+=]*CAV+)#+!.F'SQ81W45V=-T3]=42S=:$/ M5RFZR^"VM+*$4UGJ?):JS6=$52G>9I2TUPU935/4A MU53%.@1,$Z\>YHS9@.+3?WQ9HP?Z385[22PPAMG[/$UG] GZ^B:;ZMFJ)7F MZY9H_M":3YBEXVJ^K::HTGPJ!"-B3?I%]:V;LF.IOFVGK-P/)(9Q'KKO_*9, M:W8#&OX<9.]8BVW;&V"*CMDX/T2!UKQD[<)Z!J@1; M6C=Y!AL,L[EO>;]IFK9AD5#6+4V7==NU9 PRGE:9>1$-']NC[)XOT10AR?SPS=_ \N,A=/5+#.ZXYCLV%GH_AQ:Y'Y+*".M%D[NL; M:>CO*N#O:NIQG:-F.[&RAGTNT8.CAVH'NW&]]J^D9+R!2(!JZI?^>/A!%;FJ M9>A^&(9R@#N/.B6&; ?XTS\3>FI'_GL1946SU[L"^FD&_-/U: MUQPU$-ZX.6HU0"-1XLHJ"0-9#W1%MG3+D .JA[H=>)12G6/ET4[UR+8$BOH+ M45GB41YFZ;3O=KRO8?41.+-#T_'M^ +NGX;>3Z7M=B+PL)LFJWMP?HRG43)C M,$[,SA&AY@R3B VE0<)Y3!)]:Q]:4M.R%19-7W/,M5J>X[ MS>;Z!_I/W3_<[L<>A!\62Z6=JMJQ,JK-V=79/5-3;4T]DOU1R[.Q!)N>'2*% MOIHS3Y'UIMT&/3@DZTF%>' HX_]=L=["?8H]5T5!@>Q37*(I/9WQ7KP MG#2J'8GU>@E1H*H&T4\I]57OEBK:])/)HM@E7+ 5H?CCH>&T:RJ&H8*Q!%Z! MV0P]5[9,2Y4=U4.(<\^DJLN]#.5*U,LKJ.C@N<<%RT9EZ==D%(_<^]]S+!)X M#Z.+L!>&,RR2K_P@ VN.L8#ORA^!DP?ER";L)]\Q%5$<%]7E75%#62;^A!$ M&ZJE.;IG$E1!9%%DR?6"G87YG"ZOQF:M'D"&MM0Y6_(( M/1QP<$08Y8<3>4:J_8%U)L&WL"VB4S'EMQ,Y/6TZ^1%3?Y'!-9QG_%;V8\G3/8ZE M/U!TU-"VP$UV90/<"EFW=5VV0MV0O5#Q@R" R"70ED5G9WK6V_(#2< Q+;FY MR9+W3/O2Z925Z/9G:+.Q40;1-)'D[>E9\F>:%C9G2"I2BGN!2LL[:8;@CJQ20W6I;Y!0=[B9U"U=TZQ6[T,^W'[1 M#--,3'WMA:-R.I$DV$E85WM$64T?Q M/"=T%-EV' ?LM^G(+GPA>Q[5#%O50!/Y7$Z!?#'7L#TY*Z?_8SPOMWK?C_?J M!GZZZ<>=25O12>_TKZ"CV\QNB#CA M+SN.YW-F[%RL%WG VLV"A_J2[<";C_9.H*C[8:IF8;8@JG M?_2=EB)5D/@X9F5;\H ^@U!5[$3;,_)>"3UON318 SM=)4O"V2^2K$3T73I+ MV]27J/CG.'4:JMH69.MZ&KH-^9X0J3"9LJ: H1'$=$LZN[NIKV?+^ZYG:$AL M;*!I457M9!,V4+*)=MZXD4.+[ H_>+I4'$*D4-&'V(:03:2WVUR<(]G,=S(4 M:RWA;3(V$=WNLG..1./FO[&.X#8)2VV8NRU(=^^I>C(U1JSE(&X-!3WVJ>?J M&CUIG&9Y"SW)&?UKP0.,ZHD?$'XYG;7SCQ^BW:"3'LXNSW6HXKN:[!'J0K3@ MF[*K.*;LVZ&EV@Y5W-9/$[.<;FRK"=M138K!K_-[M$9+BT=VQ\K5-U8*[35#/;)4&,:WH^[ M+8S>)-%U,DEVJ8#>D3/]X+I*:/J>0V6'>(@D%(!1]'U=#JEG$\\*35X3V#:* MAR:YXUUQ]SJ$Y9;6#C08(HN:*EWG0W?(V*:YWT,+LD^7&6\"F6ZA#,?*F6K1NMS; '$-G9 M@ &U6&O+_%-<%!->C0$B]?MLD2^B"7M/?E3^]&^%*X1:H:?(IN\[$#J9V(?& M"F02V(ZM4M6FEK5D)7:BIQM@Y^RR4K#.THM4L*6I"I%C*ZQNCWNK%1%"Y#(; M/LD586&"M+WO]# BEQI0QU$V1)WJ@PF9I&P'_7QUI(7%G[9EB5O,:RA8EOGW MXVICYPRIPZT-8FJM]J[M07=LVG0>)1EW_=ZDLQO6CXHG3?\:3_ T\>]'G,5> M/68[U/85UY #E>!Y/UU!;%E/=@-+\0D---TFR][N-G1LD?W/%O&HC>,JF+,I?#I$=8O1#F:Y0:*'.KP'UT#%]XEEB/; MKFX&;A#HMD_+'MRVNG2";C,MG8@W9HFGW\#7SZ()+'UG-$UF25Z@DOMZQAM> M)J)+JYIMBB'P5L1T!$!HN/=^W&U!=]+R$=VV0.85V5447]8]'_Y2(8H#OQTB M.(V8.BT7?&OC9ST!V^[T[7P:\G0+'9UYG9BVO\YZ#P M&4XH'@S0%2JB4ZRCH'M<-T0AF]1=GS/%]3@I!89MF!0<$^ULK*':6M M]H((P)_*IF/SGX-IPL()+F&U/3^:(HW9)NF?VN>(%+[+,52]T?%,31 M%,\FP!S# ='3E3#$KIZZ' 2^[82&Y6A66 -5$+/C9A^"].,6M(IH'I:N[@?" MM:WB5_2)*=VV9/(X]OO$Q.YJS\_O#%[+6"DZV5U3$"TT7%VEL@'_ M K?44+:(K.&];<5@_-8(1VS*TP#-D HR1=9,$L')]B*]\2GR/F$0Q;&[AF=>DDU4M5$X+B+7$_B7]]_M;Y^-OK M=[+[_O/G]V]?2^_^BS*U^_^PWO_O:+Y+U_\_[C*RF[N7ZA#.!_?_Y%"M^_^_Q* M4N'ATG]$$)C^\CF9@B_R+KZ3/J;3:,:_A*>]]M__XQ-<^8M4CNOS^P_PT<)1 MO0D^?PX^-B]K#>SU.S_ =[ 1R'?Q]1])(2.7Y;S(TC]B^2X9%;?L]^<"&Z[Q M;_QC@7^\2XM84LE_1-/Y+_\'&YQK\%:<4JD\&X@"@%>_7%3WO:R?\'+^5-EK M;,U=Z\_;,O?]3/+C88Q'W$MV.LHOVD!"?3R0(E@#T_DD2B 28XP:-1R<=7!S/1N!9 M2-%L!*R9Q#?P(S!ZFL(UC']P/XKO /Z-"GP8CH$_3KH&@S2\1:4<9P7,BA15 MK4-SZ2Z!Y^ELT6X!H"+-! MD!^H*0)R 7&, S7D&X=, 2>(C00D:8J-#8 0G#,^ M"<1?29^%YU_'DP1"K[RDI+FL42#V+Q)['HP '!=D9;HHI"G82CY3"9)>Q AZ M7:1L#/"I?&W)AJ_)39JEBWQR+[#!P4N 004L] %[2@["6N HP*%D'2C':=;B M1I%*6&TSQ=ZU^/T$7>_R&N:\PIR(][/?$RYV&&"R.8MF8'_'T5<(PO :( ;S M-P,40:7;I&@^S])YEB!5R>Q?(+!,:V2XZ,=K0$\K&YUR]Y>-;N%893=;D$-3I+A?:E$8PB/A!7]K M?8EF)UOD11PWRL)_^[?RBA \I FXD'@%N(JHP/9R%ML*QWJE&M[?=<4J- 7] MCM\A'H45R-0?##KA!R(KM^]M,AJ![-5?H_4JW3NX]Z_)9))?IVSM[N+^-_I_@G.'[KDC?MG;NG^=9R_4N.L<_\N[M?%_7IB*O$UL*]$XQ]( MXRR=,E:C//!_!1E![V-Q_2^P3%P7,.\-HZ+IL;IEC+1*HVCE+KZ(- M>]-RI9(9$C,KX&)A37/_"8D$XF!\LQ26;NG:,"W;-@&@&<$DSK,8CVNWA6*4 MQDRUP8O8+C,\&W5]IL! UX*/QX"97A]\!\9V :#KQ9,LT'5GWX5[7<"V9.AXL ME8#HFFY>=D!VW@'16CL@?-.U@<>3$*WSL@NRI>]7[8*@?ZP.5GL';@KJ@Z7/ MFM1$W;0)'@4$1%SWH,N.7AQX?\,L9HX N!U9,S^+.7X!G),@_IWP[,D+E85D M\/\_-VX[5Q2=-%M[6&D+]1Q1$>%A.:[F*Y987,R$O12#10&$4]E#4/M%\*"D MZ@_+OI\Q1&2\:K>!L< -A\8'QMT;@5^)R,H.K^ 38Q?SBB#HK5@FO=!6,HQ1 M[LRS9")D!:JM+>XW;R1^,^GKTH++L[*2='3 -Q$OYF MF%RYKKS[1>FOE_E(='-G,)[LC[B0ZGL&X&HF7^%*<%IG\4U:),Q7O&:F 2*; M$5R"L0>+ (8LNR) /6;!.=^Z>0G^,SP[7V#^ XAAT3;'->5I@5G%EGOF M[H_2><&SVA#6IMF(Y?M8FN/C OQ_5;FFLMIL4#6%ELR_#;X!$1BN(T9HDN=E M* )/RQ<0$G#W%V9@!O]$.?.LN7S.)_?\+6Q+J3FB7*7/F]?4KW!8P@AN5VU- MO\36_5L;+0VD*<(ZK-<:+A$("C"!P>,LC-18LU+<>8@QM@.YZ>A/D[(E(.BB MA)5=-ZMM(+&<_ISUYV7S]!,VOL18C=_%5TN5BEY:X[B_D.9\55ZS%%8Y@FK+ MI35(7'5P%ZQJ^-V\,HT_\W?6.'[SWQ83,=ME5:0W M^610)3%3*V.NC=@\PD,H-0>60M=*43,?$3RIH<7[)1VA,IVDA9#3]']A@L/R M WS$\:B2Q$J":P[5 EDQ9<#3#9CBOBYX;,YW[0<6&&_+,#"76XZHBNLY M/SC, ON\<=R!D6^7;34LI9R-F1-V\KJ-AH)!G;$$R[-;,&3M '$8P,(R+;Q MDT11PP<5;/)YK:$@)^2*6LUZZ+7?7 IZ3;=HD]OYHX8.5=,&U*3E#C!0K1-U M5P*D$>L645KF<9*!Y);9,O:0,2M%9$QE;^$Z"-XPC]GN[>1^T.8 )ZA>*XHA M\ ?\!,6;C;?M9]UD?5E66^[AZ-J@EF"$9ROVWA2[MKQO$ YK5'!M1 7L6;? M(8NG*6Y_L;1YVXJ)]BTJ3=CJ)<8F\QT\JU.05ALQYZ&/& C+DI-!!D13!U0C MY9"[@GB'"=I^AEPD:UFR/BVN\_C?BY@[^:@NKJ,)\]WSVQC4$VX5M#7ILA:M MNR(#;0.B6COK'Z8\\$E+"E2[TM7-"K11G[@WLT*!;IW^[L^NM3-POX$T0V $ M9OPU6.GI+!DGPQ)T;C8JFW-#T/&!A5H[G0]:GYK30TH(8@KHAJ_#?U1#M@TS ME+W \G45;E+L2VINB]3R\^;U;^]>P?KA-:V?WS*Y@EO;10_PSILLFEXR>]MF]I1. MP'D-OEI9Y#7B=1JPL!:@0J;HJ& V OWI&6+OHFX:@__2?AP+5-FV H0KY<3S M^J6Z3%8HWV7E&JQX"F["^B06N,)']MY)PC)!7,5!#)K 2F=;PAE:J>M)FJ): MXE*6Q1#ZQ:QJ-I<6>1G/1##;,1A@%#BFJ3"I4E0E#E@%E\[8)BEZ5@F$0R:)N!N'%FPJ"=34XYA M>6W6:^@ B[19DS43YGRYMD40HEQT;J-[E+^?U%HD6,C-10*3Q.-QCJDY5EX/ M0E''>$F5_FH+3$=<1"&Y9@EG8%UZ!Q.(^_=%4BS*XCU,MDG3^WB27D]X];4@ M1ZS, 3S[6)SK]\,B;3E:JE96>>MM0F75L,#36CG4@H65(44&]P.7^)+,&=5E MY8^$?B7H1%82 &HF8TG8.MM8LJH=F8%?Q#;V< 4)>W.9@Z[' M7)*(RI/=S^JG6#'(J-SBKS;^N:2Q%,A=[62L*"W 5NVL;J$IOZSJ+L756+V\ MKFY J.GZ9J8UL%B.Z9!NY0990JY0'#K;3,"RS+G<]QS<#,_ERE__ABY/LW97EKM2JK!&&Y^."U MR?0:ZW78U5,L2(''888C5&:L_K'F#L;8H%'N M\Z1VKV$^0311EZ!>J1[7>4#%G.;B59=RM<(3[J5;S5WLQ?6$=8.LU=5U-/M# M&!J[ ((&I 2BAFB-!%1\8#1LS0I>%U0F\5$!30745*EXK!4OJ:P7!J>SC[$H5JV7-B'X5RSQGX!. M9Y6E4CY%BUC9URI/S>6MS-[6BIT1T\.?O&)0!,8#GYG<\+"$6=_NLQM1Y$-; ME/GQ2F*;?-"Z-7S5KL-C59?\%YZ;J-_*S*80*/;:OTK=\KI2KG!+SPR^P%QK M7<;74J!7&W.!Y6RLSC-T(EP2\]P64YEU(6E5V8FEI'B\X1OC+/AH M/ZDF4T4LY\7_'O"*-S%A41%8%8-5FVBL-K1Q':K:0]Q>8^,L6V;7!7WMR#U? MSG8LA[H[AK&=$B8L;EY,XO?CC\ P$+;_C4>O1V@*QDD%4ED?PYZ)D(WPVV** M6.S8C>3@Y2N6[5$:FD3673? \A5/=A6?RJZN!RJ$R08-U8TQ,KA<-\E,!C_E M%<^[E%]_ZJ$TN)B;PQN"#I'=LH6DSAL? M[FY$'.]1J"XNT@*+,UL;$-Q8L9\9=WGAYJO5P:0P3*1$H$QI/C9TU;%RVS$3 M'UUP:$%P!/-YA,"ZK-(./\]QC9>?67CWZW/#^O-S<&-A067LZW)4+L2H$#E" M7/K&^? I>%7]L9:-79X_!YZ!FOOU^1 W\#(QS"\R\<.H&HU%__R\=C"+4?N: MK^73.#-J"M;<)!?3)#-?]*[GZ7G2>?\1+TG&=R\'G],4,5^E M:3H9Y2>7A=WN6!8*C0XTJIU8)AY!6TB/+28E2E=SINK)B8INLCCU>],?CRX9 M7ID1+@LJP)>]3>9/3Y/HZB-+!^?Z_-LO*P1 ?-L)^+F7G'&WDWOQ(%'S;Q*+ MEJ3_H[#_V<+5?4)#VR1U%[O!W N,J)(R3&5QS PWD3DF<52&JT].6X"R,.E MIQ>%<6ZK\HR'MK/"^/[5PV]I.L+,Y5,)0M6!:9H#BY#+NC_4XM+XXAJE"S0. MY[7P#S6VW5;^2Y;O$[]82B0?.!=\= C30X)?;GGB4T6\4KHW7NDRIZM;P@2Q M4EAGJ&ZW&/?^;?2O-/,0B^KPB7;=]2Q"+4/6+RN%CU:((R<5R\OE&*(Z- M&TEK\O";*&4C%VG9)1G?4WBQ!>>Z27@0CO:%?L_C\4(X6SH!A9F?U9AA\<&*FS$CLSQ^? &KB.K53B((H6JP MH5UO*Y%G/(U;LJ17'[=80@_+DBW6UF;]^WPY [-;N'0XV_DF"+$6&*.FC@7J M&%,9KJG&\B'"PJ_3IE:78IK>#6#P8HC2//@^CK+#+_7#17&:/J!F?^IF _D' MS#M]3\0>9GD^J<7X)L[S5Y(S'"ZPCA'+@2*AX][)\QDG><<#DZ8OK '5U7TE M\>?3KK8#$*N8]"C$7HSAL\?>D.XQ@ZHBG4F1.\8QO-4*;*V<)NY\6VVA[1SM+KOXD(L.> E&2;U*T@67N'2(]L4T) MJAH#C5B/[WA>3.%6BDVKJ^#.4.L>=G!/RAA>YF7%:E^JH7R4 K@EHN8]5&R# MD??P*L0#M4,)X.W%_>L9XOBPUFKO$;GD\VTT*YN&_(88!H_0(\7W3)OJEFR& M%B(1^(KLPG>RI=A^:*L^4;20]T@AA^F1LB,C./N7&\[_,XXRUF[^8%6B@6JY MQ+1=F=C !-VRJ6RS!O&Z33Q#M6W-Q7[JVO._X%/^\^6:,36#9AT\V163Z.;4 M0U6?_V4,,Q_SL;:&TI;JC]AB;A&7)=$X"PQ)X_[PI;@&=1S/T4(Y4$@HZ[:G MR Z,7Z8ZL73-]E3KTK)E&US(OQ)!A>/)\2E@7 M%H27&@GL;N&M)=4VS==8RN,)@U]@4#,YPW="F"QXQ##)0"DC.O20=7JD% QBR!<.#W%A4M"IJJ_5?2 MBT3(0<(-HS23&9K4.!E**0.-2ACB7(R=VV8<7'@< >'@8<+37Y1WL_8 ?__T M/F@^^[_\/(#GBR\H;I-L)&/+B_O.(]M4M9[Z^4/WH8@*!0\6GWP-_'O6;N2W MS*S68X-/'UJ/O9)P^-(-;RO- )'C;PEB"*8S;)5R&[<:1;)'<_0A@;GP[1S; M;R.&%3_PP)NQ/]/4J\U3[DM6=_JH T M.9@=;P$@"D0]^2FV(\;G(MA9C=C&;H.GY(A0.NK>&2=EJV1$Q9N!W#!LMX@U MYQ4>4L'-$E7&7=KZHG$0*JW(TY-&=.LG!\V-L0@ M!54EH! W# M*@5FW$L,/I6/H>HV+ I V8U6.9QBD53C61>07- MBTCGO,=?Z4A@I[FO488"6K:PEQ;S4F4L9LF_%_P.CNW:\E8K_&2^;+O2>B7] M5WQ?OZP:Q[)/PRSM"#37))U7JPRU4JW/VYI2ZFI*N'M95Z*9JII K]1]+8A? M7#)\/6)G"^Z+XT%6;)>5-VBZ,)AQ4I3GR7O 0%=+]+?C2?3\V[X"_>T(0?_J M7.^36N[*D;U2#H?;!)2L;5"_@N>*7,#Q9<#10A/)JCB^3 9,>-%\!RY<-&RK M7\L\(:8 2D/-?8N6Q\(&(#RKY45UK;)HDY_]J6.5Q37&P;%AU;(^]CBL++V/ M)JS+Y#Q*2D3QFC81O1W1Y674D?7CJY?F30\*@0_H(''PX4GW? 'PS"OOC4>= MT>:E?\ =1;"Z=W##O8R]!%@!9.VXH2ZZDOP83&76N+^E(_9L>[#A2H>580+6 MEE6ST>/V _NY)] 95TLKEI#E*[4FZSZ*R/$QSQ/4GM#.\]G,'CPE3NK66(B$ MG]S,FIED@KG57":SY>G$R<3 9,':#:37D^2&E\8V\-++L]Q=&$/<1,'P, =3 MU)FU"., ^*;I2U*]F5N%G'MK-:L:/U&<^HI[,U 0H'FE*1!UN[1 HTF>+FD& M7-/);)5N8(L.&8N3<9O,Y]4%M_ ?YF)"9#KAO&WB&9:Q -F 6/=*^B32/ODL DHFVQ@1\<3;S$T1ZQ%PI V\P5YYT:,4K>R5">H2TX>HJBUQB(.0:^ M9#]DX&$/[XL8.;A/8Y#*. ?<.)=M063/K5M^P,2S3BISUKTNF;-PH XK^#6E MN]_?@:P2L6V TC?NY+0W?EQ,$< 2@!=?)S.VRGT(Z"9I#DO_\+L_@1V$IN;K MLD]]5]9=PY(MPR"RIU(_)$Y(-46[[/YLWOW!/Q;XQ[L48D,B-(W5?A'!UIF, M+.K-BLOFT'9MI%6UKXTT.Y[!=#'K,L[+Y*0/3;-?I[*%T@N\3\Q^.Q^<5O:; M>Y7>?9&^C4G'V =#^BU+00F]>>/!\UKY<^':3GJ^ MFOT?>QS4B%OCIN5*J5?$ M[L8=A8LJ\D-C@#_=LR9CW!E)FCX?K.M88ZC1RXJNP4YCG%DV/2OC^LJ$QTV[ M,F[&5W4]6YXE8>6T]RH^8PLFH4MCG1 L7<_%K&K^S/J]5.2CQU_IU;(/5+M' M,V_3]1,9Z H[83F0YI,%]TWYA@^RM@*<'[ (DM8!I(U;*94&Q"3E.Y!A+M9 MF%7B2&6MF14V:-!'Y_S"IDIQU99H&HU8#K:=2P#^BE+ZXB?;, ;4-EG/5C 3 ME6OT$[6,@6%2B?7[PGY@O#_3)VR+W8] ]7/94V:&.@Q&477":L;Y[$_MSB4E MU1KG%6=H-0ALZQW7[;+DV(Q07.<2Y5]4;5P.NBBV<(QG4EZ!@DM:U"1 72R)_U"WL& MO+FE1.Q??G[&^A?!#_V$+NF8P=K+JY2D*!,L852)'^>^HI?M\I*EO!-SVD5I M:=HU5QLN9;?F=K-FRB:OR7R6L5BU5+#%_#HY&D@_@0\QH# J?,YH429_,<#& M4;9%&*9?"/M$X1HM2KE9\RY8 (2PGE\_LY>AL@02F0B(O9":B++7I1/:PTG# MVY1+,(R3]5WB&]VUSF*.O]AZ#Y4=ZT)5\;:E4BN/LM4JFX=&2"^VLA](SN)F MP?LM-\16JX.INI(E=TSPX7E52O(G5;<'JDDWSXDH&'PYE1J"+VI4FMF(!>9U MGSJ0;[:/#TR=Q5S--K\UJKFGVR-O0=?I:40(DU1 /SX-!HQ/72>'^$<_UJI M>\AQICI,]D2ELB8"/ILS*GM?=WAY>+*S[T$8]%3.KFDF'6BF_OBGN7Y87>'T MQ\H\_CR]HGC@\7CLKJ$-+/L,S@?^(-KF72=Y\60%ITRJ/#7!^8Y4$0OCD[J3 M;IV\*'-VU_=U1N0)RA=/&SV^=)W+L>5MY/""XW ,'(?OT@PM1SI/P/LE XOO M7US4PMD=&C_KP>VF&'8[T7[)SAZKO?LE27M)TEZ2M)=HAX_K=;6M_%2\%4KL M@6(?&6?JXM+6 O(Y35G)[#2=C)Y>5VR-#C2Z-TKU)9OR8/%YW#8'AQ"A,P;= M_RX5SAE @1]$;,X$F?H["*DOF;:+I=G&4<'@N(+#8 '=+"[JTNL2=N[)Z1'< M2Z0#?7^T[8LJN:B2B\.Q1G'\EJ:CNV0R>2H1L#HP37-@D4N^_OQ2XF<]N-UT MP@[Y^@L"Q-/:S#@& L2J P,?G [@8%GI% M'D:+9QP,IG,L:I'S(_]#?ER[B(>W,_!H;_! PDH L\Z1\V?":?_RW ;NJ8@' MZ:+9'W#QE?1[??0>3_+7![J0S&>MDR82FA0L29*B$C" G]RA[.32=70CX9DC MA E&HS\:2/F"X0X^8P<\$C#=#&M@! :Q &V!83#_DECYU]^G$,/NYT_ORF- M.@-S*HHLN5X4XLDV&-H"(7SX\9SJ[&)YVK&WZDHRN[S6+[@$IS!(YA?8B):>DN1M"& M$@>S1%2I\/'HYC;(_,#C$HTK1\'8 $S?/XCSF *5O$+1)(O"( M:1SA$?P2/V5Y2+T8'/S\;IG&>O:G=B)K>:3".&>5<-0#8[3'\%L34RNO]Z]T8B7.&R$%X"NP"P;9Y!>7; MR6N;R8SIXTD\+$IW\+\XO'K4IF I1IR$X1 M7Z6H&YM:D6WP3+8#*&F#FOCQ=7%,%!/-4(FNN)I,'-V4=4?79,MP0UGWS, A MEFJ;NG-!,=D5Q<1H@9BPKS[PNGHF&1<4DUU13/K/8K=13-K@"PU$)VS0>&*=FX/*Z-,_-^1B=(-1RY3!9,##A_Q)Z8P=>A?X4J.[X*-+@,YT M!??L*X1G8+B SVHLW3JVK.C,X^&B!.*,&%0;IOX'(G('=Q9YR(<.9,Z"+^Y/ MXNGT$B&MC0,%+ZEZL@%U>3HK<351BT-4=QM/..8(A[1"6 _PMVK$^WQ08[E( M+(F7#\H!<%Q _AU#4"GA'G TU8GWI.Z-@:P4MR" MIVNQM2.:V&=_ZL&]^7V&*8,6X@_[JHT:!'.5+@JL]&Y0P>!Q)=8#PXNM*C;O MX@D88K;D:JQ% 8^#22[ZU.BEQS?);%8_H;U:5'&5+"^1^ED8<[)G58 1%3H( MLH(C?ORDEIJ$8=RL6-/PC-Y5C?+]$Z$,$[OL ] )U<8Z)S9#2!CB5M=8W*4 M;&9+;Y]!<,CK,C?"R,YXB,V@W7#I ZE?8PZZ>!=7( 80+D4<:[A2@97:Y6'4 M97WUK2^L$N5X'TE[L44BNDD%D\F GCJBBY$D(NC@?/1K][9MK*80_L-1;IBX MP/N+*JE2XFYBP%P-#R3A)Y5PP6Z+Q)7T5Q""KPBMDE1X@VTU,46()*8F.N_C M;X.[A=>TK.(R+M)6:^/9GZK5()#31;Y6)5"UQU E+ L*WM3"E;//54 M*];6VJ@0?TN2VBYNCBXM&B);USER&7PTC8%FF.7B2/(J]=!T>FC!"W<0A:.R M+]>;ZNN_-5-H-\#^XN]HB! M6?M'C %+/'*P'<)-_+%:^UZ#GOT9'%IR,,800[,5QPEE1=%T;(UIRTX(@JKZ MGF>Y*M5]Q_ZBE:TQ/^C_M-_J74D]+>4]K+\%K)D@5;JNJ+*C&50V/8?2T-$LDWJ7_-BN^3%5:DU# 6VU;P<@*X M(.4JA.U4%5E2-5X8_C'@_\BXS1)%?Q%7?.QS@_S!GC0V+IINH<:4DW:[XA7(JU"?G/B-.* MN:KQ QPKY"?$#[CSB6&+88$/JM1#01;&HX%TO2A8P' ?H^L99T-$V!T(S0[J MZ5WRU$K/>8.+7 Y!(E0;&*;=S'CT-4HF4;4_7S9V9P"7X&7]&F;='KH+ M626E3MQJ)!A-8P%FV(^''=&K<@ZJQ"%ML_1KDPIS4U@>*"]^ M JN/=7%BP*+MRZI57)KN*OQF(W-XZNDM!!YUUKJ5\N"23ZH NR9'2F&5)S/6 MC$_00;3,R+4T4!.8[Z&#^,^X<%?K(%0A//O.,]$;E<<&1?%Z)KV-[AFQ@X;1 M7'D(K*[8C,F;"I:YBBT;1L$7$$AFF$HOF=&D2'95U#6G.:!IS2]X!^GP?FM5 M@JDH5"9Z=3N\(1G&/D.OHF@PHB(KDB\HJ7\:=-C&YU6"><HUOWI];,?>71.\8I/"=:S3ACX:4G M]Y;5;'R;B/>!8#J7M;ZMZ\+*C->H:>L,3V$B+$".NY,(O,A/0[!10!\^FKN2 MTW043W@:=Y'S7/0SL?%$E:@MT]<-!$G!DWI!5<7S-<5BH D:[207*\GPMJ;- MH'C=.JU<&Z6J:=04>REA-A_(*G<0^*YQOF!Y[GI[6Z@K&L<;8-U;SG>[>R_C MAC!N8&_$-Y2;'MI\2BH/E.^[3>>3]#[F6W5E_4O5O8KSML/[,B^:Y'_(8\S# M,F+05E>)\M;-8G/7DKZR )4],6FW7Y=^O_H$S\]8!>"]=)_$$Z9#%QDK^2G] MHLI?87W0X'E,=/BP:EZR8C[XK615)6 \WJAH9GU5@5?#!JOS M=G8USTI1$6:]R.+9J".H+/1 DX7+H'[04S<+1W+T*Q=@EM834TF.L"6XO(FQ M.3W?\[.U37K^,C7(A4_"6L&=11!CT,A5?>VVFTK<)P1'E_4#R4OSD%\PI2Z8 M4GM@2MGD89A2AKX[IM2:6P[U_>75)WWU%J=1K0,<5][[X/Y.)UC+L9$5KQP;177ZJW/SO?"3FCGES<0UC2TOO@G=I7^^8=BL'-S MD\4W4='EY6M@63++DV'G^[]CHN 0'+J@QJP!?Q"V]S%B7IWZ7#XD<^; ,3;? M9MOJYKU!(LX&%(-EQZM\(\*3K:[I99 MSE^?6ZO#E.:2QFCH3^'R"TQ0 Q/$$UPGM0,;)'F/)RPOK5;B5C_64$^F9"XL MV^_>Q[KN,LT7SWTO?5Q%[A>-?.;JY<*RBT;^7J;YX@\+^G>.@+HOQVDVCI.+ M9WSV2N7"LHL>_EZF^0VATVZ[&_] M@]O-I=^AW>"/C5BTB1EN"(<;V&.!^!*P EXT"3*"^R0P/811E&- M\E%B=E1@UC5H1GE[-8X:A&JZF!3)?)(T8%P-JE,RD^$+>0JS=M]&?7CV)XYE M"?PT/J7ZHT>7*ID45A@'"?B0,"FL- M2@&#D%H#4U BCF'+P1H@N3MWZP&^VH@7PUM$*NU @%235?'YV28XE M:PK9 M%HUP' W*XC(9/= 58,>2,2P:Q-'GZ_@F2Q?S>D(VYSM*1+0*KIRO#=;;K(NO MD\P8GAB'R8#IOX!<7$ N'@1RH2K*PU NJ'U!N;B\^A%??0'8*!E>GXE4E5Y$ MC::@YCA)T],3:O31*>PR'(+.TXI77SIUQQV=G493&[!U,]!CJ<%D??XKO$NY M$HX5?T1_'T.$ZH031R/)]\H&G%:2ML.D^?Y6T 5AY5ZK.=X4M96Z/O2:7OM2>I[RT%6XD\M97Q\(*N'T;?DROZX]7K/4VI M/ML9OGC\ZRR 5ED _2E: $*>XE)Y*-7&E?;DM.*>Z@'$TWIJI#YT>E5MH)(G M%^:<[03_(-7:%]R*XRWHQ[KN!QOSN4C8.8_M>Y3^4V=DGH(3\$2A-AZ>V_AA M\"=^1'B1RVG3BV_[Z(=DSGIPI[?O9T/Z60_N,B_G.;C+O)SGX"[SY\0_7:\DSG @#W/3'T[ZK+M7U4Z4)0?I31/O;+/ M 6;MO#J#7FJ+Z\5]Z=WY)#3 #\&RBQ5>LU#_SBSPDS.V+^C V+\W]<]/:]_T M/(SM#V*YPDMWO8OM.AN6_2!;_)<"ON,9GZ-?=_&OMLYR5'L1TM/M&##0S"=W M)N-I)SF>OGJ_[+!?YN7,Y^6"C;UI=W_#ICQNP".X+P=CSM)OR30JXLF]]!-+ MC"LE9C(#S5[,LGB8WLR2_XT1*W8ZCVBH27CN*L1($F.* /DVB&8U<,]F>-J0W4 M$/8-AY)F0TH0%7<>#\MA7?-AU#2D7^'1D717[D/)$=]^JM"Z@7%7FB'=(T(8 MKVYXM@[,F+^7LVH<)1DN+(YAS2C.),9:P.1UDP73!+=W)TK%B7KJ6,G6 M$80?N9#@WQ_BC $9STJ@XVF4_1$7I0SBM.!T#-/9*&&"F K[L4EMJ)\L;XVC M8X+/&_Z63$VS#4Q^5J/=UTM]CV7!E,)F'/'-:I!#8J^#JR]64=RE%9ZS4J2D MM(&2NZS8-2OV(W P2YCB!AL!@E JT_1&DO.#2Q';I=?-)DU[Y?F$G0U MZHN:2_Q??I;NDN)6BJ/A[;J2PF<(V2E[P?O\JEE\'[CE[Q_)H/-,=C-8?.:N M5"TO6#<(KF"D^-^+I+B7HKLH&\&%O$$$+F)\1E;+&]Q?VNMU%9"54/*>$4T! M2^DE^/!ZK(MH?E&9'M$&DA]]34;2AS0K9ND]4UQO07G47S %4VI$>)"I#(BI ML,NH/="IO>O@!LSER=$) GY,[H7!HKM2/@W^F4S /P+^Y8N.U]7["N9M?6(- M.&HO["Z!9Z#JD]27FK28L]8$0,@ /Z.^GZWDBUZ[<5D%Z,H>LN(6KO9IAY:V MTU4TU%69G-4N7*GEF1_\DVHHS/7%(8$'F<7C"7Y^>-:$1_/I*#+E\=97UI9?* MZEY%_8HUFN3@5F0I: >FEAC#N>9ZH'YJ6N(,XZR U06/$/V7:1SE"WS@=8SK M+BKP&MXM: >UO88T)N)2,EZA^^ A]5<@LC%[1M.MJ+)9,/ZJW*R1][+NC)LW M) Q\,Q199!^HI>4%@JY<[=#5SV:JBS-[,0=IAP>IEC'0+9.-4C7(0#4T@?$] M(L]^ZZK;P1+S6ZQ'/S?'=DLYZX7A&I3AJ)@JK_S6HVQ'W*P='Y2K= ME:O&1JY&S=A!=>[(XUKT!ZMXG"?39!)E:WB,X3?G\EH>KPP8JG@ U7@YH=SY M9T3TOY<;]2E<4X8XXR0?,O6+N86V_7-3<$_XF)C:Y>S;.,6:.E!*1A)SH&C[ MR"I?PDM6-*_MZ-8&5-,?8D"_QI4![;.?+>N)$K&U_5P7!9:!Y&#_284G\&FM M)Y7N.JGPB)8OJ*K60#$(7QX*&1A[+8\5TUH]B;GG$1\2+@Y4U4(DSN@0">OQ M*#3-$.:;257/C&\_WZ@G5LWX]O.-$U*:439P'N2L5G9755*C2^ S!%W529D. MW2X96BV5U:^3[FX3,*[X-N%)HTX,!X^HHCAX=4? C+4KK.(WT[HG66'X]D;< MFR"F6E/YXOI?7"I;:ZI'$+MB6.5Y! 8\=>_RN E/D(@XPPB?QV@?,<.=LU#M MDD%9S;_W?B>';I; M#F=I&0'#8X![>+*13UVESJ7Y(AO>8AZ#[7%++R*ANLG[A4UM.^.":H]Y[OQ^ MIHA:.0$8364,?E(03!26([]XT*$&WM;LV+'W>?Q!G_#J]FN%W&9Y&+1JP@2>LP- K1=RDQDMBMLT8]H3[\0,!D_+.O4Z1D76RM.V6L(*8ZFL.SP U-$DP<3'*IJK?J0^*N#D M>L$,!3X$;GZ!5B>916-4\J5O^O.@?-L(_/;ZXA67E@I^[8O#!"D.OLV3,D6Q M]+S&,?Z9G]1%EE6:>XEKG&>YR#2<5U$"QD69OELB>@"6 *R*XTAG7^,L9YETF,AO_!0QNS0>@I4H$IRSC$4J19P_==MPK,Q#:0987-8D M^T"_X)(IT#.-JFOJ\%WB;A>+G%#M[;!N.T]J+5Z4VIY>RTSRL'D3".(,_2QN MO_#;S^ 8Y* :X8]%7I2Q7/T.'.GJ$73??K7$#I";RE%B.SP%YL:YRUA@7B;^ MBF_ \'7X[T62E[LZ;5V)B^'9G[8S$\S)2EB;Y7'T-^,$W+%'75H[G]U"OI8X2)/\[=8;3(XW;#Z?+RDO)I!.-@%X%KABNW M2(#EHV2R*+?HV( D!TEFKM@'>"70W:N'P"6>H,81G@_C9-' " 6@3CWT\.8Z M!FT3=]B+[\SATPVA.OX-IJ,<;@+('@,]S=5#.4D0&0)7,B'63(7Q0*CARQA#CC\ M,P]@Z\]&0E: ?S\Q6<\T>N?.$J[= MRGT:9^FTD_MB]N;_9^]+>]M&TH2_!_!_(+(9( %(MZA;W3,-R#IFO6^ZD\W1 M@_T44%+)YC1%JGG8\?SZ]SFJR*)$R99M.9)=B]FT)9%U//74LS'"ILNV_]3Q;ZQ',^@H+F3_VE1T[?5=E[C2II M#[!/2YYN=;P5*XH*02LCYK\*@6KB'O1XP!744JZ:>##79O)N!^X M%KF<'/,,-".3#_3;@:PJF$'1V5@I85Y^S$P:2Z*)N2SKE^4\]/G [14B3?Q. MZQ]NTY>I9+C$FJ(0\(08$S"N4#!V$>6D> W%F^$<2@(BB9*Y*0)GEH=*QSTE MJRT,+#D#BIO4W#R5&%4:BYFVI+DLC6@]6&4W6F;JCM'576'F\#O4F='=?6^6Y0UYI=H;ZH, M@4#,91:JO[W?*[V_^A+%=@(/N@1]Z$93;HO+@%3-1^&;OE]FD\"?PA4.HPSH M'#%+H ;RZYF?H*J>L40Q!V:=D--OAK2/;9[(_] N@X0,Q5=)'RKDU%]@X$<, MC39%XM'=B?R9"M7E\=:\ 2XLT M344^W-76NXQ] M9O*H4,CK2E>5;&#KE_6=1CMH 1Q@3Q'KBX702$69=/"\9),@I@TSJA]]C<*>8[BW)RDVWU7Q/](#9?*0I]]5.\N2CFKRVX M; RE >&BX*R_K(#_-H"N0VH=2DI%3I3N@JYG=2%I1ZOFQO)BF4X5,+6M#'87 MR$7S4BD.D&G.MO6B(Z(X*XQSB+*+2]V#A>23#!K),O#3=VI]N6< 1JB=UEMW M1XY5B-IR,TQV+.H9%Y<)QS^1E0D M__G:R:Q'I M5EP4Q?[RT"2)7.*[SXD4FEY.NFFT9:^W[Q25Y=OVBE]CN4+,!RLV#0>MT:A6Y[4.^*/6NJ\A'QZA/:!V090=C.;T8[MV:I0IO?KQ((B1,Q%XS >B*<,@7RSYHM;&S<\T-Z^O6^X6&485X'@G MJU&X]1IN.ZFT16PR0>#%VF:$6#=!K-\01(_"'H$D]-3Z[^@:;CLH&V&4(J?+ M&3X%L@%L+R*RFVZ\X0A ,D(SF#D^0+L_M)0;YHB\89(#*VC((\K$A*@+[]]1 MC#[#=7&&!2_-0&UX06780<7M@_.V\5!1(F*QQBZ=<:%6,QVY32.UI9=9)XZ* M5M,Y9ZETZDN:S4Q)$90B"DJ28KZTY2BD/!;G([Y6#D5ZJ^GS$GN9*.8B>J77 M6UV1#1.M6>9/D;N"UC_SV1F0V^3+)+AB+N*7-%V4N^0U8.4N#3J">1;3'9*C M>9"!=@;$89C0JI I]!*JR WY>Z&BY$Y<]@N5QE=N%(;G MZGF8RU=5_2')%CDMWX 92,R)] 9YH83"A!17(XN_*N'9.56^61?U*@DU6N%S M*V%)NA/Q!2E]I(&SV,9*.UYD,@GF[Y5_+[VZ&E2$K"#GQAMU4E *"1BJMK9>U$*Z";#3+0!" 1]_> M:$LA6);DS'4IDZAZ822Z$RC8([OZ+?ID$J7ST\WP\$8QL",0HBX\&:)85E#T M]-FUD DR1R UP](H*$#-4>C 7XHE(HX421UD=8%7,,$@F=\PT]1FSZ=;#PC! MZ!3-HE5M-UA3"8@<8-@9725I>2RR HA;\PT@JY"'$0,R^LN7;ZH+3$:4Y3*@ MJ3#Y(X=#'CRPAI8J;4,9_7(3B%RZ"KLR%'^=XH>YH,HQ9^L!?Q. N,SX1S@K MWCS;*JIHLEDA*BC/@N:@*$5GZ!P#6(I8*FM 3DFE0)_LP#= "6+Y"O= B(2; M(HM@0B94UB!X)Z7826U]*V I&P=$,2M>'W;;&&2[/:188'BYV!;=W\GIA-15 M3XKP4#L7.^#/ BV)QVJAI:*(82=YFSPCL$S"Z/53^@DX"W[\^T]9XEQXWO+G MSUJ,SXAJ0O3#&7UYAO:'CQ[E+R=?8,RS "COKS"2]7?U-CSC)Q_F'UE*I77@ MZ_Y%2(%+8=J?3M%@ LCS$:@E$/9B)+PL"-%/8OZ/UR(*OGTNXWS'>JU>N];[77EC_[QVM_]LT% #;K[=T=.TSUK./U:O^TTFH-^=USKU'J-QC<7WOP502 A\,S1=A?//X!AHC*@ M,OSC=PS6=&+ MTE2?]21(Z7'3TB#?4QKDN4R#Q!P&-):.@^@ZR<69'?O?&*D5$]4R_PDX3R .9G;,9Q^ MH:$);#J*\1:>6@.9J%3\Z(>48*KN+QLMA&;T1)L'&?HY !:QFD)<$=_8T.Z% M(:I#^9@GI5S8'.;XY!33P@@7V>Z8$PC41N!E$( 1S'D<+#X!\E!AT/\:^CF: M$6SZ(& #M;%+YXP%Q3!MET2W:.&GZ4K^#KLV*@%^:IVGS"V3[.*"J[@HNT B M[G 5)W@UO%D>!?SO+%P) ZY\#9=!65ELYR<*%.6=%8)\DR0894#;438K3+*75JL"%$!B9:T.=NS3Z48@[/*QV!([56-, M@ @Y6N8Y[< %]ECA:PN9D@_96$J8HI*BG0G=0"R5_PYV5%355T:V,?.ER4:CTQ46./C/5C6??/G9!_.YYW_>1 M:#ZA22[C/-6+D/#.2"-WJC>X!C="X[Y>DY;HW&]L#".?G@C\*\Z/,(4);PE] M(QNB(P)I ]/ 6K8_ ;&+./\CED?"!BB@@3,-W$7)'X[6()D-:9*L?L%&P(1X M@3393OUXFBW0G#NEO)0J%FUA\<-)X"<8^70)^JD73R\ED<\=QNSZUN?AXL)6 MEBCBQYO WTN[*.W 0[H<()7_N6P,AQ=F4>Q@!1=4.*Q(5;=QCYSW[,@(IJ*$K"9$)D[A0NKR.RBA?B+]H M"?%DL*F*;]-)K1]>1<&5G2Y21MC"3[$C!@Q8DJ 50$R,=PYM?)RD/T(EYG%14Y!=D: M5.>8"E9X%CG='(R;4.M,2VO4UA?)\:&V S1:0*B7R,F;(,[?7C@9) MV!KP2\!2AZI(.NL3BJIS( Q 66='U=H,$+H$(=JG>"K]S*B^0(Z7&G9X%'": MUX;RE%6;%KN.SG13U+L^.9" IZ58^&QUSI-7>0A7%2:OS@RD%(!QPP7S96@6 M7."8J6@^!DOYI^2$0#V;)[T 6(9J.G7.>6F ? X@P-Y2^8T5B1N&A*MTS)CHA'807 M%V54-4J7EX%@K]K)JSR(=N9C^@8Q9I\*D@5^,8+B;Z7Y$)Y\4(9/;>53Y8LI MCYHHAD(=/'[YV'?3RJ-J697H5!2!GTU@6="KM@@W\12 M1E!1U)A$%Q!$T1RK:A/H4H]D;)NG)4F("(!DU"Q;E"06:?) M'#:B=[/1[AA[NV7-1EI6'-UX =G@EYZ/A(/NNMR;7@4<5VJ= 3OBMF*ZM5I8-84 2N>PTOW#@8/"_;\4C!#6G1J354 M]4T4K*/;ZXA.I.\H8=^1I&%234"W@CJ-"K$?P,^2P,JZ2E2Q* ]7337)]NZK M*-#5MD2[G&=Q>C(8;,:GBH'7_D58G.3)J[N>)<7.KAPG'B8J)M)Z6QF M';* MJQ=C&GB V7-<[&SUU+PD#^KRRP%5S!62/.*-057RUN5'KZ 7 H$ RBO-W:OK MH'+KJY0![[0?;J(-=.D0L'@8E_YRJ1ZXA'](Q 3-E./R-'V&+!: &Z#KGEJ? MM=?H=L@7L6:L5L.JX-@ #Z[0(NNUSF2!L-Q]0J(X5QY$+=D$1=V'&>@V!KZR M']&Y-[U)!4(PR7(8ZL4 7 3!'Z-/7\X'_?=.__WY/W__V5+-315S'C%SAB'P M6V=PEHY"BQE(N2+WO,DQ9,ENNG4=^^K)UH#"U*+OO3#$)'(0B!$&Y(47&2SG!294[ M++3<1+-95?B1K2EHS<3%/6G,@*N2YX<6"R5VJRV5F3!Y"%1)=%H5&FR2TZI= M(W/8O&_9+&,FC6@B9/$%AT2%G(/1]):#!*DKTLB-;9$OY8X*Q.E+1I5(<)K !!1/H)W2 MHJZ;\BG /?#_%.0"][AO1*GNI@S_!*E%XH>&:S+8MZA.&@LO0/Q"H]F_5LW^ MN;<\+3+Y),22W,RB,A=)[=V(W;2FJ1?J<[)TEQ^#M/_Q0: UAF(!Q$S5+(>C M0_!%K-3[L$2FW26D6JFX7KC$6=#B5//25ORDY-M'LP)Y57B5GI[Q4\DA*C9= M(#<;(:0&PH9Y3K4NXM'A>3:!\^LJ)TMBAA:(J2*.$:CR@DO?&TZ6Y.;F4"AC M=C62EUV!P 3_35*?1)8 31<<-\0+XT 2:NV =0_E9$0M9,P^:$Q:V-Z_L]E% ME4PJOGN%N3!WAZWT/D+1&L9@4P8%66/I^\) C)Z#:.%/BZ9_&Z1HCLN0M E% M]*F7Y+1+[IG>AHD7WI]242AAQK%S_#T)>;)Y0QA97T\_G^I77=V]S8$PMQ// M+:%X,W+P2D3(4E^_G:%(52@.W +&F?SH43LC'@FWU$<;(7$Y^(6:U*D -=ET M,J4RQ'Z4)5CED,EE'D)ULJ%16U5(ED&?N^D(ZH0*1)*VWTL12!7;#P&L02!S MJY"%,UXU'W_!1#3K3?<$4:%? 378.NHA./V[?/W+;; M;ILT;VZ((=42P4#88BE&155R6(BJ1%YX;W);"K!Q<>6Q-*-Z15#<"U<_6Q5: MB/X?\:'DQG4CZM[3=E<3]*1[#B8I<9:I: MA.N6F1GI'G-+E911)X/".S:)P$H7#!!U@FI/+.$Q3RZ:Q6435DS34K X$;!E M1(7V /)4KS%/&T4W[%16A_32C$.M,,271RQ#!TX,YT0*7MR?9K86[= MSB5R+&A2">5J@GZ:E]][7,G/7N&DG&; E5V2//0ZWP[67MFZFQ7B=O0XLU_3 MWGMT8+PG?T>?E%ICW[O;51.L>ZL2^FQ.D*TQ9)@=.8<"@FU1K(#5D5RW1D.' M'Q.#D'I-8?$B6Q80Q&*>B? M,D!*TX4J($9[(I&2UHNVHZ+E*P7^^(G4YD$7D%%1!(TB7X+M&T7:!U:N@CEE M#!>/H*"C]3JA[?BE;&7ZQA3BT(ND0@K MU]\IZOG=+#&D@V)TX;_3C.D9&4970IK_RB+\22_0(/LUE2.3"_AL@8[4L$D2 M0].>?(?LKV6E9>;/.'\EHMHS-SJD"JOUXRHJAF1O(]G<$F6@]O(* MAZPEPJ!UF55H_<8*G#*[WVX!J;?JA5/&[;G*$+(7^E)A"-$!7(*KDGZ/^V8] MI>:Q$92E &]DA[H8H,>A>&2Z/;6^YC$Q6IY.7*27P?L7V ))9=YLFEC+4Z*T M7GO;[=8L7(4O5J*XUEA7WPQ&]*SUAJ9-6'EWX0+QDWP*+1:0/#S%*L#)B57U"*:B8"UQ:H!R0Y"%J?2PG&(U:7+=F_8OJ?8V%QX:;9: MAK4<+LC35IYJ"0=Y9*< A4S:L+Y$$L#ZFEGRV@1F59LYKU]%/@IKXJ,$#11Q M#3[5MV<5&RDPB=Q]=U_)R2O. "EOCU- BM@NN%JDFI3QK2R'2FJ_?1-9;MLA MZ_?*,RH/27#=KZ6"%?:B]>.5XOL M*ERL+ -C!&%>@%26RV1$X:P&6*27DOX&[,%/_G3FP').BOI')!O;12WW&U\$ M5'!'5FRD4?*VKW,ABYVC0,TV3OF5C$5;)2VR4+GNTJ6X55#5A.;Y7@M85:JTN&?(>B?:Q&D18+#@E(U9>(#!UI*6"&M+;!6Z]V6LZRIOZ0@AXLX MRI:)O, J38%0-O8Q#N#4ZI?APT*ETDJ+J@TY,+@:-(.KW&=1!YX6+F6R&TQV MP[V%5VKBG%0(28)JF^6\EQ0^(@WH$9$,QIM>8C"7"CV=KE71T8:U+B(OT*\2 M72,9N1UJ04;QA4@IM$[WQ@E6FH#14!U@]GAQ\EV5=(-7ACJJ(O$H+Y)5./J% M5J0$4.1.BM3I%UZ%V-#??&OU$D)TJ4_+I#;GM?!)2Z[,^9A6)(+DXRN?A4 F M86P4*^\'MC[1+*R\I2+5D0N,\@@YO"4D.2.PJ#[#88C8%5(IP0Q4I:]J1%9& MHLG>.+3.?,US6>ZW3'WS .BBA/Z*)W(-(_(J,2" VH6\CRQ#Q0PBVF%_3O2- MK$N(*RH&YS^RH59%N[#*HSUUF\K+A8X0/>.DJBS@49&0O2O DH:L4(Q-TKJN M=JT1EFUD19-8R6TG"<6YIB4R-DG635F L@X\Y\-H>5(23ZLU =M:L=B4<(3O M+&-&T2.B>Q8 MNU]+\A@M"7\HH\4XIT_G(;R;$:4TIN7-;PL[,0 ME5P..Z&KB?0";J?T[TC'#A7$(P;$Y".IMOWHM?KR,RN;KG(>*CU'LM\+:;9Y MQ(8M@]J\*\\/."&Z/Z%Z;-3H)+DL/$\TNZRJ%M(H:F(JJ$>^/NGNU()0&$+1 M!*\YQ7[(T4!)HM:+$6;TDU+##2T*3:#D;CO5@2[#Z//D<-W#N-ISAYUZW'Q' MMD(O"A@QG\.T/^[F/>5AB_C3+K9@%\FRD[.5FW]K(K@5BNY MC.*44P9#+\WBDNU$.\2R@:BTU56+*+N;3["2'XN26(D78= O4FU+!8,^?>Z7 MZTVJ#(V;7-UD&Q(9?_0D3TZVS*NB%-KI)(K^5#:S$".&BB#W#14#6##1(Z0* MA=$NAP-?P7;P62['34>IF0A5,QJ92D"I_;##8R?]^Q98F&25C.-4,@:MUC)< M?DX1_1JF>=Q"$Y.&4F7PRMN-Y$J*5$S(KD(!@FS&X*Q:0HN$LFZ5XQ]#>C!E M&L\[]L($E7Y/PTDJ(VI1!UVR#=)#JC>,1$;E%O=B5GI(R.>;(M.-",5F).3W M55]"6]\<9C^4A37]3=H.7%[>S\DKW2J>D]@U$V?5LA@FF;SP>2T''1SYWG&M M:$4FTRT%QDG+#:>94%$V;5);:79\C'DE-F).Y$-S* -$VS8,H!5IX[X1Q)3R M:%(_7&8JX@3S*1@H.E&6F,5.NB+%Y-8725#DA&A9Q>TP[FQ][W8*TV/[,7ML M=[7&UU-JG;%;Q^VN[+B]K4WV)$K3:)%/V=CRBAJUM^F9Y]N[_;I=B.9:3RMMQ)1L9SJ;1/%_9< VV4S^H8ZL_Q;%]* 1S2;6U=AXES>2D7'E:HE8>7KBB MQN!Q)_X"=(IX7W@,5<.%]IL_ MINDH'!"/X@MFIT9 4J17%%^N5&4,YFJ8VW@*S/T:1FNXFY\EMDT"=4ODY7A0 MU\!C#2-U:H019+(+9]J+6A2L5-RJ E:JJ1=GTN;5<)3I3@IZ&&9 CG';TD(U M\]!,&8,0!=&%2KY7N)Z*Z275../$Q MN&"_V"+*_=FZ7C+IBU)5[J"N]^L/4E79[=WVEN?F5Q_K> M3/VD4]]!INL^@DA7+:;M6;!;DV@?,O.3K=6MK5[KLI,-74:%13%YC*V\%"38 M"E<0(@X +23D)7-2C+]@UZCE690(\GI7% (A:4NVPU>,R3X^9 (^>QU[RW^\ MYO_J#V^5HNZ[FEQNV'8T%0(22 I?_OMGJ]$YK;<*/7U(*3_+//NJU"_SX-"J M^@)5H13..HFMG^0B$,&>R]VJ!,+]3:-'MD?ME%_29N]C@WH"\YDUN8!M1"#P M_]=@,!J-Q[<8U'8DC+MJ5'*X]Z,QZI-B44$&2]J0 \\4"9:HXZ^KPOLV_/VP MY\R:MXAJK0>N_ZDMU4]YL1J[7:PO'*BE=7=]\COVYDZ'+S_&Z(^@U^IMUW;; MG3N]7"$%/@A;S6X?OHY[C+ .EL(6"$)D'J99S<\6$.P1JME]YIWTG8.Y=Z]T&V_"')C0+87"EW.]/AQFL-=:+FT M !#Y+:G_WS<8Y.[@9SRFM>W9SG+ .S_DM9E3.<2UF5,YQ+7==BI/;=$Y8$M! MV^W8;JU[3$+5R]KMBQ A#>R)^E[8_:1V][,M;1G"N]O<\?GW0UFY?A AI0&:D M;A.\=DRRA#D7/HAD> M=O L^O7F7;9NZ93(O?EBP1@1"VQ>G)^[[!)7="Y1R%5UTMC8:HPK6MN4S4-; MUX!>;]^X/;M; ZJ"$[]]T[2;^,''YHA9& L@7-@^]3(*:) @2A(3-F\-.N8L;#H@MP=".0 7MJ:LSPXP:1.)SL;B$EQ%" M.+>"L6S7M8C"]#*Q1(B3WUIDO^*!;E61?=-\;\L=6?=A[G)=AEFL.NW!6Q$< MRE]P(MAB5W8$3;!)#A^)UG\3SIKI)^(88 =?%J[(7TS.S7FTUG:JWZ3$=4\V MM48TS5L2%Z_/XVAQ\BJ_+]C574)]/;4?($Z4BI(9T>"-E'U/XEMH= A_0VW@#TB -.%^A M1+)U>KEW!;6]7+_N%P"B1-YBOOHT1"QD8QH&*MQ2P&[N5PJ7F]N/([5#T*]= M8]DF'KLV8OMUGO'4^J3FICFI*PU/2+WJ9WX"..\KMK=*77&&#*?,$H5>Y-#GW6F?TE77X#R-G/-DIT>@*1*LD MUR>E)JW!#1#L7M.N*?+]IH:+VD*V0^S02/VNO>_K1+P 1 7A9>*-"]#W6]KB MRFMO\;UW"JB2*; MR!F@M#F JT01@DFVK+)/N3CE'Z-/7\X'_?=.__WY/W__V5)&\R^_$>CAU3+% MASDO8F]!/TYR"];1GM ^6G&?A]903"GC U"ZUK+USL/61%QXV'\KNO+I+B/_ MFV8)Z)$BSKM'BS O5U\:#DCTTKLA/GJM#CZ#:Q?+WMY\*]5T'K9=3I## MP$O6FU8-R0M^I'D#'X?AEO56ML"F2,BP4?R#,29!%*%HRU@6BS3&OL\SU(F4 MI@.+28!B4'<9[H6[#%!E*%N(M\"] EJG M" '!YBEV\9O\&PC!"77D5FV7 :5A&=1O-SFU1O,YDXH*FN(2Q:G;*P !^@7T ME-K PIX50-8@BN*"]:;3TG^%44J_PY:YW340XFL)3%A4?\;MH.%WH,-\-'(- MZW$,^#1<\RHE#CECP,#9JGU+_=KJ2">U:61N0 MFP)-#"UZ$/1/O-K4G5P#5;G#^R6\BATJBR;H*%S=H!3L+Q*>F37:8LURBT@\ MZ7T?I35LGH8-!:,DQ:O+(KIH/3Z(I(#HKD0$Q(] *T!34>%@*XO-(]<4// M>#DB4DG9DQZ[T2NK )$623Q@N8K*O$4!>[G$.P,G"W*K!Y)?MN#+2/1';B"_ ME?*)7.>.A;^89''">A1(YJD/PZF>DK!K%-9IF[G>Q$)O'"$MA0?#C$@N$*XL M].E40#\A+<[C=8!PN M#A3E!AOJ28L'G">@INS#FP^W,H "3O'PID>9K+#M8AG[5\AR\*%E-@'@Z^1J MXH5_:DNC!Y)+NB/40W4S!B@XT![N#(HI-5R7BBOI6X!)<(PD;].WRHJ4:;#@ M_0,FK0.$3(;J36[GSD>*JT#Y?O;OC'4K1>*+3NRS_&+P/JL BVA5FO32 Q(\ MP3[W<(]N+&P32D8N*UD@1U3\5>E3C&^HK\TUPDZ;J8!/H@#D83M13V\H2F=: M'KM 15X:,1SX36&LG_=3W':'3U%B\R339@8B?P$RJ>^(%;:=X/TM">HZ[\N->#GMRR41(KV29.9JL;? M[J^TA+).^L;M$"DBC93_1FY;UC;S#98:,H-N&6=BIHD.E5IG2K7NQ9 ?PD,!\7SN@\21#._2FU\$68@IX6PM]3K0*&4=:A<5!G!J/;LL#9+)%&\E7 %V].A6 M51@TFOXI*53^Q-LOT1+X5,?MOOO9.E^@MBC-,D U1HME$-T(87V^A OGG"'O M@@$^2A&B6/!IEJV>2%"@+WLI THZ4>M]%8K/L,A<^"K'H, O9W)8!^;S!9TA@ M5>8OR=\((+IS3;/32I>:I&VY68NXK.IN+9D>BN.)/%F+Q$J1:QJX4&G$OA%> M+%>&5MO87TA+HM:9-TJ$?!Q&D2^ ON^'Q(G*NKRFO;28OI>E+EH)R<]TPZ7! M7 &3EYA;Q.6!SHJ-$.="5HV<%T2A+-9:(1=FOF.GK_OPC3PV0>A6$81/<-_" M3)"7 LX\A(N#EPY1"8E!;A"2E*!=:P,E^ AR^M1?P@G"94VRQ.I?(%(/T.\ MO)UP'M'F[2JEF=G@(QZ.9D7X0 M(O%UN\B B2/SIEL2!+ +N2CV0"(HSR( 6%D.PQL8RW7F"/RV_WE V^9KH9V M'*C_^2O>;Y1#(E2-2+6#R6.<;8;*W)P5(QSS3X'$ Y9NLQB9TZ6(E*I<,7WK MOBN@L2)&ZDVYR9WJ*Q<)XD,A7JWMI;3;S< L0>]M75L(ZHPWA3#KAS,D<%%, M1/KZ4I"> UH5;EJ:#XI)I.U-'E@HA:^8I\KM %O7C("%VQ*H00-!AP)#K1#/ M74FGM$2L$,^=26?'5B8->!&(I3>+.%ACB>>7INB0*M/62LHJ$>ONM'6-LJ)X M;VCK=MJJ%)S'(J_U*O+Z'A4V13WAO6ZSOIGBX65FFB@07:'6"AT, GO*( 5%!50S4V/_D;Y/_M3 S:=9R"G'F M!R+0T2_D E !39F8\44)>']L:O)CI34A_K'>9)VGEA5:*&=&,T M[=)&+S:^3-5DIKE02G$+[N**VM$1QU_5#K__'"QR36;A6Q'FOL\SQ$9P8;+;0,CP^DG0;6V\_9)"6) MN%MO.6X-A.)/3%WI^K&%3*O]21:UG%KU"_*KS_E>L_C?)A7GY-0C!Q(']Y0" M6(!P3H2UX#6L!N80S2CLO&Q<53_F?(*,9QC1_5CRX,*\0.]*IP&MUF?.*&DJ+Y&CCU2\FF:Q M1G:?+9;,PLDVC>YM:;->A3)1?Y)%Y/PSB4EJKMGFC>C8AJQK@2?\'^EX4_ZH M$I.XA9FR/:;$'7>1Q@L-B[25._+?4VM49J8$C9RCYK&BFB$I5YGPF'/(:*(5 MZ6E*+]-Q>IG'^]U1*P!5%S1T=6E*D#/VE5VYBO)AR)"OA[$5X .=*K9RSB3O M"UH88<'5SRI),P&01$+O*<%GP"1"W@ M;P!-.)&8[_@$P[-% O0F@']Q&HP4FP0W9.,$@6_*$? <_B,#B@/!;G8.O?8" M)E8<&0!TJHC#7[4N)I<4&3 1'$)#23=1X8-FFK=B$, +'8("$U10P;O3.WFC MMPHR%_NG6 +3-H"W L_#,8I(&I7BRA689*^5. M1"D46D3A_:63IN-66B@?XA'NEUVIFA]8>8$3ZU^@94G1]8NT4*+VV+]&!/I( MXWZ-LI+W59+!5WQXOEW^CBHX\K M27,;(_TRS0G'VDZ4ND5[2>1>^!*C.1#H$AM>*5)+FQL%@)G*&SEY58HX*F+U M"L-$KKL@^+6M]HL(,)M."W:>WBR)O%9/M_ P(B^ ?ROF(74'$W'D3A7[D7DO M^7 2;C 9T- )$FE]3?H9K=M8;Z6D)Z\VT]*6U+E7%3V-,A;O_(M"1-'R24^2 MQT\MJUA3Q5Q:KHDOE6JDKFCK1I>8%!PWDU#CT]G97W[S2,2RULLII%U%31[B M0+]5H..L##2SG:RF=^D^:OUB+R*XC$QF"B.=)8/;3EZ5W3]J K/A54QIR?9 M9\XRW46$%PJ3"ID6)6P1\_(4$32#H3>7_"EJWGE E(^D23T6 +&?18HD7XI@ M:R!\+^UV3)I0AEF;O$23\;P*%W7)M:3%1!;JCN5-,$6/K"4>QO78;)K2_$!5 M;B %(TJHS%U"RB&$VBX>> Z.J3IY;:V D/WL IZHUBJ(I6W3*];,"\U'B^!@ MNX(7***<)S5LQ?4AK&ME"?PL&R-(A4TT5Y+TYN%NY#SYP<')[WXET>^(*1QH M*UBS1(31]2:AN\K]MJ-3GS9(/$!%-6=D@66.0,&L?&T3&6;"ECZ9(UID(VNY MR#UM@]+BR#'Y:[SH\52(OUG((>%:)G(5E9]6Q6SF^(1*9:3]#TBGY'FZ/J 9P6B M>/B!?05C#H44L_.0Q6JB^U9[33%*]!)%:R:OX1RFH.<'R3]>G_\^?FWYLW^\]F?? M7+AMS7J[\ZTU''1ZK6;7Z8R[=:=Y-JPY9_"=TZWUAN.>.ZS7&N-OK5K-_=9\ M_6NM@.H3PJ+B$":W3SQ9G5@./_HNXJF?H 3\+VH**69]=#5>B$\"TX< #11I M!Q* BI1[[\-8!7:]W>C5^OVQ4ZLUF@CLGM,?UVN..QP,NF=NJSGL][XU$-B- MU[]^;/Y?[[<5@#_MOAGP,^'_/"*_W=@/1#R .W@1D57H<8#B=OKCSJ!SY@S[ M]9[3' &=INCNC-J-]U!R^V.NZWV-T*_SYAN C2NB'64).KO/VU8Y%/=WS] M SWHRPOXU&K76T]Q?\NP*)\ %MOY PV2'^:Y.UX;BNCOXV'6J#4^&]0 *.-V ML^8T6^[0Z=:';:<[[K7=!HPXJ#6GV,Q*#EJ-L:Q,@+QA4C.#Y7UF=B.T6"N!9- M?4)UZ:F!RP8[-/:]ZH*("J689(5Z#$[AE9*!$.@3+!6CXI)3<%)^RI2*JA.Q M!I;G5F@&K6MEKY?F*AD6EE"65\AT@N((/)^K"2@#FAZFYE.>.>)93 Y)+3,M M1T9)3I9>S(9ATBU3&=15^&]1%\7T7/+P3B_M4AQ:0B9D'$> (C&] *<.1[IU1B#R?PF>0JHR =%^R XQS4I'99 M"2_2PW$0JN[D!%2?L-@V#)"S*EZS9$K^?R2[\L-EEA91;RJD3R/*$K.X?!1- MD+"G_)87*%WCSTLT4;?UMM:PP,">D% M/J4#K%3J?9:__[<[5W!7KS2VO*)&[6UZYJG;9MR_8??.E9W_]Y8BJI0O3"E] M4YFB3$%:&LW+0[=WK]*?KL#ADNPA;0=HE:-APY)>*47*D ML MU$+_M9K=>42>JJA02;W8K29O29(7M)6"WLDK]C0G%#A'LK?0_*/2YQ(%T86O MZ@))7"_*DY_(6&5T$>E+S=:!<2M&[E WWB22'9<.N8]$,K)"Y37UI02:+> V MY0I#892JILXGKS;E5*$*A:IB%I."PVJ/M[F8THE60WQS,:75>KJ)N(C%!0># M+:(\%U^K":"4&"UV_(!+]AMUY;C4E5[]8>I*N[V[OM+<_,IC?6^F?M*I[R#3 M=1]!I+MWJ^Z'"'9K$NU#9GZRM;JUU6M==K*=E/*9D\?8RDM!@JUP!2'B -!" M0EXR)\7X2YU94^[,^GI7% (A:4LMR:\837E\R%35L?$N4M1]5Y/+#=N.ID) M DGARW__;#4ZI_56H:K,9N%TOU M//R<]YMZ\CMVS^[P];9KN^W.G5X^D%;G+VNW+Z*QNP'9SB![68+.CO1XO;_F MT\L\N^'!&H(U6BV[U[R3MG,H]^Z%;OM%D!L#LKU0Z'*FQX_3'.Y"RZ4%@,AO M2?W_OL$@=P<_XS&M;<]VE@/>^2&OS9S*(:[-G,HAKNVV4WEJB\X!6PK:;L=V M:]UC$JI>UFY?A AI0&:D[FJ^T "^,(NR22 .D&D][N*.2I8PYV+.Q9R+.9<] M2=\;LX_<]F:NI3U3>'^;.S[O/B!AZ5G$-3YXYB=;JPEN-<&M^PINW=('W02W MFN#6^X0!5J(4SEH.;FT]E[ME@EMY=A/<:H);37#K#S$\F34_ES6;(-QG$(3K M-MIVIW=4[I>7M=L7X3DQ(#-!N"8(MX1@S4[#;M?OE%9Y*/?NA6[[19 ; S(3 M#F!"V(['N6E.Q9R*.15S*CN=B@G"U<)2:W:SWCPFH>IE[?9%B) &9$;J-L%K MQR1+F',QYV+.Q9S+@Z7O'0JN'V!-\;WUI2J*BE,CIED1@Z:J[0,*9-S9N:B$ MS]V%N+DSMY#V4[' UFZ)=4U=IK@F^84(!3;KG@9>DE"Y?#4R-:Z@EV"(918G MV4K1?YKW\*I^']0!(A2HC;GRER>YOUR3&AM\-U9ZHX]S&">R@[UJAG3#GFW4Q0T'++79UEIK4X-(?"X6E_ R0@CG5C"6[;H6 M49A>)I8(];+ MCJ )-LGA(]'Z;\)9,_T4W)R=+PM7Y"\FY^8\I1;OW$5/XKIG32^QD3"BJ>IK MHKT^CZ/%R:O\OF!7S_6]EDDP];E$LEV^[8BZQ97%F=5 W%/(DSTXJ1]>0GT^ MM1T)ZF5\\DI?&_+)3HM$5B%9) MKD]*35J#&R#8O:9=4^3[30T7M85LA]BA$9>2>M_7B7@!B K"R\0;%Z#OM[3% ME=?>XGOO%% EX2:^=C?2?0OA9LI^*^G^27;0+IJ,WZG=]R/U:*=_L/>:,!N.6T^S7:TYWT.XXG=JP4^^V^\.S<>^;^\U]_>N' MD!JG L2IN2YAM$6K>83.Z^L[W!%TR::19>?VT?>E']-+B6K?_B]*QQ.S_A7( M.A=B]%W$4S\1'U&F>GB;>S^)FG6W\^WKY^$W@-2W];;W%:ZPS-WX#1& M]:[3[-3K3G_8:CAGP_JHWJGU1T-XB)K>-U__6ML![H\,GHK#F:S.3M\F_0QH M)/9%FGV%.QI_3J/IGSSGQ\##>;51/^%J/V0I-6\%1)!K6UG()[$ V@X_#^"( M8I![,R_X KRZ_FAW8CBH]1OC3LOINIV^T^PU&DZW/>XXPUYOZ Y'_4[?'<.= M:+S^]6/S_WJ_-8\,RIC_IUH">UD=-MU=O.Z*Q1[[G=WEFW4P?8U5[_BF154M5CE(_W MTSD*H#!1!OH,__@=]#RKI0O$5G&<,C>#&%26V_7S 8Y7^6CON?$W2!-97+0E M#,0%=FHC.8Z%SFF4I"2ZP;T(!?79AB&HN?H2'@ IE7HE@I O4.9&>2J0TGQR M:IV#!&O-,VIMC_I)M/"G\/I$A"!@4P-Y+^1FV#@7:@RRDWR2!=1#7,XA]6Z> M@H1TE)P"T$Q"[- F9\ .B+ZN'4C#C=RL[$O*.Y)JA;?T4RG;+D@H.+>Q4AVR!J-CA'GO?)1<&52/+6 MWK*G:*ZY_3N;7> ?IU8?A.?Y' 39,"59&#M,)BA'3ZFE.(-0"=6QF&53W7PV M]>*8),XKV<(R-YEQFSZCLZ_?&XW\#'>$235)1=TD+0>%R0O*U%JQ\SU MCR2N/FVVZJ8@,@U;X%W0J.NU8N ;X<6/3P(>+X*RT;1;G=I]MO_0!3_3S3[G M[/(=+^E[T!!_MOJ:PT=JH][^:^_\J.H%#TPC?-NU6_=OY?'N:6_A(VRVUKE3 MC:*=-VN8Y[9[Z4\IW,*[B 4989Z6C:ZS3;=F/1F??"C2-CLU]*<>&\<\BFT; MWFEXYP/82<.U&XT[50U[#LS3[=@]]]Y]&0WWO._-'&0) %7$[%!"K]"EOWQB M3;2"A;:.B(6Z+Y*#/L&N#0,U#/0A+,7NNKV7PC\;=KUU[^OX8/9Y**F<3S'' M7:B$*7%P1,EOYE0.0E N7%>-0^?&OXMT0W#;$=0:;=4:=K=S;U7KR)PD+;=M M-^I[KC5J6.2!)OL>].*.BDF:<]EPVTV&^%I$8%]338ML6$QC4RPSX03%4F[7 M&[>.)@49@_FF!7_NFOVJ!W'>/_MU/87J#GD)Y42&?T;1[-H/@GTF,/2ZC=ZX M4VLX[<;0=9J-LZ[3=]MMIS;NUVOM7GW4[C>>10*#VWW"#(9F*8-!G2.AA4E< MN 6D"EJ86PE7C-(D.41_*I(DC\W/XNFE!Q2!:@*H;SEB^P3S+?_*_%AE&PQN MTN@W,?,Q3?HM'5#]G1;[GZ1$/69Z;J^*E:?LSR(B/)S!#8(E^7.?HI+]M6AQ M-3/E">!*PC"#:?W%$@:GZ'XM3(U=H).NBMB0BB:\HV+^<>G%J?4['$183Y&]4@H3S96"35 MT] J,.461\;D0\S^6)^.#VJMS .BD)@A?JR_8EL7"O$ I+!AN3X\R?.J= H8 M18ZW,HVM=A?XJSBESW'R2NUUIE)8UO(U\N?S->C#P@BE?56- 5^%&W>&UXWP MY=I/A$U)\<694 (SX\-$%-4J)C=\W(LH"U-Y)"MSZLM9!\,I:+I\O6Y)8-Z< M0&&OP#$6\X#3=V2UC%)&^<0+$-&MY%+0!4U!2+ [G8[=K==-!DR%X'5+?DN> M6H__A!$64E"Y8'RN^L6&<\1'5M$*:%V.42B?Y7A>.@_^7[4TM44X6DG7%91+ M]4F1C7U*4[76L-7N#<:8RUQSFJWNR.F..B.G.3KK]]O-6F\X;#\+:>HITT$[ MF^2F3-.Q\N(ID[+B)4_?RH]_1?3*C!!6=11:R9GTTH_UBC/E>C-:YF4NDZ'B MI')-E52$OOKJ^_@Y<#M M9($7@PH;H6J+!)?H8'P378B04L:3-,+*%TCHL@522Z2%&KECN@D?4Q^H*V*# M6##<9(7$N;?P08L#\HG5HD 3S"A[GHLCEM+QL126#Z.75X-:,->IL>9"$FJ2 M_UFM5>NCWX#XQQ@'GJ++Q;\>O#+UYVVA".)^ K4_6*,X2_O M*J!_@+950U0,4=F%J-3O253@"+(YEL:)I0WK(_!9;WJ34M>T)%M6G:V+@/MC M].G+^:#_WNF_/__G[S];>6,'N:$1;PB&*&]S<$:&&*ZXIE$/HAS3RS *HHL; MEM_22/U>3UX%Y*W_F.H1LN*TL^WC/,H"'(4Z; M.B-'QOK:W8?5&>G>H\[(EE<>YWN3OG%+))HD?\^Q\?USS@#8L9GN;AI7KF\] M-4[<-TS/KM5K=K-U[WC]'Y51QY4N4 B/3=+?CX5-NJVZ[/1-0?G#7[Y#7]O2DX9#EDEU3 MU'6KCM%RCHLQ&"U'%ROM>A,UG7M7]3!:CM%R'E'+J37L>MN(,@9XUF9TGAUUGJU1=L?"M9JNW6H> - M[!P +AI1YGC69I2>'96>:$5\.1I.U6K;S7K=4(=#NX&'O#:CZ#R 7IRO9!D: M1>>XV(-1='39LMFV>TT3TF84G0-0=-RFW3!!*X7[_NIVP/[O66C]^Y/6[3BJ,C=[*6JRL6^8%3'TJKM>ZA M2YS<<&4' ]D12-$;1;;-&WS..HBQIND&C+;=:/;L>GO/Q4<.:M49+)R@<4C!55M/L[CQNAIC)YWLFO8G5;-[G:/CF0\?./=6LUN MU%L'0#J,2>=HUK8[ZIE3^?&G\IQ%X'N9X;VC:COM]FP7B+7;VG-&Q2%MN F" M;:_9-MSIT&C-(:_-<*=#7-MNW&G-#32)K6D !/L?K_O+92 <! M'XK7UD_Y-5SKF7>'5G@KO?.FEV*6!>+#?.3%(;R1?!3QYTLO%F=>XD_[X6SH M!UDJ9E]PI7OHIS=T!VZMV7%:[5[/:?8& Z?7;8V=L\&HW>VXP\99I_LL^NGM MHX=;I5<(/4%S./U+V2PTF&9!WDMM@H?*/='X6&&4M]BP\9TEY/ECLUDK00PP M/B#C _H!/J!68WLUB.>FT/J:(+R"<7+.<:3YMH$>ZA]BH7WDABO%9^J\(CGR3VJPC<[T_1BR M7BY8NQR$\!A@?5G&\5W;@F0+S$6*XN>867",:S;&JP(W16J]?4^BZ?F/R9-[ M>^^4[KK=:]S;G//N*,Q6]6[;=@^A0-*+)=Y#$48+/S3D^W#6;,AWCIW_H@ & M,7.\*T&]@Y*[=Z[AVH[/G5+;#VWC/[M:; M=JM] (Z*ETOTT6R'C4-!(@+E2MTJC&8C\U.VA"_%=Q%/_82:BB L&W&.$=90L+'*@+S;WM=2CNJ7U1M.N=8\NS_9H;^0&1N=( [MA;\=R M<=R:76MU[7;3]/-[#+=J8_G=FD49,*4#]/D^[N)VQSYS+H=P+D;2W,+7I.UM M= >W\/$K[L>X9B.#Y;AZ]D,,"?>U#]=.:_=.8CD.XS#L\ 4$"-$'=/BC!!U MF(LS0M1#S74_P A@6)-A34=%90YZ<88U'>;B=F--#PBVAQ?4(.LA]_>+H-\4 MAG\>7HDPC>*;01;'\->>XNX[\'_-\6#DC(?UEM,\:PZ4G0)WM]<=LD"M,'B31S57U'/Q$3@ MFPC\O4?@M]OWB,"O_< (_+W/;2+P*T+%UT/#*RF?]N%YAOVE9+SW[%KS *HXO1#?R+^B^$]0;9QE'$U% M\O0WXL%A&'>*VZ[;;.H N52^$O0Q -193JB\ FNOQ79-VQVZW]AS1?GB[;G7L9LW$ M\?_(UE[*8!@++#W[]-F-#T6AMQV[X]Y;97EB9^$!;_:%N M-!2AS*@=\*D:B MR\]+-6^2#.K)&=,]K4K-7M=NU??EP=MMIV>W:GBV&+X0UF8@)>L MUZL[9V>M4;/E=D?C3NU9!+#IS:A,16A(;=7 M4?R@5>1X'N$P=ZH6?L1>FSM!+5W\8>[X67O.'%V3B M,6!HC-7;2O$5K-]+\^A52P6M/KF%X,&^]99=VW<6R,%8"MS3W@%4Z7OV+=.. M]G(3I7WB%#53&LJ S'#A'2_J'\2!CX[9OFW9[?MWWCLR/_%A,-L7PKG&43P7 MON%=AG<= LA>B+/,1 SLC_GL_3DC7]W9RJ%\$5:IQ\LQ"5X]N]%Y*2E%AR%W M/0/R;GSNYEP._%R>.!;B+E$-*Q$1LOB'F*$C780)M5_LQS&N =MSGMT4CWST M;O"K_K47ST;?EWY,#Z/CX]%")?K#SMEXW.@Y[J ^=IJC3LLY&[3:#CS0:)V- M&X-V:\"A$C!*QW'K3JVE0>)Q=K,CB))-HTJ_&5DMD_/PHXC]:*:\2M*7-)+U M[S_&_O3^8,Q"GU_RDZA9=SO?OGX>?EN*^!L7^'YMS<347WA!0M[E5: /QKWN M\,P=.(U1O>LT._6ZTQ^V&L[9L#ZJ=VK]T1 >:M5J,.?K7VL[@/OQ(,-',A/^ MSS+,9^PG4R_X/^'%HW#VJ"CH=OKCSJ!SY@S[]9[3' QK3KKW1<%CK.V<-%[!B"->M=];H.N-ALS=L=[NU7GOP+**6 M,"SFT<.6/@//\N?^%!!"_I(H!,4HP0G' MWC3-O, *_+FP_'".JZ593%4>$WCTX, CMU9[8&/<+;$\F\)_FC\N\LA,_=RF M-J%>JV%/;JTRMJOH<;8?8\_3;[1=M<]1P74?8Y]/BUY5IJ =K9,[K29G8-M. MH()3 \OZ\M\P5^U4"Z(A\11#KY70:I'4NN?T^R>,CGQ^-^A.^\[#(X-2T&-U MC.0GL?#\4()(^WY0B+(KO[P'P;;8ZUO4J))W!L"; *PN5[%ZNF4O"F#F)OY8 M1#$NNRTNNS?N:%MNW5:?SG!UYT] MEZ(ZO.,]4JP^V!,V$7\%O:\K>M\X2GK?K=FMVM'=C =O^^70^_KIRZLE=Z18 M?; G;"3^;1R@H3A \Q@Y0+U^C%?EH;MNGS:.CBK>DSP >AY=S.5#C]=MV&[] MZ-2<@SW@%Q)I:A()]G>A?]1S+VS-AX)AA[RVYXC]3VV1.08AH-?N'J/5[^&V MCVY$]N$H=TP@=@VW@&LJW)UC'G8L[%G(LYEZ-9 MG#F7PUS<;>=R2S;HY@U\WU]F#@#@GCE3WY\T,V=;VNN^4NF*I,-1F/KIS2=Q MX<*A^_K7P:?_^V -1N_?6^>_ ^!_[W\Y__!['S\-. FQ:IWE M!,317QD\\9L J,S.*5N8$C6'?C(-HB2+]Y!(.&ZUVO5.H^\,>V=]I]GK]IUN MK=YP:JU6?S0>MNK#]O,H?^YV]Y*N!F"8*$4BPS]^CU)A]2S'*@[0\D/KLQ>* M. JM 6"(]>52@+HCLM2?)C8\.#V%H=[*"P:G-?A%/EY\-?R%XZNS7&O)I_WQ M&83W/9/V/DK2WU))GI(T*_MK4PU:&ZO*G[Q2I>NM2V\&;UC1-9Q'+LWC+91Q]][%+='!C-1I_TT[:AD&N+_WI)5:<]Z;3**.*\_,HMC(D=E2] M7M"%MQ9TXVE$?M /+TYY)S#*P_9BA2)5:X+!_ (K8S''CHM8AS^D)X&FD+F6 M,EHG'I#@J;"22R'2!#?QIH9H.N3:^SB^!2?L<3(Y#';EBVMX#P=2R*Y-ED;6 M3 #D%GZ(X/6I04 LK&O\!P'MAS-_ZJ51G, O7FI=1UDPL_S%$B!+7^# Q8 ( M72_!WST_%K-3BU@,[J185'%[L.\ K]!6\WK4+N#*GPG<)8+> AJ;X E>83%H M_ .GG$=9G%Y:?\$)P/+Q0=HZ0KZ,*6HIJT#7%FUCD[XLP./%X3UL:!!?X"!K MR/2FW6W:0,1/D5A8F)]AS;UI 9X )XK@;Q_W@14$$I_FF@89MD#P\#NL48$3 M72"[L>891=_C(F89=]KT$24$P#BZ$2*QU:[@>V_B!XB:,$>2)2G.CUT3O!@0 MVN/:%3YU8A#P" P2>,"48!=RDE/K7S[@=,;'I@VV%#&F0UM3SLBG&>=9"KSM MY%75#+:.9!,1^ * R=CJQ?$-0M);X)61/2?**.X7&$(SA1%BZC3"X'N0[TZ/ MFWSN)3?^/+0^ )YA76Y ](:M-_*P**T!8 E$, (4&V!)DSCU,2_[8QPM_"2) MXIL3+($%3/!CAN52$F'U+V+!!W@-2*'NQ:DUB&\B9R"" +Z'?X+("TN42ETZ MN Y+KD^1("WV+F"\"ZPJ(4\^6W(H9ZV&-\8&A)W\&P@;C %?3V&!B+U W&8^ M%;;@*^6'\,F3L\J!D**\<5LT#+X[070"],$-$R'05N2'<"N"@%<%N/>FT<&0 M'$1P]=2I=8[TVYNGDMQ7S&GG9 ) !;@^$S KE?4C076,2-@SL02FZ.$*:P=>-"5[UG8+Y0N M$(#52I9(_6.FA$@Y@!H'5AK#>D^*.@(HJ79#9$^I+ MQI0:"#I0M\2:PXC6#6;*67,8B! "62WO"S_A '+)]!*23#P.N'CXT\H:Z83Q M-:Y@P=@>"]B0!7B)9^Q92\ AI/.R'P_A'=X%+[G$!^3F)-V,B@PMK&<13OTE M !C))D@E<<;7GF6?0H(!KA4 I@!XY+5_F[QC\L#5;7!JM>QIM%C ?Q)4\_@2 M*KI">(\ HONV=HXY+FR4=9JE\6 4&C&,=%3)!U:C;1:L#&-89PSC*%[KN'1K MOR59)J7B@:XNHRH\0-X0&@ MX!+;BE_!;X5(KI$SQ1\(*RT/"R I"13EQ NN:F]-;C36Y*7<.0I$,C\&5(O_ M!'&/I49M1$VN0LD:Y#Z/.1A"9$%X7+H>FJ!S?4E7F?M42>5#?Y3'H'[/*/(B M29Y$L')\9@;2#@F*920^V5*D[.YVA[*](F_OMD\+1;MQY@ZQXE7/[;:"NJ/R16PC4)!6MC)!WCX_V/?>LM'5/] M'3,V8)T@%DBV*'4<7L"M5:JV& BP'M7)*U.1RE2D^K&M\-KMW0M2N;4?5R!I M_W.;"DD5Q1;*&(9S5%(^[4/M;G%(1[O_2M)>VO^=&J;LYALUF62E3+)/WC6J MZP(M)7NNF_2(V>9-NUX_N@2C>VZV9]>:[G[W:G+K\_OPKRC^T_%#!Y3RJ4B> M_D8\. NMV;1!)SJVN_'PY+NFW:GO.3#;,))M;:C\T$\N02N\B*+9\=V;>K=F M-YKW;M!VK/>FWJW;[KXC^PU[R6_) %1C:2\!S?7XKDF[8[=?7FV/5L=NU@X@ M)^3%,I?"8HE.A?A*'-W%>=NQ.^Z]598CZ_^YQ\V^D-0IDQAM3N6 3\5(=/EY M?8E2+R@\6D_.F.YI56KVNG:KWCPV2>Z^N^VT[+:I6'. B4T'O;BC8D[F7#;< MQ ?T1J37UP*.M@4.;>K)-O;\^ ^,L>HGB4B3?CA[[W-@N2^2WX2'@\P^A)\$ MQE;XX<69E_A)N;WBX\4DC5MNMU\[<]K]7MMI-@=CI^>Z36?<:M3JK3&,.6X^ MBYBDNT=4W#UXY@ME56"\"4::RAB*;+'P,!.08_OG?NB%4PR5]NBP*8XE*([[ M! /H^,0Q (;"\#C^#H/C,(R0<<":(!)@@,NFG" 8Z4Z9-*4X0BL1,@1]AF'< MN N*H*5(Q&7L8U1O(.#1A&)Z5"9)LYM3/*LAH2^#,@V=^LK56MX%#R<&D)(.!6@_QE9>"A)LA2L($0> M%GOL)+@]2OAK\DA=F4SGO2V=]QJ=TWJKT-:&(IG&/N5N[=?D]=3AET&II=6S MC\%\CX*^=:?XLN/>HW;*+VFS=XH$>P3"^')]TVS065>%]^ZD_5'/F35O$=5: M#US_<_:L-7;TK,4>97-_1GL8&_([=MX)LV[7=]M&5"7XYN[UE'?<881TL MA2T0,_SWM50#,A.$]T3TN'_E^0&:L)UY%#N)%QQ?%%ZCU;)[^\ZF,=LVY,: M[ =2Z&<09&,B##7=MNI/,T%+3=CNT>7V?0E[/;%R%" M&I 9J=N$4!^3+&'.Q9R+.1=S+GN2OK6)><.7 EGO/UZ[[ MK=_?#?PLXAH?//.3K=4$MYK@UGT%MVZI<6N"6TUPZ^/5U@Q6@UL?I<#FP0+! M!+<^[\V:X%83W/K(SYDUFS4_NXVQ7B[,_B^*QA6S_I6(O0OQ>X:Q4A_F0S_(X-O/EUXLD@]9FJ1>2.[/ M^Y9>ST*?7TIHR-?63$S]A1*'(DGZT[\R/_$Q BXY MN]$^#0 0\+X(4_@K\6^!I:-->9SO[V=G6('N#_!7 M;D+[>P6-X5HF^'>)1!!X)CG8GE.<^U&=\L!++I_\).]I!6IT6G:CLV("(G_[B/]!G[]JU3L/N[CNNZ@52C]^C5%A+[X9$ MD#0Z7@1IU$"AJM6. 4&.G+1\C,72\V>6^+X488+8 Q]RU+$F-]8RPS9>R3'B M4:UY&%ATK ;D_ZK1_QV>QW,O"]O-X/(B&,JZKG$$8%/])+*,8!S@/Y]AC#M\]NY$_ M/KX%<3 8-@?U6L<9CH=]I]EKH"&U4W?ZX^YHV'!K@XY;?Q9M+MG^]]B-#"L; M75Y&UXF-HE;"IP;3B-2*Q94(,V'#T24IJ7M>(!+L3ADM"4=@@&48Y:TR83-3_KK @V:4R\ HA3/K$D013/B/O0Q]9,D M0Q(H%D0<@$'&5_[TZ;.S[JF)M.Q:O68W6[T?KXD\'UJR(X:1@6MZDQ+2)-FR M"C@N/>RL]=;O;,9'.!RA9H_,<%ZLP.D])SNS8O=8!V,^>#SDQ2L]]E1Y0P)N= M \!%(\H:)J3-*#H'H.BX3;MA@E8.3UPXY+4916='16>U2,+1<*JV M:S<:!U"&T5"'XUG;;M1AK>#-YO5_WU_=#MC_O0JY=''8)ZS;<51E;O92U&1C ME1LJS^U1N7FMW@U\8T5S>&]SZ1A2+'Z/K@168"]^;M3HYY:I+&,JR]RCLDRG M_;#*,IWZ[I5EFONN+/,#I_ZQ^BQB'QPZ?.H>NL3)'3=V,) =@12]463;O,'G MK(,8:YINP&C;C6;/KK?W7'SDD#;<[G7L=OT0K#;IRK6XI+8VBDQ6+K!XI*"J MS<=YW!@]C='S3G8-N].JV=WNT9&,AV^\6ZO9C7KK $B',>DL_V4W.D>W2UW*H^^L<8Z MMG@\\Q(Q&T0+] K1^Y]3>.7#DDJY]Z>I?^6G-^6^F(]6;KW>=_J!YUAZ\M'+KW;_=U01*!V5%2T[8DB>EJI??N78Y M#(1'9%O77H*F:K9L5UAOC,W9V)QOM3GWZ@^S.;>W6'%?HLWY94Y]![&Q^PA2 MX[VUVIVD$[EV>;,5U2Q)Y"E+Y*_7 )Z;F^IKPL;*+<,Y)=/>CR9_H'M63:QQ MXDEL_237(7M:KWP[^B[BJ9^L?OTQ5L9F [4*J'T2"\\/@="O?(^M?6*0.S(O M6/GEO3\7Q5[?_I_PXN3=BP)P_^(B%A=>N@K+NB7BXLD5](=:57OMKMUK[+E$RL&HZ?53MW-L6WWH";=.:WOV MMAW,\;IVK=>R6P?A(C@L[^*Q^2Z/EE/\,_9"*1\]&1^X!9/O,<+ZU2JL&,#F MFOM:ZI,1&0.R \TD-,=LTN4>DQXKS=U0Y ,G+P9DAB(_EV,V\K!&?Y=^+&8_ MS:-X+GPC&1\\43$@,W3XN1RSB>4L'\-SCQHTU]JL^>E*%#TC+7G%O[4YX?A) MI;=[\"3CWWIQ_JWF:6?/0;<'<[RNW6I@G?H#J+_U#,2F!H@FLRB;!.( Y:;' M7=S3"TX'L_6#7IPYE\-=B#*^KCB]*+WAF(GVK9[=:>RYA?3 R M'XCT1R?>/H)(O^<0KH,Y7A?#U>QZVS2I.SQN<]"+,R+*82[.G,MA+LZ1?JWDZB2VIH&7)/]XW5\N ^%0N>+II1=>""<4UX$?BM><+$.O;\N,OV=2 M^TJ2?.4H_3C&%6%R_=E-\M.KSXX10: MZ.XE\1UO*/Z-Q^70>ZC-@G6"\3%YX8PF@W9F7 M"JX1' N@Y/_QL"9B>F-%<\M/$RM V 8$6ZX2@Z49KB_]Z24\_U?FP]6W_/P2 MP>/P$ P761,<$ LIPIM1J(T#[\MJQ!E<6LL/5;LKN*\PL@CAJYD_]=(H3F@5 M^>BVE60PKY? $#$0UBF_ R/,Q +K-D8Q#Y 0_+G, :L"-801@M_:B5!=#V+ MKN$%(!@PPA*6#H.>6I_$E2^NZ6L+5H(E2V!=L(69 '*_ "*/HP*$N(3%U(OC M&S^\@"$0? +7Z(6\)\M7T! SVYH@5<+-3Q'>L9_@:F'<#/:73*,,[.4Z]M,4 (IPPY7K[S 2P$/IS1*+: 8W, 3\ M=YH%'NXF2V#NGZVW_KN" _^51?C3PHO_A F6F.$,:XGAQ;>^_EP!GRW0L;(4 M4/4_Y%:&$=0[%N"2."WA^91 M20G)A@6HWZF^P%,<6X7D,QCWNL,S=^ T1O6NT^S4ZTY_V&K *=9']4ZM/QK" M0^K8=CFS1P5.^6!6GOP]PR1M*=DG6HP+3 W<9@]B=04N1\"3<)J$,!;/@9>*#G+HZDSS5ZKYP[Z?6EUG&YOU'0& M]7:_.>YTAN-&S:@SMZLS7$%-/S^CSVP&6Y^$V\% M, %\03RI)(P60>N]7W M?HSS:ZNQQ&(91#="K"\*E*JIMQ"6F,\%FHMP]J&8 MKI0+<6GC+I;-\Y;+.$+=;7)#8#B+@,X@O(8@YT])PP(JCQK9RH.TGLLHF E\ MA+0,'+1N]<,P@\W])@06>*2=G;S*P8L:'ZA>_T$= D?\#N0U%<&-]:;>JMM M2$AL?N/V7/JP+]G;AH4D2P91<&/CAG4 E^ J.X^MB^M'=;/V4LI15Z'RDTTV M@S+7=Q%;4%74562V,+!JZ"&[@VOQ%0XZSI^6S\J9<$1X_R*#BP5<:^L9>E/2 M_% 3C+- P-W=A,H?@%LE<+;W)I,S"$MD"Y&=H$H2*,I"-^ MDD\!-THA.!E+$A\&EFTDT-0 _+TT&A.*TE1(&_@%N?$K7#1L%*C.S.?=PQ*D MW0(A57Z.Z9-\,BG5YJ1#P,7G=@ZIM#.I"#R X.7 +?@IKQP'&)UZ41]$.@S;6-SX:&BGY0(-T&PC('5IUK"01[9*4"Q M$.EEA&".)(#U-;-58A.8$WF0ZD)D:.?RK(F/UB6@B&OPJ;X]J]@XC1*V0>RP M$A@#P;VR/=PZ'*;".3C5F,QV97PKVV@DM=^^B2Q1.)^(=41 J])5%%Q1C[%L ML52P@AN%K//?V8S*_F*5:3CK2Y!FR5"4 1\I,_(4GFYC(0\-,Q7>;QTW<)I MD,V8:XC"/A3X\_QN,D9*,L!V)@L6Z:5DVP3VX"=_.G-@.6CU4CTHT6YD6R"7 M^C/@0-:-+X*9#>.S1LBCV+0"F6^*YB@R-L$HX_PK-B2ND1;X2,LKP(*U'P16%J1*'KFB Y<& M;!A#H2D="DMV<"0I?L.H3 4%4:R 0=!D:65+%OC402=D@@3!++;F<;2PIED< MX^OY[\IZO4!6E?"*=",YBFMX.[,%7DZ\&=[LWUF2TK+D)9$\ _Z\05DP I3Z M,XRNPQ*UD2(I8'%,ME:@/W./A3VRCBM8(:TML-:6]TK2?R:X_M+'V2_B*%LF M\@(#<&-JFH0H&\/O4W%J]23=#8D/IH0RX! M#^^%>F,7S#_ AIAUTQ#S,>IBWT]XI4Y>2860),B4F_->4OB(-&1+DCY),IM> M^N**-#EB2R)./4#E0M'3AK4N(B_0KQ)=HRL19CGKPCN;>O&%0+UP*)F>$KI( M:0)&@P(H$PH@1AIW*$DW>&7@AC*3*2^253CZA5:D!%#D3HK4Z1<>U@^:I92_ M^-86^Y.7^K1,:G->"Y_P-?DIYV.%%,_R\97/0B"3,'88E?<#6Y]HWD?>DH*, M7+X<(8>WA"0!MR"7S((7(!WE2C #5>FK&I%%5] T92?>#:\S7_,\8-&B3'UY MIS@*$3;II!/;,(+6@QXH$$#M0MY'EA'!D> OB'; (B+X4"$AKJ@8N%LB]$M< M<)0E*&V3RJ,]=9O*"X-*](SA$2-9W(F&K%",3=*ZKG:M$99M9$636)'^*$)Q MKFF)C$UYS1-\&.TH++3@00=""4*,I]6:@&VM6&Q*.,)WEC$#9E>TL&I^;YXJ MU_CJY&KJ0HO-)U?/K^$Y7@8U-8C?5Q@0H'8BYP_Q9X+G7;RL][")LU%])OR? MA]&4G'QLC1^%,S2^/YK)?.1VS^J=WIE3[PUK3K/;:SD]_5!V^WU&F?= M;^1@P%&<6AT>_/M/&]?U5+YA3=DY?N]-\W&\-X\*M)6#1)IPCO1G-LQBH"Y\ MZ.RJTV,(\WIT3Q;5YXY[W0XB<-MU&TZSUVPZW7&S[0S&M>%H-.HUW%%C/:IO MY_V4X0$\H9];_#[&40A_3MG4SM=W7P%[C=JXW7"[/:?6Z8Z=9G/0=L;#=;N'ZY- D@LR"R.!59RF53Y.X_C:#,WST/K-BT&N*+Q< MX_[G,Q942C#]C*Y\8IQ?R6@!+_\>G6J.$^(M/;NL3OHXCTX$M7I+C5^XSY.T MA^9/O/T2+?VIU7&[[WZVSA?D4V*!',23D?)KT45WSJ156!)1;<',U/UR\/87 M#(-CHXN5@- >^',?3<$H"G@!!16B(3#)#>K_O[UW[VU;.?Z'_S] WH,0G (Y M@)GP?CD]#4!2XJF_/R?V$SLM^E= 2[3-EA954DJBOOIG9G9)+B7J8EN2*9O% M:1))O.Q<=G9V=N8S%?T87BT/U5_C M:@M7>HA"6B ZIF/0O9Q+EKGRY;$@#?0FSC%*,\6 )3-L$27, BCY&*I(=N_2SON;>HU#Z/4H;%J<:[LG-@KW@/*U+@MWV. MIK]M- XA*,BH.*V9%&^6V".DD-Z,]H,4B4VW\I"19DF2 !5%0G)(\SL(CNE K\SKWTB6PV+00)\ >YEU]Q?N,)=8J[\"GN]^'E&;YMA%L1,&QT M- //_$_$#^%/Z*2BLDMI7AVGPA/>*6+V[.JH$CP%73P67V'ILK/R$':1EAJU MJYE9X]X[51@(O#B95P'E>EYWD5,=CGM(]!1-1R^L7H)!=LRK9@)#,>"(,_8J MVGAO'#,Y?EF:% ]-R@#0@O%\J.G$'/AEX_E@TVF=\ ?UX$8PEN&('Z5.4'[3 M:31:M*V-EK4X"=O:MBY95LI Z6SK6MM:))SLRKRJ3>;U+ KQ7)E93[C/UM75 M%@\G,[-Y97 WS6[#?L@O0ZB6_Y (995)TSXT1)&'TL!A9GO>LP MP?F,^G<7L4C7M ?;S;0B":?J?V2D=YD>'42\G4-'@2>+J=(2>OHRG.5;*&-&.8Z:0@_ D/J):LAR7/I<]/Q!/^#,$H79G?]W9WP.M]?^%XUT::Z7)6 ?"\BD$ M_D18XG/:G2:]=Y>SZREYQ+9J2(H,3O$7X82,G9=_ GLQR\H-7_EX7M7(TAZ% M=YY5IGBC5UR:4Q@-;A79,08SDN4._3KJW;,Q4-J*D(A&-J,ZR*\GQ EG"&"@ MQE@Z1IOD$^&MI9,'K^&5=W0H, DSEI&!=8!DI/%0((ON,#^(LH/8=AN/WW!K M4!TM3+%U?7D*5VR9ZWEZ8;EZL?5L26:3V<)0Z$ U.KX^1$E, MZ5)1L=<1P@MT[V0&*_&0C39F*R.WJ6R(+!FN2-80:R;%3"XJTH1;RV/?!2Z3 M]8^%$^81UZ3B7:/5A(C:ADO7/4J8'47ET^)8N+9(;%A,63RFMCH^Q!NOG=MO MO?Z^[PWJBREQHUQ1R][G0B"IRFH5$PD$UXKV:0W)L>P-#]D55.?;TT7.=?&5 MAZXJ16].GF7^M&4%U@&K:5DY92;O"B.,9415AR4#GN'QR7")DZ'GUZ.&F-Y7(0G*4T-M\_I6"H2W-"BB1M^;U;&@AIG(+N#'/>'!2I+]6/,LUBLM"[RP"32C*"# : M,1$^4L"8+=X\J9CG"Y16(.6EVS5#522KTNX*UR-B'TNVJPL3]B,_(EAP"C8C M:T2VBY)[\XNXO^,K86.]R0;WFP;"@DJ/=+]?D3'XOUDR?[@A #/PAE6I2$JC M5WD*/MF8S@_XW-G]X%WO M,=0K_%A!&(#:4Z%"R 91IEF3,YDD9"X8K "?!N!JP?J689GC+&-S_!JK'*(< M[$V"6 CPFCP=8]8U2Z@:Q4," J*!YD4J.LMKP?QP5J?/C!69 ;138;DN+T87 M\[MTEHS0BF(X-*:$G;2J3BHJ2&H! 9S0K-!JV0IN;^_XC%[KR/#7\-\:@P.B M,[. JU DKS&[QKRGP'GOG[#+XJ[K%8]0XNZ1_ M=R'D65Y1JAR\G$TV>(3+,NS$!+4O9176)4]'8ZDG31;S746<_U?W\BNSVLB6 MZH?^7W][OV&_S%8HN3-ZHHR# >"76*! MUS"OOULH!J-]KWA4U)2Z6^Y=J#RM(M7%YS(/YH2DQ7!@R+PVOXX2_L&WF#>] MA[8[TSAIRF->3O=%<\F2A9-('),HH^48ZT9+^J:QF);94H/ON1H)EK.[Y M9T3'.GBVCU?2B5\QK&I,JPIW67EKS#?5:%W%1.^U)K0[TWGP>?E\1\92=DH+ M>=)D39YR@+[1H9LPL\@+B&KQ,_&,6IS85+O'S$P5I&,P4Y187CO^*1Y F%@P M*E[1AK[/#?/I;E.<4%@1RFQ1SB)B\$1.$(;!\#27%S6P]U)^/?*QC]Y'$[9IK0AUEZ>F%U^F,43BF M2M03%IH2SH&:CH'$,@\!HXH?".%NEQ4V<78,"\D+8P6%=&>W<$7SKH*6M'7[ MBJ7P@KZS# X65\!#>6:4!X496ZOKF-.Z, 1V+0M&T!8V%XZ2^&F>4%Q2"@XD M__ IB>>.8*0H5K 4B1BG/U8YW4W';P\\U"<":0W@VM:;4026K0A42\NF;5Y@ MV+$2DBS'2.A_9V$V93.+!TC0%Q8(Y!%'W% ,PZ6U:'=;B'K:R1:A&9K7_-&1G\6"S>1$6#SC7QU>6BQ@>FO-<53!<92$*[W)^?YTF MN\,NM=S \BU/ZKNJ(^E^7Y9L?:!* U-7?$.Q ]LP62JT[P_.6,U";23UE.ZK MC.(.<]I#N$-VD/ EFLP0;C>/W!F()N-Y#;NCH:]I@[[7EQ3;E27=<5S)LRP@ MQ%0-:P"/@M^_Z=^4MQ_/P6,M40OYF&"S/,GB[^ST"M;9VW0:L[ :Y9Q/L3@? MKIF16@RI4D:X2$PX)=_R YW89#EF-J"AH.J<*>,8 W^AR85N]#7?9;/SML7C MI"^S!/%IKL'^%XH*NYWA+&/17-3!0;&&PN2XA\4%!E%IVD-$41%!KK7=UU#\27/5TS0S/Y M);E*UVAP>9" _S'#/]!H$UV/5[Q[BS-\]]Z_+@%-(NF ]@7 M$BJ9X5E9>M 5(31R&L.T[Q+B8USQ<."\02'E:\)KN"AFP4)S,6_.6#B/C4I&'0^W]OA]#4O:?' M["9WB//_B9VM2GA_8,B9>W$)#QB"B,-)'CV FP)+=L:!WC!*DGP2#D%+J' 0 M/T]P(\@_T[5_>VN9?RD;ZF"Q4I2][5TC4$>&5XD,J_6^&17W&]I?MNYI4]RC M6*OOV=7WS_?N+;H$V3OHGO;H3E$/ZLC!Q\ZUO+ @M=;D4]::_.T2QV$F@ *. MR6U9T>:>:QQ_9Y *.S.PA^*'+!(^LM3=ZC,!Z?%&%A^*AZWOU;;S!EROEZTV MBQSO@JU=?_$US0@_S^XQ;IAFRTO]\7>6/\8Q=XTR[VO^L;C/.+B*OGML[T!5 M/7&T1W>'_&V/J\0.^U_:YHEBM: ]XJLUWOT(H2?'G?ENSY@[\UUJ9P'4(H4, MJ86%%/)>6O5'D"@:<7C5?= =RY;//G$LY42SM/W:OO81[IS8JGYBF'ON>]P9 M_75&'\-V>(HG!@IS.N:F\!.!I)7 NR6@*\NZR0\ZUS9HP".>L*R2542.:L;V M--2CFJ6JII_(]IZ-4[?0;5KH)!Y@[Y:W8YDXBGPB&_:)J3O//W>ZGN_'-+B' M:U\GES;(I?,TUZQK//8VV.)8^/@W[LY9 PF/CPY@U]5@7XSB" MPT!A"S8@G1-U3(/KG*AV#JYSHIX:KGN&($"W-'5+TU%9F58/KEN:VCFXARU- M'RA!=UL"VI:"OI!SS@1XD3 (^1 MBD>\7\.8-^L2%NL=LYL8 S2J%K5PA@=MYM F_KSY91V'MN+/VG&LX,_RS%RJ MNEM9Z5,O"&*I75?ASWTU'@D4MS]P E]2%-.4=%TS)%OV#&F@Z[9K^:KA#.RN M'FAS/9 (K482ORY]E&>O$&E364\)(U=UNUB%#H>5/0( : 4)777 Y1T%\2%8 M)4M(4P@1$$ZG67P]8R4GA$Z)_4#IMS>_E !H3:#-PS#+" >KZ*:*I<,_8]; ML!HH/*4V5 ;J'&=">W@:U37#:6Z@^LTOZ^@NX2M9V^QH'#)P-WADQEO"BHAO MO-OK=^K+2G %TVFRB*F$I<=53]@W8K_E$(NDBF;HOZHGIB:C#::AB1\YJO?J MQ8_N*+ ,JY_A?KX 5/Q)YB<,\D]<$TKC$:N^10R-C/5V M8"7S#)P%1E%3JK(%8ZVS)'QBP '4*;A.2IQ30\L"8JSH95R I(G(N(TH6@U$ M5\H]BB;4-(,2;VZ!^1E#^ M1M:BQ/L0,6Z+-JB+K9.CGR'6^W,GA'J!#VNM-A@T)):2\&;(!/^!Y8>\9ST^ M!.Q<>L^*GXLFD*5P1;+22426HF@K3EU8"]O%:690_BF(_S]1@=HI:$8'[=/8 MN!-TY =!/O2^OK]\+T[U8N[=/- ]%HWG:N^Y-V) .1Q5%#O.5[,3*U^9R'$6 M,)TI10_*R=9(PIS&;06N2DCL_\6Z>T6PN:!]"");@_GB+<4F!:(=RCT=2UET,QN/>'ZC!#<@ M=F8\9*H8<3W(TGF8$# [O@4M">Q :BV2A]R$LE9C*25K$41E1L@3*7X;W5-9 M*]Q.0.8P##(_MU%ZFX63.RR>1I '1#3G<.6B]\$'A:O#+8Y[0/%G[#$0E6("[Z MO;'9TV GXJ)A+T?'*MO[5G@O L8+APNM$+AJY?'=;-L\VTBS)D6./K\)U MX(YJO:?""EY@RC3#UD5<1$*.*KA#)-\1_.,M84%FC")#1F>3O!<:2GR7LI;F MUU'1KIYYO]R4^)J%9-!Y1ZBH< SL)884$BQH8AX>1]DN,"D$ M".1X3'B33*$R,4#7(P2#LL,D0]]B> G8\Y%^P:X,/-2%#@;'B.-&IU2,S@YL M;0<(= R1I'%5 (L,ZR/NOP6/O$3B6^1RLT%_>&!T.\_O9&$E'=&>5T1Y8_U# M.3F(][26F@7CMA5,V*I(Y$)#Z5+9!PCOG>\^8&D[ONV:BBO9V"195^R^Y,BN M+QFZ-5 -Q[$,S7H1 M;/TH) ;KQ6R"[_K51H>9G&:8^'DTQN@*;SYT$PZ++D^%C>2O@2?P%V&?B=GU MOR,6:HI^1L-9T5@*49=A@-F\H(F/AD)AW*D #V64#GE3GK*/#W7M*ZY_WSN] MX3C^L,)R-$5:7S%&.\/#&?9:9 5BH++>/_",3^%\*<;(S]^&(BD4ZZ- 4E2$ M:G$3SR. 8$FKSH+EWIW3 I3AYHIO-G"$W0+;J/KN)(N32AKZGC5_+$+L)N4L M0#<77\EZ,Z#&D%)5LT$I9@/3>)0MZFA::6"A+^3>E8I?KIR$'$]J6 7@TMDT M(2^P#)+05!3Z2C60P?5L>;!,43$RGBZQM5#RNA*R_YK7[94K9!@RF\XO0"&G[G@T@&\G[!BH?52# M1Z/)EDCU]O34^? YFC)O#DL86D@J4"HI\!;-%%%JA3$OJB[!3A^4$JTOJ_Y MEZ7 UL$+[;L:4*+*DF&8@:X$CJ6I&@KM[4=#,53%L45=9<-MUDW80%Q@*"X: MY0$8NE.AC6+[!*4"?8H!.FDO*^5J0A;Q>1ET;XDC^W5?"%Y/N&9CJ*YEMZO]!4QY9E$>1V6WI6*D %B7M^ MPX!#"3&WC0I@O/VHR[8N-UBEU834"3]C06$P5[QS2E[@R!^27M]1+$LW)-5V M0-Z#H"^YKNU)LJ,-8#I[CA7H\ YXG_+VHR#ME8-?V!:'2?E+<2$".!V00L^W M^I:N#Z2^ZJFP;S8=R3,-5U(,4_&,OJD&N@L2!?(,695UPQ%/8.>;TLX>%:*[LCKR*X3L8GD+^!^9C$FS/G80Z>% M)(.BKU?R.@EU@GWQ9)@9 5BBSV^N6&IDR\R8:J,94TS3%!S'-20TK% -5[O? MPSC!N7^39CGX+)4/[E(F';JEQ1,O6,MW5T@4O4HOPJR=FW\-ESA'LU1K88G; M'Q>:\M#1-<+-'/9VBLTPEY\4#8C]2?@I&@Z?P3]2%ZIIC" MMKRW=L/[Q[)D1?T%7V4\G@31OIT-Q@?EAN/:^L 7MJ6\#0TL*&)GU?;9/]BU MJ8:J*<)JT3SVK:37I#^5;3R_*;+UX49RI\YXS7\EA;+(:;10Y M"P#9<%OMP.@)5"Z<48!5+(UE?EDF+.:@4U_'LWP6)A=5+M9!%PE%5@T[\&7) MZO==2=R"I \=U%$-Q#-M>,H,/HF=QGYG395RS6NE! K&ZXQ@P"G%S M61_W5E,B*')8CF]*X 9;MS5;-3=.B2VI7#QTS2-,=@*6]K%@*J5SYO8&3H$? MMFGKXC'L&@*6=?[\ICCY:.$28."BK]NJH]05OAKTPJ)V/PGCC'E^9^GX]@R3 M;5CD\.]1,@+WZ.L>A=AHQQS78:=2\>WJ&Z0N; M',WV!J#A.ORA:^#!>ZKM2HZG6P-O,-"=OL&.)<&OE\6#]NUH6=CP1A1W^9/J M4!.8^NX("SGR:4:]G]MKOBP\!'$LU1!WP%L1L\V.W\TRK'/&B>3-JTOX2;Z+ M58+G#/%BP*'S\],Q\YZOTFF8@+N9Q>,\'OXC3 Z[+7)MW3,<#"F5EF8<6M)V/:PL;V)A9@56P^(C\JN%Y*IO/UHZ?"4(>-7HZT3VHTD&[V=3!LS.,Y&Y[?X8 MU@Y=,72!SC4$+"1E%;L@X$<_G5U/;V9)(?\62A3]0 >3=X1LK#44U&G],TU' MF/A<.55[S>%I#GFJKJ4,#$.2?1560\ONPVJH^Q*X/;(+9'N.'BQY@[KTIRP$U17-^4^I;OX\ =R;9Q61J .7%]PS("[454)1VTK;JB MU/NJO70!Q"[,Q%O:P@#@'$P OE!6U"B $6+S[E9748'UD-+P;ITEZ.Q?>UO3D M.BX!X@YP9 *&9Q"+2';AS0WL>@CTA&IW^;V\*B/.>ND/)(57/4?6@0J9P#R$".U$<_E[5-I>5/HO#$L$[B^Y MS&KWS^*;R(=M:8\.(%@E/-B!BRS^CJ7^9UC!CK!76 8?90D](8_#GI_-4XEN M7+KTG8C]53Q?1/OZC6%%13FFK\3Y'8V0S6?"[9K=8RQD",,0D$SH&J!GFLT( M]B"Z1^ -' #,[]LLO*<9>CH>Q4<_X_9=4,\PTAB*YSUE4[ ).,M9U3F#N5D MF<$Z/=%ZUL!I>J-9AO;U)LY1;',PO0P B6QK4<#/027J=Y:H"PQ B\1>P 72 M*E=98#X8JLPOQL+KY E:B2S\<$KZL7R3<$L!G%8P)&3N=0E9&.><1ST"S>#_ M!O7B%S)"BE%VZK:L;A=\E6ZP04T6".?Q"2_R1;RVWJ\*/.03;!$8C,>D\%-* MZ#[!FZA MBJ$.'@]*B%7%'R>_/C'H0=2H$1@E2@O/5U+&RLBA5>]RW]#A"4T M5F$RG#%HAU+I"^(7L;FJ:12-1PAUM%"GKA&H?3XK-4W$8E=04?XQ^')UZKMG MDGMV^N?GWWM%;X&<80/ K?CI/5CS@AYX$RL$7^WFU,<5K06.Q()T3AT"8""8 MS/".6YU?E9HT",TCC$9DB]3_:O^ON(-$EY7 MS!GZOUQ$K+!Y*V4\<@NU7Q?T4[F3Z#S0QWB@@LM9;!^%_2B!59)KMP:,L-'C M*['K:AX>GI(B2N@7N/RD-TAZEV'R/1REL.'ZA./P/N2[THOP/S%BA!,:Z?EPFH(5PSFJUC>1.:Y3(>);Q QK5T#; MQ'F8KK:6_XC&T?]F48+(!\7NDJ;T31@G!(*<$B88^KQO2HQ $=F">QS9B- 7 M2JPMRD<&1^>]"/M2PJ\V#O6D?/P/ABG,T!IP- )6^NK-,H$2H@$BAZZDK X% M2/!Y?!3%3IX@WO/AC#^R-P;%#>N+9.F6LA0&P@;#A7LXC$#K-ZA&Y>@Q4.6: MN\>##_"A,N(P@EO@$,N0(.'W@1OWJZ5/ !6-3%TK_4KD(,7!<(8JRAV)!OEO M+_TWOZR2_Y;21Q=\A?RWDC[M[$ M&+JX0HG!QWPNMJ*GL.>+.:(: I=DM^$X'O;Z*1?".[!@YU>_T>(;!('<*YT%[W^M7.GJ3SC(0=Z.;H2VVJP ')B1=O$80%/R-OSB&KX=)3&9X M%,,(I\F< =&5,ZD6X6+P>5E43!H.E+@IXH5">6$QKWWMP"NH2 9T/XJF8 OR ME2%8 4)?C+^6X9*&V&_S%"[WW>A(^C\5II5U#LO!N) M73U\8?!L+Y5%-PG#TH?)M>BQ-X"TUB!::5E8#=**&*TM46"U54ATJ_L833GR MY>)6U'Y88SK>8PGX<>9>7,+]:)L19O,!S!0XLC,&D*N13T),N:337OP\03@K M_IFN_=M;19;_4G9H&U)D]FT/P:*B#"^K-5&K-Z7B#S#5OVS=*:VX9\TMN_J^ M>W7WZKV_>HLN@P\R)UOT(SQ8!SPT9& _X O%7C00>&,-A!:>(L+0/F)L!Z-& M??J;7[8>\+'SA:WP&83^@0JL\.28O%VC,W*CSJSTP5J@,8>EFSN7G?;M0PIJ MDQ!XN)EBJ%GO W]M$$4O1?<:J;Y@FY,%JF&?LO#-)=NU+'S[I=C#O&@>45KU MBZ:PT_U.]_>L^UT+^C4MZ"G'A[ATJ ;T3:W3M^O6OG#CO73BZ=7(YF<)UWH?J#Q%_*+LN;T!;4Z I/L\ MPQI1[+N1Q-^CC&H$J6$JH4A]X1 GT>CI\'OB&S:CR9NZ:?FR(IE>X$NZIYJ2 MVU<-2=4'O@=7]&V/P]BIG-IM"1%I+V'(R^[ V&'T_(;AB%Y$&29!89W6DXF? MS+)()%IM .!5#=]S E!S?S^ZKW^#N:]YEY?SF"^\1?!7^Y,U(SL<5,/_N.=$H_L% LTW7\B5% MZQN2;EFNY!K&0/)5V3,]1Y,MQ>?PBQ4OGD*7P)[+V?U]F,$=?/X$490/J+3P MBMJ2[1RRT9%*2.4QVG.DX]%Z>VYTR7[MBE.[:QZJ/-8]NS6]IB MRML\MDXJ;1Q;)Y4VCJV32AO'UDFEC6/;))6N_K2K/SV"35+'J8Y3':>Z$$5' M[:L)R'1U*)U<.KET1A+W'LT0@W44=,-\NP7SU6%WGSZI(+U@+4_1%FH_,)M3_]$RZ)K%XSP>_B-,9CLHY8SS5%<5Z]O7R[Y8Q]A0V.?:NF# MGY,X8[UGCXGM^N[8_D!^")*XFD^BO)P>5;7VTUE6/FMCO:WO.0-7]F5)4P)% MTA5#E3S/LB5KT/K?NS,-T/M]V;4-#8C5/$EW M95/R%-V1?$/57*]O6)[-2Z@O5.5?G/:'CUT3?50'>!5M!V15,LS2FHK0U8H,3G;;>C$<\Q9GQA M=NU\_'C:'C5-">#@HI31IL%M2\?5C_30=-25;=/HMB:$ZL8/3 JX)V?Q332- M[Z.MR,$QUNTG6 MN6\JEH@#L^ I3(+]*O>@R378 ,Y+C*KT98&2@J58@RXX4 MZ)XCZ0'RP/ &DB('EFT/M,!RN!!U>&5E+;S> H\#7=J6KY-HNS;Y3R?1O??\.T;V>1HKJR9=B -= W8I&L!NE&> M9&BNH_GV(-0)1/P9]"-Z,?73]VS?BF MF)JB6_9/(,R1#?M1IM>']Q@#V9-,TY$E'6RM9,NJ+!F&:?<#WP'/4H6K90T9 MH@#'E#\^K"&E3BM^-H=D7U6J+6T1]DT7]G MT7@(&\?]L (_6[:A_U1LV9$=O0/-,U0XLJ>_;X%!I%NPH!C 5;"U0;=ES M=$,!0>/+0-J?L+0XF:^B?#4Y=2:SZW]%PVINFO>AG-)P1"8@_,F(@37/\!0NT MS[ D.T/,D)MX'(X1$*(W2H_TACXF:3CN@;'IC=-I M[SJ*QCWPY9(Y?R7QW!"WKI=1+?TLZNA'+A@P=2;F;L%AK2^TH7-DBUK@(!@KA$9\ ?W#/" M]C,&-Y2,ZM<\ LIP)7Z"'JB::J+Z@'4Y?5WQIX/7!WGNZ+SD..)=: MWW(45_<\5??87"0VXWXV2C?/=M!LWU-A^^0%#FPA=->07$NS)=EV M=3?HZY[E.4@Y<^R.A'+;-O&SH\DZ?@96&(^4.=DY,J/2.:Z M;#U:QAKW7"X4XU@HW=&\)ADKCZ>\AD#X_\W"#!; 9([+?Y@DN+"S0#-,"TBV9%71B06R;,!GQ8 =O^#C"0/8Z.E;X.N8ANI) MBAH,)'V@RY*MVZ8T,/1 =P:^81@ZLW^@(?H"Z.*V)#\OMS19/2BW2*N,IW*K MT$;N+\(.TQV2/^3-D$?-GQ2H.BPUS/ZP&#?-"7;5@(WT&7/"@9HRW2&/:MIVEZ.*ANQ:ELK M"$>#Y<1Y'D$8AQ5$89?YT<%3%AJ3!2$<\,_51RTL6E]6?5QM UANP1BXFN08 M+!85Z$K@6. =EKLT0U9EW7"JE:6@H$[7^23"L]KQ[2GAG)X];2T]((D*1AE5 MRS&$,&,#,8LA5?S^*OS) Y$<#/E(*+;IQ'X#+6MCR$="*/A%8$ <75L90:Y3 MZ:?Y%-:S*/L>#X]EBN(1I:K#+!6(K-.Q&"&>9!&>5J-Q&X_<^S2;QO\+GQ@8 M/2#!#@C5-JU:?'PE2?LTOMK^""VVTL7A\S/9WKU3J*$L=:LUIG?O!#LM,;U[ M)]3<=':W?\N[;QIU(%'65--NB>'=NTQE7&IL2WZ$Y2WVBE^B"5R"<9G+Z/8I M&7HE[?"58N,I3$E[\>3-_5$41[4]PY>,@>-B@,677,\#^EU3A:V"9=B:7";L M;:;D>>)R!XM:?G.J1,\GA"P_A=-9%D_G/-?EQD_'WR/0&KCJ(DOOXSQ/L_GG M=+H[GCR27.OMQPNCR#S:>M1-BQ4N8IC_-OCO#![Q*9K>82;K=["%3YT!(J'5 MMMER9$UQ'F4-#-_4!P/'DE17@2DA6X'D#0:ZY/M^7Y,' 4Q_N]P:+JUD&PA= M.. (XXS2>$_'D]DT[\Q5E]]RM^S-+?TSOCH !&C) UE8R8"5==6X4(6D_O;^.Q[1JP+S*XU'$ MTKZOLG"< 2Z=I>7U%A80!62+KBZ9*C6ZXD!Y[B]@>>'#A!&8A7 M;4-3+6'!> B5!SNL."!/8!NC689FZ0\]G"A77#"K^9<($V^?YBL]F>CM\AVY MB5# :9(%$UDG0U@1&?[PG#.%Y_CME4S*8%Q,76Q*8-)L<"M5D*^A [U]69=< M6]4E7744L!5>WPJJU:!(76PD1R#W ?/A#"\+\SMP+2^R:!+&HZ=O@@YS+%?D M.ZB8^%JFONZ"] /,C>5LETUL>D+::Q'ID#?/EC(*PC1LM[JPG.CR***WFC)% M>$2J[XHV#HA!R!R1]J\%=5J8?ME^0%D-Y\\L6-5=P9.=(8]%[]B@B2= MO+(#)ZPOR@<_HVP8YQ&5$7W!DZJO$S#N]*^S^/Y)ZXBM:@YN)C1573$;:!W9 M\@1:E3U-L0WP*5W83^B>[DJNJC@P.W33,@._[YDFTQH=)L9[D7?[Y,\>)7&6 M_CAR2<#\5=_+RIXDL<"?!DE<[^A-Y[ GF89C;(G'#VO_&2&\3S1RLL8Z4MN Z6U'>([)C-B;M'VKVJ'R7K'9VK V2P,!U9\=V(K1'V;$R M^]OH[-B3!:')BK/"B=WY[-&*Y-O.CK5!$BIYQIT=VX'0'F7'"B%K%UVRLM]3\K2)$Q>)A[Z>$?$\<68PA[;*BO@@?/;FHODI2/1T/LPAN M/>4Z>WXC*"'[:D<\P6-*6=,PV]>R577=&54CATS54QG5J6U#^(V,:4?Q'(9>D.?I*Q*]4Y')LH#1K&9"PE_&]% M;[OSS ^?5ZX]3U[Y;M_RU./%9K9;FN)HCS"*6+O3#P)8)@)0:-U03^ M%WBF!J\-JM"A:MF.;F]RD9[$F"/DO.7(M1RI77*^"'KK"R'OCO.4FV/I\B,* MMK;B?)&,H:B.I3H=YVN<=S13,[0]<5[G&V-%,57]$#K/X< MS#Y'-Q6["-=CX\DP M-32G_#8$\R X?83WF/!1]VZR])Y^0DZ%XWDO'4?X?PEV2[,<7(WI7:_W3OF@ MG,#0?T-8D[!'(L1_7@)_P"5U>_\'XDVSWD683>-A/*'4\5[)IQXQJO<.7]-[ M*WS-5.&W$Q%=)1S]>\8RU7IAWIMDZ?=X!-?&8QHE405O+'SK][W>U5V< QDA M.WNG 2Z\@N.WH.%$X;7U>,)R?$E CY MO/@N>.1=^#VBVWO?4^3$22^)P4T;A15H3(Q/@7]D[ 7T0KP;X6&^APF^"AY$ M3.]-J1\//8]?3D2*PWY?(N.M5,VZZ1C<3Y)T'D4\2;IYPGQ.*6L0-KPX-W)J MXB/^CGG6G]/IOZ(IAYR$S76)1"B@4#XA;8Q[WZ9F&[:86VE;JF8W@">JJ@); M-UOJ!QJ"P-FXE74-*3 ]Q=--QS,M[9O.#G/JH8/#,F1'=IQE>%;03/DY@OQ< MW85C;LC^0:,M#!F-MTP2W)M0'I'-LZ7<\$Q?V8UW\R36+0)=,>#8\:@H.7AR MZH0.'@M!6MFZ\KC\*-MWL&;=D%0;L^H'05]R7=A^RHXV4 +'V"XQ,$TX 1[NEU6D'/*8]^V.1 M#0B4YQ0603[.DUY\T^N'L!KV+M)L.D[GM#XB*F^O^@871D9C"9Q6N2N]S^GW M""-L!12:05!H8X0X2T*$;X/5==SK!=%U-@NS>0\OJ!#3B@<1,-HM2J4WFY!C M4(TR3'K@CY[HMD6CZX&[>0*L8(X0+<=9R6V"8(-1L=].\)<)N#;Q]RB9G_0H M.(V#+CR0WB3*P)>X#\=#]!G@ZKLT&<%]X/R,HIMX7/D^88E,7>(^[T=+VC_5 M'06^M?8TU;5#3?7B!5<8!YUEP2G'-K6!;THJ,$;2 M+74 ZT??D;R^H?9]U5)ETZF2K!%VQZ@XMH:@-907E_#C%72F@&5/M5LKV+#Y ME+"A-F-[IFAT1FBN8,D:2A?<],82GM)5N0*KF&9@TT[!AL798R!%#471Y+4U M; _PXK2^X6HNL$?V--BDFIH$;HPCN;H2>(%KJUY?^T8K@&GK-3?NX73RQ9(1 M2R-Y K'T,'@&P3_!9]RC36,PGUDO'][!7/_;V[OI=/+[AP\_?OQXGT?# M][?I]P_^Z?\#>P'_LTW5=-0_/E2W58_*67GBQS]^7F?)*/X]^CE)8*L\_<26 MKA'L\<8Y6(N_O2W-#KQQ-$NB\YMF[BQ_&T6?P_O(_1GG;S^RH'@@P2J:PR^]C&1%R%!Q*"<_"JV_+"V%_6UVF M*)(FXZ-'PD5_?! >#HL:D^:C1+MJQK=3M%/@025#7%;2,2[L3'95'7/5IF"? M(E34+41H2K(J87CS$"*LK?*M%"$M\-@Y1)ANK)<$N0&X>V29 =7(Z^U<=16RJ]IV>.!PB>L>UN_/F"0^F%2!6[K%D!(ZWM= M<[]^?MA*W<$\RX4-2OV\BIVVX66O4G8KCLY;*L6/ MJ:]^1,GWJ-.=>L++T>B.N(8(SOEF)Z-,HC M[!L[!6J# KWXD%&G-D]4FW5%&JU4FY5;5[9\H<[@R7^4L5U0F7*X*T6BFK:Z MRO*4@5>L.NU4E4Y4376-1R.J\.5HGI"E;8W7RX/%HPW?:9.T:]3 MZ R4XC4*_7S\.D7.\91>H\C!^WYE(E\+X]=*%7CTJKSU&P@CE)4<+<02L),F M_)U4B?3;NO(O66_:J2>=%)^(SMI*J3YZ^[0#O6E& .E4IELP.I79&@^\E2K2 M"?#Q/5!:*=#&4T2JSJ#BWEU-_"-)XV^W1K53@SK1/E*TM99AK13M199BTX/S MC.<5""+[>G\=)YBVZJ?9R$O2= 2[ _SW59SGL^AR&MW[L',H;N2=(X;S:32\ M?HUR+MKB'9N<.[%1&]EC$]O#IN=KD^Q#&KZW4O+DG"&?!)'WHR%=?SZ.A-R( M(+Z!]7;3TMJE?1R?_MJ6JNO&B]??=)9U"OS"%-C0J4I#1FR>(U+8@ZG-53S% M_=3IF!#29F5M&.J/G_I1^OJ.WYC*6+IL&,=DX]JC,J_OD%XS+ >LC*7KLMGN MZ.HHBG\_BV[#9$"C$44WG\),'Z$GWX_R^';\9Y;.)F?)L(O('TB'3 M=+8T@ MRH\A'"?TN#X=XXGMZ#MF]&-_VYL;V!,"QW(?_KC%#!"&X23(O(3$PI;I7?"W M)=HGJ\IKT+Y3Q 7M5*\5JJ=JJHD)#K(E&^U>/(72@G@:G<7?$:]T&HYOX^LD MHD4L]^:?PG^GF9^$^2*XT"R?IO=1]B5*2!OSNWBRLT.O;FW=6L5>N4J]4-%J MIFV;QY$N]2A17P ?8:7KBI,.HSXM3IUJJ_J\RBJ<4GUDU7G!O@O+RHW'MZ4# MT7DNAU>P5ZU0+TVP"COSQU(NVO5HLD-0T4M)]%HW@:A$/87!>1PU*> MT72*+1?9-;NR#?WH>MIN&-W,.2/$*&^G0@-$J%]&!%V,.0O2(P= MGO71":[#LSXJ>6FP?21Y:8[:TFBE"\\8Q_(#ZM"U[21X$C+J-BM!5 Q[SJ7P;-4K7 M'#H(,0VUPXW<*AUEF-Y'Y?)TE@Z%G)-2&Z,D ?/V9P0:!#AV_TZ"G:5 ' MC]]ISQ.TI\/'[S1H"PTZ4N]P[^S1NSZ^.U9];3O9ZON4+1TO:K(-_Q"JV.!O M77'$:+"AF"T3=6,56VE0B_*/$?MU9Z&DS:'G@;\G99'M+92%+M.4/2J+*AN% MLBPMM(ZAMSL4S=;/T_$H^AF-KM)31"?)>;O\!G;9OKC#PU8F7WF[_(:'IJC(YG:Q-7-O*^R""(^@NN"9 M,OO;)ZKVYU.V*L6Q70)LU6+2!NZH/),0/K:,.90BN&4FH:SNA3D*BP"HLL:M MM(.I^ Y8::NEJ?AG\32^I?-%'V>X .(!'P\!OZ)M$91@E^U+7EH5DEC >.J. MJ@^S^S@6C"FMB*%LVCWO+]32K+$EQ%2GL<>FL?NUL6W1V-4X>IW&'IO&[M?& MEH4>SUV\A\Y[>$&:;?'^'/Y9U>.&"_7I_VG;G*>RR?>YK=/$\Q=(L2VFI_-:>IUS=9='^=Z+Z M=OZZOD^)*:HL2LRT%Z%$G=&)TM+]O?VN\4YPE=_X&CRY=PM@CP MEY?M3X7*?)<.3^R(E,?<3GGVEDZR3GE>KK(JF4KIDF@:+#92TMC0K" M./M'F,PB;_XI"O-91E,KR,B3'BZD:Y<7"Y?F7Q Q)(,=W&Y%&X,FA7"U6'U3 M?+='B2FV(I/$9*VE-KG<3A/FZ_D-0_18V%)G".!RD44W499MMZD_"O'PB(LM M*XIE=B41.PU]7,8_=Q_W>"8U(<\*-PBJH;[PI/ =N%=G\4T$?R=GA!B-[;WW MY&,]ES9T]93');"NQWH[A=%2I,F6=DY_)GGIEDD>K*;JRM'M0&<*& M?WX6?8^2%=N0T_%D-LWI"F57RV2W(:JK4]?7ZS@%1NV67I# MFNO=&0B:BW> M4CL[SCR#N)Z]DN^0-.OMHUG?-\U54JM=4[*I-<#2(Q#CQFRW=;PWP;H M,=B-'+JUP;.*ZL7GQAV',+I3CC:+ISCE,&!!L@4S9UNJ=AQS9PF?\W&6;4A.OX[O].M9U:0S'YUJK,7N[52C7>4"+=".=FK#ZQ('RUK0-8N= MY,B:AN*Q;%5MJ=<>Q&/8U<9ATMQ2&!?UNS091=F7^/9NFF^;9O"D+(IXO'MH MO6=2"%O5'%C8-5EQ6NKOL8YB:)<1F1)^I<,5UM7!G4WOTBS^7S3Z"OY@)KAX M.&-S;S[X&67#.(\N8+L=":(DY:'/>Z@3>5Y18F_REL8:]RS*G1>//JL@+4=3 MU=?W'U(==(,$T\*+4U6]>-P MKRM'.C\=$UC4=\RCRJ_2LB=9[L,?MQC5$-"FV,9HQ,Z(PN0LW1U.6N?Q-^J4 MK"JO0:=.QZ!2G4+M4:&Z"I3C%%A7@7($(NHJ4(Y!7!WX3SMDT:;*F+W3;%2= M:#OPNV,ZD#&*AK+[TXP"$KFKP'FRJ!C&[YY%U2;#M7>:5=D$,]4JFE7J3VGN M,L.ZS&O:D>"]>QG8*>G03B$S?=BANNA":IZCZU4Y=;9H6 9EV2]VB%D&:.SMW- MP..:#* 8^CZ79*?K@/T8K\'9+^!#A_5]M-N=?6M&U[+^46(Q#R66#EF]TPFN M$ZUS-(U].YJZHJBF6,#GZ*9BMS2LWU# 5P=P8)5A>ZWA(TPA=8^;<1 (1D[; MI(6*I*@/C G.QC$C.*=2D9*:>Y8.\Y%]_<>'XC-[!-ZU<'^N^+3R/-6# MFRBJGKE\\Q\?A+$WDCZ!QRPQ#K]\&-N6'K&2!8U/$NM^<&8M/8XGRM6OVN+! MN(*%24(';[CJ]T_^_M-?__+QWSH=,AR2:RD$"P*V)+]Y+&"*&D9&]%D* M.5^2!V_&YO1',J::^40*\MOE\(Z"72)4+\O[T_/ST;2IE*$/A7Y#TIRO%J %JXH,2%^3\]=G[SNNWG;.WH[._ M79R_OS@[^[\TM5PL%9_.#'GE_0#$K]]U@.,-&9X.3U-6_3MYD$(#]7Q!Q9+T M@H ,D4N3(=-,/3+_-!:JK;$$2E#H3RG$HU[4(69]W?/M]%A7+RU[^0 MB/;B>:P"GN' +PG/FRX7VE#AL11+P,4?#@Y,QC)/9U)@B=4Z^_#A0]>FIJ@] MP')%[*FE[,"'P**#Q?KZ_/Q#BCK4G2FEBQ7#A.JQE1TG(,^[SNNSSINS+)=9 M+I@N9;,IY7P"L GGY=;[1G61M0M$':!BBGMIUNU\!1ZD\B66\*9GFA4E#7-K'&J1Y#U929 M+W3.]()ZK(JW0_LV9\+<2C6_9A,:!E 8?X8TX!/._!-"C5%\'!J6(0C%FN0G ME/*1"B&-;:GLW_AEL>!B(N,_X0-6QPLE S8"IR3XX^NPOT%%$[>V723K7DLO M1"6I\&^$X6;9!\%J;K,[(=S_=.*D6*F0*.&S"1?<*GOV^HQT2,*>_@FB2"2+ MI(1][.8EY(6'T"T,Q$_VMT<#+PPLXQW\'3/'%"[&A8*&6)@=.->:;>:+OR98 M' *B!]#5.M)@W4FM?R!1 M?BU^6_&[HGIV&\@GW1<^5\PSY?@5R=SXO:^!'X@F5G8+5SE<7Z1A>B17[>"Z M_"ZIYGHPN4]9U!/^ Y\*:!X]*DS/L\-HF)'>0_%['.2P9W,92.^/%-!'RL#M M(G_#,1'77B!UJ!C\8?-"CTCG9D=+J?S(.D.2Y-CZ36V_"3473&MH.\=<6(O6 M4-3TD&JBW+[PGWE?Z'E_ACSJ[5MTZZ+;A^FE,%(M=\74*<"-Y(<\DBM9+8YU MOWRW&#>E:L MFHE($LELT:V+[C4;FUT1W<3K1O$\CR)F0.[ID@*.+8!U 7Q@4_Q_R!92X:!R M5S"KR'$#^R8/;"R2K&2VZ-9%]X8J 06G[YEZF-&ZF&[F=B/Y-H]D)BA!%DQA MT&(.DQLKMH6U-JPP.3#+S\S,I-^W:RE1@[ICW:TAS@W\N[+!;R2-<$";"J8 M]:NKFSLRFC%%%RPTW-,_HFN#=ISN=2.W$\WS0FAJ+8A822V0WW(5*?EP]-6D549N]R@$N79>52*ODE_M M:/R;NM0((UG'=Z@X&[<[%:)M>[A3E&'K3$=:K:SC-G4$NAVD$+5+K5RVD!]E M";,&T!7$N.$MA/)6$EMPC[DD5@OCJM+<4)<$[W++8RWDQUQFJ0%Y=6ENR(OQ MN/R22POYX==>:@"]388;WD)\SKT.TV+]S8+O=>KZ;J+=GE$(ZY4%XEM_.$)$ MO@;R6X6X,2Z$_8K1^1;A;>>C5N6WPTR[Y_M68QH43U4=7J[3&=X4HH:[S^-A MBK=2('V B[RZ9H;R]M3(49QIU3Y$0W$@O^-TS ,P@^G/=E6 ^3US2[GZA08A M&X@APV.@(,+F=@"_VUL%MXL>,'+9(2M=DZD+LJ74)8F^A!J"&A.K,IXZ7RD= M*]"Z=56W3H5^*K5]6^G=#E.(3:9#3VTK=4@X'\+YG*KE8+*NW!,\TL1]O,,! M"&ZE&LW2' ZL=Q#F=@1G#!(7R&Q^V)*D:_J$9#(EX"+$S%@V@-DZRQ[.T@M@ ML&J-&4Q&TM#@/EYPOEJ*=#M.(;JYT7'6^>)?-F=ROUH^Q[Q;_]G+ M?U9Q93S.*@7.3O#4;/PQ[QI;J-VHE^Y2C&+:';(6B$"GHMTMDA613([*5!H" MN(G=.!:BEXFPMO,_1'W,KBK@/41^&#"L9MF48MVLS.G&MQ"^+"Y(=$@B/:JM MA06+%N\=\:Y4>ZLQN5$NA"++4&ZK\Y[P8I0Q/B-5"=FM]&Y0"['']"&M%L_] M\V'A27#%MZ#P_N%P6\8BH:L)_S!PDY9Q?1>R0DW@\D- M]68QQS;(JPMRNT$A6%?F!I 9B7.S\;=5?B3*$/MLS'+%W#I(50?!A=QH&?>> MJ6@1UZX)7JW+8C#!^*4'.%_S(#3,!S@VL>7=YM#BW&6=I:#W0B MJXEUL5@7ZWK;5KM;9]O3V2IU.O68W8Y2"/1M=92V)SI 7"8ZP=D7\>E,/+Z9 M/KT)I1^G5)PT["W1[26E>Q9W.H7:.M !AC+KG27)_I5*8]6*;&Y7*(3Z2O>Y MM"@? 67[9;! G7J>X8_PZ5:JZ$,A9E27W8UZI6/&R6<2R21)+C:.'^?3.L ^ M#K!>I(^*\V6;*XQH# 3&\PN\;;==0XE.JBGHFI,$=GQ0&IL?*QNU0 MA4CD)H=*[4N(W2K2AJ3425)PN,J-CE>/\*^44@2U:MUO'_=+E@R_2/$+=/^@ M2^6V9R.KVTVJ[:K,K"M"#ITHB[;-J3\OR6^0K#8AJ<;EAKK*YLIV6'%XA%=5 M,TZY9J#8AK,KG!KD0:RR]#*,%^@! 9R^XJ 9R M%1XWP,5K!'/W8[38PF?\!]]\&K()L<\Y7>"#1I].-)\O IAU1=^H\I#?_1!4 M=Z'D@BG<5=U-Q"8""MS9EZ>LQ^3*+]8JD3!3;/+I!%^8ZB2OZ_P.'*?/\R A M,=Q@+NDU 12D?R0T"$ZZS;4\"V,%PX&AQ/#KE9@78G= QRRH:#+0EIA\AQ)> MB+7Y:E[!:& I,3IS#*+$]H_=],M0\%?VY:B/8+I4AHC"(U:.1^1(]$[=7;SY MU<&"?W42O@Y^ZIR==]Z/#'7IGGWSZLE/N*R?[:RR.*KRA6TB#%%O_>RQT*CS)64F+-%?WLK 74 M5R'WQF,E!1(>_+%?YKG7(JOEGC#97QORCQ^0M I\.EG/6>XD%9_9?,Q4-'W" ML0P,;<'-I$ICPQ8%@>U>@B-"?3PAOEVY4/#H /<<#")E/\9D=Q@ M=47.M!-HF_0=S<;-ZQV*@ZR1K5N)9JFM2BKX(;/9*7[$$&_E;[-G UO^Y!TXDZ]^8XRAT( M/,H7,)0*[0@-F+Y2(%%QNK4$J@N*"B69YZ'!R/A="T9Z'.J6;4;O4\%RN\T@ MW;G$>S&1[C-5?T Q($6V;/:5U:!>JN3.R\SY[Q'T,7K"8%+BWR$9U;.>\.\5 M6U#NWSPO<$4O53B'$7>\08T'&1]H5%-BZI!Y]X MK(H"HOJ4,6X;:;-JW#5;2,WM%9<#,V,J?=%-;% YP0N8W4##X"D>]5&3SUSP M>3@?,CN70"H;[X.2U!/._,OES7P1R"7#F]7*@O6%(^1QZ1PKBR;U.-=@C@<= MB'6"R81[3.F^T) %('854#[7USCW-7B53;ITZO&]B!#1M?1"_!-,NH%YJEFF MME7V8A7315")O!K8WZ2MZPL/7]YCT$K;__MB:Q-1G>5%()R8XV]>O-U,\A*F M6'WLD#8LKI>D-:DG3MV&& 30M@#G?_.<,VZ@> $=5NI%ZCZ>XNSYCYB%'LD> MM)X!+E#HWG2JV!1^Q4LVDQ1BN6+83]0_:WE9UZ;/V%/O6UX94?^LY?4_(86! MN0J@YP+]@@#9#^%LF^6^@)(L'+F[X\(N\J>;(A=1@WK\XN,;-#N,VT3PC6WP MS<5LB8NKX=B68E5KLF_5;K!H393I[DSR_?L-OO%X/)Y 2G2&ZK5Q%T<%VB;U MYM$"NGW<)W4)ABZ8M86NH2;A87>H$U=21%.]"M9M86F6H294,)^)(XIXK?TC M'AT!J?=*SKG6, ;#NS SEE;F:5:4))[9_Q=HKWWN11/WPO*RD^HE3 QB ];; M70"5<;RX/9@,&0UP@79$GR^98'B-HGA@QD0BBN6PHY@&;:3YPHQ=4HN.1>M; M\%'<%#68Q*O-*P-3QM?@:9*E^#17?&EMH8$J2VQ24Y3LXKMF 8?VQ+[S=2M5 M-@3[C\QVW.HLZ7K+A6%3IKXC3+':22#1]H:VY\"->]#EVZQPWUJ)K568]K5V M-?(^H+&I^8'=T3$0UVQL2@S<1-A$HSY+86:9N8\NL:B4JI$>63:;ZXM?9]R; MX:2NG[0?)4969VV4Y9NC@R\R*+CNF)+@9C]:BM EAS/2QM;C:U"?M^'X26H5 M1B<[@?57X3,U8OCO8#+)]([[B6E6>=BE"6&OC=MA(K.K@":-)5(V;)^75B%N MF'$@&'>'R7!L)F$ H]+H34$-0Q[&'U'^=N,R.?%JS5%]/^38% MM]".!IE*GI6(;K?PU#D MU-)=+MZ+*S]Y#TM5]6++]5:J"8,L\<(@@>=^ M>525=#\^;]$7&*71W/N%!ID9VC?/^27,VO.D@7GP%4O[L6TV^EV1R(;I9E6'/(>MA MC5P?KBU=%MJ0WJ2F)*7B W_>9D6.I*&&C)Y8\,BVV5*D:I0Y& A;M=;K;?1I M6S:2-&H7S]&0_+#3\\+O_6(&,>4?#PY/ST[:2'B4@^3V<>37T;M[NBZUSOYZ<=O MO_GPMW:[-1RV;B@AR/?1JO6;BWS$'(%:8^>9$KI8M:X=WPU\1T!KK7M,ODP< MCO[5DO_U6O#IMZOA?>OB]+S5F@NQO.QTGIZ>3AGSUDV>NG31:;7;:W*?(\8N M6^].+RY.O]_Z94@#XEVVMC]=,Q01]H"ER];%V?F[]MGW[?/OQ^<_7%Z\NSP_ M_^]V:;I<,3R;B]8_W']"X;.W;:CQIC4\'9YN8?Q[:T0)A]*+I4-6K:[OMX:R M%F\-$4?L$7FG<:-^#+<%$B7\X\D6PN<)\T\IFW6 S)O.NN#)M]^THL*7SQRG M*CR]61<_[_SV<#]RYVCAM#'APB%NJJ)L+*OJ^?OW[SOAKU%ICB]YV,H]=4,I M:3#84I:0?[77Q=KR4_O\HOWF_/29>R<_2H(?&/71$$U;(0^78K5$'T\X7BQ] M=!)_FS,T_7CBPB"2DG]W=G'Q7M;_[H:ZP0(1@.K=$H'%JD>FE"U"KD]:LMU? MAKT-^RY;T3:TX8=C1\0#L2.+=7);ZAS+YQ!J_CX2,-@DC?[T#A/H'>SX \JQ M)''M.YSC*49>.;8UVWQ) .'H9+"+]&PF".!7<>O'E(/=-D"=7V!&(%N?T0' M8]AOJ7)FKQT^O_/I$^\1#S/DBH.9W6_I:&9O,'=]R@.&KAR.>7\Z8* 86[) M_NP2;X1G!'K4=8CHNBYH9P%+R(#ZV,6(=STO['?'/WPN5T_?K$PVDZ++.1(< MBM]C9X)]8!3Q!^3(9KVNN',P^^SX >J3(7(#QJ")D-H+BN]H5BN4=-?](\"1 M%JET5!6V6P^&4;!8.&P%.G(CO.DU6!S8DY85%+BC;#S?KE$!P .(UHP>[*K8 M+NE/QU3 2A$P=P[&Q8!A%]4J@[*D*Y1$CSS"%*1L)T*;0HVX*NT= MO<8K1/.)"C1P5HZD6"60PG8KQ#!",VF7#=&2,KFN5@I$K_$:T7Q"\&_0+@$" MPZ"_#)<0L!T8G6(P16\==Q[7J JA/L$*4=]3SB,?8( 8:-8%+"%S<%ZV(A[] MJ;1V7&#J!ON!0!XPJJIVJ"RJ9N,%)%3I:"]'I.*UF@LYJGIDY!#$P(N]OKT' MXX Y2Q2 _RKYBG^I6.4>3;G*V2^H^V5.?3 5^2U816)5K3;3;+Y61.&7_C+T M!5SP]>$3V('1AX.-@;)DZD68N'L1O9\9#9;\]ADQ%W.Y*,9\$:\G>&@)PS_! M1Q#,<47@^/=X>K .JXN=>B6V]A<^4?(9YB/RJA\/2A)5:FF0'>&H.V,H#!95 M:QYJMEXGGHT4XU_N$.*W#B-EH["'D:@2&9J!,\JHBY#+1:;N:$+1TA?B8;J)\FT R/R!6 M.$;/XLH'U58.>$T\-%E ZP]-$-2&ER8+;"P-@4:(*^:D=F$%'!/$.?@Y$TQ" M%A,%4?U$TZ/6#- 5CX4R-.L6P"946V-?Y](P";#:?M6@5#?8=3B[QL[,(U%_ M7Z;CP;6.V6)2#8!;]0C6)5@W]!LT$37VKJKYNF'M!I=KA*A#J@%PJQW ^@3K MABX]=.GJ#A +G<7*^U=-P!BT:ONRB$SM,,,PV0,2<^HE4?$ZUYP2%&N?N5+B MZ<@XN"ORXY5,KQTXJ[!8]5JK+-VF":)B?788];J%LA>CK'PL;HACUF8/QAMAE6.4=%Z[2HJ';RM02DK M"<30W"0?0)[#2$&$LHAX-IAZO!)>.0AX.V9XRP[, +>=I O^/J+'!-OVV?G\1 M0Q[G%UT'C(7I+Q$EWYD@_^-)0>&.0;Z'R$7X47+S"0D][C.K&,+ K2=H%P( M0%'>$/?!0LX4Y/7%/,QP68*Y :L2?D11WHO,@ $9]Z=CYUF-J50K1I!N-K0& M#@;;^MI98N'X<4J/"'5E-KCBBD;PQ)FBV3QO)WF:X*M@#J3*F.!2'EB1-@C\ M3QK5CXX?)@^(:X>Q%5@E89*Z@GN]ND90)6,R%\!N,1.\WJ I@O[WXLS*_ &C M*-P OC]1XI9A?:N\2>Y!"T>3L'#!S:O1% 3:G:"H5 ['OG4NOP"-I30&I6L3 M+H*9"CJOI EIKK=R%'+;_&R"M]VM".BSVV?7#V3^4 '?6E7-8(HW"($C)>]; M14SPN&6:*EC<+F&8PWSEU1 K^YZ2V1BQA=QS*M15BL(F^0[C K&_6,!UJJ@) MGA\<]@4)27XDSX1J#)*\&B80;(LPG_.LDB8XWEK%\AG.*&B8W\+IF%W6&-=; M&DV/]>P*)O@?L-@**W10LDH:XG@)/O_M\U*&Z?.'=G99,US3)6)B)5.2!=B8 MTDE=RKBEVN;(K6("PQ!QP; KD'>,IUZV%3-(A8,)\M9[W5NQ-/!:L(M5?:91 MT02>_6,F"OXS"IK@-[5CDS>8,@IN^-W:;^BR-.L.<]<-PC]3FPW[]QS%)3I< M'OB0K;6Q0(MU_2FCB[T8WYH858776I2!B,.[MMZ?G9VTGI"\3RK\&_Y:,DS! MY%E]/+DX:04VH=Q91;?!:JKZ9#R? MOR+PI5>\1 P7KT@,N>Y; OG-*X*.Q66AHVQFV&00+;('\X-6:=7 M7IU=TT0&%OE0VC+(PFF1DZ2-LR@7(D%OD;]4B#XWVR*!;-%"7;RSDZ/7LLT4 MVZ:U-OKL/>D$N&WSO#3PW22"!+I%DUR]2[#C,N_O&"9X+8H.Z.'=S]],P%ID MA.N!U4G(3N!;9(WKP<_:=TK@IHSQ]FO 6_JD02(,B\QT/5GH[/ENX+\Y),+2 MO'-1Z80F2,%/#2RX[!U'J>I8F92PT&C MP.B+K];J+N0-$'_&M^)ELIU7PTQZ\%H/WH%:B4[(!J AXDNG*>%7:$I9K"]! M32)^^RR8 \H"9AY;]6",AV:DO*F4^L#?K$=@G".NSC:NCZ(E$GS )%2F:[[E MI:^I5A27,E0GT8,Y,"_A8V33/%30&[$&NT($5N+\6;-?VM QB7#0Q*PH.4Z7 M,I.V'UYWP./ A8+3W5)&4K"12(:J@L]T&3.)XH2N7R.(6,D? ^KR1M*9TZSD M2#JKI+$$[+)"+ZA4R=&S :->X(KL>955PE!*+P)72J8VW0 ;/@V3]O*%EU_' M#(I0@JJANOG92.JMXV_4YMII4.=\JTH;X1R%EN//L(PRQY>6N+? !'/!0@GH7]HEM#(-2@>H;F];F1JE(X "56AENI0.[EP'WBE+:^ MURZ\E6=K-%'NV^.*6L9#[4XT+A97%C>0G;=Y;D\>6P"#*"ZDH"IO- MSC@@L)+:0SQRN;(REZ FH6G;.E;>S5&3T+0-92N/P%?C':2.3FNL\(J+4!J^ M(52]K-0KD^*:*SLE5-+'VDD/*/#$%1E.?SE)E;%$%:DD?UF9Y7E7EN:A5.+E M[RR/F?EP-FUT5R^5G%U/*S?*JY>0RH.Q\DK=ZL63[V!;F2=4O9#*)CN?O0)3 MX#AQ:6PB*PZY?)76WL:5XEC,5TFE-U\5YVB^BBES=]?.I,CJI%4R3T%Q_N(O M(ZX2Z4YVIHV_C*3VTHZLO*?U)82UE\]TW)&=ETR-O<'<]2D/0K\#\_X4%G0. MJC?J).*-\(S@*79E7"2:/""? ?6Q"Q)+;@?LD2EE45^\_+5A1V'8W(86:4\H MOC7F'\+K_Y#7%7<.9N$%@'TRE&^>,&@BI&8D?_C1P;Y48. (R?1ZW41K)#V:H_313P%!9J#FMYM$1#KXSGVS6:QGC7#S4/?.I/QU0X_B#> MZ!LP["(%^R^KOZX"C@GB8 $M)IB$O,(B1V'5_!-L)0_&."R?SN:U@GC3Q$NO ME?!;L("/>1FY-1 RH>^KA%&4]%0/+=NEUH.).L4$E/P]?I1_IM_3> %9%G%@ MOX37@%Y&F@DU^R47/ZOV(G);TS)J4M6W@&Q;8C5UDI5&K'T2S\JIL&F[USZ) M%RZ25NXKV]@/6TOI<=O49MR:C;*4:0F41$EXB0:MYA3FAH3O(UG $8MCQ"T6;*FN4 M:QFLB/4&1^PQY\BMLH)1_G^E[(OYTII4&F#;8'5ULI96C IN_6%J9 Z?=KQD:]<@T-C/FU/KET\;%W7<]A)$+ MLRCPD33V=GP' RO3G=J5V7J;2^,ZI0,:,K$2Y[#Y,U,?Q"ZLUC L:@NTH))1 MI:4':%N-%7>GE29(I8)0SF.%P=)L/;^'KFGZ7IZCBU/A&L?;",UDL'"(EG(< MD%GC&831'N=_R7S,=7H9F-Q3+/K36\>=QS5,,BW/!40G! ;AZY[RG*D\='*= MD.U/95Z3*Y\]P'X ,Q& J:J9, /"]#LIQ\TSM)(3WA6"X4D0YG6,:7*2)CZW MUF4,YB(JN+?OV(9-+*V_AKH0%.8C#+D9^A0L)HCUIW'G11CZ@>"@BV3ZC@)\ MV58:A'2/N7#\EL.I:,/HRGI@QVXOM24E9J4!4H&8JE I-N: J=1ZX];:Y.A: MCXP<@A@EU]>W]^,Y=/D2!0*[$D?\2^.XWW]OV@(6PR_]<)3&*?*K.\JB#[QA MK";YW1%_X$\%2W[[C)B+N9R],0[B]00/T^[DY2?RX0C'%8'CW^,I:ABD=?;@ M)TH^P]!'7@,D']]OWITQ%&F]Q@WC/0XWC\&$HS\"^=JBW/EI"'_AI5-C MNCDOMGE4@A]PZFP,;%SY\H*O5X)C_>&UX!D[8;I6D]#L9Z0E4Z:9XTF+X^9) M>K/AW'#YYO'9/*FN=[T;+]3TIHW][#9O*-R@B6BX7'=W=^QGMWG#0#KBTD@> M(!::I8V4K)+)!LHS^[*OI@]=*=5T=)1X>\'V9EK,97EOWIC9BY@U4LYJ+ALH M41D">'"$@#$1AYE!?R#26+=OS,);3J*(?R,YW D(Z(CQ0T<2G\ LA#_^#U!+ M P04 " !.@8Y(_L#-SL'+^>'E[>_P?__Z/__#S/YV<'#T\'%TE<8RB""V/ M_N:C"&$O14=C[S6)D_GRZ I-PCA,Z6!'=V'\^Y-'T+\=L?\-CNB?_G;Q<'?T MX=W9T=$L31>?3T]?7E[>81RL1GSG)_/3HY.3U6R_%G1]/OKQW86"]R]( ( MPL\H>%<.&I5PCRA#8_+EN(;P]0E'[Q(\/:73?#Q=-3S^QW\X*AI_?B5AH\/+ MQU7SL]._?;M[]&=H[IV$,4F]V&]T9(/QNI[]]--/I_FO]=:4CB!=-Z^3]<-I M\6/1FH2?23[G7>+G/%6 S=Z\D./YW-N'/.(G0 M YHE\ MH#U_>TSITF1SC"8W84R_9>A%]PG)]\MEY!$23D(4Z)&M..8N =Q[&&DR7V/@ M=(;2T/Q42/TI(AM&%1T(RFMQC>ES2O<6^YWD4QA10A'YACPV;'">WG@A M_M6+,C2*'Y"?84R'R&?;(?NV)M4@I\_]/[*P.$6,KJK.<8?!\)C-YQY>TC-R MS;S))95/PH")8;3!38+'LWH/ P![3#HP>BJ%E7+):#).4GI39-B?4>'B'H<^ M&I0'NE,;Y,1M_$RW8(*73!A-8OIOPBZ:\H]]07:,:I#^KTD2O(119'0CR@T2#"[5XT"41M\0#3?$?TW/5TR1 6#T2*_0JCL@)-)2$71 M:\^?E3U,(52?T"#JNX200@>X1YB>K'-ZA6&:C!UPR.AJUYO$\%U-4K:J;N-'+T:8:K&7UW=4.,#> F54?V5T ME;\8/G*WGMGD[D\3__=9$E%1D5Q3J2A=FCW-%(^)_&O=#^BP/QZ$$YA\I2FO(L).I]BE!N+S(J'BJ,/ MB6?-Q?*7&X3(M8=C72MLORE,(D-3JHSBQ$>(^6X,?RBEP4WN*'9+4Q%NI5Q' MGME;4GE\DYBR)X+^R.B2N&;:M5D\*F.;,4$S58B,D[65;VU()CULA6/TFEY$ M]&C3 SX0#38S:/4'&QBUIL5FAHV9(& %NTI*!F=61L(8$4+UG*^J,-/08%?F[ $_IFR*X;]ETQX\ MZ)KMGLH"N*97L.J$0T._0D_I@%]7-/S0L#:-RP-"5)G* KAF%[#ZA$-#9QHZ M4W7O$/?5SP!SW[)KFL%AYF:R;RB=)4%E%1_RSM&8M(Q3 M=87]\8(%X]Y[R[R9^5-+=U[;&&'X/.LW^]!,:=DHC:\#R0QPX,Q^V\YY!@?* MK++?O#2EBZMT<-#S%L6#&-;4)AL:\ACG\8.%,\PX1L'H@Q]13>/M (>R<((2 MFH=]572"*/]5_@ +[_\A!^U%T?%1.7 =PKI7&*>G03@_+=NI;P!2GJ#=;X32W=JT$PW&8H#YD@L_LJ&VCX1I9CVM#GO<+0H9I?D M!% 2Z*'2F#49.IIZWH%_P[(=3%*5D]1=VE/YP\OZL M3!CZ4_GGWTJ#.RG#\BXSC/.HL6*FR'M"T9?CCL:G@'0_(!^%SXR:[RA5HY[; M!0@#SE ]KK\3@* ]$/79G(6_H6"4SO+ L 65TMG&?D9%N!@+'*,\'DW&WJL8 MD]8H($C7?N![+Z0JZ:6W"%,O*B/ATES$X(/K[@B"IPRPYM-01 M1E+ZUHW@Z.S8JXTVX%0J,76S+035+(N.*4;T_YBF_^Q%>413>NEAO*2J4IXY M(T"AUA<$%;OC1Y-\RU^5LB@?0KLA"+WTA H+L]NFEBHB7-(#"D%YQDJ7S&8S M"%JOT 31G1>4 ?;R@T70V *ZOR>QKT-ZK3TD]52J*(Z_3@%2UL,6!,H?0=!) M#T?;2,/^0N=8,.6&G02Y4,<5.&0M(;BY\N@+^+;^&8*V38\T_6;7KWZ4L3#2 M#KJ5NL)@*N-$*$5"VFM-(&BLJ5H"$NLM@"ED/I%6?'LWV?QN-F+I$&*5NP-C MDU\REFCW;3+4N6^#'E$CI[K=U"%P^H"@2.+I&.$Y"]3IO-D%C2'IKKGOZ9:L M#&_L%NKZ&#I#0&+,'4:E1;0#2Z,I!,W?//P[2MGTCZQ8B,)Q).L!@:#.0CGE MO)80%-?D6CG!G(; ]'8>.?RV8%1S#W 9Z?P.$/3?XU(OZS19\%H"4;SPPN#Z M=<'B-^1+F]\6ANID@7"Z9+EJ*;U0F&BX8+>+6 N1=H' \$ O1!SZ*0JVL9;J MC@*#-/7"& 6K(,B:MXB5R/1#T3=3Z B!YQ%AIITTM_"WTNO/!2+K 8)@Y*M#E'#HI_A?E'AS&O MO!L5FC];CD9@T:N#4I0LUY@_G+F/65NNKM!_%;2"N!?W &&X-? TF6^CV"E M :$5^/WN$U"&.39-\TGILPQKO)R<$ M#S6\_-"J"JH38H8>U,T(OPJL$W*%&EA9D$X%V&(QHD=88]-^HQ+&7QUA%F_I M+3G!0VOQKMX2;5>B3L4#BS=[3QY($X(JX/N[Z07QE!5T*#=#JSH*#WUGO$_# M2L Q&%9F(*#3S*M2HP30[C:#@9K*?S,$9X7G_?L245$GY3.K38>"+\T^LH'^'+,5D]RF3E2E=CR*9#O/K ]AY>:LC4[2059J!SBUN,1XJ\ M$4'&7>#M'0Z^=Y4^K8XYBQMF75FP[/7XZIMKF]GO%49[;5=Z&%6JLE2H[35B MZ:'F1?Y5*.VU86E^6]W:0A4+[#5NZ;% )?2]0FVOL6M;5TO=5:YV"]E6UNW> M8Q+_#*6A3VF$J 041"6D$R=^K*U M%92/LI2P:IWTME,EO]X%/FM3YMT]3ID M/AXR'_Z<'U8=CUH:=([X]G1%7.!?>+ M#(2X+0&[D)+<'^E*1G8A*;D_RH8D[4(NLAI4)3.-"\G*VG!EV]1FOT OF.T] M:K,3H!=$_@:%2K&QT^<.XNTH7'#G48HP>[G[&0$^J,.2]&^H7$9NZ4+!R$]W M34OU,&6/Y^TK+S;@\T1;(5A[OLK H+B>3O(M]U:CX#R]\4*X(BNHT7&7M1E++W3&I)E_4 1<#CJ]05KM)S[Q !>?MYE)'V]M9&)Q[C3:"T MZ6NN[R*UXT/6]5#-O%\=1X\IMQ4Q KK;[7;M,1A$QJRKQ ;%LSWV4PS^&3@K MT@4WQN!\4= 877!^#,XGM2J"4$X391.><661>]1UZ%K@_F/KV"56X4I>?; A MJD 6/J&G9W/9H":I@B\>M3"+'?'#BG ,_2729;+HXD=+![6)!VJKPC +[%@( M&A=UMT6A3_ ]4[+B.4_IEJ5X3 M$\]?_2Q2M/N.9@GR+B^.M(L>!L%Z6LUPFU<)HR,?TMFZ_KS*_K M.BLB-S6;H6>U;6VTB'U"0^;3YG+GP!U]K7?/;Q[&R M@EG>LGET$%9C8'".=XWJW6SU91 ^U&*Y0*)JRSL^S!2SO# M0C@]+$"PJFY6EA:E"_ EG:G#$7<'P<:T,707/M.C=Z/4XL7RF_=_"<[C+65! M'QHC6(:PHNZ[-T=RA[7F*&\&*=2I(J3R%X(F67073H3[4:7K\"?W'9IZ47$^ M>9W,IQ/"1H9T6G*,BK>@$8*FO8^V>.P.E7F M&71QP-?[&)XM UIB70A*U-V2@SM&7(A0A%MSG?X2\/!%J]G7=LL69 /A^_M_F>TY"=Y\+[X48X( T3 K^]1#YL2'Q M*S.,[7,3?EE+][LF'CLVJMK)WG)"-J3.NH?-)D22,UD5D!T?J?LLX7@Y&UF[ MS= "\ >EU$OM]?3V;:2\M_T\X!]U)RS@'DG@J;0[_?JUG5X"__@V@&N)G25K M/ME\Q@G]RVM-2I[L!O]$HMIE*_%+"XXU1P2D;0'VN8R!$SL?L_GQRR/H7FZY7_KL' E@5))>.S8R1+LN9$40=G'5"5AK GH3D6"0E/K M9ARHJF34,SQ4OGC?5M1H'U;WDGIB M<#;[PQ1[ @>-S[8_#-+\EI1HYN#1DT,8F57D5_M=+KNT,5OPRNL %EAW[:_L M:4\_7[2CR3A)O6CU">]QF+_W>;#"VE:!SCY[4M%D!Z:D^\W0$ONRAPG\,K0+OA9C6;^YSC5[(<=BX(KGU-DN EK*QP M&T#7/UMN>3[40#C8D@\U!79D'=8U YLXAETR%$.PJB:#NF1&AEE5'8*G2S9D M& ;6Y$J7[,X0S&HO*OLMR:I\JH3'O30''^R^![NOA7;?M51$CZ=%$C.?\FA2 MB4I@=*U. \DK+S#L:M[OU0'0NOG?6 7XP2LIJ&::W4SW].Q*Y6SHZV84#NC+ZFZU"[KUV M5R%OM#G42A='NZ>=7[_9YE!AW+T*XY7<+#E@U?PPG0.\H4(V%A@.A(X3'>&) M[T#I7BI[[#KIRS[-VF\66ZG-P3WEGU,S!GK]%"5!9(0\.5H;*X[G(7HJ:V#%X\N8>W3U5I MV;:VD%.EMOHPI5UI2KG$E@WN'\N\4RR)K\SADU V2(;&):6 WJM7[5=2%3L9 MJ30BF":9T__S\W]K$KC9NH0E$>$L*%=H:?T-B8ISABI$F,D MIR$\O3<8_9'1O;4<32B7PR0(_3*I70F%I#L\-GI-((Q(7F;^,67Z-:61:AZI M-Q79,S4&@,?7Y>P4M8:GO-.1*6SN,.U ;P4VR>FSR>W;V3*7!*\E!,6KPZ,L M/L#($E#,:PGB_2U?J5"HQL5M>O#YNNWS';8*FT"&K(\HEKTYK< XE#^])XEY MVVADADNE$,\.-B^*Z#)3%+Q+=$#@$K3VA@'U1BNWRKD0 Z2ZE57=("[$^6R) MN>Z6[9<>*)95R(1V1Y<>*I98UES M[;8N/,JLNW7;XK/%#S!W^6"JU$GT-?YMG@-@6DF9S'04D*D;J0Q.V= MIAXH)*@*%M_+$L?U3+_U4?"02QF+J6HK0)4:6K$7?Z+W-69\[WHDMZ MGE]$2<*JS[%_CT-",O1(9[JDI^QJ[\9!_KR)OTR1_R0.G3 P*JSS4W:^-7+I MQ+L27A!5$@"V1FJ%"U1!H.L\0->"G8D] >XUZY'%HWTP<];'QCH"7QA"W[C. MZU"BINM("A=[_J"?7?B$H>\ED;$>27I7")L M'TP(>VQ"*.\G8>CQZN>#>>!@'NAE'C!E$-B9"6!(O=@"Y0=0*W:INI Z#PZ* M_D'1/RCZ>GRLI X7 JK[HMS49%T(I^Z+5:H-NQ!,W1>I27/KST%KR!D=Y&"7 M7<38\/;PIK/R3V>W/<("%+IT/5]$R1*AQS3Q?Q_E]Z"T1H*X/:QE=JBT9UD[>KP54D/U5=2.)@3]*2M"CC\.C%""?QY>7UW7B& ML+= %);/E.GREP&+7Z]'ODL\O@ H;@G/<$!I>ZTB&)[;Y32_3:>>?$8S1<)]O#R=K[P0BRIZ-IC((OP MOM#SA#V1TEF_6;V_/>A$YX&H-5S((K.5LDM.#X=:7R,A,K?LYNNZ%-J-#,V] M!G.;N^*"9R_V$1DGYY-)&(5>2B_ZZ12C*?U764)D4J.%3^J68$AR]E;)$\; M0U8?$P[9?V<>3A%NU&8S^@&%$\#L_&X$E_1_IE18+?S.$A&GYV!NX)9*%[V' M>\/8M64NP2[_YJ5,T5H6=?9&D\N$$H13]G[0/;V10D(2O&1U8W@[6+VST9+* MO#/@-O[K+/1G["BX%=3I[C>&H7#WQ$7&G_C[(5 >>:4]EZM;.3='Y-$1R M.K<: ;LK>7:^ACMHD(\+[EI3=$I"<,<*UZ."VT;-:+E.?]@07."+<*IMD.W4 MR6:(:%\E!7XU*.T6>%:YLG6VU5?7FXIC/W2A\JLQ_'R_FDWE\V1GBPE%J>$4 M[SB1X;>&TCFR6[98<6:($]"T]4A^+(]<2]OC&)WM&*CAWG,ATF8(9CCRRLL@ MZT#JUG8B8[$75PPYV9Q(<]PQ@QK^52?2(?LS2-]UX$2ZY(Y7C-B[ZT2^97]N M:7C)G$C"[,$74^6"P_?;'=?*X;_@+]ZTR-46,7?HJ,#R+4I<,UH!QSJ:[=R MYVF/_KS9L(##O_BA<'(,Z(ZJK-EM9X_NJT0@A4<9V;,DHI228BGL(N:]4I-' MDU&6TGLI#L)XFG\$->D#W1XX]%,4Y'PC*X&UF/4K M75!I%]UJ0YBAFPH\K+!*\9%7;XNP=7Q/*4!U#I9E UB[;Q[^':5Y"RZ2K0<% MRUY@CS=V92^LVX!2*<]KWFCE#*5 &0A#9ZX(=M]ED M8]:J!4RAYO7!<._A$2X>T?W5BS*T2C03?">5GD;X>$6UH_Q@CA'EU7B69(1> M,#?AA K#DE@[E6Y#TI=DN!>!S7Z&*"0^#A=%'F'Y9-<#RN_EO,0=>U26RA9D M$J+@8KE*W[Q),.^NK!?:X:(::"[0 A%%^3>^]/H]*32S0D2EFDG*2FE6O[,* M0QD47>IOPMB+J1@<;;[NR:5=U!HN#RZ_-PM+H-^=\B+N81&"C@0.69^] M0&$NUX2I:OEQ4=MKD@A6>0?3-/U*3S^JYU\F<7%SZY G[PNQ"C:>,N5^]68; M,SDZ*+WTR*SN)F#/OX\F10%'89*R9F>89S/8-[V- _2*@G%RRZJ)KTQ;I8%+ M?-0I=K8-%U-'8N<]Q67J9*Q6-CV(,:(GRFVA)A"."9*W<_0&,$5S;L2- M\Z?EMCE'>XYD&H7&Q:30"^39EXJLXDM+3W]1:Q#*2Q>(['&=>A-(&N4OZ<#G M2/6@T]@Y1G]$&)<;8F7"?PBGL\W:*YW-89Y-JM/S@ (TS_?TRO\@LQ^J]1V MRSF["/N>TI>T9#W,4%5^OH9WIN:TB=4N,OU10)ZH8@Y>R6%5_0Y&G?3LK[> M>>*KX:N4T\IM"_SX5V_'O^*38%N.#_-06$3'G'Y%,<)>E >WS*F"23^>QTKZ ME:\5R&42O3',Y-(61M&;2B)X2 M3^&*$'E C$[A+(\**61(%I4S.,6APL)06?-;+I4\CH?GWB[>_ MYOZO%;C< W;CA3@/ M@YIZ7$N,7WUT6("W^"URHD97ITISASUU699_N!G>+' M*F2Q"IXHHRZS=,8BHELAD+N8T4D.[HIO>\6M9R^,F/ITD^#\GAN8::WIS,CF M9JC+/1[!15;&?%R_(NR'A!^#//243JTIKJ#T%>=O,)I=3I*98%<2ES"YZW>P MN5Q<.S4;9[%#!EHY[7G N/74C>))@*(I**]E9*GV/<1T5JXTN^OA&:R&5V0: M%2K_^12CG*2.XGBR/B!?DQ%5W()7&5X;>8K;L6[+$]W&6PP$AEJ06]G2ZR4<33C@P80@>NYFGFDK?;Z>. E>3T&C\*T&,"N* MZ*D\-\LTV[#@U4ZICNRE.J/, M7L\V,4BR?(#X8\>9J5H%NS.-K%U^29CM9!-J:3UK M@%EUH]A=]ETOKZC.$-4,%_C5H+0)AF:$*QM#+W%)]ZGJ#U 5&M5V R\3I [1 M9LE(LK;U8+FR4CLJEPE,$=52M+O86TA7'5S;9K+&]\G>VN,= M^+KR9RJ(4#JWTI'2RD&IGR>-%! 7CA).SDH=ST8Z>[7+@.IY]ZB':2AGI,X5 MH3H)_L7MX ^_I*A3550'X(I4V00ONVH'CYKR6LF43V^<*;4;I^3(#V^<(ZHJ M:\FN']\XNP0A%"5W_OS&N;/A"2NY\A<+7XHREN_ KQZ_-6_W^9&I87AO/M_ MB4>JC#)S-^'W3KR 9?4B;:=Y./%^EIT\E:5J.?'JEEULE66/./%&US#L[!$8 M[<0#7H-P"[#\L!/O@+G%=$%M;2?>&;/K;-TR_]^)I\SLXK@XGPW\.33WF*E= M&J3B\4$#,Y*VZL)[]P,NVD%R-'6?,G.?I_U>_JKX]%9TJ8'?>JD8^M:T*:5' MDBKVO!7UJ;N";<63MZ+=]*[L6K'JK:@G_1ZBK/CT5I2*/@7OJXC!@[:@."JW M'&7%Q[>B$1CEXZID9<7&MZ8'*%9(KQCTMH3Z[9_%K3CWIL1\C6>#*@Z]-;F] MO^5HHP!GQ4*'97LC3ZMW5->N&.6P%&N:4:(BZ55,]AM?52IO"E4Y!@Y+M":8 MU?$H8,4GAT4MTSNPH^1^Q3.'98@M>;8.6>8_-%*QR&$APA"+A*^&54QZXP>Z M^N-V%L& A?!D:6IBPM!B@->>^J2@>>NJ66?3@4 UQ)?>Y9 M;7"]02Z32Y2,XG:.YD=[!1TCF,_@.Q1;&@ M;\4B-;?)SZ<5A^[H7,4?FW]KL V]IB@.J@*[#<;Y>)F<4$*C=WXR/TV]UR1. MYLO3G'=7(6%9)AE&-11E1ECM6Y_[*=U#Z?(FP:O@29L(#:=Q. E]+TX+ZK[B M)%NLHFM9['R)(@YN4Y*;+ND_Z9V>8L]/Z<%P%T[0L8GZC7G*8>V8++K42S9N MM#!2-3(?HCA MV@')] OZ<5D!,%"@LXRLM>HSP_(,5GT=,G?/GTB^+Q:YOS79E?7F[]7Q@ M#;7P)7W4(K(&=#,-MMX=B_ERE\6N1)4-Z,=:1]=LAE2X6TEJ +[PHM.3[TE10E+TPHOTGP59(]I9,L.O?])*/, M?4 ^"I^9Y%,DQ*]*#URAXO]%Z+89LC\/"/+?39/GTWPBO&0L^+CZ#X;^8PU] M^>??KB\W(\:J'[:G)$ AH^(3^P>CX%.- OJGWWBQOR4=K9^'I^8.3;VHF),3 M,L1K822 K[6E15%=7:V'H887=B=K:8B*"6)GX6J..&@%]/((ZNH$<;Y\\U[K M[Q!Q#XQF&P@JNP+E8,/;\MFE'*RW,!-6FRR]* U1[<#F[D=N.Q >Y80L'] S MBC/1S;31",056SB$OJ)DBKW%+/2]2!X^)VSO-/50(7RK-YSJ%,D"9(7M(:C/ MU:902:='^EU$UL;9C!2U^ MT501&U?8 '^:]/!8=0O/AI'(BT+6WMOSE!B%R[>&8 MSK)3E]KM=X%+C?YP;B]H#4J]'R0K/-1L8D7B!3DEVV@^F*G;KK<*HJ9#>%#ILUI%[8N.E5]J:NZV'CIDA!.16$ M!6JZKYK&SA,<['MHQ-%C4/=M Z\]&L6J*:^#&[&4JU_)91?Q-=3/\ &2"\GR M01_0HO8@I36)AG3E$#*:C%EH68:+$ODRX5'<'D+NK3_C*4MH:;>#H+;(@^5Q ML$O=4.D)B"B9+Y*8WBA2E8_?UDFJ@;34H9/?1%Y*_E/JY9[*<]U7;^V2/-5] MS Y,3"\IOC%KJ_$.Z7R[3.WV+8V;!GZ]*)FW6 M?!@G%[4K/Q"BW&9,$"YD3P3]D;$/\RS*'Y:WM8#JC@0R46M+*)='60C;.TV] M]HTK2N&KKA+VP#DIGWUO7U+\AJ9I&">KFZXFH:X>J\^W?P=M"@/LA.;BJ.I# M;-D3)J6T)DB?^_2BP>LR;)<)207?0+N[-=BJRV-UJ11ZIP8^T1#@&)N7YG^B M2'3G=O4"1U)>^R7#55!L] !'\*L796A%#ML*WQ!=*TI01%VAK52==A)NH Y? MX 5WF0R#NIWS97$^6[_O*A(CP7/NC)K"TU0Q<<%3TY MHR>%@/LLS#-"2WAVP=T\!/X-A<<%SW0?-FQG1P7W: ^_..H:N0M)NR8.Q4UA M'[[@SFXO ZZZ#9_MRC$G0MD\I-741)/2M2;H]86]4X K3&\\/(WZ![]Y<[F$7-@=)6T)IRL3_XO-+ M8TFX36$2W6*T(F.]8!'Q<;B0^%*[>MF"I!2$+Q*,DQ=FG/(6])=TJ0%+.(21 M0(1'%--K;F-&8=ZLI#50. R]M,.8U5EF&U$]' MD)HD"I_;U ::WW1@'8B**)9D&W8HKBP&KRDI*8;](;JB#LI$Y48&%%=@@G<- M*7U&L61=ARB69UWXD%W2^-KM)9-C7'" *HK!&V:,#>D'W.$M#)OIDGYDQJB] M#Y/188Z>DN%"*,RVZ!N[!#SD13E03B:=BJ]AUP(>55'R[C)W@AY54=H;[[@[ MCX(%JW?7_@3%D)O=^1.^)RDBX^2&R@ZQ'WK1VA%(+CP2DM'D'B/"0JMRCL?! M8SB-PTGH>W1K%J^JT%OF/HG"O+P )>."*I:_[_K=X6%0K/ZP'VC&Q7-&]F#) M"+W"68&*^1.37.FTE7/+QI6D1*]M7+Z-V3F4X*75O)51:1M'OR9)\!)&D>4, M3;UXRNK5G!."4N(ZL;8M B:D6LW3LACN UHDF%T'KA-KVP)@#W:P*KVKR%H+ MN2HDT3I>YK%D18 NNPE(6NPQJYG3O+8N"X^Y3 M;MMJ:1=UMX_'8AJMXR:K.O[-8[X/5OZN62W./L8VLR;MHV]#_U=@X<^G;.XG MNO7H?_P_4$L#!!0 ( $Z!CDCCZ]W7^WH -3V!@ 5 8V-E;"TR,#$V M,#(R.5]L86(N>&ULY+U[<]PXDB_Z_XDXWP&WSXF[[@BINXKU[KN[)V39[M6N MVM+*ZIG=Z[C1056A),Y4D1J2)5OSZ2\>?!,D 1:(1&G^Z+8MD?EB_C+Q2"3^ M^?]\W^_0"PXC+_#_Y8?Q3Z,?$/;7P<;S'__EA]^_G%]\N;RZ^N'__.O__!__ M_'^=GZ.[._0A\'V\V^%7]%]KO,.A&V-T[WX/_&#_BJ[=![R+T+7G__7!C? 9 MHO_?H,!'__7^[AHY/XT1>HKCYU]^_OG;MV\_A>$FI?;3.MC_C,[/4TY_XC+] M@N8_.G@^37T'I]B]&[](WEX-#LG;TS0W4]W/Q74^[_1E\"/R-/[9]=_11>[ M';JC;T7H#D-"JU*M/A+/W,A=_0?U$]+8N+O,?8W>),*2E]O,1>CSBS- MB%*RP;I$<$=M'H1"Q1FMK1L],(*'Z/S1=9\)X?'L9[R+H_0GU#EGYZ-Q8N3_ ME?SXCXOUFB A)DB]#7;>VL/1Q4,4A^XZ3KDQ'?_E!XD7?L[DIZ^4- AQ%!S" M-58R"?\\BE+\L7N@+^UWY!4:?K!__ON7'Y"W^9^'D=D'#S')^7/N4V#/92_I3R#Z2M\C,<@J);]]5]V.'+0QABOP,]U8?- M(ZC:0DU$4I(G:&$&"A@CE/,*2GVS$E9 (\&[Q) 0Z0_)"SN\!I[ M+U2BSSB6 X?P%0"(B.20]Z>5,UU5@)(3/$.$I"6 T:!F&39A1A"]\W&,@BUR M=[O@&QU[HFT0HDUP>(BWAQURTU?((__;.1O/YF>SQ0*Y_H;^3>09(2@P5J,%C48MZ3E$]_/T9^Q&.@!'3[FP5N+18 0@KA_UA1R=^-_$3 M#ND\/L1/Q*PD&%WYZV"/KX,H(JB^V=Z[WYN_KA(5L[A2$4W>'1?SR21#6\H" M,1ZHQ 1Q+N@=Y?,C2XPT'1!F8% ;C4=7J-S==>#ZO^'] PXKW[KY.6D#"_!Z%+) M455I:'1WPH/BMUU[D"2<"7/K>ILK_])]]F)W1P+*/O"_Q,'ZKTVAO/M%DZFV M4QKY7#*=+1@A/ 9XJ01HPV43'7K7,74,R%[3G1><\*@.5/:34MI M4LY"FC/CK?M*T]*?W3!T_?BU/0!6'X;+D15)Y./Q:#&;U1+E,Z>&OB7DP)+F M<6K5PP!7*R4'FCR/4ZV.]O(7LR")-B!)D$E%IM -:TP^(T'2([[9WAQBNMU+ M-^&_/+GD&U^L_W;PPGQ;LN$ # $R\LFZV8HXVG19#PP9#SH3#7(N*&)L MD)OP@8L8 UBA%D=R*]QL48$+XFQ0R@NL8;]B )_I\H/.-FRWG_"L-EUUA2XX$7-B2DD_2 M38DIR=_FM; 59CRXIT;(9URH!R>!ZY$S HM;0YBA&K=R'GSF$R'.A4:Q)'(E MC$ #UQ"FJ(Z7"AZ1AC!N@#A #SCU!@M"EU($$(0N>6/"+&#\Y1#%-%)\"L*+ M?1#&WM]%,:/[>:/+%0U"2,_89^-Q-JPHO ^U$J%''0:Q#_@YQ&N/EXO2W6JW M0##==X-=B^CPN/(21)MI8 $3W0=WF"KLL;WS?-_@/KATHZ?;,'CQ-GCS_O7W M"&^N_)MG6DM,!BT7M%R ;2%VU3,.P0H$IOKDEX;$9.I,G30!9W+0[)))PO;S M2EM\]-=4()1*A!Y>T3LJ%/+\'U$F%\H%@Z_&A+>R([!RF%F9UMGP;4/Z<_JO M-37Q<\'$0698-Y/E%SN"E'Z4B^.;YH\'$AJW6V_GT5W5CW[LQ:_"_QH-!XEB$HI\VGQ.3]F522./C8/ M90T@; C-&>*^\(6\9Z;CNJBP#6-W)?\M 5'>8%# 9$7 9)KQ(2D!KE?(=A2C M*M$P#%-IP12J.F?./$=K7D*=LD#"XG+86M8!+=%4:'[656$.#6AEOZ_B6LVB M]L+[%H=>0,;6ZQ"3^/0!\S^/]2QL*3 M%+:$!RVV:HD6^1KYR0>.=D2IQY$6T___08O/R\P1Z-*%/Z%QI(IH5 M0G[TQP69IF_84N3.?:QX4/WW!B!>8ZHRPW/2$OB4 *(4S.+N6 4<.06&QD2C M).%&@+*134:>FJ W32"E/+*6';IN 0,J/O8VW.]#SGU_P^A"RA=B/W]>[ MPP9O/A&EZ23W$"=R?W1#W_,?(Y+&V#28:'5HGDYJH6T2H#H$5MAYF,_3'=P" M8Y1S1BEK1+T/%9A3L*?LZ2"4+S*=(2X"$.H!K,>"P^>L$*=435A8AHI(S"A: M5$H3:=K+&1$X_$YU(;)(!H<:(U?E=3C".77L^OHKQ?J"@ ME9,_G0B5R2R/M?E\-M4Z!$-?J12(B7&:0:RO%5LCEFXKGDB^K9A7D)?6!37 M';4;G15+Z3FJ0U> ;LFG?G(C?/$88DP76B]W043@_L&-J_MWDB\9/X[3)9&L M;RW&H^7*20[@4*+H.:&*W)0L6G.ZK)VPZ0,WFA4=YXJF5%%&%B5T$24,<:1& ML[*.]%>%.S@CB\?\J(R4D88,%L&>_+%F?U>,&-4W+0D;%;&DSYBN)O/%LBMV M%(A;%$".4[DCBA15MBN4'*=V1SRI?FG;@DH#;KLBB\AF X:7EC9?;<_;$4H4 MNTN-5J/5M!A !&@:M#9>,6ST4J\]6$ V!M.GH]-;1\" T-0QK,LL X(_/>W[ MN^_1(S[O\9=@)^X7H/"Z':%!*)M* EI..X8:>8^ ^61' V/"!LKQAPZ#- > M2_+N (P'N@_0>XPH&VNBBPXC5/:A;T/\[*Y?8XPNW].3F&L7'-Z9O?+ILNL-\U?2+N\/19>@1Q_!<>9^0 MIFA'(),55\FK9QVQC19)T*A&S^<3MB@Y[<,9L[8HE#5:)[RM"'@#&:H]!M)M M#2R+D*H!IR-H*AD:9*>GM<#6 M?"&M6AWI=+E<3 H8A:J*[2,U \M]$-.S% /*3AEHEWTN([NQ/:#FRES@"ES& MOJN12ODAXUA3;ZLQSYN7, KP74:.480O)GSY\O'^"[P3M[;CJ&L)Y]0=IXU+ MSQAW:=4SLO2$>W&V._2M-G(AN9\6AKJ M=UQ.5C.QRUL2S8]3C 7U5*'FD2&(_W?'>)'NNM98 MI^#[-&'NEDY9:8]#;T MUKC8R+;02/\W-_PKF=K0)QIFF$<2!5AI.4YBZ?V*Z6(US_>L.=/D^$JV[/), M:*!G2K;20+O4/7G/N//GS*^WMN&PNWG0F6WRA?!$C6^FT7;RU W'N_#F8 M51>C)F/Q[K>"B[!#^44'.K.BY[:N^%-<==%@:)#!QHOK[6C?@$]!2)>"\DK$ MCK%UYWLF!R%=PBA;H"0PFPLB_8TW5'Z.%(ZV$, 2*7 M*7E[35U0SVX_DU%Y"L*[%4\@3%;3V:+NW[#'*X[2I>;C-AR=$+N/T,]['XS0 MZ.GWA$M7#,^>,>WE*6.%4S;Y'63,+R@%^!C>4P]'6@^CWEUUF9IOE]2%\.SW M;N1%-]M;\D73%8L+?_/%>_2]K;=V_3CI,^;YC[?!SEN3 =4]_AZ_WS7?WGD4 M28.X.49.^? [&RV3#6+&+RGARCBR6R@*/%'.%*5-EP&1DIPO\R-NPYOR!?]W19J /)9/A M0UT\A4V$V2*98*5L4($/O2$XY81*K"SH$3"\79P![&(L1O2'1RDT]#2R-1$A MBF^VZ=6$']GM _>AZT?TAA/^:Z6H($$-.C)TBZC2O' U:HL.!EGRNGJ FT_FR!9IVIN>^:C;F89NS MK6I:M2=_7@;[!\]WDUR?9W@&_BT.2308=WQT*1( F).12WZ0.)N-YQ4,%AB< M54:&!1ZPB!S "+P,J4C,!C2J.+((G=*&LARM'15^?2C9B5WURNC5=-X/PN#5 M@\.;Y61!W59XV-=L6LH2%9A?T\?(HN/&/RC_B5/$1" (YBY$7104B1 M!BMVB6MPB+>[X!M[^YG;)[U@ +%_Q &*\&Z'0THEK<<,#5=7 GSO7H']FCU+ M[4K8HX0_S$6'4'9K[3MR5JCH9168N2,6'!!D841[D,W*+[5]!$N&BA^\B#:J M.X2XN+I2W"1?S M\;!CZT)%7B:>-7-T0)OS5G7TXE;>E&Z=VVG79J=3'&^W0'RHP7?3![)O)%X7 M] YO#FORN.@"7//\3WJDWJ&]9Q7O?QF!?,E8/,_B7^7+VI;>DE11[LKSO%MV2 MOP_N[UW\3SJ]=2BGM+W@&?5>HBH<47@1#*LC^=WSOKG3UC"\ M3G25*U- H5/XW%D,&DHSF4Y_0:NO>9,F\L&.EF3N@QU,@9D1= ZU5%4V_:D' MM2M_@[>>[\7XVGNA_XR)&WG9NP9]P M^H%/7,$X+*^3#7J*]5ULDC=LR ,JH;/)O"S"M=KA-(.:H"1N>+.?>D K_,2 MRQ:YG6A0*_Q$H01KLJKVU],;U@H_//W UM_$:64PJZXH;@S2:UC9QLE;"7<" MW X5\*J?PY*0UW719.LKL,&GS]V-\UH/OB)!&_N0]-72Z:LE((Y;;[+LM(V6 M,II+-$W/OX-TVOK13O>Y0=,%Z*4N$MOB$\F\[12A!) A +ZRFD,X^B-Y1O' MR#\V)W][T<,Q2CB9$I^#GVB0'BVF\_'YY56K0D;J$(2NGQ4*U)76AK=[\D0' MXHJ/0&"NP%_V@R\FB\5X7D =HP&(N_XZC$WJT(V]_HJ4T(>6OXSGEW^:CI;Q M9&0'_ 1(* &PJKD^"'X+.@"8/0 "OY2[]"!H.5XLBRF/4("$7D_YQ^;DEX!= M3R7**6^\(EGO3Y>_6@*XJM^7X5;2&&+&EAP>I7_0BI,7=T>@$EW$EVX8OGK^ MXY]HV[2&R83TTH"GF?,\P5723*HH\/^^W83^0VSV^&\\M MMH2"]:==\.TSL0?Y*]V99,UJB>"?/-_UU_3OZ]A[88OW>1N\CI7SH\D:AO\Q MLJK1H<^M:,'FBYYD^!2%A\W @?D*_R,WVT\'?5 L M9-X 6%)I$4=Z19O\.9MF:RQ/_'#=-@C1ID"4CKRWE*SA5@A:=G4_Z6;B3^E)!+-A+(*Z[A=-D&9,"QQ'ZV2HZB2L83;Z%*E%"I6'Q #]W3H M?PA?F4CWM)2F_/B+H0\D.YD3,;58"1DDO=B5&$!S6;H-%Z#+CS>0M2?'J# VJ4+' MB.\8/1@P/[@O9'1'^QCZP:L%&W%"Y\]'<75]]6&N?>.[_ 0(YI1W75?D;XMI M"7. F]_'J# VJ8($YOKJP3#WFQO^U3+(M6Q^U]4%&20&^[T7[]D>D)_W4ELW M'[-H>\/D0+%9#/F!U'PU2W=/&. MD+$A8[+(^]=BM'+J>#E# MA#(*0L1I\Z)(6H2#&'EP%&G2NXBKB.O][";7#%N"K"Y7;BYPQQ>I9 IY=RS;#Q&G4# M@TS9WUKA4C"&%5"Y.<113":C9&8F^SV+KT""IB"'?$R>C<>3-N04B%H"G_YJ M-F,H:-<2#$@";VQ%4]4VP)!J/596?0P&.FHG9J;SY70N@@LC8TV>Z:-4#1SH MW?_^:33.ISMGR!F=C4;LO$8[?]!8^=LNAR?C>:S)!>QQ;S5V6BU.)LNG"*X M:"E@L$6?\$-X<,-7Y*PHU?&V8H F(T9G M!KZR+W+\!L0"'T(*]L\A?L)^Y+W@*W\=[/%G'-]L[]WOS?[5^(99[#:)H>3Q M^6PK)XNERT JU6HV@J]O#9ZCS>$ R'[B/FAY!NGFGQQ8U?379R[Y@O"&D7 M2*':>S;/2D12FC1[4*+)05D4//-K3GULNG1?KYKCBIH)T?3@(2=+B[I ZDJT MJNJT?M&H\$D!*T_D@%BH19$PT? Q@K5>4?Z$_"VKX@032L2MF? N4_&HF M&S&^!5;%"V4U):/%M\"Z6*&LJFRD$.MJ09S(@2@9)1(3PLCH7+[(6>'>I.EHF6(F8E/TE ;4?/P(/9RB'I$[U(TO+SA\" 948YS< M!D@["JR[M#&WA"#R__*J04UG**#2HL#TGM.6+U1ZS#!8B[P5_,/)3V%$2:UG M2@6H.<]QNLS+KLXUPBT:F?1WD1M5/;ZFNPT^WUDQWO X( ;4FZJOIJM9$Q8L MJ/C6HIXC5@^VE4R'L[4A!+XD.\0;+_[DKNG-#Z\7W[W&_%!_T"0Z:MP5:L-& MJW&""T8%I60(* @A*$ [43T*!@*5-N#3/)J MZZK7P+8\.5XK,19LZ'K2XES->-#2^23"ZY\>@Y>?-]BC8)C2OU ,3 L8(#_Z MX_(0TNWF3UZT=G?_C=WPH[_YX,;5G8361PU@H(V_O+SH;$@XV04"YUV ,D.B4!!B+U'_][]GHS]4P?C-&D12SH21^\2N@.UQNW,)5JU97!*M?1X 4],E$WF MXZ")13%*9^WI9=0E>M"G M1[7IZ/34T1RB.MVPC*9VP^C9MWV-@]_(R) DPP\X(JC]-0P.S]>[=4M'H(Y7 MC._:MLNCL,4W':5E'H0D2F@B3A0QJHB0A6HCI%7-,;":'=NV6G5U4EU35>%; M#\FA+M^CE; '1&+]@!]BZ:XI#0\;3*=B"53:.J;%49223>U.M&CFJ&MF*G6V M.UHQ:[98 AXA]_A[_)YP^ZO49\R?!L-()H+""AM7/@$H&]^U[ P)'C2,B#)W>7\93Q=%,.1D M0'>&CM;(4=/()!;$#E6%@4![> 1\"O'?#MA?O]YL>0V>MR8!AOY&ZCNVO Z& MEF:9%&Y^&:>W@%8\[@QEY&G!5LH )1QLP)8V_1GB[O S?QEY/A'DQ=W9@[9N MYVW&8(>5X)%Y1F(^(*!,#0V2:50ME,=L-=#9\I M T0YG*7MMG(F-D!4HQ$82"]\_^#N.$*IZB'0IEA_3VX&:J>MX*%Z[?GX*L9[ MN;%D_C08"#,1%)QM/%XUC"HI-<3(63&V[*N<>(#9H1P,HFH.UPR?LC7@L?+9 MW>/6=-HSP;)U['ZSN=BP%N?O@(%80!DC* M4RT[YU=MMYZ)G@2#C]H]8).ILTHRSY?U$]X<=I@N5%P'_N,Y\><]JD I@KWX M['A5'3VJPF"I\>ZS)KMH*<#X@-=L#_?&Q_??@ONGX!"Y]#;?;8RQWUR$(?.: MZ4(,"9FD=^XGB\EHQ8LQ4K+LSC%Z!U)*&26D@0HR]*L[MD#=]L(,_3H[Q^ML MI&1# :=9V8:LM88,),0!>D62\GN6A)*24+*.MEPXT^FL,Y8DM.T*)L"-@TWAPT9' M]B()%'I0.LML68E30@FI,Y00@QK':U#,*2D6_!@>6(6L/);#4>B7%C5T6E7H6=XQ0&0IELS:6,K2S WF=B )6L5'@>#FNY M$"K]D2>+IMR4T[,"6;W5$V:H,^3SOM<)3?0/0]:B6^.BP>J7>\8WZ&V"Z0]+1A/'72J\*KSD3^S*@F/?X,MVK4K*4X MZQ:H)GLY(%-!K9H*@X/@>P)._^1 6)CZ21@(,L?>N]\OH@C'T6</YHCH+I*?5.<'L%@9Z7P8+9>ABMPN^N<0W+)DD'J]\&6KT]+J; M*&]A#FYQ4E$6;K*.+3B3'M VO 2,MAYCO]EX/%_U!)PM(U\M)FB&G;TCX';7 M[0+@46/A@3"8^5GF9K+?7O F)!KKXLA/QQ;3U;(%D@(L6H*_HY5F(,SU<]OT M P-;LX^V(J[!.)JFH,]!Y+%&E3?Q$PXY1_&\0/BD^>FF2 QI;UF-EN-L"Y)3 M8NU% THK"=S&IY8:-!J7-"*D$*.50!]D&JE!*Z?U.[$$"SAO;$-.8;;8: >8 MO/E,YMX>#R?^YF)/QR1_%Z%-Y@VC>;)1#)7QVB);C$[1; M1]-8(%J''K_*;/N;YWO[P_X._^W@A9C56P;O\1?",MIZ>//^]>/^>1>\8OPI M""\V&[;^Y>[N@TT%0QDK&:%C1UC/@PX M:!PVQ!:&G0-^4CW9AHBR)@^SD?%VZZV)BU[YT2&D$]S+G>OMHP^8#;OJ1U)Z M$#">%U2DD]]3(Z-Z)PGV*0,^+TI8T$-2G =:,R9D")1R,1VY![3 N&P!-M]- M+9#Q0)P)RKE Q-8!K>!(^<%SL//6K]P="MX %P/[ #\/;,KV!)EF9Y57-UMZ MI3CV(Q8I6 M9&E"C.&+Q],&-\"8Y ]AU=]&11$U.UH^25*5;XBJ=S^?U>V34 M4.2)$J:(<3WC@ZQSQC@])PM_9Y)1@SF#&\S8+%H+S$H3[>,_A)[143*^H!=( M^;$7OU[Y9&B[YPL XC A_Y[QL9"$4-(^/)\O5^D0**'+\C^GC JDAT9U\\A' MO[YC"_3M&.CH5]HY7FDS(QH%L.8#&5E[#7\O4"H*OXN%5[%](C^K[@.V/VOH M9J!& 11:9\[&\PJBDAMTDJNR&3WS5P/I4LWIHYJ)NX$Z'2V]'*C=$J8106\G MDL-#_B0(&C+V"HV4QY.1& OL-BDKD-!7+2$.VM4RCX*:+W2HJL_7M3?G\?>$;,N' M8;\V[-^4IT('(/*WBEM3 G"^W$-\1TI\DWY;=(NJNV8*0JPU?G1#W_,?(X(9 MMC+1L8K8^+C!]<$F&13R^VJJEG:NVMR^V*JVJM M!K$!,^_=R%M+?DW^+"!:F *;>OGTU435,X0(V8'3/KHQ3 RG X2A6M:O@Z_ MR0;'Z-TNB*(?TQM(G\EW*M8MH'/TT*0K%.Y+T&D#?6X8:Q!_00:8WNX0XXUB MTFQZ&SHJU$62]\3Q.#U V1@GV!9SPL"Z+*O' R)[ZX9"C,[4!PR /YB'?*: M7;@3BPVVL@&=B5R27SY]&A!]B0@J"[7.N!EM"3D[@-5/MV27>3@]>N3FGE]) M/CMOFO6%BA(5*+5%A:)Y;(@"7;C9?-D%ORR1ET:%E/K M50ZAKN)G*."T7N'8;I/C%RO7M+U]^$JQ,TG_06$S*< F^?$?'R^K^_'Y+PP M(>>FT(EM/$^7;RY_O_APX8*&OR'Q)9GUP-[3.?+OU=IX;8]@>IC4O8"4& M90U!HGE25/X%AR_>&J?C3E9.GM55?0[\%QS1(>@W-]Q$[-16\?>TX.IS$/\W MCI,^.W]G5UVQ[>"PT'IGW!2[S IA,N\8U4PEU*?%%=G!ET3$4B5A40IVR)++ MB;B@9^6*1"HF>29&KV00EDN:WGC"3GT4I 5*DS9_$!:X_HR]QR?"^]PE8V?W M$0.VWH(-$J5,;OZSO:EHG%/B+[%3[O=/KG_#3A\U7?\')\];B-%=2LI'A^5\ M/M,=KD61NDB,OY1TJ(B)U"@1^XT%;LU?B<7PW_TPHT]7'W*KKVF2#)/:_3A M?N"?)U\I*AB_](X;AH0SYC7]C^3OT(L7T%'*2&:0\@O0)!&3F2P71GA?2??S M$$&V*H3*=KM3"X*46A*7@&[FT*V@(U#PRJ>W!GLO&-T2&J 366DG%&)4:)OA MB\9XZ?XEL6'H[J[\#?[^'_A54 HE?LY0&9F0N4I!UFR2H(,?OT@H(48*$5KF M2\MTJ.2HJF2BW*S5H=*ZLV;MC7D\;PE 4<>R671SB*/8]3>>_]C\N=I>,HN% M%DD4E@1GLWD9&,E2-J6;#'G),#HZ1ZIK$$,2+EH!5)>93*%+>!=X M[==&$:-X%_9T-!F/2]B N=S[2 4<207,>77]MFZABJ8\]9.WP^$EF7(^!F'S MN*?\E%&_+;%6BG6+DOLR.B@E!.7$QVCC*&ECSJ.%+E1V[+K:IOS[#C]ZM#;* MCS^[>]&Q$.%C1CV\S%O>*5;CV:SDXCDA1"E!^?A1^CAJ^ICSLQBCC2BAA;MQ&Z36FQIJXP MG']?[MPHNMG>A]B-#N$K&_5?>SZ^BO&^<=-*XDWC2&@51ZG4L02/,\0(T^Y M*>EDS? KI8X8>5#DZ%3(Z?!0 B*- M+QG'2I,D\E':F8R230A.A6Y9G[%QO16@T:2@HZR@6?1TN6$=1JV&L0-/U-+9 M%OP])K /W?#U:O_L>B']G?2'[R0$BKLNZ12N65AFYQ5XH.=L4-%Q"\4]&2^4 M,[,%JYJ-PO&;O4W'D%[&A_P5?7%]',)>/=$? .WHEC*E18C_1KY$].0]W^*0 MUD"XCTTWQLF_#X_ONE#R&6BYR X -\,Z98!R#E9A^6@#, CG:GH^D800MQ"Q MS0XL =0&.]F#S_8UF/K3X-B37W*8C59.!]*@2F&U:%:< ^ZY9GD6M ](+8LE M8DM8!)(+?_/O 8E1?R+_.!"7D%JUEZ<"#ZHFT51:04ZG'6!C?2T8&Y3RL61W M8"A[.)KM 8S@+AA((+O5L!8A/N]0WWD\7IX /,X%4BEL_^Z#M_-B#T>_L0T:O+GQ[S"];MWS'\D#GP-Z M (C_DW;QB;KV+/7R,!@HM JNDAYG24-L*@"[,QV?)?%-*D#85)3D6H0(!>#F?XO=ZKQ[MZMWP>HG_Z)Q3DFM$(% MT60^KL:X%'@L29ZU0>\KXW;"(:R/M9P!K'5*T:D$.]V1*?\@H%'I_6OVUW_S MR* X7#^]7N,7\J&^>YW#J_:7(>))JT0J9^7F@@%11A%]I>2@HX%.76LC%1E= MC6-9REF%0.VV%3 *"['U$[WX&?OK5SD(-KX)@[\F<53:0\^3G8("+901LP5\ MFA1U^B@*@+PN!VV 7:N50#%WY3\?^-(([1MW5[_J1^8-"(S5Q9 /]HO5JCX* MY@3/4$H2W1F_!DB_DGE&>V%*NE%TV),I]B95,@2Z&$C!$868:K",!5AB"77< MVCVE[0TX+!7%4 C?SK2&I;,,3(PF&@/W4=&G*,.3C%) ^!$Y7PM^:I:P 3^! M_WB/P_T=D=FGESGI]V!_8]0$7^R",O;^S M!O;-7UF5D%E\*4HG[YZSV7*208]P.6=L4,XGJ6P]0P56J,A++RY7W!P^?J2, M.I YL%6F?&,DBGXI*>]V*&\0N#V]OX+I/F:T#.[O7W]S_Q*$K!U4>[*4IF ' MP*MBJ;1@28_EMB,;/;PBQB/I% :<;0 M0.:OV8%>)HO">?/I9"R7C!EAZS#:1UT&S,M#% =['/(;G^BM04_>,^S<4M(O M)?&66\8RD%UW';B3>=4.L%VKG^5:+E8+J1QIP6DW_8K+Y$1KSJ0IN+ D)J_A M3Y U"Y>GY\[VB*I4[$"K2#2%-K>KM U&5Z8LCN@L:+ XK$4D$*UH$0OPW08% M2:@WFM8RU'_&3;UN.EZR ]-$$I7F2K*#74)V&+#2ZRU[@E5=U3E5E;Q6U]!2 MW!6<41)FJ5'L0U5')RG)EZU!F7*?I.EDOAQ)HPV\7=0@VDLEQV[M[4!F6T\H M!>O9A=3?([P][*Z];6-=O,RK5J TET=IXUUF-GJ&.'%$J=N&S]YZ\_O N6([ M0MC2K%AW43GD5>P"@;M?@V#SS=LU?=/LUP;QD_)4&DHENQKINS (Z"FYTR6Y M*0^O.D/1BTNZ07KJA5]+8'G#LXXAG1H- )^7$DSAN,)L,BH#@W5OJ:_H%?L$ M @_SAC2%H],4IE&IY/@BZ,I;%!+?\MT_V]X P.Y1?2P7L_FB@E2K>G?J4]*Z M;"?9;+/+ I"8R:^@N&[>'F]X& I90D4+B!932L@.2M MKM>N02_30!%[F0@C CN P./@TJMF,8ZN_ W>^][66_-* I(*_^R&])<>YJ7= MY,^FCZM(Q22@U$13*8^:)/^_X=WF4Q#^'C6M)\J]:Q#E4@+)KWNO9K-DM:1\C1=KKL%7%Y.I$*5^ MO@W"\T,$M*8XA.JU&\Q\UEV#+3!N:.,HX-TW)=\M@E/>6,"0#,D8^CF(W%U- M3IXWNB9^O4C! %9:/H7#0\O1JH[?$*6EJ]_=^JT%:U DH^_#O:83D8_$4$O S)* M]0^>_WCSC$,^?GV/R4 '\^?NW>\X^O@]#MT@W'@^O>.3EH1^)HJ3-XD1B'R/ M5\FUB4WA;4".)E/9<&K(!_/%:))BDK%![ZA /R+J="B7">5"H09W*= MH9)DO'[Y#)6%0U#_RNXC)[S#TOF#LQIL?_%;O?$?[^C'WQI,!8*AT> MTJ6,._"7.9&H^)OG!Z$7OZ:RLSVE(A6UJTY-2F!WU.RKE@*L5U.G7Q1MO'+N M[!\AP!KZ,H* B[G=/9]M >"(SNS<[=;;>6Z,V3KCR8?D8^/)D2'ZJ&\+'[*/ M";;6A4D=,!HU!CC+KJ$>0O7BC;=9S!A$O1<)>1^A,30 ML9%54Z17/C>U0]?.!C[>])9=P>&GCM,=J,[$VQ-G*)>&KHJD\C B M[YA(/Z),**NBG2G3\@/4/WWY"9U$/#D:E!*!Z#C3@T8PR>K(IL!SV8E';33NR);&,']M))8W)MM?0'K[X'BKJ*, I+#?/EN!5R MV>MZMVL -%R2Z+_WCI/GNQN^LNJ)4E M (JO)JE4+N>8MR\592Q0PL.&A85K31[Y5#$?3ZN#T@I0V? LH0XT(AU2 M=98EN9+K1$D+VB0IN&L'$L4&L@.#MR%^=KU-4L,@_=$KKX%BKRR+@O--%DXK M[A+":<&0/9 [3N,I;RO(=;-S$5?LE>TP$QC%#HC=89)YO37YRI=N]"3]D2NO M@4*L+(N"P\V6[9LE.6%$*=L#L>,T9A"[PSNF<;!%8:[FFI!#3WA'#]V)W;<>>P%I:5W0WM^XK725-FZ"V+9?5GH5:L:T*(NM$B]5JLG+**[0; M6F3""E&_)=2 UF*/5&I<5BHAEC6W-=P.3:-B3OO7 E]0;4)0;0%5: >P1,J MMKL,]OO __)$>QU?Q"32/!QB6AUQ'["?O2^(?4&E?L0=?2J.)6PZ&1\EK4)7 MR\EB6H HYXHX6\3YHB)C% ?H@[<[Q-X+1A^W6[QFA?+LR?.'$L*+ @$N+IDT M)-^_3R0_Q=QRN/3Y4B.)@_5<4/+/"0 M0XCC]!B;U:-KV'"<,HZ2,H:&"@UP*(P11$K## Z:+IKJ/K[2_:;1]-XICL(% M2.-5MK_:=N^8!>=:=&OM"+6&S9_2+EI.D'*FL0%UGW'\\?MZ=]AX_F/'39]2 MKP+B3B2/0G'L>#%O !Z_WOE=1AREU,'.QVM7O(H]X$*B/M[:AL!&"]D*P)E$'O#G,45]F6OHT5K1P$$*A NF:RA:@ M]@-^:$F]M2?AT$O9*]PE/\EKY\L(/D.4DA4X[J$2P_+G(,;90>XS*5 # :'H M72U@R RA::4T*6&^#'8[O*8KE?_A-1VD$3]J?M54*(?T88G59#[/CLDDI,[0 M.B.&_NH!'(C1H=.XI!/*:2%*#&0M58=:O,:W_'T UU); 5-846U6'2:5)?+D MRTZ=L\GF-XRFMD8Q5+;M\G*E%![%=5/P2:$N'9V>.IK+>9UN6,Y][8:Q!$G= M6Q,MK\!BJ<>R_&K6#B8+-B&TJ5G&DV7(Z=ANZ# "*'8^>;X7/>$-7:!I+N<1 M/@R!EY($"M.0Q6A10*04K<")T,2%" MZMJ#8N,S[AR2T4<@<$#XJFPAY=T],N__+-XZ,NCKZCHX%1T:MK^.UZ'[$KK> M.LR+"YLVI;."MPO!F:H*"LD[]]MO+G$QS]UU9JO2LQ @+0J@TD)\YM302DBA MC)8=J>H([1B.J4K[E( 5"! YEQ *-=5!,?$G=W=@BW1W.,+A2TNOB\87(-!1 MDT*AY>XT[]&83GPRL:)DK$"*XU.)P2,V!*@J/ES$/Z5 M'FD,UCCJ1$SY80BTE"10F!BL9I-:,J&T^.E;1LV.='*,@BR?4 +GGG_^S$E8 M@1*ADPD14E=?V[9201;6+/>V->K,M M%"$W;28<11-BH^H8@:4+SZ>3U6*5[V@E/%D[%'^#W(0M/=.3W?\9(3?EC%S& MFAY1\9*R]1WA#K #9M!8XZJQKGS6&RYEB^X#E#-&&6?$6:.;+2K6^ /MK1DT M6.E8 _6/Q&U -^)TA)C2CMW1!H6+GNSLAOO=VQ_VVMRE2/,DHF=!8.E-9F>T M7(UU1$^&BCWG?@K1L[^Q-$1/=C(JX7XJT;._P5CT9"I_<7T$"['^FG^O*CV)WM^,756HF(PSFNO%R4DQG3:K*CAA"=28(*HIS4<%>3+5GT_D^15T7H M&8>IPYU6I.X*9\>%[5;+0RW =6EQ2?[W&(3>W[NOH^]%S/ "GKJ$\L4QD]E\ M48\Q2:R^*,3J0HPI\P.^X]Z >9R!S&-R.;$_9*K+C3W-?1JQHGRS^='.EI"S M.EZHWET_GBV.CA@M5]O;&#-ZF>C(J-%B(GOC1AD^QT6.@M'[QXX(KW]Z#%Y^ MWF"/AHTI_0N-%M-"M" _^N.:#'IV'_W8BU\%PP71$P8P+6"KDKG2U7%& G$: M(,GZ>#T+NU"';U(6(O\Q.7YS8_IE".;XQ=>/V%][!'@=I>YR[QK, M;%("J<3HY;R(CX0R"]$EVA;4P0^A>@%2;-<8TV/VH+O>2MY:S"WRYH$!(17L M9GL9$A/'PC9VK8\:A5B=O[Q;S9S)*$44I4.7\#@EH#9P&M5*CB[N]U[,%\^X MAI =X63\JXR2!BN @*+SCEJ@JVA[W;PZGZ^2YH>#7RG;55G>7_Y"8?FN70MC MGMU^0ZP-%\$69""9YPOM#/L4[#8D(GW\V\&KM4&7?@W&XX6R*+G1K 8#-J#B ME("BOU[]'"%,F)91@?8_H0W>>FL/M+^:K',4O/3K%D&O1_^P MI3-O@R#X"?F!5.:SF:N+]U?75_=7'[^@B\\?T)?[F\O_^+>;ZP\?[[[\$_KP M\=/5Y=6]S7AL.T&O9#A@?"97:76[0/H@#.82[O()8#&=3VKH.DOO?0,?\/73 MIS#N2^]VLV_\5_&H!F 4#6 '!.234O4%4$BH1^&5XZR:H6%3VCE.1;X0D&C5 M,=N#PXED(A&9 A@WGXFZJM 1O .#GKH@2LM,8P& AH19W\0E'[0-3L M@PTX:C '))1>/P7A[T3I,'8]_][]?AM$'KNP1FYLUODZ ,"Z9%*8R*]&E86* M5[0-0I111X0\RN@//,*3Q9UF_1D$VO:S?/B,<3\]J-KS\=7,=X+>V^V/&VZ.+Q9%.DS$7-G-$G.*R;44$X.?:4$ M$:-H^!XC;:J-H51KKZ'6II_34S\CU=#=R,I*FSL,,@S0[VDG8JG/PY\$!S@3 M0[ID?K*3G@+/) M>%2&"MTE3,FAA![4C%>/>B6D?,*@G:\Z_:P\C6TS "!,Y, !"(D>GC*;CTM ML,/Y>RI2='D.Z3!X=7VZ#O8#Z=2]27F,3OD.I04 EH"M)6#U_,<\T;;7 M'3<^;QS B%4;L]S2L,_>DM><0 (6X6L23_Q\,^.4N0NOZN#IFB9]6TS^ MW.7I-./5?)U\]TOFIX =$DEZ$#60,\O6=+;XDA!%F2O1LXE2[C3D'%"OIF-H M3;NFA'K5=83JNM+J&IHN2H*R,&N4,1-,HO5Q>J+BD[MF.T\?<+0.O6]:1Z QMVM4SEX.E M7+*1=X&TU( R28^^1C6\O79+ FQLR M"1XTBLHJ=X7JT-4J6T9*J2!*!K0_TM$:.6H:F4--DT.5L2'4'AX!]X1=:ZNA MQL?!T)#+(.]!R^5TUH )T Y FC038\."QCU=SM:,D8HM0) 2^(\T:]/[L?/" MVJ8O*7[8)$J$$BC> M8.%TA%I.JA:]#X"^/X@F+SA\" ;795Q3AEV;2M>6TG-IST$(ONC9 AM1#*@9 M! ;K453J57;=<')$X@6CN&^20G[ZM)AG;2H(M6J_O6NHPQ7:571ZJF@.-UTN M6$9/JUFLP)#H4$;'PY#84:KTGT\GB\FR&3<0!QBT:M8(%[@S#'*.UHJ2OB<9 M]"#D-S?\*XZI"%_P.ED]:#\#W/:&0:RTB*%PO>=DD@PS?BDY% MQ2BC!U/PJ4\S.XH_)5!4C %=ZFNI;N-,WKL1YNV@;MANO;C24^(%TU5MK=)( MGV.=S">S":]HXP31 Z7(>_&A@-,T?)))IV:%V(481<1(HH0F9/6:3C6=FIHR M"AJI5Y."65:KUFT4W=C_$X[H6(,,.3:LQ8%*&&A_%S BM HF[5MC8KA%,3B< M\^#PPJFC=4H>/E#H5+@>,Q+J*"-O6?S0J7TAE)P?H[WIX"*%8U&II## M-A]?;W'H!9N;+>'W@L/8(X.<6Z*0%T5!^$H7UL3?6O9E\T%'4C(E-URF48<3 MI[<+$NILU32G3_OM) R03S@8CS[#:#XN:,KEX4&"O<=C1/.Y.EA;JP MA]:.4<.15U5;/9G3\RG9?R=XBC;>FF8B=\EM69X?'4)ZD1]Z#G;>^A6M=ZZW1QN\.:Q9KH#+?-V@RW-=AZU MLAN7J3V[E9XQF=V*C%4V>:;C,EJ L]L1:CBR:AC+;B*'*66WFK8ZLQL9)ZYI M)GFDP\.'I*;S9GN'W9WW=[RY=[^_QS[>>O&-_P7'\8[5=;8$KG[T@/)C+V'E M&[RM\C7NQ.&>,X9T$IERI%..,.')&KH^<*XH\%&4\87)LR9,5 HM.4-4X$@G MHBE/UN4WX8IN?)3SA11]1'4$08 M4 =V&8N"AQN.?$/I/DYUI]33VULC1.DCRH#&.,ZB$ 0!0MI0^K/XE2C(OO5S MJY9&(I(R?+/PHV8EB*E(+N&+1V9V[U]_C_#FRO_D^63F1QOXD!G3"[^9JOTT M20]"!BQ'$K4R((@D ME5]/6$TF\][!X0SES%'.':;LSZC%YJ4AX($;21@U3B-HM&&H7P!I-+)%P80? MQ],PBF@C!!\T6J13N#IK/I,;163<3F 4H<\RPE&$EYG"[E&$! XD@D"7,>T& M_O&C"%FB5@:$(W/B*+WQ#A6?,PCUGK-"Y8389Y>CE%- [2N-'=!''H?=PX,<$XP#=NG#G M'X]1STG5>[=C>D%>;W&,'EG(2+[/5:,>!D-#'1$5I%?4!0=N]Y*!X%DH(*M/ M;^?3F:,&:!MF^T=KS#%^V-,D$830L_9F;VL$AP5S[V\7ZS4M9"39EJ1FG_QU MS5OJW;*"3?[_ILL0>Y,Q"BTUV>3CL[/*4?<-Y4Q0F,VF@<6M?W)WB8A%)J]SYJM0Z_!)9Y$1WNUP"-6X])@/XN1?).M8^AQZ_MI[SHX: MHN 01['KT^[JL!!O[U=J19_2HA#MG>-$3P+!6+79V'2Q&D^%#8E!.\0=KQ(O MBBBWZJ7%\7Y'?V(("+1T5&LRA)ZS%P7BS7V3!$\9/TU1$T&Z='ZZ&LV2KB0E M!P>ZZ?-H3>I0A>QE=+0ZCIHZ9LXT-,(B/[P@UALL3=WQ@^>-5V]6'C*=G#+. M"DTP1\M27LI( ":DOFHD"X?)R[3.QJHL5'.>6@(J*ZXG]QPH:FZV'_#.(R-C M=A/%IR!,KI"_P^O@T:?G#X511_9=XWE*4C#I(#ERQN.DAPBG38SI>A&#]BWY0FV?6N)MJ,C3+9IT[EJ.9Y-)-?;@ MA'[2:)CW%5T76*!G0A8H_&A7OA* 4OI)+V+>9;/( E$>@#%(NP&_I5R*+D?7W;Y11FA'."$ORTU 860@4U1B M2\:E&%W(WQ%CA"@G= 6TB6_"'+QITH9?$>#N"JY!OKX=D4@5^+7PI&0ZD#V* M1- [3'=B^?U0CZ+QC,0+)O_42;;\;FI5F.S, M#PQ(CM?)*10Q9YI!'MP[7J6YZ#-!8KP%(D5P-VD.@VHZ)KGR-_@[WMP'[$!) M&'W\V\&+7_G_+[Y[S4"7>MDH]F4D4CISDX4#MK:]IGH;R9BBSC8(:1/]_*+ZB\U?#E%,%WH^X_AF>^]^O^7'1HJ=1NX#WF>DS0<& MY&H:I<.I(@^,^6JU*N*])%-Y@>@,9=*=$_'.V2T)N8 HEY"$"QS3I4HB)6UD MP<\'&6P2]1Q$1*:7[N1JS2>8L%3]NY_=CT,;4-&JG#V[DSE9[#6;-Y@!#CFJ_MHZ73"-(2V>S>2F7 O1ODTJ+NE0M9#L+VK?).6$-2?8U MOD9@U@I,5;H?[M<)B6L"0'@J]*/4<.15<.4YPL=INCH=6UA M_)H7YGX*PN+MH/R*CK:J48D7C2*@2QJ%(LOE?)+"@E-EA\#?W18O $ZON!F@ MH'3%U?7Q(_&033M@=&L]96H349_<"$?L/(EPP='U-\EPST;3BS#H;)!&9=*PG G0F=.E3LLI\Z/C M%H!3D](,G/$=[X&@+DF612<;[ER*HB+ Y1013G9,\0(0XT=M:J;7_^.TFR(+AY# MC/E^)K]ZJ>$TM8EM(MU?-[O6TH8PTH4Z41!I-805(82,+]\T+F0H$(,-*HU0*0\_)+)8)7WK M$A+H6T+#\&GKXS0H1@"4T@ X)'V<%H[H.X =>VYP^^Q4LTA7/7C#(;V[QWVD M^XUTRD+^_/+DDJ]UL[W)&Z/S'PF_@A(!XUA5D4ZZH<=R.4N;L>0,Z.%%QH'V M5(@809H4"MWEDY^:!ON )AA73)!RH+T4.$':;J' )?DI1+08T PLEEP5/O^: MKVOPJ7_1 YXS*>!"31_$YX%(V8R:PU2)3;(&P9AE0['?_0T.[S']_\UV*^[? M?A0]N""F+JQTDS+RIS.OQ;1* $O]FD,[6]-"!\H/Q8PM>8?P!0MR@YNH&O,J M 2Y=TN0FRN<'C"OB;!'C"QH$!S>3T\>3-@)/LB!0]H\Y@KC9T_*ZPN@V"/>?%(B?;!1OHQ]#"2!T]A!3>BHQ&RV=618T4TYL M_L_WXY)VL"^<&_'ZA!T*.#_S87)X5M =.N*&,'4KX05[;8<0V MCLA5.*_S8VQC*B >$3V*H;"OH74'0<:6;6&I!+RFMP"#6X-(TMXY&:\FXWH@ MX]$KF<9 1RP].M:B$X<=[UYN5QC2HW MY'"%;8PJ'7 419 V&X%L)^6B\5%= M>R5BP],F-XK$(LB7]3FCJ5-'53+_ 2Y4U*);#4 2NAG;X&EWM])N3HLQ=.55 M+]A\"L(/P>$AWAYV-]ODLO2(7A#OO=#BM \'3(NV+G=>?4>U+Q6 O*LHHO3< M>30:CY99'B9<6-'4)N%#)]%NPHE>(H MY4.77E).*&>%""]$F2'.#2:)#VL2IV 2>A-2:A'J+1(> IGL>\:(8O+O8UN0 MP0#YEI_=/6YI65AZQ&3:+_"5SX>K^2QI,T/?1Y0 :)O!([1P9+4PELH%SE+* MWU5=(3VZM=%?Y2$ KU9M7+>8+R4)E7?MJ#)GMAQ1/X-W#3OEM#" M89A,*F_=\";\$M,JLS^YNP,FR8<-GIN^FMS+)A$A)9%"(];9*CFFF5'F:R=G MM'D!(L,/3AXQ^H@PX-,E(!0-H;U3UC[BVC\3[5\H55"4*3EO"7WREM(S62SS M2[:^[KS')_&LL.5QX]._9EFD1_&SQ8)XTD2 H[R.G5$T/)73IIHH1)A0K6-> MIDT_WKX>A_ODYEE*@E9#)SO9K-:G'"+@YES=4,LG5QT&@L_(=WB#]VRI]S;T MUFH)N>E=L'S<()!"0AJO1@WI.*>-&'&[S1VAYF&N^7.WYC"YN<.-FU-S MF^$&R,P,^A$=F[=LC;:_ 9N?J^)(Q_GI?+QFHDK&/5%04+J05!!K2-="Z\!G;+[;='&(GX*P>.5]:WZHO026HZN2 M**PS.@W@.DNW$'.J-N3D(S45SXN3"D^W55.8'-SDF,W)5V@A6Q#&KI]005?R M C"RN!3R [_1=#YK1Q6G: ^B>FG8BB:O44-())4=L M%!:O8@J!"8;;"YRV^ M!8RE@BCRP7NZ7#CM@"J0M0=5_75MA5;0KBLDO@3NV06RJI'@D<;6DZ4^,W\2 M#%&,O7S07LRF32LQC-*916FICVHBT-@#D))7-8,B5US74LFSNWZ-\?JA=76D M\A# @DA9 NEI\VI"MY/3-1!.Y/SR/=RBQU%ZC,WJT;FP<90R3DD9U*&,J<4+ M,1R*ZQ4"I8&2$NT+E;2K;;\>3_RLV<14%T#^3KGQ>#PJ.+^W00DEX'OR=*CE M%-5*&BG#]MAK^60TN-O1;'$=N'Y>+RF. M4$H4S&@X^;23+BHDS'JC !%$NA=ICTPEQ0!.,;3)!5RX= MT XLPGSRPBA&GN_%GKM#?\OL\,S[\@"FW#XH+^1C9BA,"9H^Q:%+LW%1,WKT M.Z&',H)0$4*'=D[UNTEI9RX6M(*JC/MF<\ ,R(/-81W?A%]P^.*M6\],B!XU M.ARO\U>X!F&ZR$%"Z21^Q&E%L.S$5514%3#\L)2;QJOV,4^/SYA-170CYF#V>SYW6; 1["DJ3@FU)R8;# M45W.)\A-#38!PHZX+?1GW+RDVO**600URB&_0;::K?(A7;$)>KD'.KL#%@Q( MNO1TBGJ6%3R'OE=(PA$K4&JW"A":7KR(C,P*1]S3 ^[-7[?Y%;-H:I1#85V_ M4(^2T&-G;+*V#RE),"CI4M*I*YEUB=W]$2=?2K=VMS7M'AGPZVL^F$ .%._()VY9)\]\;' )D M3!4.#TQ&R7EA]C+H FA?\1T9\4VE[9IC%'-T64,POVUMBUA\PK3OJK8(G"Z7 MRY+W@BZ8]%?!D5/!J \W-S.LZJEE8,F(WOABWQ0]87I 6&8O7\>PG(V3YK[\ M P<^-CQX.TKR KH("C(:KV9%I,64" 36^DM?0!LC HZW_JH4$#>Q!'$"UR]CKJJM1M1]"[HP MEST!@[B4O72'\]7$<4J9+?X6@*"MI^1%K'T+X)'64XT"SAQ;<%9U]@K*2IJ" MS()P4CL:W6P_!S&.;MU7025VY^,FYT<-,JC,<:C6+_ MT?,Q#H$/;$MY9QE?7:;2,_0C;,(73'NC!^$&;]CE^'&6/L+Q@>& M;=)(#U,69*"2SLL2@K0[/J.87#GXG- T/7S4J-^XI%]*,;EY,J4),;;4J*,C M\PWAAIXR8,M'HIUV 4JS<>BM26B]=",:G>@?M#+FQ=W1TF"SB0]XZZV]IJIEB1>-8J=+&OD)UYS, MN5(@<:HH)8O>%0BCA/*/4+#2K')2X93KM^%D8%$EZYYEB$F9!@9O[&P/'>8^ M^JR0[#;8>>O7>_P]?D_X_K7Q:W>]9Q1M'<+(1_?)PLDF:XPH*E ]0YPN^IK\ M21D@Q@$LE^G5W&G0'!9SDBY:AIR,80 1UU@9F/[:/'[D"^NFT^5T48()4,%_ M3\GY#2%![.Z0CUN/81ZO N4R@ KS7 7 4Z1-3BV (N2J"1?@XH&,=-UU\PBR M\A@ E/>"I?*D;^7D8B^IE1@DU)?98HYZ!<;G+KJ-R+G+NFJ9W,@;?N1-_D1 M[PF(GC.^%2 00OY@_&+I)&V],CJ%IE7#I);F5?_C51F;5:5CA?]X?9RR/F%K M/S$SB_DMX,C7\)LT!TE"3)C7CBWQ\D,F$U")L\)N\'):\O=7X#WN8]1@;OZ; MYWO[PQZYOG^@8RO(UE'MOE-*0W6]-2:AUUM>;7*+P]_]V@IDZ,Q)F0T]0(<.A);I'6@-^I3 F5!BMZY16F#YZ#B=G*9O]. ^HHC, MZ.BW0E&P [F'HQLYE10E,@9@CA(WOVIXR'R.4NR[-)_.IY-)&08@O:.TJ%'R M?!LF_D*7$:0FZ"927]P='0@R(=+>/,T]<)J>-NCM#2+(^\MLDIX88:12IS_+ M^BL!]KS1HURQX2<]YE[LU;K%L&.V#G\K(J3-&%I&<5]<'X=!RRVAY0=,C]I* MW*6/$8UGDW$R6DL(&!Z<'2/VN" VY-&28W1P9'4P,MX2^G@VSJKK"9*#UD]X M<]CAFRUKW!'BS2?:MAQ?>R]X7A'CCAA[]/6>KB'! M[_H:-Z!3-6#-5*"I5ANL2EE9CY&!XXP?>QMO=XB)T%_P^A!Z="WKX_?U[K A M"A$S7@;[YP//S3?;M$ EO;G\ON74FV8F,/%'@^0*O3S&HXD@%A5D0+D0*)4" M46='!3GH2UD!&%W(8;(DP0D^(IDW:2TZ&3 I0&S3".6&.*?KT\'&O/<',AFD M-RCDS=%(?"[\ZS(@BOJ/9$I"_A9Y&QPRC>2"W7'40:+<42++3\F=^=BIA[>4 M.2IRIP.KPK_/4"X!*HE@2U0S:<):.!O.A.:CF!9PBL/7\=_H1..6].3P> ZG M%;^49SO3T7@T5 RS:=IHVJ(\I!WV>S=\I0;]Y'HAOWJ9_JML+=II.7["1=N> M>.B2FV7J^2:6AS!-8RR;!U.*,YC%9#27C#AGE9!S,H.C/B:1&P6IF,3"B*%C M5&/+\*4Z'7SO1MZ:-M"@,TJ\86+*#U74J(%$ B41Y;U_.9L*AB#UU8DSQ!CR M'C.70=1]".Z\M?!'K-"H>*!73N" M12_\B&.&NM&!0P<)9O'K;SA^"C97_@N.8M9NI_93C#^[^[:VZD>1A DBRG*J MG*88)04@.>4S1.F ]G$WJ+RCJ#P ZGN[?@/T^YG41OQ'UV3@5,,"9@]!%G@ H170VC2!EW%G):S:,EFG"[!L_967 MKY"YP;7G/G@[MN/[&W:C0X@W-_X=W06FW3OI#")2G,+KX &">@V"*UQ1-$^O M-ROB(U\@/TMKT>BT(2!IQ*XY;NKX3<'AKKM23&XIT$H )3!U2*0VE!66Q'=6PEHQ+-%NA M-C;I;P6 >"#IZ U@E[$D+)+IV,DG7%Z3AJR*8Y".UT%0W"Z3TAJX8. +RANV%;#Q3KV7LC, M1Q&G4D1 T"HCF8K#S@1+ 1F/I.XXY6(A<@WB33@>0D3'E:0'YWV"OO\.OA A(3M(BN M,DQ="2H"^H0EBPA#6::VFJ#%,N:CB3)$Q!%#S6/A $9V+#22$+UB?R,'I_E;YQQZEE7A$3I$XI52XYLCZ.$5LCXY/,( M(ATE??Y ::.B *@H 0-1X<&T,2,3PYI!DE%#UH=.@QH2($[I 6M#Y-+PK6R, M9?Q*K8M#_!2$=.;)+F)D-U7QQ<%;XEM$M8_?<;CV(LPFZ?P:FI8+EUP9RB^+X_(A)B ;)Z8R)@LR_&Y["P>-=GP' M'E6]1]_;>FN7!,;$GK^&P>$Y2HW)C)?\AH[T/!)8N7G9]9B!SRXWH VQK[VM M)0=FAHX7*G%6TV>U,@#G6D0]=_=Z$[8I@'9*JS3Q$RSHMP3(0B D,=#B[4%# MMN-!K9@>,IO0]7FKM@V/1952&)(S-$B8X9/G7S&]0OOYB>2BW8=@[WK5CK#= MSYL,"DU"J+3T<:8)S49Y,>JXT76I[6V4 Q]GYDF[9P^VAG&3*/3"2 CMH<-B/G@1>M=0$O5 M.\>H$F\"XD@@CL()Z*4S:8)43I@,(L&'C]JU%D/-)GRUN&@;U)I,8P/J"GLE MUUTGMV5>!<2=2![YH=%XL9HV :] V893VOKU;LAR*GI#8;+-@=M V6@U&%3N M",W'7[&/0W=WX6\N-GO/]VB&IGU]V^\?E'S9*#)E))+VT=EH,=A%%"5?+D-4VG;V@C027MC3CX9UD(W4 M[IR93^8S9Z2,W CHWSZFU3/'5K8]X+P,L0;+_[DKFF% M\VO+A5K-3QN_7:M1%.E;H$?+V7B67+7%J"%.#J7TAD69*-CH56T,I5K'[5RZ M]',:]?. PX(DMO*+O-I- I/,0WK6X9:0Q"$1C&W"=*3NYC>,)NI&,10F?:-) M-MD-V0DCE!%,-BZA4[ N+9V2EO]^8'"Z=LZ!M>U*_]J5M@Y5F%#Z5@6G(6T+&4I[;&C6/ @%S<$;T#&C+HXLBZU M6*Q&SDH4+TKE0A;$BJ-U%,0)@SK*QXBC%17$!WE%C<>&9O )XT*#=;3'!-H[ M@HS%+@-_PXYG*X6']IQ4_;'*50"B! M_-1Y.1ZGZ_8-!L.<+H)QNA[KS'I[BQ M5DXCAU.+3UQLI7WQQ4#AB8MRPN&IERW3\0V]*RWBRY/X^_J)';EEUX^>?( J M8T][?"I8_:3"$[^_XLHG&8DM442L-\P]^?+)).I3$&ZQ%]/.T3P&Z_;='A*< M0GA35TOAKI5I=M',\>$ON:*E(&G2'R@FLN:'43-QD>>?YAAN\"_";Z)(B:3] M#DXRW>$!A14ZX MMQ2OI316.%[KS!R@4$XU.4.I+BA1!C%M$%6G<%'.&PWU0WS,:A80&_A =Y6;F%*1F!#^@K[-Y$?RCHI-"A?3?0MM4IF "[KVQW)'_4M M>+,+2J%]$'^T@4B\>0A.TD3C?#4[0H_<5&AS8+?HG?""=L^P:29C"3[8V\I) MV:TIGP]M-?7&^+^)K%112FG3:FDZ+67"DK\R<0<)NSQ ??0W,('WN"\RI5^$ MWIR47"1%KS/%#^&!=A5W5F>(ELP-FK2X];[$;AB?HOUF=?M]#EY8H1":C)C] M9F][Y:XAS)I)8J*/]T:SF'UK=@JBO:W4 MRZC]5_'>4,;5;7JY9/R/O("JGDT,Y_%_Q,53?FDIV.)IA?V;2-5EG12*E\83 MXY40R9VU RV>KOAG\/$C01%0KCWN:["$^J=DP/*69U+B.& F L^T5L.LNR* M5KB94ZLP;S ES54."NS6AI?-*R&X[,W7+:@\2NQ'1Q^\_&6VNN%TF"GF?BN M#A_>_2,$;G%L@0CC@@_ZEH.Z?2MDJO*]P="OL1QJ/)I8D W^,0OX4O/]V6.GDWRJB':,E:F?1*POB:QP@^!LKG%7(Q."!=E3 MBZS'F)#%17X4C#;63LVP:3"#_?%/"# ]T:MNYY.*/===5U\<3_@4(LZU\O41 MD\5D,M,4;&RX6L.TY1PSEK,^-M4 J"4L7<-?[-%7=%Y2<[.]V/ N2.Z.+[[G MM]7J=F$)CJ<0P[K54-H"T3>2XH+11;E7QKB822W^DD0Z2IP'C2X; _+,>+ M[$9"G4'PK42^(PU;ZM7"8EPQM*'G0TC_%J,X*'>F0^0IPC?M0LU^=]*!T$CX M>W-![\7U=O2J\$]!R-8 !_;R&KL3#(%5'93Z@@PQ'$PC82H8BP!,M-,.B4<: MNG@JD<9#8L*#OR$FXW'0(R')9S=E/1-R;R'T-6%YB @H_#9ZFGKKD?"*??'W MA_AS$/\WCC]^Q^':BVJ#.R,LC3<0'U8?:1RN5LYRE+0=IQ01#V3K8L!SRP$O M*CSWG 0\ERU1^5F\BTJ8?CC$R ]B](ICA%,13;89)6IXW9ICW289) MGBNO"28)YB9+,%P\1.1#1$!$)$29B! ]TZTR.LLV?*LU\4RX-NIF(FC>?-W MAP ;8S]TZ_50U2O9<4\TH&GRRB<3+3_RUFQOO;4K]3 ,38^S!]%"J4V[OI, M63E10;(SE,D&7C)D@ZU9^"M0$QZ< Q]D#PKFVC![N.]R4BL.=96&:>G1R.<4 MUAB:A%?:#M;7!5L<\@9LPS'2"DG?8#U93I=S74L'Z98'+L#W6UJG["9URGQ]X506#H:QMZ:5@_1" ML6*XK-6%0R03&VTNE5@$=?7I_!C=AAY,#8/1L'O\:H/*YSOQY8:*8G=X[WH^ MOQ,O#MUU?'!W]SC<&UB'D);D-!%0.8N"O#4L^5LZ'&1=G$YL17O8#Z)Y@;L@+"+2EM+259J68,?G)_!1'&N2 M%V34UK; W>=CG>+XO7P%SJ]A$&GOOM#"Z83&[P+QY:N[1K/E )5TU2O'Z$^( M6*>Y='&\?8N7C)W,#ED2NO0X,>UM3RMR#L_$_H]-;1-.,)/4P^9 6:3RG4Y_,4ISL(I3.%N2+U0#GGNH+5&^R<[R1CU->UGG##>*/BR7#+0F]P6;OB9XW MASB*77]#\K>1FL=F?B<4BAN5D*^O&\^&J%(O"&:FJG'86VPUFYO5^!2(29] MU62FX>Z-(8M!-!G<]I)@G5\_+.;#E MR6-1T3NAEW7^D7-#+0+US@/V3M6--PQ?'"KV D;N.O1=ZGQIM')KL M\+V1_#A<*POQ9SCQ?%B9*:;G/]@1\^'=N97[:>;.-I7D<3L=3YR!,VJ/_@(G MEVHU?@RI! QI59,96J-=I?*VE=TP@*+Q0"FM\Y.>8H>,9OV:#H8[;> Q+,D) M=B14XT4)N7A^VI29[L6*/ M?4!4ZXR6K1_)R@6?J&F@S_YW3^2[\#>WQ+4^NWO\(: AO^\LL0\KFY9R>LBO M-!)*#@1\_-N!+K#RVLVOG(ZM=Q0/;Q)'R236S-R/@)72-+WO!SBM6-348VB( M-6B]0IQ$_.JCF4)AWV2NL,<;'=7?#&(1=< H:N##E#N?G?9RZ2#Q0T\X[OTE M3S10USI)P(1J-3%.*U@KZ:9P-?IL,DRX%K1A>[L!>\B/(VZ"\]9#=Z^(HCEX MJW_5DPS?K4<"C$1N!0E.*6C+JR4?$I:S^6J >"UQJNE-A.K!/DG'4:8W%)O5 MPX76L*SX!>V)R%S^"W]SE=XO3A=JHMM@YZU?E?R]G1)XA&P53^F$8$>D2^,7 M:WF9,4.,&^+LT-?DSWO\/4;OR4?_JU6+JSIM52C?+;*P+]A((:$[:'3;SA[P MLY]&%X?X*0B]O^/-[_X&A^Q;<2V8Y.]?2_'KCH;$B^^>6O/"XSB!!X^CQ%?( MV4ZV_U+*S(C10E\I-:L"A4F[.#WL AM1M,"K.^(<_Q%.+"+5->FQ)WP[&)D5&5Y:F.H"MZ M*%W$VKER>'RT9N(EXSXFX!L85!]G>8.$FVT]-YAP]Q;NIQHTFU52: 8RZMYY.3Y^H-L\<3UVPNR1W^)ZJGTMQUDFR/!X$&VX4N=_+)O7:^VU8WW^-'SZ6GZ]RXA M9V@9^%@13W59^$B]56;!D]'P,5T0R?\1EHG-?L5Z/OA'63;6%,@&6T;6X0=O M/]OHZ5ME7KHWFV,TM$^:SR936]++:?2]LOUC2F09L:&OO2VVM^T56%"#2SJ6 MML?2-7O[_?G9]#9FE>6I+A95]%!8_!V/#,PFF'AO;!OS.)-W;&.ZW]_4-F8# ML@=;!Q)]&[#P^!3LB- 1;SATX6]R39.39Q$]-\2.#;7YK0H9TV%,03:57DW3 M8FA*>/P32CHWT?-8Q9B5OQ0!5NX'@ M.G9C=I#T5J)0"UF@(4*1S/-+<'/@6Q#%J$[T @1B2(O'=-IK-1J0]C3L@.X&A0 MSU%5SSA^VAQ0B*%&JX#BZ%<^E&3Y]VP;?HXB%BJ\5=WT[T"@0J!'(H MC$9&DV45'V0X3RDB1I)$V80H-%:.U]/IKZ=Q!+4XI!!+3=8!1M4GSW?]M>?N M;H/(HTN0\NAJ?A4&98WRR'OA:+8:"]"6448I:9M0ITOO.OJ4]09 8:<#-Z"Q MW6J@J+RGU?1=WYT_!($TQEEA?VB5+A<4QD.,!C1T^BA2'=@U*V(<"R6W$7I] MKK":?Z_7>$>]=CYRG!7S6?J3/_AR'.TS&/V&!5>_-SRDV6:[FB1373Q&&(&^@YHMKT#@M06@:1]9+%TG&D!N)PFXD111A42R/K4 M',.J*8%S?;I6]XK5=#47!B206(X*72:"&9!F@B7[UXTCJMJ#1@>F5>[R$Y_I M:CJN 2@ORKB(X]![.,3LF'4J>:S 1N?"2>,+H%A17BR83,?3B3)F+%@PT:1Y-041 MS3_8"*#V=9!68X !ZBJ*#GCSX1!Z_B-O5L\K)@LEDEEYY*;M0ZL1,@U )>GD MH[PSF8_UWQ,LN$4.$,%#FHZ?+$GUQBD5O=JNN+8^?G1CO '5=SPMW6P''KYZ MH;\6UM0M!A;NN#3""7KSX_SAUJ3?FZ9I2/455&&D M.EO,B@N^.1&4L"SVN:F?B"+C]@=<> LV"9JR%\N'N5DB;A:W9)8P(P\.^6,Q M5 L/1]D9))0<'H)PX_G4BS[@A\:Y=_4QDX"O\)8?H\V<65KZ4Z"!*!&@['F< M*DY-E5W@^LC=!P?QFIHQ,#5X40D?(MV!7#["?SO0@NX7FA0.(XK%P86;EVO#$]!BY^.U:AAT65#YW.)<+;#H6P4]#"(( MO[9SSPU/ ^(B$4'E%LEI0^9 E!CLX6]G;:KP/^SW;OCZ_U=W MMVRSR,AK58WNV_A!L<9_A/C['.0QGC+.C35>XC9O82;_O>.<__,8ZM4-O=DA(1U1\8C+1TP!X#O: M.>WWCQZTQ'ZXC0"&@*TV!)CX"J)?7@>_KK;_%EG.ZM?=X3R/6$IA=A5O[^,B M*X+H-DWV8=9Q7I*9#(?]MU'#]*<75OZEF'0D"E!-PP35=$Q8'4BA!E5Z8'KZ M<[J"(;>Z&^V2%(4Q:1+.E644Z<^")V M;DN]XVJ8[/;X?0NB'#&JLW*F%M^H>N!@K05NB&W M(G_]#WQ4P 61OH)(0AD5A5ZH+,?C 1OV>#5[F"3$1$&<7F/-)K_K&8%UY9U@ M.?3;:OMM(W:=W(K$Q;-*3WGZXLZQ411OEE$TSDRXB26'?B5,.!( A. WK%&E()T]5 =&ZSB4*CY5KQ]O<6ZT$SH005$D! M@M9 8WQ]8YSA115$#41([1Y%S-_'*0XBNDWQ2Q+1G_XBD/R69-I@4 N 1(FR M50;;\*:7O@H^$W3]Q,[O"V-4J4)"%Z+*T#NJ3GIV*@#0;/F#(;!F\9.P^)%9 M'!&!./MM@G+AL6R<&.T-^D[P=OOR=%039[U_3/:_;W%( 3VC'RB.9S49:2Y Q"6YA,]0 7\^ <\>[,CAH.,MM!.J# MXBS8T-%@][M1ZSJW/4I3N4%]>-^?'F*Z% +]4C/0'-_$'(>\+@^D(_J66 X< M]SV)[+(K86+?/,?[PW(^:T<_>.[Z<)M:$!A)RGI'6"EP )ZJSMJR(X^,'O&* MTWVXH5Z=,?(VS/"WX>:^D+9G\I_[.PY8*U]BSU&Z3>EWE5$%UBDE-W!@Z M+QB?^*?YQ"GV+0.I11HV/0_#-CC(BO25'RBP^:\(4[R]VN,T>,37298KLH", M;W?*$GIM,CBO93%=E-TVERU6E$OI$R3D(ZH *MWES Y@<"_M/$IG0>^J:F9; MZ;R..]2;!703T0:.&PU:J_)I95DU6=K)22*@4:MHE\$,Q/QRWH/<6D'#AI(1 M8=>.&_Q#/>=:Z4'T0NX='5Y[0KH7LUT. \=MLQ3B%QRI2I'VW06%SG93#")Q MN9C) "DI(DH%CP"$@ZWU&]9FW%JXE"S#F%1B3>$7<'B)"J.""72>\-$=4+!J M-L-@<.9Y2SFDN,3)H;,; 9H&&>E+J^JFW;6%0? D#T(EEB1> <=17SDJQ<50 MZ#&OTT1BJEJ+: P.X:M063&M-N"K5^T>TX"OLPA5AQ/ T?%/$!5:DR+\0BA4 M,.WZB433Z50Q.F."H$JW#S=I)AN#!3G:D+?ZT8"A$5-*(%3VCP,$9:]%)TC^ MQN1M2VO,I;H5%"CM]N@/]9?+A;0S$="9U&8K)A8EDG(;V M*CJ! YXZCKNAJ'"=G7UO/Y/U4U)D0;REW;;Z %[YA]YT6@+8\X$!/-",-H:Y MP#'!>*")?N-)C0K)*OC(P"SU@AT\\S0;4>SNZC'%O/Z5]+&HKG6.9$5#].L7 MDJ&9@#&352]3&1S$N0:V':N\RJI:3[5CF-YY7T&F1&S3W@*>"Y)DA7/G&J-$*&0*?A?@#AX]/ M^2%UO,R4^Q1&!?DO3_:Y*?(L)T\OC!\5JW2F4APNG1HVS>3\6D_P0*GBL+.B ME1]:4S!!0C7,>NIYW>$WW!$(=Y0%_K@ODDHZND#;7F$]QX(A8KM7 CT$6;LR"12$#GN'D#=//E?!FY4XR0WYC M>D;%;E9<8SP0 %0 &-C96PM,C Q-C R,CE?<')E+GAM M;.U]67/DMI;F>T?T?]!41TS,1'15N1;[CAW7W9':ZNJV5*F1LNS;\^*@2&0F MKIED&B0EI7_] %R2&U823#"1?+%5$@ >?-C.?O[ZGZ\;_^P9H B&P<]O/KS[ M[LT9"-S0@\'JYS??'M_.'B]N;M[\YW_\Z[_\]7^\?7OV\'!V&08!\'VP._N' M"WR G!B<+9S7, @WN[-[!"(0Q$Z,ASN[A<'O3TX$_OV,_-<[P[_ZQ_G#[=G' M=Q_.SM9QO/WI_?N7EY=W"'G%F._<V'SXL/?_GIXP\_??CP_ZJMP^T. MP=4Z/OM?[O_&C;_[_BWN\>GLX=W#N\HD_^?98QA$N/5FZP2[LYGOGSV07M'9 M YXJ>@;>NWQ0/Y_N&88TB'Y^4YGAZQ/RWX5H]1Y_YM/[HN&;?_V7LZSQ3Z\1 MK'5X^50T__#^'W>WC^X:;)RW,(AB)W!K'Y M#=T4)0D"SY@MR+_>%LW>DE^]_?#Q[: #+LY2&G^+= M%OS\)H*;K0_>Y+];([#\^8V+=Q%!_H?O/G[\D?3_M\O0339D%P7>51##>'<3 M+$.T2:E^^Y([_O2^8![_O:(-SL@ MWY@OKV& 5P,UB*'K^/JG M=(,OLPV8^3% 5[V9]!Y#NV1M!-[X43K:S]\B6X"#R+@QIV);8_4F]A+&+E^ M&"4(G#L1C.;+ZET_"[Q'N KPBKI.$,]<%]_.,7Y#[D,?NA!$,\]+U]WQNY]E M_=\WB\G^4,RB",01;GX+G2?H8T)!= <<,JPWBZ\=B'YQ_ 3,@P?@)@CA(=*O M'1"^WJ1J1'KF_I' [!;1NJN$XPXSA\=DLW'0#M^1>_"6%YCC@!YAK7"#ZQ M MUM4>&B;8X:,#SQ[S53E?,E\NPAB_% ERUYBYN$?0!8-BH/IIC4CACQG %GWR076N$R_82 M'Q"PZG_IOA+27QAP7EI71VYPC;/Y&L;@WMDYY(LZ)R(<5^,<'L&*\&4/8!LB M\JYJG8C >('RS;O 3LL;"RX7CNXF?OQ^$VW$Q49?03V+@84)9W;IBH9N, R"D M=;>K?43S6QW%9%?=!(]. !"68B^N;C%S@)PM2+#\2NC*_Z+YRNW]99VG/P[= MW]>ACUG%Z IS1?%.[VTF.?R@,TI_,]^FLH"+97W\*\P'9K_HS RH?F;8&9;B M7O:]+RA,MM'5*T NC,BCF-,5>#=QE'+"^$/$\6_ALO,=-A0YPR)6 MR M?P^ 7?!Z!IW\_,#^A\Y;&V 41F*T02)5%>ME#R=&'G,\>Q?POUP!$5PX* M5+6PW3ZAD1QUT!4NP&M\[N.K36WB ]$P9H"* M7XP!J#TM8P9L01B!4<"54S(X6$D$ Q!%6,YY@D%*8GE!Z#]HU;\J1%,5_<. MEOW@T%._!$_Q@*O+&G[H:365RP-.4>93(YBNW@TL_\&AITXD="+JW@.4"HO: MUY?] 6-3T[N6HL\,/LU4378'XG7HE5KQ(=\#TW.1 M(.*\?HV9 !P+,C)T,',)0^\:_RZB ,EN>V@ZR2K*45FV/!R-&3+L#4EO=SCZ%GA8#EGI MGX>G)MOU%X#X$?@W^$I\_2^PHY!%;W=YNG MT*>05?_[GI[J@S]#==HK?97)D$IM01IA6D+4E/&"),P<]O M/KXY2R(\N7";VIQ.>'"1\V5U'"])<))@[+7>+T?R:<^,J%$JH?)ZB8LL8>)X37#A;&'L^)6;D34Y M<4N0OPXT# ]84V@V-T(MO*)AY M+C4-_2S".3U,S2"_8[E;IMG,!*V7.=.3W&,@/I16!TTN-> +9$O"$W0*-O$*BQ5 9PN0<4Y_;7",JF$NMJ0F:[QST.XC)YQ]) MOE6)ZXC7P\0,JA#R*:>U-$%QA:_E$TQI:)A>X95#;VN,:NH%SB.=WL$$_?>% MY4RHLJ"U-$3QUH'>U>N6A,#PMS:]K1FJPRU \8ZD^TFMH9@UW)+7A2V%<+N8 MF,,#?A 1=&/@]=&6JHYB9J:Q P/@%7&D%6O1)5A"%[+63**CB?D\ D2DD_H1 MO@.;)X 8$^'U,#*#PIQ=U53/7B%+/F:W-TK]+=X<-_A'(=EE0Z/T4MP0!/RS M5%>C'S4UBJT.UJH'K:\/-2GI<0Q(,/2R54 DY8,]7A_M M"JQ2QDM9LBJ1LROD2ADYKF:Q1,FN@"MEE/A>JR5,-C,$$C!Q73-*E&QF"R10 M8BC@2GQL9@,D\*D[&)2PV!57I0P+S1Y1@F-7,)7Z!M950F4^$?-3CE1RIN:LY6JWGA[K#[;E6>C,U9T M1^(2I@XLZ#- 3Z&U0#6]X4NHK.E#7&LN$VI47 MOJ676$\4:4A9*DKW1$H4Q%OB9^GEUA$_;J!Q"9JEDG3/3<>(\2AAZV* 'O_; M('1>KBD(*;:14O-LY[7/]H]N&\EH^G@[KR@Y5.1U@[;F'^[BM5[7+-<]PT_F MM-4\X:F(M"^L ISO)G2JYW(/B\6XJ%@=J'&%I:'!3D?3%^_A:I_W] .,F-,7WV?(KP&,70QG292E/I^^(*I ]4&B5:4QIN2?2JDS\0Z9HW0S>>DS5M1Q9DU HJ?A&64Y[&=)O,;G]<_R:+%G MTNHQBAG<1%$B3WW>>A24LVO1274QGYQ%\5!(=C8_+\FC(>@TEGEP#PBGPUCH M%Q\34:\IP69MN1@TE*5V1K2=/.4/&N)5N-&YT@:M])MEHR M.L'#*,5I.8LY>14-[U4T@6/*J9LPD$?[Z(T#/T.44V:LU,D4G\6_-LT[Q**TU&P.M H4B ML[F9VFYX>^(G+KT; V^V"5$,_TS_R2"?U\/$# K/E$(..'X/AQ MP^P4VJ5O'8D&P3WQVX#I6]T$^#$ $;L\VW!?/!($[V"0/N<%W?C@U4?)/(WN M !;UO$JTCCY$.U-@'N$^V(QO5GM62/#,L%J;HQSOH_S-.PQDP%L"#,KD/R7!!2 M^'N W7Y4U MN#7$_(U6WZB1Q]@VMI;$Z813A;_;L0)_H!/#S&CG5+-8S[Y]) M]KH4 N(]X:PQDQW'"#XE:=+K19@YT[)F/_!7QX1DU6N?0[-@O^L:W1@RJM>4 MH).6NMSW*/02-Z:_1+06AJJ; 0>Y)/O^)2;##].*('SP^'W,S")%D'4=[O]L MDC;!$6PU,^),A6_%@BDJ%%_L4GVLUF9<(5.)]@MFDI'C$XV,MX$!)%@2[2I_ M0TMV-C&O7P%XRLZAU5MU3UBX<= M?WHC@1ZR?N":+*#M+MP*X+!WF>T>R0H@454__7R0K3IA$HH^VWV1%= ZJ.FM MGX>S5;M4&;$.O.I1)",>=J_*&]IM+UVJC#/%.-G-6?J84NFHO#-UHUT_3VFK M]@_# :F7G[1M=YFBBLOVND@]=M?>4:Q7#:03V5]L9;'M-9!4)"Q=!E;;TSU* M^U2TT.48:?NE!K,4M);75;?*\7A!N'87F&:Y5-1LPRR?!E*<.QD>F3 :;G)EJ#8R;7P0*%Z:Y6 MV&EDE]DEI5M5B487\_E1I&Z]<*+UM1^^1#=8.$*@@D@>D?D]X2%X$9EDA+-T M""/I7?>O[W6()"+8V.U->/^4U$2+\ &X8>!"']34;8N0 (S/Z3/$2WV^^Q8! M[R;86\9F+N8',CZ$[VDWR*>,1%QB&DDU;?P_8DMXQ@\>*4T47S@([3"9>2YT M*@AR?:VX O1&)*(TGLP27(_J\T/<80IN9(+D!B;\$_9E8MP4_2=QEG5MME-T*@4*7K M:.;4J%JN,J=FUW',J5'R6'I"S7Y:(CUHGZ&72JQ1J=9W'+B3^R? 7U/91-4^ MXYC%GI/+J^N(@XAE!QC)_%*]4UZZF+;UE+J.8T[W"&P=Z(E"D 7=QC&7!_R& M(^C&(.7EI.?2Z&8H:IDF&E'8,%&(K?I XYXOS36I]]RI@XX(AY(5[[GNO('& M/=_^ZRX[Z(APH*A"^N,@.^B4K6&*MQ^\2(BS2X7LZQ#A;>H"X*6BN%ATE^AH M>#X/8)L@=XTYBOFR5E92-!]61Y/S680S]X\$(H#!QC=$O+OWG8!XIQ.E21K7 M)IB7Q !FBM3@NS'")X*2O)\U(UX7,Y'OVQSD^?)K& .!BHC9W$@\>>[#BEEM M?+'A6XUG2F$T-ESB96_0DB_MTNYBTD0YI$VH7G*7:3GKY5YZ!%;@0T',.DZV M.Z >"E_^- =@X^$"AV8)!ZHT;IP8_RRXJQ&M+=M:!\ M!P.X23;X,G()@[@B5JBGG(#Y\@$X/OPS7>)\4\R#1Q#'/J"$4O4?3\N,]FFN M@0])XNLG'V0>"M4+^$] O:VE^VJE]&JS]<,= *G+1(N](N9 'JT2O:?84S.Q MIZQ*P.(+K=\]QOINRG%40D+FR[9+]V4"TLHJ/F2<\ ZC:*&>E"E$SR1'J4OD M=N\;%HV)E7>%G TUE0Z_@XDS05[*TLQ57GS$C_1;D$0)%A:+R!U66*?:&$9F MB1Q23J \8M\"E-_[?PM]\J6DG:JGQG6 M-LCT*XIZV6NMPU>HE.Y7^<\6N#1HE YGDATSD!T%1MLK!*J!)Z^'M3ZMB]IC M(F=+L3Y7B[IX+Z/(M3[YBM)>D_5+Z)9#Q5;45#1LW1)TV(K< ;/*G+)<0C=S M=$O5824V;.-VMTP<5H+$\;>SO4"L DH"N]CA\FD6[P\C[F=B M-ONMP=M!E6V#&WP-,9=6W47X,(";&+2LU\-\XUA16G!R!.L;WR@ZY[O]CW^# M .%G8KV[!<_ G[U"X>;@=S8\KWP-TF2Z"/R1@,#=R4V*V=/HC&Z";1)'*;P? M[@"1^D4SH?0P.@,:KI?A!LN+HIEP>HYE1E'[*"C/C3W&:&:YO\_DMB"OJXDY MW3GH=Y#*S;(\ *_'*%R<9#V9CD"H&.#M+JUC=DIK@S"#7(6?_9Y.@V,J(8_8 M[B U.,;>L%L9X[:+_?[=_P M4EH#*M1R$M/)<&UB-84(Q98D?3+8B=4)PAW8DF9M]QWNI+F@PDA31QTN@L24 MP2?-EYKY<&E(5L)*]D&>H_L\J?5LA4"Z3%2%B[B]"1W%>1+A9S&**FA=A%%, M@FC2=+/>51#CU<6B91 Y;O%GEB:CZV@CF;G(U,+MHB5\L?C"1;AY@H&3(11$ MT,L=LU/D\I-*FF69H9K%8MK[3LNX0\VPC&R[\?!I@$M(V,"$LS- M98[P 24#^3'PC-GRM8XE_]EK%D5 -HZ\\C ML*H3!I_Z8D7_"5>RT^'W=W(W& 8Y &?]Q@ M82Y8P?UE?;Z[<_X9H@O?P1PSQYM#8821S;"D[JNS 7P? L51QC73;Q%8)OXM M7#+WJ$S7X>^R6[!R_.S&HNPX6@LSJ;]<$E40K/8* /Z[Q6YOQ"\CB]SD4EQO M8X+*>G4L*I&U)B9H;-7V*3@_$.%;G9GX1MC-Q%P>\)D'G%N^_+LQZK@[MMK" M"(7ASO'C'3_%;J.1GH19V9CYIKH'Z%O0RI_*:6@"JT=WC25A'\R7%(4<9AHJ M_^*Y!2L/8\B'K%"5Q*OOI . MJ(BRW2U.%OJ#Z91M]Y$SM]>%:FK;4Y*9@[YE?;+=)4'U6A$+.+;G-%-%C%'4 MV=+T94I'5V2TL#T76=VYZ 3'6S-=47MN<84\5'3K5N M>X8Q9=1XIC_;,XOU!(MC9;0]N9B,ST45.75]HJV.VRQ_@)()$WDXV)Y(K(.] M6^X=8!B3;=UI/:WK]0R>3'.J[;G$-*#'=:.R- 8-.^!FT_ABWS;8VY MKUI/3P*)NJFX%JM<]WZP/9%C5U-K(RU!VRAH?<1Q'^2HUY/U <0Z]EKE'BOP M^CCAQ<9+B9TM$/TT(^+/&_;/@!DY;>.';4;?/TMV8XQ!\!21,'Q(UQ,Z#!HEE\[ M?N3HN8Z'_=9(4#LZJ]R7,/1>H.\SZ-W_>>06K"F+TF23&GW>&6H>#KO-4R9@ MKK"44U*?(7>S@ <]%;N5&? K[.FIV+I, -W>S%VL5^,O\JB*<#V,SH!$F$;XGB4L#4N-P6ALE.ZO0 @U:6*4Q@?GY<[! M1QTZOA#:6ENC5)-HOEQLB !Z9IH .!V,TO]KB'Z_">Y1Z )FS *CL(3WF.V"5$,_\Q>*_K$.@PTLOG:7Q>6E\U V&UD7G4W8=V9Q. MIFYOQ-9B"CJ-:QZFZP_WT1JVL+UZ=?W$@\%JSZZ(5/L*0TSUC%6IOW->Q?6, M:VVFJLOL##^QK@.@!Q39N^F8C\F"\0 :#:,$UT\72&.="=37LC2FL8B-.JJ&=L+$ZO+ MU;U+N5@;E] /2TH9(6MOI,%VW:V9.)BQ6-!'XX)4%5 IYGRZBD[0:5SF(<*; M"8PHDIU'RK!3YE<]A*(5/IR@:.KPD?3$>79B#>=.*9W(/(M? \D03P/2#R=#[+;X-'Q072!#RV)X)"?@O2()EZ"2_ 42WNH M,AJ;HOLFP 0D!&*.!9+2T#R]UPC\D> [83=?XMT!0P^Z>8$#J5EPNIN?&WXS M 7ZBX@=\U3W&1 F/:73)B[5B&3$5!C _OY9FGCN96Z..6W5:A!Y:S.;F:>]R M3,9W-GB6?%I+0VY6Z?'+BR(0LMC>5*V61IRFPF"U &@C4;B+VG1RE3IN5ZEA M"[8QN,?JB&RNF]+*&$(/P$ME'+VG5QLCN^G5D-2964>4.X5F1Y: MJ;H+@WCM[ZJ?XI%$:SXYW1V?T]V4PO0P6CB^;%G5NE&Y)-OMEVP1E@W-*?DX M"L2NFF\*E0.TW:E' B#Q[[X["+I+7T=CNL-,9- Y2=KH2=T:*KR:SW8]8 M]NJ2M<787K.Q)UY5NYKM:7#[0<4P5]GN/:9PC35U";:[DO7;3_+FQ#V.'TZ6 MG9=2&94XG2Q7SU75E_B4O[T+.#25 ME?5>O9+84!R=/YXX),RKVOYD_E.83L_ E ]V"O(=@Y8^V"FK:RMY\<%.[>)4 M\H+MI_X(5F0K/( M\=@/5J,)$BD$V(PR\C;FI++LMIP.1C(/H9 H=^;H$:!G MZ/(LSM2F!FF.9H&7DQ)Q3?OL]F:S #4W=64KG^_R/\JE Y(?R7[WC. M;#X&VBO(MK01@GE0NVIQ_P"_!N1^&I&H@^7D!HR@!C_A+%_B& M+2W^(I;PGB^O'+<==[#2( _-Y#?7,#^11C%Y"QF+S*#OD8C M,^%.>#NY,#N5@4P2?EX/,^%/>#.#A?.:&U7/00#PSF10SVH]@L M)L7U5B8H MW9_Z##Y.$1E:2RWRD92XPY%>)GV,Q?J8_'UBQM<4?YYT19.NZ.1T1;JT0Y,^ MZ!ADGJ'T0:>2>%<>OTD]-JG')O78>+0[DWKL0.JQDMNV/:RN*T)-[4^OH+JC M\&3NBA17_]0KJ,YJV*@*&=MCZKJ"U=*SV1Y1UQTHABK5]FBZKH"UD\P.'5)G MRBA$;IAL>]P#1,)YP^!QC7&]<'PW\?/LN^=.!%U\BU]"/XF!]Q7$K&XF3$57 M#@KPVD:8DI2&E%J&+H?>UH1"BDI)B;% MR;;>PPSRVF2G$G1VI#)":5NS41W MLM_3T2R.$7Q*4H/Q(BSP!EZ>6V&&$/$EYSF6:AC82+8R$ L-0_4VQJD4G!MZ M6Q-4_PK@:DV.*N9GG14H7!/R[9_MCWD21[$3D.H\C/FHCC*BF;:(X]W;:F., M>9;YTE1J+! F1+!M-0UNDA53?.^JW!CC@;==8ZT1L?T3;+LBF_L65!'2=5QM M%SFE 97>K;;+G-*(-;@KV].WZ'T@NYSEUKMA:_J)X:#6(2'9GHGNX!N=+3/T MRUZG4G]X;/JKT02ASH(8>F2!X#-X!&Z"480@RJJN N\:[QR2BBJ)C^/D\?#&X^>G9[LPZ^/0^#G.^OEH^8Y'L.<*?7;'3" M0VZ[GX_N)T",KC+;8KN.3O:EJ6E*V+>B[>HYT6-&=^W3<_W:?AL,\UQIO!/X M%_P)>0F/='UNS3@9FZMM_@RB.*L \.@$ (7!Q<75[6(-D+,%&$27*!;ROPQ8 M@'D_\FWHT-EC=CLCPM6+@SQ! :1Z&R.BQQ\)WG1W(%Z'7K;2 @%0$&G< MC78C3=_>3^8F]>[WGIW !=$BG"V7T(=.C-=PM4)@A7_**RXL*[302>TYIKF9 MI?!FV7.US:PZIKF9_=_$09B9JY4JT[J S ^8.?GB&5S@_ZPP0YN%LG!8H(Z# M'<>\N5Q4Y^&T[/,[)R:"SRXK@#9?7H28'!1#+#/=XSL91E&(=J3L FT/RW?6 M6OZ6=@IN@E_7T%V3PW##J*G<;0Q-65M"%P O?>989_@!N ^L^A6'$$+U;DP MQWXOZPW,&AWHW -+1.'<1+V&'",&D3D5U#[M2.-QLKVZ6D>% MU"Q+]';=]H_>26NGMG5TE@PI@O(^V/ M.45O8WNA0&W8T6TEMM>>T2$2U/P/!.^2[4=97;S@H\J0/O5+9US/:HX!Y( M*]AG;(\4[H&BJOW%]N#B?CR5I,M'*6B>J&#$3EW;2T0](==?56"[JO:LKP7? M'=*&MKJI7H"::D'M&Z61J"V];!\=886WHT5)B.37H<^GF>4[;1# MN-N7FKKYLI(T(4]HX6(Z4"MI8:@QH+G+@D M\J,@<&+?QBB5_%#Y1BL; U$8._HBO #A/."4WVFTT/?5Q4LH^&K9PDQQQ/UA MNW?0'#WB-P-XOSA^ HH@,\8ZR?34@N,E%HK3RRX &*O%.DPB?&E?PR662#B. M@3+=AJ0O3% G NO]-%$8N0ANLQC".Q@0+?@#2-^ZM,9&> X>\7L=+2'PSG=% ML/-UB&CO3S5U-'56 WW+2$G./<.3/DM[%O(!^$Y*7A1'*75/%092%%'3':I2A&O?OXK MTNX#*Q+IL$18A7,Y4M9I;WS,DADPP]F,T3/EOE&E_AH&3H!9;)_HE%&2BK)L M+HO5VESX7LH_9(IP5QRIP^XQHAD(8FYX?30%UA#Q*3UFE3W*<7+F=]!-TR_X MUL"R]T489"^_"GG\OB;V0,[K<&^,>AL] 4D@OG"B==6Z].BD*2O2@BC,Z&O% MSF9*79,UO0D\\ J\17A#2F$6ZJ91/#E7AN2G?6$C.W7/TTB MB\_=39X]EJ(\H^TOM0%TT9RJ'P.7Z&[[W#8=1](]"X7K6Z*7D8+F)5G92G/O M2%9K(Y3GJG]>V?AJ$Y,T\FO$#Q V=5^8-6HJW0>2[YBZ.3G-C>!6H^&"3 MGI1"'\W3?Z-66QBAL&Z[XM-*;6LVY+>[&5DN*KCO^$;0 3X><_4%! Y?NKF MLL'"#=%1DEQV>=5*_DNO-H:>4-],D94"6=EJ;*Y$MI=VZN0X/D$/[50I,]'R MG4<9_L[U#\GGDZF/65IKK9\X6HPR+F1(B/(O'!5"F=1>:F!;:O#4KR.Z";+U MUPV?ZN?MPO:7U&913"ZU6EP[$*4&[(,CS27FN'!_W4*4:;*=5L8FW:,?%3*W MHA0X_0<^*CP*%[;2\)][X27QFOA&,^L/#_G%HT3P4+A9A=:S WTB/EV'*'WG M!@:M]3D]O+D>ZE(K@G>>Y';ZJU> 7!C1?5*'_N11[2DJH_0%L6MO#_$ELSN) M2AC?[#C8MXYQ[U1TG-D)&6CGM+]C#*TG\2R>&+.H,\I['IDK?0_QN5'NM)-) MUI=%GF0B_VR%0$J2(';&4[DV8\Q:T<_5\"[;L[TQXMGV$;=R 3=[E#[9 MF4&K(TKUL*D2)#OSM4QYD@>!54]<%#UQ06]O"]O!%P1Z5%'5RR79#JQ$'$H[ M!1$SZ.-$T6(7T55T&2J?)CM3L:I%-U2!E(T?L'T'JL51J-9S_FAG'D":2WL5 MFE-C9039?1@B=[E+[$S.)X]*0PE0WMIV9G^5!Z:MD]AC\]G.%TV C2B2H83' M3H&]%490O79K7ORVW[F4D(4J%HU(VO)*L3U;MZ9 @RJ63&'QA#)X#@ K(R.E MM2=V4#"Y[ /+S!&0'(&4U'P7*WT\H=T"9 MX<%0@/K#!&K7=[\TUA9@_F4"LP.8.B(IIB36\O$F6K!GQQQ87SM-ZT("%FUA>#&]>2\")F>I6.>P;H*3S1Q>C@2FY]9;E! MD#:8H-?Z G7'M6",S-76%\ ;UVO2,\N#]37VQK5:[(A'Z^OTC6LAE!//E.O3 M0;8_0WRX@F\VK$>WZF@EQI.<+HGQ<'5_RL6PT\UO MF M(JMA6">TDF$ON@2--;+L$D7\HO@61%B1+<25B4?2G[EZ0N M49_$1TG4%4J+E>A.\N A]+>-),LE_"J:P75%TJ03U3"T0TRJP!' M&? U[>;.0,M4D"LC+D]4VM$!M*#(:HGQB;+2NF\-00F:$N\3Y?-ZXKV/=J(7 M[2KA/5%&3Q.\S)J8)<#3XZ?C3I:^+D[4.J"9UU"JN5N";R='S4TBS(W5$^7M MM3U#1,=$QOL=>1%>@' >M#-J?+*3"]."U^(E;.-EY[4X1/KHED<^(['8)TN/ M[$"02F;]+^$=VC;ZU_=5=&\QG=FOF[^M@0Y>8Q!X90[_&NPNVH5O\33]=VZX M>1\[KV$0;G89:66JU0H&>;!\99?-W!B?_'AW':(B8L! 5G8]>6'];,DT#7J, M54[R.!T2.W@38#$LB* [:)T3S@='6>E$X#E;F;Q^/';]3J<9YC&@=_^YJ[)GQY(]/PXD!7>A9)2[F6EU90A=?;<4I=-"Z%8Y]$M0FCT"5\&T%/VM M^;9G+QW?(D@K6'KE*9T8IM?1H7Z$: MK]8E9>G)\6H'\CNT/7'I0"?FT,8;V_.9CF^9.GF:VIX2==3O3].]IE=*U!.4 M>P[@;6=[*M7QG0\Y]VW;4[*.[) H.S_;GLMU?.>&YT;9+^WKR4DRAXC!.UR: MV!$%F\)5 )?0Q0]NAM 7%";;*DQY)&K@W<11*H;C'RM,ZRU<@BDHM4M0*B-4 MX8'LY$J2@W9P0:.%OJ\N35T>O.7 X\$C\\HHBY1^PY'%K*L]TZU?SRT@!U.]+1X98 M>Q;U;!/Z$&-^:3SNWQWGT7KN(YX>7BT:^D D'?VNO0U? ,I^@AO(XE &_>31 M8U@4F6IOGD/ R?FZ-Z=#IO.);9'#!X,4UJ5#4MC_ Z':=4=Z7!1>2-RSDLV&P?MYLNO84"*+H'" MBW%RN#- [18.T4!K=RC&WA#Y?/N0(&5"!.?^08CF(:< MD+++UPY$@Z36U4N<7>M2#_@Y./*-S]N%+7X[GM.W8YA+/7#=,,+@/P 7PF7A(%EGC7 3P/KX$V?]9L^LS MI D,+O.S\@">09" W(9#X5_R#S^%291_[K MWZXNFBF2RC_TI\0#D%#QF?Q */A69XK741,42D)N]^$;@[3_#3NPE[F3BIKAS M7N$FV7 O]WH;$U2*,D.9S>>4?IV+8+6%GCQRX<[Q8P@JSP_U/%+;&<$H)627 M/RPLF.J-C!CNP(J7(X88)+&W(;-TM3G(A47^GYJ5AF;/>* M$&K3:F\S&SW;CQ%3;U>Y<(4&$]OS.W'4A0S^]_#;9S1.$/M<$/E?K@&(KAP4 MX*],UO3.UO2;KPQK.O[#9"ON:RO6L]?*&_(1H&?\CXAO,F.W-TB]',T=*66L M]CT*\>0C @3N0O)!%JH\VHIS6D]6QQ%8'2=;U A9F0XZ4:DIO,Q8=-')VR=)FO2]0VBTR'R@:V&X./5Z1@3RHGI('V< ,G:K2,P M@<&Z7S@1OP9PO8$6<8$,*:@ W&RB[[N\^K_U!B;8^8MPLX%Q%HR25;_&RP\" M%W,DTJH/M3&T('L)$7!Q8_+!^7*)KWT4W03X.\0D?^$[\)@I$'W>P)F6T(ST$[A;SF)AF'3K=B38!A+(BMV@+QI547[UA7 MQ6GAT[XD]Y),@TVR53?0"1=J1GJ['.FZX4+-*F^IB57\9.^QX3Y*MLO "C@I M,M6VZG3EF"KV>V:Y/JX#/)PM>$BMG+'R%R2#Q@/8)LA=X_U!ZH6,)O$#/M91 M-%\NB&-Z@G9II0Z>\,!N;TI[$08I$=R0W'8[$]1F.5,$RI1&(W-TTE9:)!;+ M]#0XHW"S#0-\TKF*"7I;&\/U6;43L0INB+&:S*-@B M/*\\\WE W#8NP>"DJ'%WZ*?S(I,='0)O$ >A.3OJ78C->YI) M@E%AZ&8NOJC1/JT?R3W(6 /E[J.96WGY%I=R)JAF?2?YLYH#+S*+1P_@,TC28!3GD*-P!O%>DIL+J:M1Z)M(I4%W:Z,RB]6HT M); H <_6FLK4=A&+X;,V+KP33%*:'?L=)>F*N"I0'%1M-U$K:/_J]W@O<;F; M&>Z8RKITQ%6-,;7=)J<(HI(L9KN/Q1#8-61OV]TQND#83YUNNQM'STU954K9 MGK)#QP/2E)5MS1HYQ*-+U739GA9%!X!,]8;M]5IT@$?3T_6JEG(\N-'-]34Q MK>W_46)C)P<\)?3B&,)E$GI]L-//4\KH3M$%-0^9[;M&8!H6*!5/&"7V+0(C3T(@;9XT,KK\#M:F9JEM/<5G^ MCH,QI:%Y>K\Z&[Y?";.YD?!&$,>$!\X6G^N#1&UJ)APV 49^^T*(A?!+<>' M0-1K+#/)F:OS$*'PA6BSG"W^2[Q3F!9S""T..(\@P(]&XXO,.'Q.:T-.8/CQ MA $Q:I"#R/;]JC<;@<-:2[#E^ZO=&G4+M\*YL57?E4]X9#2TH,E7GO3T- M[ST>@\UFET[$UUH6'!K?8+V_M2PXI^MJW1&AVU-RK9[,:P"T7QY7UVOP'N$JP NH>O@FSHKP(GYQ_O0AVE. M&DS&N1^ZOYLPP[7)$:CJ.!U,J(]ZX4V?8:\A39Y8\5I6CVP_Y XG\MAPLHM? M3"=XHD MMOO50>2/&/G]QJ'/3W44$S.]V6SQ*A"\Y^@21MLP)>?%:FZ"]J_@I7(#('PW)H$+*N=%;D[*PQC)4Y35 M;GD ;HBO<7)PY"8G[F?$E$;8+TP0PN2GZY4"+Y(']'[C>$Z]9FQ/4*F81# )/7\YHGX MXN#/EJ$[1@T#DI0Q5.ARG8T8#-JDB2XT;A>3AU5F+C65O^2:3N>0CHRY1WBP M76OD(2Y(2_,M1*D&)CK?5?ZUK\01XY\BB'=C2K_\,]S_"V81RG53?P+OQB/R M[A(6ZH-]IH_:"XO_AH4[3Y%9T?.58[H!M>Y!VY6$W<'5M'T/IUTU$^/R>/A88ZU._XC5M[[ M>\HNL)1?N)_*\R."[D=T].0A.;UC^"4,O1?H^R-YX@IR4N-2[ 0K4CDR8U:D M3Z3:&$;\C3B@\^PTWK5+#T\*$[O.+)!G([E 1Y_,?@L)D#<\ZB/J10T MTW$=%2][&H>V9.X*;09>)QB#U,FG2?/Y[L[Y9XC2!*ORG'#G@8_ZR.L ]O1N M!!().I)'NTZ*X* S&IM*/"?_]+):FTZ3(7?(F',]O9/S"%;D_P]@&R*BZQ_) M*6J2)4J>Q6INY&V4@%1N&F,[8:)5J3UD,BA,YVU4O&O)?#3)K&3*/=_E?Y1G MY=1&&\.9[7W?C/UT=EWITSNQ5PX*,"Y144S$Z+O8)$:P3YG-39PQ-I!RQ(_C M#12M0"UW/WO&TSD:P7MWS*>IO,&;9!&_8G<6>)?03V)EARBUT8[E)'9&ZP3/ M:5IP)*O]1"RW49RI6,8A&#*HPPOX]Q &\2_X'PD2QF>HCF+DN91?!Z5)CDVH M[+BB[1HY;A%SM8TSOG5W:; 3'6NK4FGUU5;%D/+>J MPY@_H,* 9254IE,HPL@@5WPL9W'/TWT-TTL?9'C.W!@^8^(4&5^I0AD($:GE]%XW((<:X:G=SJ: M9;7,>NC:4]Y6;*YAMA]1=1J5*FLC>F7^^IX0^^1$ /_C_P-02P$"% ,4 M" !.@8Y(>;.Y[U0. 0";7 H $0 @ $ 8V-E;"TR,#$V M,#(R.2YX;6Q02P$"% ,4 " !.@8Y(6GET2CX3 #RSP $0 M @ &##@$ 8V-E;"TR,#$V,#(R.2YX&UL4$L! A0#% @ 3H&.2/[ S<['*P M_T" !4 ( ! M(S0! &-C96PM,C Q-C R,CE?9&5F+GAM;%!+ 0(4 Q0 ( $Z!CDCCZ]W7 M^WH -3V!@ 5 " 1U@ 0!C8V5L+3(P,38P,C(Y7VQA8BYX M;6Q02P$"% ,4 " !.@8Y(!W98%%P^ #>SP0 %0 @ %+ MVP$ 8V-E;"TR,#$V,#(R.5]P&UL4$L%!@ & 8 B@$ -H9 @ ! $! end

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company